US20190127359A1 - Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase - Google Patents

Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase Download PDF

Info

Publication number
US20190127359A1
US20190127359A1 US16/224,088 US201816224088A US2019127359A1 US 20190127359 A1 US20190127359 A1 US 20190127359A1 US 201816224088 A US201816224088 A US 201816224088A US 2019127359 A1 US2019127359 A1 US 2019127359A1
Authority
US
United States
Prior art keywords
group
optionally substituted
derivatized
linker
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US16/224,088
Inventor
Craig M. Crews
Dennis Buckley
Alessio Ciulli
William L. Jorgensen
Peter C. Gareiss
Inge Van Molle
Jeffrey Gustafson
Hyun-Seop Tae
Julien Michel
Denton Wade Hoyer
Anke G. Roth
John David Harling
Ian Edward David Smith
Afjal Hussain Miah
Sebastien Andre Campos
Joelle Le
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
GlaxoSmithKline Intellectual Property Development Ltd
Yale University
Original Assignee
Cambridge Enterprise Ltd
GlaxoSmithKline Intellectual Property Development Ltd
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd, GlaxoSmithKline Intellectual Property Development Ltd, Yale University filed Critical Cambridge Enterprise Ltd
Priority to US16/224,088 priority Critical patent/US20190127359A1/en
Publication of US20190127359A1 publication Critical patent/US20190127359A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)

Definitions

  • the present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins, which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention.
  • the present invention is directed to compounds, which contain on one end a VHL ligand, which binds to the VHL E3 ubiquitin ligase (defined as a ubiquitin ligand binding moiety or group) and on the other end a moiety, which binds a target protein (defined as a protein/polypeptide targeting moiety or group) such that the target protein/polypeptide is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein.
  • the present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
  • E3 ubiquitin ligases (of which over 600 are known in humans) 1 confer substrate specificity for ubiquitination and are more attractive therapeutic targets than general proteasome inhibitors 3,4 due to their specificity for certain protein substrates.
  • ligands of E3 ligase have proven challenging, in part due to the fact that they must disrupt protein-protein interactions 5 recent developments have provided specific ligands which bind to these ligases. Protein-protein interaction interactions are notoriously difficult to target using small molecules due to their large contact surfaces and the shallow grooves or flat interfaces involved. Conversely, most small molecule drugs bind enzymes or receptors in tight and well-defined pockets.
  • VHL von Hippel-Lindau
  • VCB the substrate recognition subunit of the E3 ligase complex
  • the primary substrate of VHL is Hypoxia Inducible Factor 1 ⁇ (HIF-1 ⁇ ), a transcription factor that upregulates genes such as the pro-angiogenic growth factor VEGF and the red blood cell inducing cytokine erythropoietin in response to low oxygen levels.
  • HIF-1 ⁇ Hypoxia Inducible Factor 1 ⁇
  • HIF-1 ⁇ Hypoxia Inducible Factor 1 ⁇
  • HIF-1 ⁇ is constitutively expressed, its intracellular levels are kept very low under normoxic conditions via its hydroxylation by prolyl hydroxylase domain (PHD) proteins and subsequent VHL-mediated ubiquitination ( FIG. 1 ).
  • VHL Von Hippel Lindau
  • HIF-1 ⁇ the transcription factor
  • a principal rationale for the present invention is the need for a small molecule E3 ligase ligand for our PROTAC (Proteolysis Targeting Chimera) technology.
  • This technology brings targeted proteins/polypeptides to E3 ligases for ubiquitination and subsequent proteasomal degradation.
  • the present inventors demonstrated the utility of this approach using the short peptide sequence from HIF that binds VHL.
  • the inventors In order to make a more ‘drug-like’ PROTAC, the inventors have replaced the HIF peptide with a ‘small molecule’ VHL ligand, thus providing a means to recruit proteins to E3 ligases for ubiquitination and degradation, to the endpoint of providing therapies based upon this protein degradation.
  • FIG. 1 shows (A) HIF-1 ⁇ accumulation leads to the transcriptional upregulation of genes involved in the hypoxic response, such as erythropoietin and VEGF. (B) Under normoxic conditions, HIF-1 ⁇ is hydroxylated, recognized by VHL, ubiquitinated and degraded by the proteasome, preventing transcriptional upregulation.
  • FIG. 2 WaterLOGSY NMR spectroscopy shows binding of 3, but not L-Hyp or NAc-Hyp-NMe to VHL.
  • FIG. 3 shows a pictorial representation shows the key interactions between 15 and VHL.
  • FIG. 4 shows the 2.9 ⁇ co-crystal structure of 15 (lightest gray carbons) bound to VHL indicates that its binding mimics that of the HIF-1 ⁇ peptide (light gray carbons, pdb 1LM8 17 )
  • FIG. 5 shows the crystal structures of V 54 BC apo (A) and in complex with 15 (B). Electron density (2F o ⁇ F c ) superimposed around Hyp binding site residues (sticks, yellow carbons) and conserved water molecules (red dots), and 15 (sticks, cyan carbons) are shown in blue and are contoured at 1.20. The protein surface is shown in green at 50% transparency.
  • FIG. 13 (along with Table 2—Affinity Table) shows numerous exemplary compounds according to the present invention.
  • FIG. 14 shows numerous preferred compounds from Table 2 according to the present invention.
  • FIG. 15 shows a further number of compounds according to the present invention and their activity. Most compounds are active below concentrations of 100 ⁇ M.
  • FIG. 16 shows numerous preferred compounds from FIG. 15 according to the present invention.
  • FIG. 17 shows eight particularly preferred compounds from FIG. 15 according to the present invention.
  • FIG. 18 shows six preferred compounds according to the present invention which contain estrogen binding protein targeting moieties linked to preferred ubiquitin ligand binding moieties.
  • FIG. 19 shows a genus of preferred compounds according to the present invention.
  • the present invention is based on the discovery that an ubiquitin pathway protein ubiquitinates any target protein once the ubiquitin pathway protein and the target protein are placed in proximity by a chimeric construct that binds the ubiquitin pathway protein and the target protein. Accordingly the present invention provides a composition that results in the ubiquitination of a chosen target protein. The present invention also provides a library of compositions and the use thereof.
  • the present invention provides a composition useful for regulating protein activity.
  • the composition comprises a ubiquitin pathway protein binding moiety (preferably for an E3 ubiquitin ligase, alone or in complex with an E2 ubiquitin conjugating enzyme which is responsible for the transfer of ubiquitin to targeted proteins) according to a defined chemical structure and a protein targeting moiety which are linked together, preferably through a linker, wherein the ubiquitin pathway protein binding moiety recognizes an ubiquitin pathway protein and the targeting moiety recognizes a target protein and wherein the ubiquitin pathway protein binding moiety is coupled to the targeting moiety.
  • a ubiquitin pathway protein binding moiety preferably for an E3 ubiquitin ligase, alone or in complex with an E2 ubiquitin conjugating enzyme which is responsible for the transfer of ubiquitin to targeted proteins
  • a protein targeting moiety which are linked together, preferably through a linker
  • the present invention provides a library of compounds.
  • the library comprises more than one compound wherein each composition has a formula of A-B, wherein A is a ubiquitin pathway protein binding moiety (preferably, an E3 ubiquitin ligase moiety as otherwise disclosed herein) and B is a protein binding member of a molecular library, wherein A is coupled (preferably, through a linker moiety) to B, and wherein the ubiquitin pathway protein binding moiety recognizes an ubiquitin pathway protein, in particular, an E3 ubiquitin ligase.
  • A is a ubiquitin pathway protein binding moiety (preferably, an E3 ubiquitin ligase moiety as otherwise disclosed herein)
  • B is a protein binding member of a molecular library, wherein A is coupled (preferably, through a linker moiety) to B, and wherein the ubiquitin pathway protein binding moiety recognizes an ubiquitin pathway protein, in particular, an E3 ubiquitin ligase.
  • the library contains a specific ubiquitination recognition peptide of VHL for an E3 ubiquitin ligase (ubiquitin pathway protein binding moiety as otherwise disclosed herein) with random target protein binding elements (e.g., a chemical compound library).
  • E3 ubiquitin ligase ubiquitin pathway protein binding moiety as otherwise disclosed herein
  • target protein binding elements e.g., a chemical compound library.
  • the target protein is not determined in advance and the method can be used to determine the activity of a putative protein binding element and its pharmacological value as a target upon degradation by ubiquitin ligase.
  • the present invention provides a method of screening a library of the present invention to identify a compound containing a targeting moiety, which recognizes a target protein associated with a predetermined function of a cell.
  • the method comprises incubating a cell with a pool of entities from the library; monitoring the predetermined function of the cell; identifying a pool of entities that change the predetermined function of the cell; incubating the cell with a composition from the identified pool of entities; monitoring the predetermined function of the cell; and identifying a composition that changes the predetermined function of the cell, wherein the identified composition contains a targeting moiety which recognizes a target protein associated with the predetermined function.
  • the present invention provides a method of screening a library of the present invention to identify a composition containing a targeting moiety, which recognizes a target protein associated with a predetermined function of a cell.
  • the method comprises incubating a cell with each composition from the library; monitoring the predetermined function of the cell; identifying a composition that changes the predetermined function of the cell; wherein the identified composition contains a targeting moiety, which recognizes a target protein associated with the predetermined function.
  • the present invention provides a method of identifying a target protein associated with a predetermined function of a cell.
  • the method comprises incubating a cell with a composition from the library of the present invention; monitoring the predetermined function of the cell; identifying a composition that changes the predetermined function of the cell; identifying a target protein that binds to the identified composition, wherein the target protein is associated with the predetermined function of the cell.
  • the present invention provides a method of identifying a target protein associated with a predetermined function of a cell.
  • the method comprises incubating a cell with a pool of entities from the library of the present invention; monitoring the predetermined function of the cell; identifying a pool of entities that change the predetermined function of the cell; incubating the cell with a composition from the identified pool of entities; monitoring the predetermined function of the cell; identifying a composition that changes the predetermined function of the cell; and identifying a target protein that binds to the identified composition, wherein the target protein is associated with the predetermined function of the cell.
  • the present invention provides a method of ubiquitinating/degrading a target protein in a cell.
  • the method comprises administering a bifunctional composition comprising an ubiquitin pathway protein binding moiety and a targeting moiety, preferably linked through a linker moiety, as otherwise described herein, wherein the ubiquitin pathway protein binding moiety is coupled to the targeting moiety and wherein the ubiquitin pathway protein binding moiety recognizes a ubiquitin pathway protein (e.g., an ubiquitin ligase, preferably an E3 ubiquitin ligase) and the targeting moiety recognizes the target protein such that degradation of the target protein will occur when the target protein is placed in proximity to the ubiquitin ligase, thus resulting in degradation/inhibition of the effects of the target protein and the control of protein levels.
  • the control of protein levels afforded by the present invention provides treatment of a disease state or condition, which is modulated through the target protein by lowering the level of that protein in the cells of a patient
  • the present invention is directed to a method of treating a patient in need for a disease state or condition modulated through a protein where the degradation of that protein will produce a therapeutic effect in that patient, the method comprising administering to a patient in need an effective amount of a compound according to the present invention, optionally in combination with another bioactive agent.
  • the disease state or condition may be a disease caused by a microbial agent or other exogenous agent such as a virus, bacteria, fungus, protozoa or other microbe or may be a disease state, which is caused by overexpression of a protein, which leads to a disease state and/or condition.
  • the present invention is directed to a compound according to the structure:
  • L is a linker group and is a ubiquitin ligase binding moiety, wherein said linker group is optionally further linked to a group.
  • the present invention is directed to a compound which comprises a group according to the general structure:
  • an ubiquitin ligase binding moiety preferably a ligand, which binds an ubiquitin ligase, preferably an E3 ubiquitin ligase; is a chemical moiety (protein targeting moiety), which binds to a target protein or polypeptide, which is ubiquitinated by an ubiquitin ligase and is chemically linked directly to the group or through a linker moiety L, or is alternatively a group which also an ubiquitin ligase binding moiety, which may be the same or different than the group and is linked directly to the group directly or through the linker moiety; and L is a linker moiety which may be present or absent and which chemically (covalently) links to , Or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate or polymorph thereof.
  • the compound resembles a dimeric compound where both ends of the compound comprise an ubiquitin ligase binding moiety as otherwise described herein.
  • R 1′ is an optionally substituted C 1 -C 6 alkyl group, an optionally substituted —(CH 2 ) n OH, an optionally substituted —(CH 2 ) n SH, an optionally substituted (CH 2 ) n —O—(C 1 -C 6 )alkyl group, an optionally substituted (CH 2 ) n —WCOCW—(C 0 -C 6 )alkyl group containing an epoxide moiety WCOCW where each W is independently H or a C 1 -C 3 alkyl group, an optionally substituted —(CH 2 ) n COOH, an optionally substituted —(CH 2 ) n C(O)—(C 1 -C 6 alkyl), an optionally substituted —(CH 2 ) n NHC(O)—R 1 , an optionally substituted —(CH 2 ) n C(O)—NR 1 R 2 , an optionally substituted —(CH 2
  • V is O, S or NR 1 ;
  • each of R 1′ , R 2′ and R 3′ are the same as above and X is C ⁇ O, C ⁇ S, —S(O) group or a S(O) 2 group, more preferably a C ⁇ O group, and wherein any one or more of R 1′ , R 2′ and R 3′ are modified to bind a linker group to which is further covalently bonded to the group when is not , or when is , any one or more of R 1′ , R 2′ , R 3′ of each of and are modified to be covalently bonded to each other directly or through a linker group, or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof.
  • any one or more of R 1′ , R 2′ and R 3′ are modified to bind a linker group to which is further covalently bonded to the group when is not , or when is , any one or more of R 1′ , R 2′ , R 3′ of each of and are modified to be covalently bonded to each other directly or through a linker group, or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof.
  • R 1′ is preferably a hydroxyl group or a group which may be metabolized to a hydroxyl or carboxylic group, such that the compound represents a prodrug form of an active compound.
  • exemplary preferred R 1′ groups include, for example, —(CH 2 ) n OH, (CH 2 ) n —O—(C 1 -C 6 )alkyl group, —(CH 2 ) n COOH, —(CH 2 O) n H, an optionally substituted —(CH 2 ) n OC(O)—(C 1 -C 6 alkyl), or an optionally substituted —(CH 2 ) n C(O)—O—(C 1 -C 6 alkyl), wherein n is 0 or 1.
  • R 1′ is or contains a carboxylic acid group, a hydroxyl group or an amine group
  • the hydroxyl group, carboxylic acid group or amine may be further chemically modified to provide a covalent link to a linker group to which the group (including a group) is bonded.
  • X and X′ are preferably a C ⁇ O, C ⁇ S, —S(O) group or a S(O) 2 group, more preferably a C ⁇ O group.
  • R 2′ is preferably an optionally substituted —NR 1 -T-Aryl, an optionally substituted —NR 1 -T-Heteroaryl group or an optionally substituted —NR 1 -T-Heterocycle, where R 1 is H or CH 3 , preferably H and T is an optionally substituted —(CH 2 ) n — group, wherein each one of the methylene groups may be optionally substituted with one or two substituents, preferably selected from halogen, an amino acid sidechain as otherwise described herein or a C 1 -C 3 alkyl group, preferably one or two methyl groups, which may be optionally substituted; and n is 0 to 6, often 0, 1, 2 or 3, preferably 0 or 1.
  • T may also be a —(CH 2 O) n — group, a —(OCH 2 ) n — group, a —(CH 2 CH 2 O) n — group, a —(OCH 2 CH 2 ) n — group, all of which groups are optionally substituted.
  • Preferred Aryl groups for R 2′ include optionally substituted phenyl or naphthyl groups, preferably phenyl groups, wherein the phenyl group is optionally substituted with a linker group to which is attached a group (including a group), a halogen (preferably F or Cl), an amine, monoalkyl- or dialkyl amine (preferably, dimethylamine), F, Cl, OH, COOH, C 1 -C 6 alkyl, preferably CH 3 , CF 3 , OMe, OCF 3 , NO 2 , or CN group (each of which may be substituted in ortho-, meta- and/or para-positions of the phenyl ring, preferably para-), an optionally substituted phenyl group (the phenyl group itself is preferably substituted with a linker group attached to a group, including a group), and/or at least one of F, Cl, OH, COOH, CH 3 , CF 3 , OMe, O
  • S c is CHR SS , NR URE , or O;
  • R HET is H, CN, NO 2 , halo (preferably Cl or F), optionally substituted C 1 -C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g.
  • R a is H or a C 1 -C 6 alkyl group (preferably C 1 -C 3 alkyl);
  • R SS is H, CN, NO 2 , halo (preferably F or Cl), optionally substituted C 1 -C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted O—(C 1 -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted —C(O)(C 1 -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
  • R URE is H, a C 1 -C 6 alkyl (preferably H or C
  • Preferred heteroaryl groups for R 2′ include an optionally substituted quinoline (which may be attached to the pharmacophore or substituted on any carbon atom within the quinoline ring), an optionally substituted indole, an optionally substituted indolizine, an optionally substituted azaindolizine, an optionally substituted benzofuran, including an optionally substituted benzofuran, an optionally substituted isoxazole, an optionally substituted thiazole, an optionally substituted isothiazole, an optionally substituted thiophene, an optionally substituted pyridine (2-, 3, or 4-pyridine), an optionally substituted imidazole, an optionally substituted pyrrole, an optionally substituted diazole, an optionally substituted triazole, a tetrazole, an optionally substituted oximidazole, or a group according to the chemical structure:
  • S c is CHR SS , NR URE , or O;
  • R HET is H, CN, NO 2 , halo (preferably Cl or F), optionally substituted C 1 -C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g.
  • R a is H or a C 1 -C 6 alkyl group (preferably C 1 -C 3 alkyl);
  • R SS is H, CN, NO 2 , halo (preferably F or Cl), optionally substituted C 1 -C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted O—(C 1 -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted —C(O)(C 1 -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
  • R URE is H, a C 1 -C 6 alkyl (preferably H or C
  • CF 3 optionally substituted O(C 1 -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group —C ⁇ C—R a where R a is H or a C 1 -C 6 alkyl group (preferably C 1 -C 3 alkyl), each of which groups may be optionally substituted with a linker group to which is attached a group (including a group);
  • Preferred heterocycle groups for R 2′ include tetrahydrofuran, tetrahydrothiene, tetrahydroquinoline, piperidine, piperazine, pyrrolidine, morpholine, oxane or thiane, each of which groups may be optionally substituted, or a group according to the chemical structure:
  • R PRO is H, optionally substituted C 1 -C 6 alkyl or an optionally substituted aryl, heteroaryl or heterocyclic group
  • R PRO1 and R PRO2 are each independently H, an optionally subsituted C 1 -C 3 alkyl group or together form a keto group and
  • Each n is independently 0, 1, 2, 3, 4, 5, or 6 (often 0 or 1), each of which groups may be optionally substituted with a linker group to which is attached a group (including a group).
  • R 2′ substituents for use in the present invention also include specifically (and without limitation to the specific compound disclosed) the R 2′ substituents which are found in the identified compounds disclosed herein (which includes the specific compounds which are disclosed in the present specification, and the figures which are attached hereto). Each of these R 2′ substituents may be used in conjunction with any number of R 3′ substituents which are also disclosed herein.
  • R 3′ is preferably an optionally substituted -T-Aryl, an optionally substituted -T-Heteroaryl, an optionally substituted -T-Heterocycle, an optionally substituted —NR 1 -T-Aryl, an optionally substituted —NR 1 -T-Heteroaryl or an optionally substituted —NR 1 -T-Heterocycle, where R 1 is H or a C 1 -C 3 alkyl group, preferably H or CH 3 , T is an optionally substituted —(CH 2 ) n — group, wherein each one of the methylene groups may be optionally substituted with one or two substituents, preferably selected from halogen, a C 1 -C 3 alkyl group or the sidechain of an amino acid as otherwise described herein, preferably methyl, which may be optionally substituted; and n is 0 to 6, often 0, 1, 2, or 3 preferably 0 or 1.
  • T may also be a —(CH 2 O) n — group, a —(OCH 2 ) n — group, a —(CH 2 CH 2 O) n — group, a —(OCH 2 CH 2 ) n — group, each of which groups is optionally substituted.
  • Preferred aryl groups for R 3 include optionally substituted phenyl or naphthyl groups, preferably phenyl groups, wherein the phenyl or naphthyl group s optionally substituted with a linker group to which is attached a group (including a group) and/or a halogen (preferably F or Cl), an amine, monoalkyl- or dialkyl amine (preferably, dimethylamine), an amido group (preferably a —(CH 2 ) m —NR 1 C(O)R 2 group where m, R 1 and R 2 are the same as above), a halo (often F or Cl), OH, CH 3 , CF 3 , OMe, OCF 3 , NO 2 , CN or a S(O) 2 R S group (R S is a a C 1 -C 6 alkyl group, an optionally substituted aryl, heteroaryl or heterocycle group or a —(CH 2 ) m NR 1 R 2
  • said substituent phenyl group is an optionally substituted phenyl group (i.e., the substituent phenyl group itself is preferably substituted with at least one of F, Cl, OH, SH, COOH, CH 3 , CF 3 , OMe, OCF 3 , NO 2 , CN or a linker group to which is attached a group (including a group), wherein the substitution occurs in ortho-, meta- and/or para-positions of the phenyl ring, preferably para-), a naphthyl group, which may be optionally substituted including as described above, an optionally substituted heteroaryl (preferably an optionally substituted isoxazole including a methylsubstituted isoxazole, an optionally substituted oxazole including a methylsubstituted oxazole, an optionally substituted thiazole including a methyl substituted thiazole, an optionally substituted pyrrole including a methylsubstit
  • Preferred Heteroaryl groups for R 3 include an optionally substituted quinoline (which may be attached to the pharmacophore or substituted on any carbon atom within the quinoline ring), an optionally substituted indole (including dihydroindole), an optionally substituted indolizine, an optionally substituted azaindolizine (2, 3 or 4-azaindolizine) an optionally substituted benzimidazole, benzodiazole, benzoxofuran, an optionally substituted imidazole, an optionally substituted isoxazole, an optionally substituted oxazole (preferably methyl substituted), an optionally substituted diazole, an optionally substituted triazole, a tetrazole, an optionally substituted benzofuran, an optionally substituted thiophene, an optionally substituted thiazole (preferably methyl and/or thiol substituted), an optionally substituted isothiazole, an optionally substituted triazo
  • S c is CHR SS , NR URE , or O;
  • R HET is H, CN, NO 2 , halo (preferably Cl or F), optionally substituted C 1 -C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g.
  • R a is H or a C 1 -C 6 alkyl group (preferably C 1 -C 3 alkyl);
  • R SS is H, CN, NO 2 , halo (preferably F or Cl), optionally substituted C 1 -C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted O—(C 1 -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted —C(O)(C 1 -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
  • R URE is H, a C 1 -C 6 alkyl (preferably H or C
  • CF 3 optionally substituted O(C 1 -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group —C ⁇ C—R a where R a is H or a C 1 -C 6 alkyl group (preferably C 1 -C 3 alkyl).
  • R a is H or a C 1 -C 6 alkyl group (preferably C 1 -C 3 alkyl).
  • Each of said heteroaryl groups may be optionally substituted with a linker group to which is attached a group (including a group).
  • Preferred heterocycle groups for R 3′ include tetrahydroquinoline, piperidine, piperazine, pyrrolidine, morpholine, tetrahydrofuran, tetrahydrothiophene, oxane and thiane, each of which groups may be optionally substituted or a group according to the chemical structure:
  • R PRO is H, optionally substituted C 1 -C 6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C 1 -C 3 alkyl group, preferably methyl or a halo group, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine; R PRO1 and R PRO2 are each independently H, an optionally substituted C 1 -C 3 alkyl group or together form
  • R 3′ substituents for use in the present invention also include specifically (and without limitation to the specific compound disclosed) the R 3′ substituents which are found in the identified compounds disclosed herein (which includes the specific compounds which are disclosed in the present specification, and the figures which are attached hereto). Each of these R 3′ substituents may be used in conjunction with any number of R 2′ substituents which are also disclosed herein.
  • R 2′ is an optionally substituted —NR 1 —X R2′ -alkyl group, —NR 1 —X R2′ -Aryl group; an optionally substituted —NR 1 —X R2′ -HET, an optionally substituted —NR 1 —X R2′ -Aryl-HET or an optionally substituted —NR 1 —X R2′ -HET-Aryl,
  • R 1 is H or a C 1 -C 3 alkyl group (preferably H);
  • X R2′ is an optionally substituted —CH 2 ) n —, —CH 2 ) n —CH(X v ) ⁇ CH(X v )— (cis or trans), —CH 2 ) n —CH ⁇ CH—, —(CH 2 CH 2 O) n — or a C 3 -C 6 cycloalkyl group;
  • X v is H, a halo or a C 1 -C 3 alkyl group which is optionally substituted with one or two hydroxyl groups or up to three halogen groups;
  • Alkyl is an optionally substituted C1-C 10 alkyl (preferably a C 1 -C 6 alkyl) group (in certain preferred embodiments, the alkyl group is end-capped with a halo group, often a Cl or Br);
  • Aryl is an optionally substituted phenyl or naph
  • S c is CHR SS , NR URE , or O;
  • R HET is H, CN, NO 2 , halo (preferably Cl or F), optionally substituted C 1 -C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g.
  • R a is H or a C 1 -C 6 alkyl group (preferably C 1 -C 3 alkyl);
  • R SS is H, CN, NO 2 , halo (preferably F or Cl), optionally substituted C 1 -C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted O—(C 1 -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted —C(O)(C 1 -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
  • R URE is H, a C 1 -C 6 alkyl (preferably H or C
  • R a is H or a C 1 -C 6 alkyl group (preferably C 1 -C 3 alkyl);
  • R PRO is H, optionally substituted C 1 -C 6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (
  • R 3′ is an optionally substituted —(CH 2 ) n —(V) n′ —(CH 2 ) n —(V) n′ —R S3′ group, an optionally substituted —(CH 2 ) n —N(R 1′ )(C ⁇ O) m′ —(V) n′ —R S3′ group, an optionally substituted —X R3′ -alkyl group, an optionally substituted —X R3′ -Aryl group; an optionally substituted —X R3′ -HET group, an optionally substituted —X R3′ -Aryl-HET group or an optionally substituted —X R3′ -HET-Aryl group,
  • R S3′ is an optionally substituted alkyl group (C 1 -C 10 , preferably C 1 -C 6 alkyl), an optionally substituted Aryl group or a HET group;
  • R 1′ is H or a C 1 -C 3 alkyl group (preferably H);
  • V is O, S or NR 1′ ;
  • X R3′ is —(CH 2 ) n —, —(CH 2 CH 2 O) n —, —CH 2 ) n —CH(X v ) ⁇ CH(X v )— (cis or trans), —CH 2 ) n —CH ⁇ CH—, or a C 3 -C 6 cycloalkyl group, all optionally substituted;
  • X v is H, a halo or a C 1 -C 3 alkyl group which is optionally substituted with one or two hydroxyl groups or up to three halogen groups;
  • Alkyl is an optionally substituted C 1 -C 10 alkyl (preferably a C 1 -C 6 alkyl) group (in certain preferred embodiments, the alkyl group is end-capped with a halo group, often a Cl or Br);
  • Aryl is an optionally substituted phenyl or napthyl group (preferably, a phenyl group); and HET is an
  • S c is CHR SS , NR URE , or O;
  • R HET is H, CN, NO 2 , halo (preferably Cl or F), optionally substituted C 1 -C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g.
  • R a is H or a C 1 -C 6 alkyl group (preferably C 1 -C 3 alkyl);
  • R SS is H, CN, NO 2 , halo (preferably F or Cl), optionally substituted C 1 -C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted O—(C 1 -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted —C(O)(C 1 -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
  • R URE is H, a C 1 -C 6 alkyl (preferably H or C
  • R a is H or a C 1 -C 6 alkyl group (preferably C 1 -C 3 alkyl);
  • R PRO is H, optionally substituted C 1 -C 6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (
  • R 3′ is —(CH 2 ) n -Aryl, —(CH 2 CH 2 O) n -Aryl, —(CH 2 ) n -HET or —(CH 2 CH 2 O) n —HET;
  • Aryl is phenyl which is optionally substituted with one or two substitutents, wherein said substituent(s) is preferably selected from —(CH 2 ) n OH, C 1 -C 6 alkyl which itself is further optionally substituted with CN, halo (up to three halo groups), OH, —(CH 2 ) n O(C 1 -C 6 )alkyl, amine, mono- or di-(C 1 -C 6 alkyl) amine wherein the alkyl group on the amine is optionally substituted with 1 or 2 hydroxyl groups or up to three halo (preferably F, Cl) groups, or said Aryl group is substituted with —(CH 2 ) n OH, —(CH 2 ) n —O—(C 1 -C 6 )alkyl, —(CH 2 ) n —O—(CH 2 ) n —(C 1 -C 6 )alkyl, —(CH 2
  • S c is CHR SS , NR URE , or O;
  • R HET is H, CN, NO 2 , halo (preferably Cl or F), optionally substituted C 1 -C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g.
  • R a is H or a C 1 -C 6 alkyl group (preferably C 1 -C 3 alkyl);
  • R SS is H, CN, NO 2 , halo (preferably F or Cl), optionally substituted C 1 -C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted O—(C 1 -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted —C(O)(C 1 -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
  • R URE is H, a C 1 -C 6 alkyl (preferably H or C
  • R a is H or a C 1 -C 6 alkyl group (preferably C 1 -C 3 alkyl);
  • R PRO is H, optionally substituted C 1 -C 6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (
  • S c is CHR SS , NR URE , or O;
  • R HET is H, CN, NO 2 , halo (preferably Cl or F), optionally substituted C 1 -C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g.
  • R a is H or a C 1 -C 6 alkyl group (preferably C 1 -C 3 alkyl);
  • R SS is H, CN, NO 2 , halo (preferably F or Cl), optionally substituted C 1 -C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted O—(C 1 -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted —C(O)(C 1 -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
  • R URE is H, a C 1 -C 6 alkyl (preferably H or C
  • R CF 3 optionally substituted O(C 1 -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group —C ⁇ C—R a
  • R a is H or a C 1 -C 6 alkyl group (preferably C 1 -C 3 alkyl);
  • R PRO is H, optionally substituted C 1 -C 6 alkyl or an optionally substituted aryl, heteroaryl or heterocyclic group;
  • R PRO1 and R PRO2 are each independently H, an optionally substituted C 1 -C 3 alkyl group or together form a keto group,
  • Each m′ is independently 0 or 1
  • Each n is independently 0, 1, 2, 3, 4, 5, or 6 (preferably 0 or 1), Wherein each of said compounds, preferably on said Aryl or HET groups, is substituted with a linker group to which is attached a group (including a group).
  • preferred compounds include those according to the chemical structure:
  • R 1′ is OH or a group which is metabolized in a patient or subject to OH
  • R 2′ is a —NH—CH 2 -Aryl-HET (preferably, a phenyl linked directly to a methyl substituted thiazole)
  • R 3′ is a —CHR CR3′ —NH—C(O)—R 3P1 group or a —CHR CR3′ —R 3P2 group
  • R CR3′ is a C 1 -C 4 alkyl group, preferably methyl, isopropyl or tert-butyl
  • R 3P1 is C 1 -C 3 alkyl (preferably methyl), an optionally substituted oxetane group (preferably methyl substituted, a —(CH 2 ) n OCH 3 group where n is 1 or 2 (preferably 2), or a
  • the ethyl ether group is preferably meta-substituted on the phenyl moiety
  • a morpholino grop (linked to the carbonyl at the 2- or 3-position
  • Aryl is phenyl
  • HET is an optionally substituted thiazole or isothiazole
  • R HET is H or a halo group (preferably H), Or a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof, wherein each of said compounds is substituted with a linker group to which is attached a group (including a group)
  • groups for inclusion in compounds according to the present invention include:
  • X is Cl, F, C 1 -C 3 alkyl (preferably methyl) or heterocycle (preferably an optionally substituted heterocycle, including as defined above for R 3′ ;
  • R 1 and R 2 are each independently H, C 1 -C 3 alkyl (preferably methyl), or phenyl and each of said compounds is substituted with a linker group or a linker group to which is attached a group, or a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
  • Additional preferred groups for inclusion in compounds according to the present invention include:
  • n 0 or 1
  • R is a linker or a linker attached to a group
  • X is H, F, Cl, C 1 -C 3 alkyl (preferably methyl) or heterocycle (preferably an optionally substituted heterocycle, especially including a water soluble heterocycle such as a morpholino group, including as defined above for R 3′ ), or a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
  • Additional preferred groups for inclusion in compounds according to the present invention include for example:
  • n 0 or 1
  • R is a linker or a linker attached to a group a linker or a linker attached to a group linked to the group through an amide, ester, ether or carbamate group;
  • R 1 is C 1 -C 3 alkyl (optionally substituted with one or two hydroxyl groups) or —C(O)NR 3 R 4 where R 3 and R 4 are each independently H, C 1 -C 3 alkyl (preferably methyl), phenyl or heterocycle (including a heterocycle such as a morpholino, piperazine or other group which increases water solubility),
  • X is H, F, Cl, C 1 -C 3 alkyl (preferably methyl) or heterocycle (preferably an optionally substituted heterocycle, including a water soluble heterocycle, including as defined above for R 3′ ), or a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
  • Still further preferred groups for inclusion in compounds according to the present invention include for example:
  • n 0 or 1
  • R 1 is a linker or a linker attached to a group linked to the group through an amide, ester, ether, carbamate or heterocyclic group (preferably an optionally substituted heterocycle, including as defined above for R 3′ );
  • R is H, F, Cl, C 1 -C 3 alkyl (optionally substituted with one or two hydroxyl groups, preferably methyl), —O—C(O)NR 3 R 4 or —C(O)NR 3 R 4 wherein each of R 3 and R 4 is independently H, C 1 -C 3 alkyl (preferably methyl), phenyl or heterocycle, including a water soluble heterocycle, or A pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
  • n 0 or 1
  • R is a linker or a linker attached to a group linked to the group through an amide, ester, ether, carbamate or heterocyclic group; and
  • Each X is independently is H, F, Cl, C 1 -C 3 alkyl (optionally substituted with one or two hydroxyl groups, preferably methyl), heterocyle (preferably an optionally substituted heterocycle, including a water soluble heterocycle, and/or as defined above for R 3′ ), —O—C(O)NR 3 R 4 or —C(O)NR 3 R 4 wherein each of R 3 and R 4 is independently H, C 1 -C 3 alkyl (preferably methyl), or phenyl, or a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
  • n 0 or 1
  • R is a linker or a linker attached to a group linked to the group through an amide, ester, ether, carbamate or heterocyclic group;
  • R 1 is C 1 -C 3 alkyl, which is optionally substituted with one or two hydroxyl groups, —O—C(O)NR 3 R 4 or —C(O)NR 3 R 4 wherein each of R 3 and R 4 is independently H, C 1 -C 3 alkyl (preferably methyl), or phenyl; and
  • X is independently is H, F, Cl, C 1 -C 3 alkyl (optionally substituted with one or two hydroxyl groups, preferably methyl) or heterocycle (preferably an optionally substituted heterocycle, including a water soluble heterocycle, and/or as defined above for R 3′ ), or a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
  • n 0 or 1
  • R is a linker or a linker attached to a group linked to the group through an amide, ester, ether, carbamate or heterocyclic group;
  • R 1 is H, C 1 -C 3 alkyl, which is optionally substituted with one or two hydroxyl groups, —O—C(O)NR 3 R 4 or —C(O)NR 3 R 4 wherein each of R 3 and R 4 is independently H, C 1 -C 3 alkyl (preferably methyl), or phenyl; and
  • Each X is independently is H, F, Cl, C 1 -C 3 alkyl (optionally substituted with one or two hydroxyl groups, preferably methyl) or heterocycle (preferably an optionally substituted heterocycle, including a water soluble heterocycle and/or including as defined above for R 3′ ), or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof.
  • particularly preferred compounds according to the present invention may be identified according to any one or more of the chemical structures as set forth in FIG. 19 hereof:
  • any one or more of R 1PC , R 2PC , R 3PC , R 4PC , R 5PC , R 6PC , R 7PC , R 8PC , R 9PC , R 10 PC, R 11PC , R 12PC , R 13PC and R 14PC is a
  • L is a linker group and is a protein targeting moiety, or A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thererof.
  • no more than two of R 1PC , R 2PC , R 3PC , R 4PC , R 5PC , R 6PC , R 7PC , R 8PC , R 9PC , R 10 PC, R 11PC , R 12PC , R 13PC and R 14PC is a
  • R 1PC , R 2PC , R 3PC , R 4PC , R 5PC , R 6PC , R 7PC , R 8PC , R 9PC , R 10PC , R 11PC , R 12PC , R 13PC and R 14PC are independently H or a CH 3 group, often H.
  • R 7PC and R 10PC are each independently a
  • R 7PC is a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • R 10PC is a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • the compound has the chemical structure:
  • R 7PC is a
  • the compound has the chemical structure:
  • R 7PC , R 11PC R 12PC , R 13PC and R 14PC are each independently a
  • R 7PC , R 11PC , R 12PC , R 13PC and R 14PC is a
  • the compound has the chemical structure:
  • R 4PC , R 7PC , R 11PC R 12PC , R 13PC and R 14PC are each independently a
  • R 4PC , R 7PC or one of R 11PC , R 12PC , R 13PC and R 14PC is a
  • the compound has the chemical structure:
  • R 3PC , R 7PC R 11PC R 12PC , R 13PC and R 14PC are each independently a
  • R 3PC , R 7PC , R 11PC , R 12PC , R 13PC and R 14PC is a
  • the compound has the chemical structure:
  • R 7PC and R 10PC are each independently a
  • R 7PC and R 10PC are a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • one of R 7PC and R 10PC is a
  • the compound has the chemical structure:
  • R 7PC and R 10PC are each independently a
  • R 8PC is H or CH 3 , or A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • R 7PC and R 10PC is a
  • R 8PC is H, or A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • the compound has the chemical structure:
  • R 7PC and R 10PC are each independently a
  • R 8PC is H or CH 3 , or A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • R 7PC and R 10PC is a
  • the compound has the chemical structure:
  • R 7PC and R 10PC are each independently a
  • R 8PC is H or CH 3 or A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • one of R 7PC and R 10PC is a
  • R 8PC is H, or A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • the compound has the chemical structure:
  • R 7PC and R 10PC are each independently a
  • R 7PC and R 10PC are a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • one of R 7PC and R 10PC is a
  • the compound has the chemical structure:
  • R 7PC and R 9PC are each independently a
  • R 7PC and R 9PC are a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • one of R 7PC and R 9PC is a
  • the compound has the chemical structure:
  • R 7PC and R 14PC are each independently a
  • R 12PC and R 13PC is H or CH 3 , or A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • R 7PC and R 14PC is a
  • the compound has the chemical structure:
  • R 7PC and R 9PC are each independently a
  • R 7PC and R 9PC are a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • one of R 7PC and R 9PC is a
  • the compound has the chemical structure:
  • R 7PC and R 9PC are each independently a
  • R 7PC and R 9PC are a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • one of R 7PC and R 9PC is a
  • the compound has the chemical structure:
  • R 7PC and R 10PC are each independently a
  • R 9PC is H or CH 3 , or A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • R 7PC and R 10PC is a
  • R 9PC is H, or A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • the linker group may be any linker group as described hereinabove, below is preferably a polyethylene glycol group ranging in size from about 1 to about 12 ethylene glycol units, between 1 and about 10 ethylene glycol units, about 2 about 6 ethylene glycol units, between about 2 and 5 ethylene glycol units, between about 2 and 4 ethylene glycole units.
  • the linker group L is a group:
  • Z is a group which link to X; and X is a group linking Z to group (including a group).
  • Z is absent (a bond), —(CH 2 ) i —O, —(CH 2 ) i —S, —(CH 2 ) i —N—R, a (CH 2 ) i —X 1 Y 1 group wherein X 1 Y 1 forms an amide group, or a urethane group, ester or thioester group, or a
  • Each R is H, or a C 1 -C 3 alkyl, an alkanol group or a heterocycle (including a water soluble heterocycle, preferably, a morpholino, piperidine or piperazine group to promote water solubility of the linker group);
  • Each Y is independently a bond, O, S or N—R; and each i is independently 0 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5;
  • X is a
  • j is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5;
  • k is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5; preferably k is 1, 2, 3, 4, or 5;
  • m′ is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5;
  • n is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5;
  • X 1 is O
  • a bond is a bond (absent), a heterocycle including a water soluble heterocycle such as a piperazinyl or other group or a
  • X 2 is O, S, NR 4 , S(O), S(O) 2 , —S(O) 2 O, —OS(O) 2 , or OS(O) 2 O
  • X 3 is O, S, CHR 4 , NR 4
  • R 4 is H or a C 1 -C 3 alkyl group optionally substituted with one or two hydroxyl groups, or a pharmaceutically acceptable salt, enantiomer or stereoisomer thereof.
  • the linker group is a (poly)ethyleneglycol having between 1 and about 100 ethylene glycol units, between about 1 and about 50 ethylene glycol units, between 1 and about 25 ethylene glycol units, between about 1 and 10 ethylene glycol units, between 1 and about 8 ethylene glycol units and 1 and 6 ethylene glycol units, between 2 and 4 ethylene glycol units.
  • the linker is independently covalently bonded to the group and the group (including a group) preferably through an amide, ester, thioester, keto group, carbamate (urethane) or ether, each of which groups may be inserted anywhere on the group and group (including a group) to provide maximum binding of the group on the ubiquitin ligase and the group on the target protein to be degraded.
  • the group is a group
  • the target protein for degradation may be the ubiquitin ligase itself).
  • the linker may be linked to an optionally substituted alkyl, alkylene, alkene or alkyne group, an aryl group or a heterocyclic group on the and/or groups.
  • the group is a group, which binds to target proteins.
  • Targets of the group are numerous in kind and are selected from proteins that are expressed in a cell such that at least a portion of the sequences is found in the cell and may bind to a group.
  • the term “protein” includes oligopeptides and polypeptide sequences of sufficient length that they can bind to a group according to the present invention. Any protein in a eukaryotic system or a microbial system, including a virus, bacteria or fungus, as otherwise described herein, are targets for ubiquitination mediated by the compounds according to the present invention.
  • the target protein is a eukaryotic protein.
  • the protein binding moiety is a haloalkane (preferably a C1-C10 alkyl group which is substituted with at least one halo group, preferably a halo group at the distil end of the alkyl group (i.e., away from the linker or group), which may covalently bind to a dehalogenase enzyme in a patient or subject or in a diagnostic assay.
  • a haloalkane preferably a C1-C10 alkyl group which is substituted with at least one halo group, preferably a halo group at the distil end of the alkyl group (i.e., away from the linker or group)
  • groups according to the present invention include, for example, include any moiety which binds to a protein specifically (binds to a target protein) and includes the following non-limiting examples of small molecule target protein moieties: Hsp90 inhibitors, kinase inhibitors, MDM2 inhibitors, compounds targeting Human BET Bromodomain-containing proteins, HDAC inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR), among numerous others.
  • the compositions described below exemplify some of the members of these nine types of small molecule target protein binding moieties.
  • Such small molecule target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these compositions, as well as other small molecules that may target a protein of interest.
  • These binding moieties are linked to the ubiquitin ligase binding moiety preferably through a linker in order to present a target protein (to which the protein target moiety is bound) in proximity to the ubiquitin ligase for ubiquitination and degradation.
  • target proteins may include, for example, structural proteins, receptors, enzymes, cell surface proteins, proteins pertinent to the integrated function of a cell, including proteins involved in catalytic activity, aromatase activity, motor activity, helicase activity, metabolic processes (anabolism and catrabolism), antioxidant activity, proteolysis, biosynthesis, proteins with kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulator activity, signal transducer activity, structural molecule activity, binding activity (protein, lipid carbohydrate), receptor activity, cell motility, membrane fusion, cell communication, regulation of biological processes, development, cell differentiation, response to stimulus, behavioral proteins, cell adhesion proteins, proteins involved in cell death, proteins involved in transport (including protein transporter activity, nuclear transport
  • Proteins of interest can include proteins from eurkaryotes and prokaryotes including humans as targets for drug therapy, other animals, including domesticated animals, microbials for the determination of targets for antibiotics and other antimicrobials and plants, and even viruses, among numerous others.
  • the group is a haloalkyl group, wherein said alkyl group generally ranges in size from about 1 or 2 carbons to about 12 carbons in length, often about 2 to 10 carbons in length, often about 3 carbons to about 8 carbons in length, more often about 4 carbons to about 6 carbons in length.
  • the haloalkyl groups are generally linear alkyl groups (although branched-chain alkyl groups may also be used) and are end-capped with at least one halogen group, preferably a single halogen group, often a single chloride group.
  • Haloalkyl groups for use in the present invention are preferably represented by the chemical structure —(CH 2 ) v -Halo where v is any integer from 2 to about 12, often about 3 to about 8, more often about 4 to about 6.
  • Halo may be any halogen, but is preferably Cl or Br, more often Cl.
  • the group is a
  • This group binds selectively to estrogen receptors and is useful for treating diseases which are modulated through estrogen receptors, and in particular cancers, such as breast cancer, endometrial cancer, ovarian cancer and uterine cancer, among others.
  • the present invention may be used to treat a number of disease states and/or conditions, including any disease state and/or condition in which proteins are dysregulated and where a patient would benefit from the degradation of proteins.
  • the present invention relates to pharmaceutical compositions comprising an effective amount of a compound as set forth hereinabove, in combination with a pharmaceutically acceptable carrier, additive or excipient, and optionally an additional bioactive agent.
  • the present invention relates to a method for treating a disease state by degrading a protein or polypeptide through which a disease state or condition is modulated comprising administering to said patient or subject an effective amount of at least one compound as described hereinabove, optionally in combination with an additional bioactive agent.
  • the method according to the present invention may be used to treat a large number of disease states or conditions including cancer, by virtue of the administration of effective amounts of at least one compound described herein.
  • compound refers to any specific chemical compound disclosed herein and includes tautomers, regioisomers, geometric isomers, and where applicable, stereoisomers, including optical isomers (enantiomers) and other stereoisomers (diastereomers) thereof, as well as pharmaceutically acceptable salts and derivatives (including prodrug forms) thereof where applicable, in context.
  • compound generally refers to a single compound, but also may include other compounds such as stereoisomers, regioisomers and/or optical isomers (including racemic mixtures) as well as specific enantiomers or enantiomerically enriched mixtures of disclosed compounds.
  • the term also refers, in context to prodrug forms of compounds which have been modified to facilitate the administration and delivery of compounds to a site of activity. It is noted that in describing the present compounds, numerous substituents and variables associated with same, among others, are described. It is understood by those of ordinary skill that molecules which are described herein are stable compounds as generally described hereunder. When the bond is shown, both a double bond and single bond are represented within the context of the compound shown.
  • patient or “subject” is used throughout the specification to describe an animal, preferably a human or a domesticated animal, to whom treatment, including prophylactic treatment, with the compositions according to the present invention is provided.
  • patient refers to that specific animal, including a domesticated animal such as a dog or cat or a farm animal such as a horse, cow, sheep, etc.
  • a domesticated animal such as a dog or cat
  • a farm animal such as a horse, cow, sheep, etc.
  • patient refers to a human patient unless otherwise stated or implied from the context of the use of the term.
  • VCB E3 Ubiquitin Ligase “Hippel-Lindau E3 Ubiquitin Ligase” or “Ubiquitin Ligase” is used to describe a target enzyme(s) binding site of ubiquitin ligase moieties in the bifunctional (chimeric) compounds according to the present invention.
  • VCB E3 is a protein that in combination with an E2 ubiquitin-conjugating enzyme causes the attachment of ubiquitin to a lysine on a target protein; the E3 ubiquitin ligase targets specific protein substrates for degradation by the proteasome.
  • E3 ubiquitin ligase alone or in complex with an E2 ubiquitin conjugating enzyme is responsible for the transfer of ubiquitin to targeted proteins.
  • the ubiquitin ligase is involved in polyubiquitination such that a second ubiquitin is attached to the first, a third is attached to the second, and so forth.
  • Polyubiquitination marks proteins for degradation by the proteasome.
  • Mono-ubiquitinated proteins are not targeted to the proteasome for degradation, but may instead be altered in their cellular location or function, for example, via binding other proteins that have domains capable of binding ubiquitin. Further complicating matters, different lysines on ubiquitin can be targeted by an E3 to make chains. The most common lysine is Lys48 on the ubiquitin chain. This is the lysine used to make polyubiquitin, which is recognized by the proteasome.
  • protein target moiety or PTM is used to describe a small molecule which binds to a target protein or other protein or polypeptide of interest and places/presents that protein or polypeptide in proximity to an ubiquitin ligase such that degradation of the protein or polypeptide by ubiquitin ligase may occur.
  • small molecule target protein binding moieties include Hsp90 inhibitors, kinase inhibitors, MDM2 inhibitors, compounds targeting Human BET Bromodomain-containing proteins, HDAC inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR), among numerous others.
  • AHR aryl hydrocarbon receptor
  • Protein target moieties according to the present invention include, for example, Haloalkane halogenase inhibitors, Hsp90 inhibitors, kinase inhibitors, MDM2 inhibitors, compounds targeting Human BET Bromodomain-containing proteins, HDAC inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR).
  • the compositions described below exemplify some of the members of these types of small molecule target protein binding moieties.
  • Such small molecule target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these compositions, as well as other small molecules that may target a protein of interest. References which are cited hereinbelow are incorporated by reference herein in their entirety.
  • HSP90 Heat Shock Protein 90
  • HSP90 inhibitors as used herein include, but are not limited to: 1.
  • HSP90 inhibitors modified (modified) identified in Wright, et al., Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 Isoforms, Chem Biol. 2004 June; 11(6):775-85, including the HSP90 inhibitor PU3 having the structure:
  • the HSP90 inhibitor Geldanamycin ((4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1](derivatized) or any of its derivatives (e.g. 17-alkylamino-17-desmethoxygeldanamycin (“17-AAG”) or 17-(2-dimethylaminoethyl)amino-17-desmethoxygeldanamycin (“17-DMAG”)) (derivatized, where a linker group L or a
  • Kinase inhibitors as used herein include, but are not limited to:
  • R is a linker group L or a
  • the kinase inhibitor U09-CX-5279 (Derivatized) 7.
  • kinase inhibitors identified in Lountos, et al., “Structural Characterization of Inhibitor Complexes with Checkpoint Kinase 2 (Chk2), a Drug Target for Cancer Therapy”, J. STRUCT. BIOL. vol: 176, page: 292 (2011), including the kinase inhibitor YCF having the structure:
  • the kinase inhibitor Afatinib derivatized (N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide) (Derivatized where a linker group L or a
  • the kinase inhibitor Fostamatinib (derivatized) ([6-( ⁇ 5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl ⁇ amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-pyrido[3,2-b]-1,4-oxazin-4-yl]methyl disodium phosphate hexahydrate) (Derivatized where a linker group L or a
  • the kinase inhibitor Gefitinib (derivatized) (N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine) (Derivatized where a linker group L or a
  • the kinase inhibitor Vandetanib (derivatized) (N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine) (derivatized where a linker group L or a
  • the kinase inhibitor Vemurafenib (derivatized) (propane-1-sulfonic acid ⁇ 3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl ⁇ -amide) (Derivatized where a linker group L or a
  • the kinase inhibitor Gleevec (derivatized):
  • the kinase inhibitor Pazopanib (derivatized) (VEGFR3 inhibitor):
  • the inhibitor (derivatized) of BRAF (BRAF V600E )/MEK is attached preferably at R. 33.
  • MDM2 inhibitors as used herein include, but are not limited to: 1.
  • linker group is attached a linker group L or a
  • group is attached group is attached via a hydroxy group
  • Compounds targeting Human BET Bromodomain-containing proteins include, but are not limited to the compounds associated with the targets as described below, where “R” designates a site for linker group L or a
  • HDAC Inhibitors include, but are not limited to:
  • Human Lysine Methyltransferase inhibitors include, but are not limited to:
  • Angiogenesis inhibitors include, but are not limited to: 1. GA-1 (derivatized) and derivatives and analogs thereof, having the structure(s) and binding to linkers as described in Sakamoto, et al., Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation, Mol Cell Proteomics 2003 December; 2(12):1350-8; 2. Estradiol (derivatized), which may be bound to a linker group L or a
  • Estradiol, testosterone (derivatized) and related derivatives including but not limited to DHT and derivatives and analogs thereof, having the structure(s) and binding to a linker group L or a
  • Immunosuppressive compounds include, but are not limited to: 1. AP21998 (derivatized), having the structure(s) and binding to a linker group L or a
  • Glucocorticoids e.g., hydrocortisone, prednisone, prednisolone, and methylprednisolone
  • Methotrexate (Derivatized where a linker group or a
  • Ciclosporin (Derivatized where a linker group or a
  • AHR aryl hydrocarbon receptor
  • Thyroid Hormone Receptor Ligand (Derivatized)
  • target protein is used to describe a protein or polypeptide, which is a target for binding to a compound according to the present invention and degradation by ubiquitin ligase hereunder.
  • target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these compositions, as well as other small molecules that may target a protein of interest. These binding moieties are linked to groups through linker groups L.
  • Target proteins which may be bound to the protein target moiety and degraded by the ligase to which the ubiquitin ligase binding moiety is bound include structural proteins, receptors, enzymes, cell surface proteins, proteins pertinent to the integrated function of a cell, including proteins involved in catalytic activity, aromatase activity, motor activity, helicase activity, metabolic processes (anabolism and catrabolism), antioxidant activity, proteolysis, biosynthesis, proteins with kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulator activity, signal transducer activity, structural molecule activity, binding activity (protein, lipid carbohydrate), receptor activity, cell motility, membrane fusion, cell communication, regulation of biological processes, development, cell differentiation, response to stimulus, behavioral proteins, cell adhesion proteins, proteins involved in cell death, proteins involved in transport (including protein transporter activity, nuclear transport, ion transporter activity, channel transporter activity, carrier activity,
  • Proteins of interest can include proteins from eurkaryotes and prokaryotes, including microbes, viruses, fungi and parasites, including humans, microbes, viruses, fungi and parasites, among numerous others, as targets for drug therapy, other animals, including domesticated animals, microbials for the determination of targets for antibiotics and other antimicrobials and plants, and even viruses, among numerous others
  • a number of drug targets for human therapeutics represent protein targets to which protein target moiety may be bound and incorporated into compounds according to the present invention.
  • proteins which may be used to restore function in numerous polygenic diseases including for example B7.1 and B7, TINFRlm, TNFR2, NADPH oxidase, BclIBax and other partners in the apotosis pathway, C5a receptor, HMG-CoA reductase, PDE V phosphodiesterase type, PDE IV phosphodiesterase type 4, PDE I, PDEII, PDEIII, squalene cyclase inhibitor, CXCR1, CXCR2, nitric oxide (NO) synthase, cyclo-oxygenase 1, cyclo-oxygenase 2, 5HT receptors, dopamine receptors, G Proteins, i.e., Gq, histamine receptors, 5-lipoxygenase, tryptase serine protease, thy
  • Additional protein targets include, for example, ecdysone 20-monooxygenase, ion channel of the GABA gated chloride channel, acetylcholinesterase, voltage-sensitive sodium channel protein, calcium release channel, and chloride channels. Still further target proteins include Acetyl-CoA carboxylase, adenylosuccinate synthetase, protoporphyrinogen oxidase, and enolpyruvylshikimate-phosphate synthase.
  • Haloalkane dehalogenase enzymes are another target of specific compounds according to the present invention.
  • Compounds according to the present invention which contain chloroalkane peptide binding moieties may be used to inhibit and/or degrade haloalkane dehalogenase enzymes which are used in fusion proteins or related dioagnostic proteins as described in PCT/US 2012/063401 filed Dec. 6, 2011 and published as WO 2012/078559 on Jun. 14, 2012, the contents of which is incorporated by reference herein.
  • disease state or condition is used to describe any disease state or condition wherein protein dysregulation (i.e., the amount of protein expressed in a patient is elevated) occurs and where degradation of one or more proteins in a patient may provide beneficial therapy or relief of symptoms to a patient in need thereof. In certain instances, the disease state or condition may be cured.
  • Disease states of conditions which may be treated using compounds according to the present invention include, for example, asthma, autoimmune diseases such as multiple sclerosis, various cancers, ciliopathies, cleft palate, diabetes, heart disease, hypertension, inflammatory bowel disease, mental retardation, mood disorder, obesity, refractive error, infertility, Angelman syndrome, Canavan disease, Coeliac disease, Charcot-Marie-Tooth disease, Cystic fibrosis, Duchenne muscular dystrophy, Haemochromatosis, Haemophilia, Klinefelter's syndrome, Neurofibromatosis, Phenylketonuria, Polycystic kidney disease, (PKD1) or 4 (PKD2) Prader-Willi syndrome, Sickle-cell disease, Tay-Sachs disease, Turner syndrome.
  • autoimmune diseases such as multiple sclerosis, various cancers, ciliopathies, cleft palate, diabetes, heart disease, hypertension, inflammatory bowel disease, mental retardation, mood disorder, obesity, refractive error
  • Further disease states or conditions which may be treated by compounds according to the present invention include Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's disease), Anorexia nervosa, Anxiety disorder, Atherosclerosis, Attention deficit hyperactivity disorder, Autism, Bipolar disorder, Chronic fatigue syndrome, Chronic obstructive pulmonary disease, Crohn's disease, Coronary heart disease, Dementia, Depression, Diabetes mellitus type 1, Diabetes mellitus type 2, Epilepsy, Guillain-Barre syndrome, Irritable bowel syndrome, Lupus, Metabolic syndrome, Multiple sclerosis, Myocardial infarction, Obesity, Obsessive-compulsive disorder, Panic disorder, Parkinson's disease, Psoriasis, Rheumatoid arthritis, Sarcoidosis, Schizophrenia, Stroke, Thromboangiitis obliterans, Tourette syndrome, Vasculitis.
  • Alzheimer's disease Amyotrophic lateral sclerosis
  • Still additional disease states or conditions which can be treated by compounds according to the present invention include aceruloplasminemia, Achondrogenesis type II, achondroplasia, Acrocephaly, Gaucher disease type 2, acute intermittent porphyria , Canavan disease, Adenomatous Polyposis Coli , ALA dehydratase deficiency, adenylosuccinate lyase deficiency, Adrenogenital syndrome, Adrenoleukodystrophy, ALA-D porphyria , ALA dehydratase deficiency, Alkaptonuria, Alexander disease, Alkaptonuric ochronosis, alpha 1-antitrypsin deficiency, alpha-1 proteinase inhibitor, emphysema, amyotrophic lateral sclerosis Alstrom syndrome, Alexander disease, Amelogenesis imperfecta, ALA dehydratase deficiency, Anderson-Fabry disease, androgen insensitivity syndrome, Anemia Angiokeratoma Corpori
  • neoplasia or “cancer” is used throughout the specification to refer to the pathological process that results in the formation and growth of a cancerous or malignant neoplasm, i.e., abnormal tissue that grows by cellular proliferation, often more rapidly than normal and continues to grow after the stimuli that initiated the new growth cease.
  • malignant neoplasms show partial or complete lack of structural organization and functional coordination with the normal tissue and most invade surrounding tissues, metastasize to several sites, and are likely to recur after attempted removal and to cause the death of the patient unless adequately treated.
  • neoplasia is used to describe all cancerous disease states and embraces or encompasses the pathological process associated with malignant hematogenous, ascitic and solid tumors.
  • Exemplary cancers which may be treated by the present compounds either alone or in combination with at least one additional anti-cancer agent include squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the bladder, bowel, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias; benign and malignant lymphomas, particularly Burkitt's lymphoma and Non-Hodgkin's lymphoma; benign and malignant melanomas; myeloproliferative diseases; sarcomas, including Ewing's sarcoma, hemangiosarcoma, Kaposi's sar
  • Additional cancers which may be treated using compounds according to the present invention include, for example, T-lineage Acute lymphoblastic Leukemia (T-ALL), T-lineage lymphoblastic Lymphoma (T-LL), Peripheral T-cell lymphoma, Adult T-cell Leukemia, Pre-B ALL, Pre-B Lymphomas, Large B-cell Lymphoma, Burkitts Lymphoma, B-cell ALL, Philadelphia chromosome positive ALL and Philadelphia chromosome positive CML,
  • T-ALL T-lineage Acute lymphoblastic Leukemia
  • T-LL T-lineage lymphoblastic Lymphoma
  • Peripheral T-cell lymphoma Peripheral T-cell lymphoma
  • Adult T-cell Leukemia Pre-B ALL, Pre-B Lymphomas
  • Large B-cell Lymphoma Burkitts Lymphoma
  • B-cell ALL Philadelphia chromosome positive ALL
  • Philadelphia chromosome positive CML Philadelphia chromosome positive
  • Preferred bioactive agents for use herein include those agents which have pharmacological activity similar to that for which the present compounds are used or administered and include for example, anti-cancer agents, antiviral agents, especially including anti-HIV agents and anti-HCV agents, antimicrobial agents, antifungal agents, etc.
  • additional anti-cancer agent is used to describe an anti-cancer agent, which may be combined with compounds according to the present invention to treat cancer.
  • agents include, for example, everolimus, trabectedin, abraxane, TLK 286, AV-299, DN-101, pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD 6244 (ARRY-142886), AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, a FLT-3 inhibitor, a VEGFR inhibitor, an EGFR TK inhibitor, an aurora kinase inhibitor, a PIK-1 modulator, a Bcl-2 inhibitor, an HDAC inhbitor, a c-MET inhibitor, a PARP inhibitor, a Cdk inhibitor,
  • anti-HIV agent or “additional anti-HIV agent” includes, for example, nucleoside reverse transcriptase inhibitors (NRTI), other non-nucloeoside reverse transcriptase inhibitors (i.e., those which are not representative of the present invention), protease inhibitors, fusion inhibitors, among others, exemplary compounds of which may include, for example, 3TC (Lamivudine), AZT (Zidovudine), ( ⁇ )-FTC, ddI (Didanosine), ddC (zalcitabine), abacavir (ABC), tenofovir (PMPA), D-D4FC (Reverset), D4T (Stavudine), Racivir, L-FddC, L-FD4C, NVP (Nevirapine), DLV (Delavirdine), EFV (Efavirenz), SQVM (Saquinavir mesylate), RTV (Ritona
  • NNRTI's i.e., other than the NNRTI's according to the present invention
  • NNRTI's may be selected from the group consisting of nevirapine (BI-R6-587), delavirdine (U-90152S/T), efavirenz (DMP-266), UC-781 (N-[4-chloro-3-(3-methyl-2-butenyloxy)phenyl]-2methyl3-furancarbothiamide), etravirine (TMC125), Trovirdine (Ly300046.HCl), MKC-442 (emivirine, coactinon), HI-236, HI-240, HI-280, HI-281, rilpivirine (TMC-278), MSC-127, HBY 097, DMP266, Baicalin (TJN-151) ADAM-II (Methyl 3′,3′-dichloro
  • pharmaceutically acceptable salt is used throughout the specification to describe, where applicable, a salt form of one or more of the compounds described herein which are presented to increase the solubility of the compound in the gastic juices of the patient's gastrointestinal tract in order to promote dissolution and the bioavailability of the compounds.
  • Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids, where applicable. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium, magnesium and ammonium salts, among numerous other acids and bases well known in the pharmaceutical art. Sodium and potassium salts are particularly preferred as neutralization salts of the phosphates according to the present invention.
  • pharmaceutically acceptable derivative is used throughout the specification to describe any pharmaceutically acceptable prodrug form (such as an ester, amide other prodrug group), which, upon administration to a patient, provides directly or indirectly the present compound or an active metabolite of the present compound.
  • hydrocarbyl shall mean a compound which contains carbon and hydrogen and which may be fully saturated, partially unsaturated or aromatic and includes aryl groups, alkyl groups, alkenyl groups and alkynyl groups.
  • alkyl shall mean within its context a linear, branch-chained or cyclic fully saturated hydrocarbon radical or alkyl group, preferably a C 1 -C 10 , more preferably a C 1 -C 6 , alternatively a C 1 -C 3 alkyl group, which may be optionally substituted.
  • alkyl groups are methyl, ethyl, n-butyl, sec-butyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, isopropyl, 2-methylpropyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopentylethyl, cyclohexylethyl and cyclohexyl, among others.
  • compounds according to the present invention which may be used to covalently bind to dehalogenase enzymes.
  • alkenyl refers to linear, branch-chained or cyclic C 2 -C 10 (preferably C 2 -C 6 ) hydrocarbon radicals containing at least one C ⁇ C bond.
  • alkynyl refers to linear, branch-chained or cyclic C 2 -C 10 (preferably C 2 -C 6 ) hydrocarbon radicals containing at least one C ⁇ C bond.
  • alkylene when used, refers to a —(CH 2 ) n — group (n is an integer generally from 0-6), which may be optionally substituted.
  • the alkylene group preferably is substituted on one or more of the methylene groups with a C 1 -C 6 alkyl group (including a cyclopropyl group or a t-butyl group), more preferably a methyl group, but may also be substituted with one or more halo groups, preferably from 1 to 3 halo groups or one or two hydroxyl groups, O—(C 1 -C 6 alkyl) groups or amino acid sidechains as otherwise disclosed herein.
  • an alkylene group may be substituted with a urethane or alkoxy group (or other group) which is further substituted with a polyethylene glycol chain (of from 1 to 10, preferably 1 to 6, often 1 to 4 ethylene glycol units) to which is substituted (preferably, but not exclusively on the distal end of the polyethylene glycol chain) an alkyl chain substituted with a single halogen group, preferably a chlorine group.
  • a polyethylene glycol chain of from 1 to 10, preferably 1 to 6, often 1 to 4 ethylene glycol units
  • the alkylene (often, a methylene) group may be substituted with an amino acid sidechain group such as a sidechain group of a natural or unnatural amino acid, for example, alanine, ⁇ -alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamic acid, glutamine, glycine, phenylalanine, histidine, isoleucine, lysine, leucine, methionine, proline, serine, threonine, valine, tryptophan or tyrosine.
  • an amino acid sidechain group such as a sidechain group of a natural or unnatural amino acid, for example, alanine, ⁇ -alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamic acid, glutamine, glycine, phenylalanine, histidine, isoleucine, lysine, leucine, methion
  • unsubstituted shall mean substituted only with hydrogen atoms.
  • a range of carbon atoms which includes C 0 means that carbon is absent and is replaced with H.
  • a range of carbon atoms which is C 0 -C 6 includes carbons atoms of 1, 2, 3, 4, 5 and 6 and for C 0 , H stands in place of carbon.
  • substituted or “optionally substituted” shall mean independently (i.e., where more than substituent occurs, each substituent is independent of another substituent) one or more substituents (independently up to five substitutents, preferably up to three substituents, often 1 or 2 substituents on a moiety in a compound according to the present invention and may include substituents which themselves may be further substituted) at a carbon (or nitrogen) position anywhere on a molecule within context, and includes as substituents hydroxyl, thiol, carboxyl, cyano (C ⁇ N), nitro (NO 2 ), halogen (preferably, 1, 2 or 3 halogens, especially on an alkyl, especially a methyl group such as a trifluoromethyl), an alkyl group (preferably, C 1 -C 10 , more preferably, C 1 -C 6 ), aryl (especially phenyl and substituted phenyl for example benzyl or benzoyl), alkoxy group (
  • Substituents according to the present invention may include, for example —SiR 1 R 2 R 3 groups where each of R 1 and R 2 is as otherwise described herein and R 3 is H or a C 1 -C 6 alkyl group, preferably R 1 , R 2 , R 3 in this context is a C 1 -C 3 alkyl group (including an isopropyl or t-butyl group).
  • Each of the above-described groups may be linked directly to the substituted moiety or alternatively, the substituent may be linked to the substituted moiety (preferably in the case of an aryl or heteraryl moiety) through an optionally substituted —(CH 2 ) m — or alternatively an optionally substituted —(OCH 2 ) m —, —(OCH 2 CH 2 ) m — or —(CH 2 CH 2 O) m — group, which may be substituted with any one or more of the above-described substituents.
  • Alkylene groups —(CH 2 ) m — or —(CH 2 ) n — groups or other chains such as ethylene glycol chains, as identified above, may be substituted anywhere on the chain.
  • Preferred substitutents on alkylene groups include halogen or C 1 -C 6 (preferably C 1 -C 3 ) alkyl groups, which may be optionally substituted with one or two hydroxyl groups, one or two ether groups (0-C 1 -C 6 groups), up to three halo groups (preferably F), or a sideshain of an amino acid as otherwise described herein and optionally substituted amide (preferably carboxamide substituted as described above) or urethane groups (often with one or two C 0 -C 6 alkyl substitutents, which group(s) may be further substituted).
  • the alkylene group (often a single methylene group) is substituted with one or two optionally substituted C 1 -C 6 alkyl groups, preferably C 1 -C 4 alkyl group, most often methyl or O-methyl groups or a sidechain of an amino acid as otherwise described herein.
  • a moiety in a molecule may be optionally substituted with up to five substituents, preferably up to three substituents. Most often, in the present invention moieties which are substituted are substituted with one or two substituents.
  • substituted (each substituent being independent of any other substituent) shall also mean within its context of use C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, amido, carboxamido, sulfone, including sulfonamide, keto, carboxy, C 1 -C 6 ester (oxyester or carbonylester), C 1 -C 6 keto, urethane —O—C(O)—NR 1 R 2 or —N(R 1 )—C(O)—O—R 1 , nitro, cyano and amine (especially including a C 1 -C 6 alkylene-NR 1 R 2 , a mono- or di-C 1 -C 6 alkyl substituted amines which may be optionally substituted with one or two hydroxyl groups).
  • substituents will include for example, —NH—, —NHC(O)—, —O—, ⁇ O, —(CH 2 ) m — (here, m and n are in context, 1, 2, 3, 4, 5 or 6), —S—, —S(O)—, SO 2 — or —NH—C(O)—NH—, —(CH 2 ) n OH, —(CH 2 ) n SH, —(CH 2 ) n COOH, C 1 -C 6 alkyl, —(CH 2 ) n O—(C 1 -C 6 alkyl), —(CH 2 ) n C(O)—(C 1 -C 6 alkyl), —(CH 2 ) n OC(O)—(C 1 -C 6 alkyl), —(CH 2 ) n C(O)—(C 1 -C 6 alkyl), —(CH 2 ) n C(O)—(C 1
  • R 1 and R 2 are each, within context, H or a C 1 -C 6 alkyl group (which may be optionally substituted with one or two hydroxyl groups or up to three halogen groups, preferably fluorine).
  • substituted shall also mean, within the chemical context of the compound defined and substituent used, an optionally substituted aryl or heteroaryl group or an optionally substituted heterocyclic group as otherwise described herein.
  • Alkylene groups may also be substituted as otherwise disclosed herein, preferably with optionally substituted C 1 -C 6 alkyl groups (methyl, ethyl or hydroxymethyl or hydroxyethyl is preferred, thus providing a chiral center), a sidechain of an amino acid group as otherwise described herein, an amido group as described hereinabove, or a urethane group O—C(O)—NR 1 R 2 group where R 1 and R 2 are as otherwise described herein, although numerous other groups may also be used as substituents.
  • Various optionally substituted moieties may be substituted with 3 or more substituents, preferably no more than 3 substituents and preferably with 1 or 2 substituents.
  • aryl or “aromatic”, in context, refers to a substituted (as otherwise described herein) or unsubstituted monovalent aromatic radical having a single ring (e.g., benzene, phenyl, benzyl) or condensed rings (e.g., naphthyl, anthracenyl, phenanthrenyl, etc.) and can be bound to the compound according to the present invention at any available stable position on the ring(s) or as otherwise indicated in the chemical structure presented.
  • aryl groups in context, may include heterocyclic aromatic ring systems “heteroaryl” groups having one or more nitrogen, oxygen, or sulfur atoms in the ring (moncyclic) such as imidazole, furyl, pyrrole, furanyl, thiene, thiazole, pyridine, pyrimidine, pyrazine, triazole, oxazole or fused ring systems such as indole, quinoline, indolizine, azaindolizine, benzofurazan, etc., among others, which may be optionally substituted as described above.
  • heteroaryl having one or more nitrogen, oxygen, or sulfur atoms in the ring (moncyclic) such as imidazole, furyl, pyrrole, furanyl, thiene, thiazole, pyridine, pyrimidine, pyrazine, triazole, oxazole or fused ring systems such as indole, quinoline, indolizine,
  • heteroaryl groups include nitrogen-containing heteroaryl groups such as pyrrole, pyridine, pyridone, pyridazine, pyrimidine, pyrazine, pyrazole, imidazole, triazole, triazine, tetrazole, indole, isoindole, indolizine, azaindolizine, purine, indazole, quinoline, dihydroquinoline, tetrahydroquinoline, isoquinoline, dihydroisoquinoline, tetrahydroisoquinoline, quinolizine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, imidazopyridine, imidazotriazine, pyrazinopyridazine, acridine, phenanthridine, carbazole, carbazoline, perimidine, phenanthroline,
  • heterocycle refers to a cyclic group which contains at least one heteroatom, i.e., O, N or S, and may be aromatic (heteroaryl) or non-aromatic.
  • heteroaryl moieties are subsumed under the definition of heterocycle, depending on the context of its use. Exemplary heteroaryl groups are described hereinabove.
  • non-aromatic heterocyclic groups for use in the present invention include, for example, pyrrolidinyl, pyrrolinyl, piperidinyl, piperazinyl, N-methylpiperazinyl, pyrazolidinyl, imidazolidinyl, morpholinyl, tetrahydropyranyl, azetidinyl, oxetanyl, oxathiolanyl, pyridone, 2-pyrrolidone, ethyleneurea, 1,3-dioxolane, 1,3-dioxane, 1,4-dioxane, phthalimide and succinimide, among others, as described herein.
  • treat refers to any action providing a benefit to a patient for which the present compounds may be administered, including the treatment of any disease state or condition which is modulated through the protein to which the present compounds bind.
  • Disease states or conditions, including cancer, which may be treated using compounds according to the present invention are set forth hereinabove.
  • co-administration shall mean that at least two compounds or compositions are administered to the patient at the same time, such that effective amounts or concentrations of each of the two or more compounds may be found in the patient at a given point in time.
  • compounds according to the present invention may be co-administered to a patient at the same time, the term embraces both administration of two or more agents at the same time or at different times, provided that effective concentrations of all coadministered compounds or compositions are found in the subject at a given time.
  • one or more of the present compounds described above are coadministered in combination with at least one additional bioactive agent, especially including an anticancer agent.
  • the co-administration of compounds results in synergistic therapeutic, including anticancer therapy.
  • compositions comprising combinations of an effective amount of at least one bifunctional compound according to the present invention, and one or more of the compounds otherwise described herein, all in effective amounts, in combination with a pharmaceutically effective amount of a carrier, additive or excipient, represents a further aspect of the present invention.
  • the present invention includes, where applicable, the compositions comprising the pharmaceutically acceptable salts, in particular, acid or base addition salts of compounds of the present invention.
  • the acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds useful in this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1′-methylene-bis-(2-hydroxy-3 naphthoate
  • Pharmaceutically acceptable base addition salts may also be used to produce pharmaceutically acceptable salt forms of the compounds or derivatives according to the present invention.
  • the chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of the present compounds that are acidic in nature are those that form non-toxic base salts with such compounds.
  • Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (eg., potassium and sodium) and alkaline earth metal cations (eg, calcium, zinc and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines, among others.
  • the compounds of the present invention may, in accordance with the invention, be administered in single or divided doses by the oral, parenteral or topical routes.
  • Administration of the active compound may range from continuous (intravenous drip) to several oral administrations per day (for example, Q.I.D.) and may include oral, topical, parenteral, intramuscular, intravenous, sub-cutaneous, transdermal (which may include a penetration enhancement agent), buccal, sublingual and suppository administration, among other routes of administration.
  • Enteric coated oral tablets may also be used to enhance bioavailability of the compounds from an oral route of administration. The most effective dosage form will depend upon the pharmacokinetics of the particular agent chosen as well as the severity of disease in the patient.
  • compositions comprising an effective amount of compound according to the present invention, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.
  • Compounds according to the present invention may be administered in immediate release, intermediate release or sustained or controlled release forms. Sustained or controlled release forms are preferably administered orally, but also in suppository and transdermal or other topical forms. Intramuscular injections in liposomal form may also be used to control or sustain the release of compound at an injection site.
  • compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers and may also be administered in controlled-release formulations.
  • Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as prolamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
  • compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • the compositions are administered orally, intraperitoneally or intravenously.
  • Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1, 3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides.
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of inj ectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • oils such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as Ph. Helv or similar alcohol.
  • compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
  • carriers which are commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried corn starch.
  • aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • compositions of this invention may be administered in the form of suppositories for rectal administration.
  • suppositories for rectal administration.
  • a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
  • suitable non-irritating excipient include cocoa butter, beeswax and polyethylene glycols.
  • compositions of this invention may also be administered topically. Suitable topical formulations are readily prepared for each of these areas or organs. Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-acceptable transdermal patches may also be used.
  • the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
  • the compounds may be coated onto a stent which is to be surgically implanted into a patient in order to inhibit or reduce the likelihood of occlusion occurring in the stent in the patient.
  • the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as benzylalkonium chloride.
  • the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
  • compositions of this invention may also be administered by nasal aerosol or inhalation.
  • Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
  • compositions should be formulated to contain between about 0.05 milligram to about 750 milligrams or more, more preferably about 1 milligram to about 600 milligrams, and even more preferably about 10 milligrams to about 500 milligrams of active ingredient, alone or in combination with at least one other compound according to the present invention.
  • a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease or condition being treated.
  • a patient or subject in need of therapy using compounds according to the present invention can be treated by administering to the patient (subject) an effective amount of the compound according to the present invention including pharmaceutically acceptable salts, solvates or polymorphs, thereof optionally in a pharmaceutically acceptable carrier or diluent, either alone, or in combination with other known erythopoiesis stimulating agents as otherwise identified herein.
  • These compounds can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, including transdermally, in liquid, cream, gel, or solid form, or by aerosol form.
  • the active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutically effective amount for the desired indication, without causing serious toxic effects in the patient treated.
  • a preferred dose of the active compound for all of the herein-mentioned conditions is in the range from about 10 ng/kg to 300 mg/kg, preferably 0.1 to 100 mg/kg per day, more generally 0.5 to about 25 mg per kilogram body weight of the recipient/patient per day.
  • a typical topical dosage will range from 0.01-5% wt/wt in a suitable carrier.
  • the compound is conveniently administered in any suitable unit dosage form, including but not limited to one containing less than 1 mg, 1 mg to 3000 mg, preferably 5 to 500 mg of active ingredient per unit dosage form.
  • An oral dosage of about 25-250 mg is often convenient.
  • the active ingredient is preferably administered to achieve peak plasma concentrations of the active compound of about 0.00001-30 mM, preferably about 0.1-30 ⁇ M. This may be achieved, for example, by the intravenous injection of a solution or formulation of the active ingredient, optionally in saline, or an aqueous medium or administered as a bolus of the active ingredient. Oral administration is also appropriate to generate effective plasma concentrations of active agent.
  • the concentration of active compound in the drug composition will depend on absorption, distribution, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
  • the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
  • Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound or its prodrug derivative can be incorporated with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a dispersing agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a dispersing agent such as alginic acid, Primogel, or corn starch
  • a lubricant such as magnesium stearate or Sterotes
  • a glidant such as colloidal silicon dioxide
  • the active compound or pharmaceutically acceptable salt thereof can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like.
  • a syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
  • the active compound or pharmaceutically acceptable salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as erythropoietin stimulating agents, including EPO and darbapoietin alfa, among others.
  • erythropoietin stimulating agents including EPO and darbapoietin alfa
  • one or more compounds according to the present invention are coadministered with another bioactive agent, such as an erythropoietin stimulating agent or a would healing agent, including an antibiotic, as otherwise described herein.
  • Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • preferred carriers are physiological saline or phosphate buffered saline (PBS).
  • the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • Liposomal suspensions may also be pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811 (which is incorporated herein by reference in its entirety).
  • liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound are then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
  • appropriate lipid(s) such as stearoyl phosphatidyl ethanolamine, stearoyl phosphat
  • the pyrrolidine amine may be protected and the carboxylic acid moiety may be condensed with a nucleophilic group on a right hand fragment to provide an amide on the right hand portion of the pyrrolidine moiety.
  • the left and right hand fragments to be condensed onto, respectively, the amine and carboxylic acid group of the pyrrolidine moiety are preferably prepared prior to condensing onto the pyrrolidine group, but other approaches may be taken to introduce groups onto the pyrrolidine group.
  • the individual components which are combined to produce a ULM group can be prepared using blocking groups at preferred functional groups on the ULM group which can be removed so as to react with and covalently link a linker group which is prepared to accommodate a PTM moiety to which is already bound a protein binding moiety or PTM group or may be further reacted to form a covalent bound with a PTM group, which may also may comprise a ULM′ group as otherwise described herein.
  • a carboxylic acid containing left hand fragment may be condensed onto the amine group of the pyrroline, thus forming an amide group with an R 1 left hand fragment as depicted below.
  • any number of nucleophilic (preferably, amine containing) right hand fragments may be condensed onto the carboxyl group to provide an amide group with an R 2 right fragment as depicted below.
  • Formation of the pre-synthesized groups to condense onto the amine and/or the carboxyl moiety of the pyrrolidine proceeds in a facile manner.
  • Virtually any compound can be synthesized readily using this approach.
  • the solid phase synthetic method can also be used and employs similar methods used in the solution phase synthesis, the major difference being that the hydroxyl group may be bound to a solid support as the other steps of the synthesis occur.
  • the general synthetic methods are applicable to virtually all of the compounds of the present invention with facile modifications being made consistent with the state of chemical synthetic art as used directly or adapted from the specific teachings of the examples which follow.
  • Solid-phase synthesis makes it easier to conduct multistep reactions and to drive reactions to completion, because excess reagents can be added and then easily washed away after each reaction step.
  • Another key factor in favor of solid-phase synthesis is that it makes it possible to use split synthesis, a technique developed in 1982.
  • Split synthesis produces large support-bound libraries in which each solid-phase particle holds a single compound, or soluble libraries produced by cleavage of compounds from the solid support. For example in a split synthesis method if you have 3 compound addition steps with 10 compounds used at each step i.e. 10 containers for those compounds. This will generate 10 3 compounds.
  • Solution phase chemistry is favored by many for library construction due to the wider range of organic reactions available for solution-phase synthesis, the technology used traditionally by most synthetic organic chemists, and products in solution can be more easily identified in standard drug target assays and characterized.
  • a problem for solution-phase synthesis of one molecule at a time is the final purification that can be both expensive and slow. Chromatography is commonly a first resort since it usually works.
  • the problems associated with solution chemistry are compounded when attempting to make tens of thousands of compounds to generate a library or a ‘book’ for a library.
  • the present invention provides a mechanism to overcome these problems in drug and small molecule discovery.
  • the target protein-binding element of the compounds of the invention has been identified. These optimal binding molecules are then subjected to further chemistry to add the ubiquitin ligase binding moiety (ULM), pursuant to the disclosure of the present application.
  • ULM ubiquitin ligase binding moiety
  • An alternative approach to the discovery of the target protein-binding moiety is based on solution phase screening.
  • compounds available either via synthesis, natural products or from companies such as ArQule (www.arqule.com), Pharmacopeia (www.pharmacopiea), and Cerep (www.cerep.com) are obtained and added to the target protein of interest and then subjected to size exclusion to remove the unbound compounds.
  • the protein bound fraction is then subjected to GC/MS to identify the molecules.
  • the solution phase screening is made rapid and facile for compounds in solution.
  • There are numerous additional ways to determine ligand binding including, for example, detecting changes in the Tm of the protein upon the ligand binding, among others.
  • Target protein is selected, for example, an enzyme or protein involved in a particular biological process.
  • Target protein for the subject invention come from numerous fields where small molecules are used to achieve modulation of a biological system in eukaryotic organisms. Examples of such fields are antivirals, antimicrobials, anti-parasitics, or other drug targets in a human patient, which may be rather diverse, etc.
  • the target protein is then either purified from a natural source in order to provide sufficient material for the screen or expressed via recombinant methods to provide sufficient material for the screens.
  • the target protein is then either labeled directly with a detectable species such as a radioactive, electrochemiluminescent, and chemiluminescent or fluorescent label or with an indirectly detectable species such as an enzyme, or particle.
  • a detectable species such as a radioactive, electrochemiluminescent, and chemiluminescent or fluorescent label or with an indirectly detectable species such as an enzyme, or particle.
  • an antibody or equivalent with binding activity to the target protein is labeled.
  • the next step is to provide a library of compounds for screening.
  • a library of from 1,000 to 1,000,000 is typical of the size that is screened. These are available from a series of companies, which are well known in the art. These libraries of compounds are used to screen for the binding of the target protein. Ideally compounds are bought still bound to the solid phase or are screened for binding directly to immobilized target protein using methods as described below for screening.
  • the optimal methods for the construction of the chemical library is to employ the methods of split synthesis coupled to the solid phase (as outlined above).
  • the library is generated using a series of solid phase chemistries such as to give rise to various compilations that form the basis of a library.
  • the library is screened in the form of a library or in the form of the compilations. Typically one would take the products from the split synthesis and pool the solid phase and use this as the basis for the screen.
  • a mixture of buffer, detergents, salts and blocking agents such as serum albumin or other proteins are added.
  • This buffer addition step is used to block the beads or solid phase in such a way that any significant non-specific binding of the selected target protein does not occur.
  • the beads are washed and followed by the addition of the target protein either labeled or not.
  • the beads or solid phase are then incubated to allow the binding of the target protein binding elements to the target protein.
  • the beads are washed and then the binding of the labeled target protein detected directly.
  • the beads are then placed in to a substrate reaction solution to detect the presence of the enzyme label.
  • an enzyme label substrates for these detection methods are based on insoluble chromogenic products.
  • the beads are subjected to another binding reaction where the antibody or equivalent, is labeled either directly or indirectly as suggested for the labeling of the target protein. It is also possible at this step to not use a labeled antibody or equivalent and to add a further step where the labeled antibody or equivalent is used. These additional steps can be detected using the same standard methods known in the art as suggested for the directly labeled target protein.
  • a series of beads are identified and these beads are selected from the bead population and subject to analysis to determine the structure of the binding molecule that is able to bind the target protein as in this example. This is achieved by the use of GC/MS or via molecular tags used during the construction of the library as described earlier. Alternatively, a pool which was positive is re-made generating a series of sub pools for screening and further re-synthesis and dividing out of the various pooled compounds until a single compound is presented in a single well for analysis allowing the determination of the active compound.
  • This method can be repeated and/or adapted for identifying peptide target binding moieties (PTM) for virtually any target protein.
  • the step of screening for specific molecules is made easy in the invention as only binding activity is desired and not specific modulation of the target protein as is required in traditional drug discovery.
  • a library of compounds for screening A library of from 1,000 to 1,000,000 is typical of the size that might be screened. These are available from a number of companies. These libraries of compounds are used to screen for the binding of the target protein. Ideally, compounds are purchased still bound to the solid phase or are screened for binding directly to immobilized target protein using methods as described below for screening.
  • the library may be constructed using a series of chemical methods resulting in pools of the solid phase used during synthesis, which form the basis of the entries which make up the library.
  • the solid phase pools are stored in sub-pools in the libraries. These so called entries and sub-pools form the basis for screening as they contain not only pools of compounds but also a known chemical-coupling step used in synthesis.
  • the library can then be screened using two approaches.
  • the solid phase from the chemical library to be screened is subjected incubation with assay buffers with blocking agents such as for example; proteins (i.e. BSA, gelatin), polyvinylpyrrolidone, ficoll, heparin, detergents (i.e. SDS, Tween, NP40, Triton X-100).
  • This incubation step is to block the non-specific binding sites on the solid phase used in the generation of the library and allow the determination of specific binding events.
  • This initial incubation is an art recognized step in various binding assays such as ELISA, southerns, westerns etc.
  • the protein of interest is then added to a buffer which typically has the same composition as that during the blocking step but can also be modified using lower or no additional blocking agents with the exception of the detergents which are typically always present during a binding reaction.
  • the entries following the blocking step are then subjected to binding with the purified target protein.
  • the solid phase from this incubation is then washed and subjected to a second binding step with a labeled reagent which binds to the tag sequence added to the receptor sub-unit during the recombinant engineering for the expression of the receptor sub-unit.
  • a labeled reagent which binds to the tag sequence added to the receptor sub-unit during the recombinant engineering for the expression of the receptor sub-unit.
  • an antibody to this tag recognizes the tag sequence; examples that are in common use are the myc, flag, and his epitopes.
  • the presence of the labeled binding species is detected by the presence of the label that is typically an enzyme such as alkaline phosphatase or peroxidase.
  • the detection step typically makes use of an insoluble chromogenic substrate that is readily detected by eye or by image analysis systems.
  • soluble substrates can also be used and screened using ELISA plate readers, eye or other spectrophotometric methods.
  • the various entries from the library are screened by eye to look for beads that have developed a color due to the enzymatic action on the chromogenic substrate. These colored beads indicate that the receptor subunit is binding to one of the compounds within the group of entries the next step is to determine if these so called positive group of entries contain specific binding or if binding is just to the tag binding reagent or some non-specific activation of the chromogenic substrate. To achieve this, the positive entries are screened with out the specific binding step to the receptor sub-unit.
  • This resynthesis results in the formation of a new series of solid phase compound pools which have the last two chemical coupling steps known.
  • This new series of solid phase compound pools are screened as in the initial screen and positive pools are checked as previously for the binding specificity to identify positive pools.
  • the positive pool(s) now allow the re-synthesis of the pool(s) with the last two steps for the generation of the compound, which specifically binds to the receptor subunit.
  • the positive pools are then subjected to the same cycle of re-synthesis and screening as just described but with the last two chemical coupling steps know the pools are maintained individually prior to the last know step. In this way the synthesis of the specific compound able to bind to the receptor sub-unit is deconvoluted from the chemical library and identified.
  • the positive solid phase is removed from the screen and collected. These are then subjected to the cleavage reaction, which removed the specific chemistry from the solid phase followed by the analysis of the various chemical species using GC to separate the individual compounds followed by MS to determine the molecular weight. This information coupled with the synthesis methods used is used to determine the compound identity. After the determination of these various candidate specific binding molecules they are then re-synthesized and subjected to the binding assay to check if these are the specific compounds that resulted in the positive solid phases.
  • linker groups are well-known in the art and can consist of providing a nucleophilic group (e.g., an alcohol, amine, thiol or other nucleophilic group) or an electrophilic group (e.g., ester, carboxylic acid, acyl halide, halogen, etc.) at either or both ends of the linker group which may be used to condense an appropriately modified ULM group and/or PTM group onto the linker to produce a covalent bond.
  • a nucleophilic group e.g., an alcohol, amine, thiol or other nucleophilic group
  • an electrophilic group e.g., ester, carboxylic acid, acyl halide, halogen, etc.
  • the compounds of the invention are then subject to analysis to determine which of the compounds from the chemical library screen with which of the individual ubiquitin ligase binding moiety element is able to function most effectively in the targeted ubiquitination and/or degradation of the target protein.
  • the ubiquitin ligase binding moiety may be determined by the methods as otherwise described in the examples section hereinbelow.
  • the compounds of the invention can be tested in a mammalian tissue culture system where the target protein either intact or as an engineered fragment is expressed. In such a mammalian tissue culture system, the compounds effect on the target protein's level is determined by making use of the tag sequence which can be engineered into the recombinant expression of the target protein during the construction of the mammalian tissue culture test system.
  • the tag sequence is used to determine the levels of the target protein during the incubation with the potential compounds screened and synthesized as described above.
  • This assay for the tag sequence can take the form of a western blot or via an ELISA, for example.
  • Other tags, which are valuable to use are those based on the green fluorescent protein, which allows the analysis of protein levels in living cells and/or organisms.
  • the compounds that show the optimal activity in the test systems will then form the basis for the next stage of drug development.
  • these selected compounds are subjected to the recognized drug development path.
  • the drug development path determines the potential value of the compounds by evaluating a series of factors including bioavailability; toxicology, pharmacology and efficacy in animal models before the compounds are considered for human testing.
  • This invention also relates to a method for the control of protein levels with a cell. This is based on the use of compounds of the invention, which are known to interact with a specific target protein such that degradation of a target protein in vivo will result in the control of the amount of protein in a biological system, prerferably to a particular therapeutic benefit.
  • 16 1 and 2 were synthesized to test a promising design featuring an isoxazole moiety positioned to interact with a crystallographic water observed in the structure of VHL bound to the HIF peptide (549-582) 14 and a benzyl group stacked along the side chain of Tyr98.
  • VHL ligands were dissolved in DMSO (100 mM), and then diluted 10 fold with VHL buffer. The compounds were then diluted 2 fold with 10% DMSO in buffer (20 uL into uL of 10% DMSO in buffer) 14 times. Aqueous DEALA-Hyp-YIPD was used as a positive control. 278 nM FAM-DEALA-Hyp-YIPD (DMSO) was diluted 1000 fold into VHL buffer.
  • VL001 >1000 VL002 241.1 120 VL003 >1000 VL004 123.1 117 VL005 >1000 VL006 Inactive VL007 Inactive VL008 >1000 VL009 Inactive VL010
  • Inactive VL011 >1000 VL012 >1000 VL013 240 VL014 4.7 VL015 >1000 VL016 ⁇ 730 VL017 ⁇ 510 VL018 280 VL019 450.5 VL020 295.4 149 VL021 36 20.5 VL022 ⁇ 870 VL023 589 VL024 511 VL025 517 VL026 >1000 >250 VL027 >1000 VL028 210.0 149 VL029 24.9 32 VL030 215 VL031 68.5 >250 VL032 639 VL033 >1000
  • 1 H and 13 C spectra were recorded on Bruker Avance DPX-500 or Bruker Avance DPX-400 NMR spectrometers.
  • 1 H NMR chemical shifts are reported relative to CDCl 3 (7.26 ppm), d 6 -DMSO (2.50 ppm) and d 4 -MeOD (3.31 ppm).
  • HPLC was performed using a Dynamax SD200 solvent delivery system connected to a Dynamax UV-1 Absorbance Detector with a YMC-Pack ODS-AM preparative column (250 ⁇ 20 mm, 5 m particle size, 12 nm pore size).
  • Method F subsumes methods C, D and E and is a general method which proceeds through commercially available amines.
  • Fmoc-Hyp(OtBu)-OAllyl (23.42 g, 52.1 mmol) was dissolved in DCM (306 mL) at room temperature. TFA (54 mL, 15% vol/vol) was added and the solution was stirred for 13 hours. The solution was poured into water, neutralized by slow addition of saturated aqueous sodium bicarbonate and extracted twice with DCM and once with EtOAc. The combined organic layers were dried with sodium sulfate, filtered and condensed. Purification by column chromatography (30 to 80% EtOAc/hexanes) gave Fmoc-Hyp(OH)-OAllyl as a yellowish oil (16.7 g, 42.4 mmol, 81%). 1 H and 13 C NMR spectra matched those reported in the literature. 16
  • Fmoc-Hyp(OWang)-OAllyl resin (1 eq) was swelled DMF, then reacted with 20% piperidine in DMF for 30 minutes. The resin was then washed once with piperidine, and reacted again with 20% piperidine for 30 minutes to ensure complete deprotection. The resin was then washed twice with DMF and once with MeOH followed by DCM. The resulting free amine was then coupled with 3-methyl-5-isoxazoleacetic acid (4 eq), PyBOP (4 eq) HOBt (4 eq) and DIPEA (7 eq) in DMF for 4 hours. The resin was then washed thrice with DMF and twice with MeOH followed by DCM.
  • the resin was then swelled with freshly distilled DCM, and reacted with Pd(PPh 3 ) 4 (0.1 eq) and PhSiH 3 (10 eq) for 30 minutes.
  • the resin was then washed once with DCM, and reacted again with Pd(PPh 3 ) 4 (0.1 eq) and PhSiH 3 (10 eq) in distilled DCM for 30 minutes, after which the resin was washed twice with DMF and once with MeOH followed by DCM.
  • the resulting carboxylic acid was then coupled with the appropriate amine (or a salt of the appropriate amine), RNH 2 (4 eq) with PyBOP (4 eq), HOBt (4 eq) and DIPEA (7 eq for free amines, 8 eq for amine salts) in DMF for 4 hours.
  • the resin was then washed 5 times with DMF, thrice with MeOH and 5 times with DCM.
  • the resin was then reacted with 20% TFA in DCM for 2 hours.
  • the reaction mixture was then drained and the resin was washed with DCM. Condensation under reduced pressure, and purification by column chromatography (1% to 10% 0.5M NH 3 in MeOH/DCM or 1% to 10% MeOH in DCM) gave the desired VHL ligand.
  • Fmoc-Hyp-(OWang)-OAllyl resin (1 eq) was swelled with freshly distilled DCM, and reacted with Pd(PPh 3 ) 4 (0.1 eq) and PhSiH 3 (10 eq) for 30 minutes. The resin was then washed once with DCM, and reacted again with Pd(PPh 3 ) 4 (0.1 eq) and PhSiH 3 (10 eq) in distilled DCM for 30 minutes, after which the resin was washed twice with DMF and once with MeOH followed by DCM.
  • the resulting carboxylic acid was then coupled with 4-chlorobenzylamine (4 eq), PyBOP (4 eq), HOBt (4 eq) and DIPEA (7 eq) in DMF for 4 hours.
  • the resin was then reacted with 20% piperidine in DMF for 30 minutes.
  • the resin was then washed once with DMF, and reacted again with 20% piperidine for 30 minutes to ensure complete deprotection.
  • the resin was then coupled with the appropriate carboxylic acid (RCO 2 H, 4 eq), PyBOP (4 eq), HOBt (4 eq) and DIPEA (7 eq) in DMF for 4 hours.
  • the resin was then washed 4 times with DMF and twice with methanol followed by DCM.
  • the resin was then reacted with 20% TFA in DCM for 2 hours. The reaction mixture was then drained and the resin was washed with DCM. Condensation under reduced pressure, and purification by column chromatography (1% to 10% 0.5M NH 3 in MeOH/DCM or 1% to 10% MeOH in DCM) gave the desired VHL ligand. Yields are based upon the loading of the resin, which was estimated based upon its change in mass.
  • Boc-Amb-OH (2.55 g, 10.16 mmol, 1 eq) was dissolved in DCM (68 mL) and cooled to 4° C. in an ice bath.
  • EDC (2.34 g, 12.2 mmol, 1.2 eq)
  • HOBt (1.65 g, 12.2 mmol, 1.2 eq)
  • DIPEA 6.2 mL, 35.6 mmol, 3.5 eq
  • Boc-Amb-N(OMe)Me (2.45 g, 8.33 mmol, 1 eq) was dissolved in THF (83 mL) and cooled to ⁇ 78° C. in a dry ice/acetone bath. Lithium aluminum hydride (0.41 g, 10.83 mmol, 1.3 eq) was added in 2 portions over 5 minutes. After 50 minutes, the suspension was warmed to 4° C. in an ice bath. After 3.5 hours, the reaction was deemed complete by TLC (mini workup in 10% potassium bisulfate and EtOAc, 50% EtOAc/hexanes) and the reaction was quenched by the slow addition of 10% potassium bisulfate at 4° C.
  • VL4 was synthesized according to General Method F as a white solid.
  • VL2 was synthesized according to General Method F.
  • 1 H NMR 500 MHz, MeOD
  • VL26 was synthesized according to General Method F and was isolated as a colorless oil (28 mg, 0.105 mmol, 80%).
  • 1 H NMR 500 MHz, MeOD
  • ⁇ 6.23 s, 1H
  • 2.73 s, 3H
  • 2.26-2.18 m, 4H
  • VL34 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.3 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (14.7 mg).
  • VL28 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.3 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a yellow solid (19.1 mg).
  • VL21 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.2 mmol) using Solid Phase Synthesis General Method A. It was isolated as a white solid (15.9 mg).
  • VL20 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.15 mmol) using Solid Phase Synthesis General Method A. It was isolated as a white solid (9.9 mg).
  • VL29 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.3 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a light yellow solid (16.4 mg).
  • VL31 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.3 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (19.8 mg).
  • VL47 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.156 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (9.1 mg).
  • VL35 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.156 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (14.1 mg).
  • VL48 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.156 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (11.4 mg).
  • VL88 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.156 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a clear oil (8.0 mg).
  • VL95 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.156 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (23 mg).
  • VL111 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.2 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (18.2 mg).
  • VL50 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (29.8 mg, 0.084 mmol, 54%).
  • VL52 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to the Solid Phase Synthesis General Method B. It was isolated as a white solid (7.7 mg, 0.021 mmol, 14%).
  • VL73 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a clear oil (38.9 mg, 0.099 mmol, 55%).
  • VL64 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to the Solid Phase Synthesis General Method B. It was isolated as a white solid (27.5 mg, 0.077 mmol, 49%).
  • 1 H NMR 500 MHz, CD 3 OD
  • ⁇ 7.66-7.59 m, 2H
  • 7.54-7.22 m, 7H
  • 4.75 t
  • J 8.6, 1H
  • 4.55-4.33 m, 3H
  • 2.38-2.26 m, 1H), 2.14-2.05 (m, 1H).
  • VL69 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (26.1 mg, 0.62 mmol, 40%).
  • VL70 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a colorless oil (31.1 mg, 0.083 mmol, 53%).
  • 1 H NMR 500 MHz, CD 3 OD
  • ⁇ 7.38-7.17 m, 6H
  • 6.85-6.73 m, 2H
  • 4.53-4.31 m, 3H
  • 3.85 (dd, J 3.2, 11.6, 1H)
  • 2.08 (ddd, J 4.3, 9.1, 13.3, 1H).
  • VL71 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to the Solid Phase Synthesis General Method B. It was isolated as a colorless oil (31.1 mg, 0.080 mmol, 51%).
  • VL72 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a yellow oil (31.3 mg, 0.084 mmol, 54%).
  • 1 H NMR 500 MHz, CD 3 OD
  • VL74 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (36.3 mg, 0.092 mmol, 51%).
  • VL75 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (25.0 mg, 0.066 mmol, 37%).
  • 1 H NMR 500 MHz, CD30OD
  • 4.54-4.31 m, 3H
  • VL76 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (29.6 mg, 0.067 mmol, 38%).
  • VL77 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (31.0 mg, 0.081 mmol, 45%).
  • VL79 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (34.9 mg, 0.090 mmol, 50%).
  • VL80 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (41.2 mg, 0.110 mmol, 61%).
  • 1 H NMR 500 MHz, CD 3 OD
  • ⁇ 7.36-6.76 m, 8H
  • 4.53-4.31 m, 3H
  • 3.45 (d, J 11.6, 1H)
  • 2.34-2.27 m, 1H), 2.14-2.03 (m, 1H).
  • VL81 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a colorless oil (42.9 mg, 0.091 mmol, 50%).
  • 1 H NMR 500 MHz, CD 3 OD
  • ⁇ 7.77-7.27 m, 6H
  • 4.56-4.30 m, 3H
  • 3.17 (d, J 11.3, 1H)
  • 2.37-2.25 m, 1H
  • VL96 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.155 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a light yellow oil (36.6 mg, 0.102 mmol, 66%).
  • VL112 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.2 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a cream colored solid (22.6 mg, 0.055 mmol, 28%).
  • VL115 was synthesized according to General Method B.
  • 1H NMR 500 MHz, CD 3 OD
  • VL154 was synthesized according to General Method B.
  • 1H NMR 500 MHz, CD 3 OD
  • VL155 was synthesized according to General Method B.
  • 1 H NMR 500 MHz, CD 3 OD
  • VL118 was synthesized according to General Method A.
  • 1 H NMR 500 MHz, CD 3 OD
  • ⁇ 7.37-7.31 m, 2H
  • 6.74-6.68 (m, 1H)
  • 6.20 (s, 1H)
  • 6.10-6.05 m, 1H
  • 4.49 4.45-4.39
  • VL119 was synthesized according to General Method A.
  • 1 H NMR 500 MHz, CD 3 OD
  • ⁇ 7.38-7.30 m, 4H
  • 6.76-6.67 m, 1H
  • 6.23 s, 1H
  • 6.09-6.05 m, 1H
  • 4.51 s, 1H
  • 4.47-4.39 m, 2H
  • 3.81 (dd, J 10.9, 4.3 Hz, 1H)
  • 2.31-2.22 m, 4H
  • VL131 was synthesized according to General Method B.
  • 1H NMR 400 MHz, CD 3 OD
  • VL138 was synthesized according to General Method B.
  • 1H NMR 400 MHz, CD 3 OD
  • VL139 was synthesized according to General Method B.
  • VL152 was synthesized according to General Method B.
  • 1H NMR 400 MHz, CD 3 OD
  • VL158 was synthesized according to General Method B.
  • 1H NMR 500 MHz, CD 3 OD
  • ⁇ 8.03 s, 1H
  • 6.19 s, 1H
  • 4.62-4.48 m, 2H
  • 4.48-4.32 m, 2H
  • 3.93-3.68 m, 3H
  • VL160 was synthesized according to General Method B.
  • 1 H NMR 500 MHz, CD 3 OD

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • The present application is a continuation of, and claims priority to, U.S. patent application Ser. No. 14/371,956, filed Jul. 11, 2014, which is a 35 U.S.C. § 371 national phase application of, and claims priority to, PCT Application No. PCT/US2013/021136, filed Jan. 11, 2013, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 61/585,769, filed Jan. 12, 2012, all of which applications are incorporated herein by reference in their entireties.
    • STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
  • This invention was made with government support under AI084140 awarded by National Institutes of Health. The government has certain rights in the invention.
    • FIELD OF THE INVENTION
  • The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins, which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand, which binds to the VHL E3 ubiquitin ligase (defined as a ubiquitin ligand binding moiety or
    Figure US20190127359A1-20190502-P00001
    group) and on the other end a moiety, which binds a target protein (defined as a protein/polypeptide targeting moiety or
    Figure US20190127359A1-20190502-P00002
    group) such that the target protein/polypeptide is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
    • BACKGROUND OF THE INVENTION
  • E3 ubiquitin ligases (of which over 600 are known in humans)1 confer substrate specificity for ubiquitination and are more attractive therapeutic targets than general proteasome inhibitors3,4 due to their specificity for certain protein substrates. Although the development of ligands of E3 ligase has proven challenging, in part due to the fact that they must disrupt protein-protein interactions5 recent developments have provided specific ligands which bind to these ligases. Protein-protein interaction interactions are notoriously difficult to target using small molecules due to their large contact surfaces and the shallow grooves or flat interfaces involved. Conversely, most small molecule drugs bind enzymes or receptors in tight and well-defined pockets.6 Since the discovery of nutlins, the first small molecule E3 ligase inhibitors,7 additional compounds have been reported that target Inhibitors of Apoptosis Proteins (IAPs),8,9 SCFMet30,10 and SCFCdc4;11 however, the field remains underdeveloped.
  • One E3 ligase with exciting therapeutic potential is the von Hippel-Lindau (VHL) tumor suppressor, the substrate recognition subunit of the E3 ligase complex VCB, which also consists of elongins B and C, Cul2 and Rbx1.12 The primary substrate of VHL is Hypoxia Inducible Factor 1α (HIF-1α), a transcription factor that upregulates genes such as the pro-angiogenic growth factor VEGF and the red blood cell inducing cytokine erythropoietin in response to low oxygen levels. While HIF-1α is constitutively expressed, its intracellular levels are kept very low under normoxic conditions via its hydroxylation by prolyl hydroxylase domain (PHD) proteins and subsequent VHL-mediated ubiquitination (FIG. 1).
  • Using rational design, we have generated the first small molecule ligands of Von Hippel Lindau (VHL), the substrate recognition subunit of the E3 ligase VCB, an important target in cancer, chronic anemia and ischemia.2 We have also obtained crystal structures of VHL with our most potent ligand, 15, confirming that the compound mimics the binding mode of the transcription factor HIF-1α, the major substrate of VHL.
  • From earlier biochemical and structural studies of a hydroxylated HIF peptide bound to VHL, it became clear that hydroxyproline played an important role in mediating this protein:protein interaction. As a consequence of that work, the present inventors developed a hydroxylated HIF peptide:VHL fluorescence polarization (FP) binding assay with which they assayed >120 compounds possessing the central hydroxyproline residue flanked by non-peptidic moieties. Further to that research, the inventors now have developed co-crystal structures of VHL complexed with seven of the top compounds. Analysis of these ligand bound structures is driving the design/synthesis of the next generation of VHL ligands, which are linked with protein binding moieties to produce bifunctional compounds according to the present invention.
  • A principal rationale for the present invention is the need for a small molecule E3 ligase ligand for our PROTAC (Proteolysis Targeting Chimera) technology. This technology brings targeted proteins/polypeptides to E3 ligases for ubiquitination and subsequent proteasomal degradation. In several proof-of-concept experiments, the present inventors demonstrated the utility of this approach using the short peptide sequence from HIF that binds VHL. In order to make a more ‘drug-like’ PROTAC, the inventors have replaced the HIF peptide with a ‘small molecule’ VHL ligand, thus providing a means to recruit proteins to E3 ligases for ubiquitination and degradation, to the endpoint of providing therapies based upon this protein degradation.
    • OBJECTS OF THE INVENTION
  • It is an object of the invention to provide compounds which function to recruit endogenous proteins to E3 Ubiquitin Ligase for degradation.
  • It is an additional object of the invention to provide compounds which modulate protein degradation in a patient or subject and can be used for treating disease states or conditions which are modulated through the degraded protein.
  • It is another object of the invention to provide pharmaceutical compositions based upon the above-described modulators, especially including inhibitors for therapeutic treatment of a patient or subject, preferably including a human patient or subject.
  • It is also an object of the invention to provide methods for determining protein binding moieties which bind to proteins of interest.
  • It is yet another object of the invention to provide methods for identifying endogenous proteins in a biological system, especially including a human system, which bind to protein binding moieties in compounds according to the present invention.
  • It is still another object of the invention to provide methods for identifying the effects of the degradation of proteins of interest in a biological system using compounds according to the present invention.
  • It is still another aspect of the invention to provide methods for treating patients where the degradation of a targeted protein will produce an intended therapeutic effect.
  • It is another object of the invention to provide compounds and compositions which may be used in a first medical application.
  • It is yet another aspect of the invention to provide compounds and/or compositons which are used for treating patients where the degradation of a targeted protein will produce an intended therapeutic effect.
  • Any one or more of these and/or other objects of the invention may be readily gleaned from a routine scrutiny of the description of the invention which follows.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 shows (A) HIF-1α accumulation leads to the transcriptional upregulation of genes involved in the hypoxic response, such as erythropoietin and VEGF. (B) Under normoxic conditions, HIF-1α is hydroxylated, recognized by VHL, ubiquitinated and degraded by the proteasome, preventing transcriptional upregulation.
  • FIG. 2. WaterLOGSY NMR spectroscopy shows binding of 3, but not L-Hyp or NAc-Hyp-NMe to VHL.
  • FIG. 3 shows a pictorial representation shows the key interactions between 15 and VHL.
  • FIG. 4 shows the 2.9 Å co-crystal structure of 15 (lightest gray carbons) bound to VHL indicates that its binding mimics that of the HIF-1α peptide (light gray carbons, pdb 1LM817)
  • FIG. 5 shows the crystal structures of V54BC apo (A) and in complex with 15 (B). Electron density (2Fo−Fc) superimposed around Hyp binding site residues (sticks, yellow carbons) and conserved water molecules (red dots), and 15 (sticks, cyan carbons) are shown in blue and are contoured at 1.20. The protein surface is shown in green at 50% transparency.
  • FIGS. 6-12 (each A and B) show the activity of individual compounds according to the present invention in the described VHL polarization/displacement assay. Compounds according to the present invention are indicated with numerals at the top of each graph. Control compound is presented in FIG. 15 B and served as minimum polarization (maximum displacement) for comparison purposes. The percent inhibition as presented was determined by normalizing to maximum and minimum polarization, and graphed against the log [VL]. IC50 values were determined using Prism 5 for each replicate (n=9), where were then averaged to determine the average IC50 and the standard of error of the mean (SEM).
  • FIG. 13 (along with Table 2—Affinity Table) shows numerous exemplary compounds according to the present invention.
  • FIG. 14 shows numerous preferred compounds from Table 2 according to the present invention.
  • FIG. 15 shows a further number of compounds according to the present invention and their activity. Most compounds are active below concentrations of 100 μM.
  • FIG. 16 shows numerous preferred compounds from FIG. 15 according to the present invention.
  • FIG. 17 shows eight particularly preferred compounds from FIG. 15 according to the present invention.
  • FIG. 18 shows six preferred compounds according to the present invention which contain estrogen binding protein targeting moieties linked to preferred ubiquitin ligand binding moieties.
  • FIG. 19 shows a genus of preferred compounds according to the present invention.
    •  BRIEF DESCRIPTION OF THE INVENTION
  • The present invention is based on the discovery that an ubiquitin pathway protein ubiquitinates any target protein once the ubiquitin pathway protein and the target protein are placed in proximity by a chimeric construct that binds the ubiquitin pathway protein and the target protein. Accordingly the present invention provides a composition that results in the ubiquitination of a chosen target protein. The present invention also provides a library of compositions and the use thereof.
  • In one embodiment, the present invention provides a composition useful for regulating protein activity. The composition comprises a ubiquitin pathway protein binding moiety (preferably for an E3 ubiquitin ligase, alone or in complex with an E2 ubiquitin conjugating enzyme which is responsible for the transfer of ubiquitin to targeted proteins) according to a defined chemical structure and a protein targeting moiety which are linked together, preferably through a linker, wherein the ubiquitin pathway protein binding moiety recognizes an ubiquitin pathway protein and the targeting moiety recognizes a target protein and wherein the ubiquitin pathway protein binding moiety is coupled to the targeting moiety.
  • In another embodiment, the present invention provides a library of compounds. The library comprises more than one compound wherein each composition has a formula of A-B, wherein A is a ubiquitin pathway protein binding moiety (preferably, an E3 ubiquitin ligase moiety as otherwise disclosed herein) and B is a protein binding member of a molecular library, wherein A is coupled (preferably, through a linker moiety) to B, and wherein the ubiquitin pathway protein binding moiety recognizes an ubiquitin pathway protein, in particular, an E3 ubiquitin ligase. In a particular embodiment, the library contains a specific ubiquitination recognition peptide of VHL for an E3 ubiquitin ligase (ubiquitin pathway protein binding moiety as otherwise disclosed herein) with random target protein binding elements (e.g., a chemical compound library). As such, the target protein is not determined in advance and the method can be used to determine the activity of a putative protein binding element and its pharmacological value as a target upon degradation by ubiquitin ligase.
  • In still another embodiment, the present invention provides a method of screening a library of the present invention to identify a compound containing a targeting moiety, which recognizes a target protein associated with a predetermined function of a cell. The method comprises incubating a cell with a pool of entities from the library; monitoring the predetermined function of the cell; identifying a pool of entities that change the predetermined function of the cell; incubating the cell with a composition from the identified pool of entities; monitoring the predetermined function of the cell; and identifying a composition that changes the predetermined function of the cell, wherein the identified composition contains a targeting moiety which recognizes a target protein associated with the predetermined function.
  • In another embodiment, the present invention provides a method of screening a library of the present invention to identify a composition containing a targeting moiety, which recognizes a target protein associated with a predetermined function of a cell. The method comprises incubating a cell with each composition from the library; monitoring the predetermined function of the cell; identifying a composition that changes the predetermined function of the cell; wherein the identified composition contains a targeting moiety, which recognizes a target protein associated with the predetermined function.
  • In still another embodiment, the present invention provides a method of identifying a target protein associated with a predetermined function of a cell. The method comprises incubating a cell with a composition from the library of the present invention; monitoring the predetermined function of the cell; identifying a composition that changes the predetermined function of the cell; identifying a target protein that binds to the identified composition, wherein the target protein is associated with the predetermined function of the cell.
  • In yet another embodiment, the present invention provides a method of identifying a target protein associated with a predetermined function of a cell. The method comprises incubating a cell with a pool of entities from the library of the present invention; monitoring the predetermined function of the cell; identifying a pool of entities that change the predetermined function of the cell; incubating the cell with a composition from the identified pool of entities; monitoring the predetermined function of the cell; identifying a composition that changes the predetermined function of the cell; and identifying a target protein that binds to the identified composition, wherein the target protein is associated with the predetermined function of the cell.
  • In yet another embodiment, the present invention provides a method of ubiquitinating/degrading a target protein in a cell. The method comprises administering a bifunctional composition comprising an ubiquitin pathway protein binding moiety and a targeting moiety, preferably linked through a linker moiety, as otherwise described herein, wherein the ubiquitin pathway protein binding moiety is coupled to the targeting moiety and wherein the ubiquitin pathway protein binding moiety recognizes a ubiquitin pathway protein (e.g., an ubiquitin ligase, preferably an E3 ubiquitin ligase) and the targeting moiety recognizes the target protein such that degradation of the target protein will occur when the target protein is placed in proximity to the ubiquitin ligase, thus resulting in degradation/inhibition of the effects of the target protein and the control of protein levels. The control of protein levels afforded by the present invention provides treatment of a disease state or condition, which is modulated through the target protein by lowering the level of that protein in the cells of a patient.
  • In another embodiment, the present invention is directed to a method of treating a patient in need for a disease state or condition modulated through a protein where the degradation of that protein will produce a therapeutic effect in that patient, the method comprising administering to a patient in need an effective amount of a compound according to the present invention, optionally in combination with another bioactive agent. The disease state or condition may be a disease caused by a microbial agent or other exogenous agent such as a virus, bacteria, fungus, protozoa or other microbe or may be a disease state, which is caused by overexpression of a protein, which leads to a disease state and/or condition.
  • In one embodiment, the present invention is directed to a compound according to the structure:
  • Figure US20190127359A1-20190502-C00001
  • Where L is a linker group and
    Figure US20190127359A1-20190502-P00001
    is a ubiquitin ligase binding moiety, wherein said linker group is optionally further linked to a
    Figure US20190127359A1-20190502-P00002
    group.
  • In another embodiment, the present invention is directed to a compound which comprises a
    Figure US20190127359A1-20190502-P00002
    group according to the general structure:
  • Figure US20190127359A1-20190502-C00002
  • Where
    Figure US20190127359A1-20190502-P00001
    is an ubiquitin ligase binding moiety, preferably a ligand, which binds an ubiquitin ligase, preferably an E3 ubiquitin ligase;
    Figure US20190127359A1-20190502-P00002
    is a chemical moiety (protein targeting moiety), which binds to a target protein or polypeptide, which is ubiquitinated by an ubiquitin ligase and is chemically linked directly to the
    Figure US20190127359A1-20190502-P00001
    group or through a linker moiety L, or
    Figure US20190127359A1-20190502-P00002
    is alternatively a
    Figure US20190127359A1-20190502-P00003
    group which also an ubiquitin ligase binding moiety, which may be the same or different than the
    Figure US20190127359A1-20190502-P00001
    group and is linked directly to the
    Figure US20190127359A1-20190502-P00001
    group directly or through the linker moiety; and
    L is a linker moiety which may be present or absent and which chemically (covalently) links
    Figure US20190127359A1-20190502-P00001
    to
    Figure US20190127359A1-20190502-P00002
    ,
    Or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate or polymorph thereof.
  • In certain aspects of the invention, where
    Figure US20190127359A1-20190502-P00002
    is a
    Figure US20190127359A1-20190502-P00003
    group, the compound resembles a dimeric compound where both ends of the compound comprise an ubiquitin ligase binding moiety as otherwise described herein.
  • In preferred aspects of the invention,
    Figure US20190127359A1-20190502-P00001
    and where present,
    Figure US20190127359A1-20190502-P00003
    , are each independently a group according to the chemical structure:
  • Figure US20190127359A1-20190502-C00003
  • Where R1′ is an optionally substituted C1-C6 alkyl group, an optionally substituted —(CH2)nOH, an optionally substituted —(CH2)nSH, an optionally substituted (CH2)n—O—(C1-C6)alkyl group, an optionally substituted (CH2)n—WCOCW—(C0-C6)alkyl group containing an epoxide moiety WCOCW where each W is independently H or a C1-C3 alkyl group, an optionally substituted —(CH2)nCOOH, an optionally substituted —(CH2)nC(O)—(C1-C6 alkyl), an optionally substituted —(CH2)nNHC(O)—R1, an optionally substituted —(CH2)nC(O)—NR1R2, an optionally substituted —(CH2)nOC(O)—NR1R2, —(CH2O)nH, an optionally substituted —(CH2)nOC(O)—(C1-C6 alkyl), an optionally substituted —(CH2)nC(O)—O—(C1-C6 alkyl), an optionally substituted
    —(CH2O)nCOOH, an optionally substituted —(OCH2)nO—(C1-C6 alkyl), an optionally substituted —(CH2O)nC(O)—(C1-C6 alkyl), an optionally substituted —(OCH2)nNHC(O)—R1, an optionally substituted —(CH2O)nC(O)—NR1R2, —(CH2CH2O)nH, an optionally substituted —(CH2CH2O)nCOOH, an optionally substituted —(OCH2CH2)nO—(C1-C6 alkyl), an optionally substituted —(CH2CH2O)nC(O)—(C1-C6 alkyl), an optionally substituted —(OCH2CH2)nNHC(O)—R1, an optionally substituted —(CH2CH2O)nC(O)—NR1R2, an optionally substituted —SO2RS, an optionally substituted S(O)RS, NO2, CN or halogen (F, Cl, Br, I, preferably F or Cl);
    R1 and R2 are each independently H or a C1-C6 alkyl group which may be optionally substituted with one or two hydroxyl groups or up to three halogen groups (preferably fluorine);
    RS is a C1-C6 alkyl group, an optionally substituted aryl, heteroaryl or heterocycle group or a —(CH2)mNR1R2 group,
    X and X′ are each independently C═O, C═S, —S(O), S(O)2, (preferably X and X′ are both C═O);
    R2′ is an optionally substituted —(CH2)n—(C═O)u(NR1)v(SO2)walkyl group, an optionally substituted —(CH2)n—(C═O)u(NR)v(SO2)wNR1NR2N group, an optionally substituted —(CH2)n—(C═O)u(NR1)v(SO2)w-Aryl, an optionally substituted —(CH2)n—(C═O)u(NR1)v(SO2)w-Heteroaryl, an optionally substituted —(CH2)n—(C═O)vNR1(SO2)w-Heterocycle, an optionally substituted —NR1—(CH2)n—C(O)u(NR1)v(SO2)w-alkyl, an optionally substituted —NR1—(CH2)n—C(O)u(NR1)v(SO2)w—NR1NR2N, an optionally substituted —NR1—(CH2)n—C(O)u(NR1)v(SO2)w—NR1C(O)R1N, an optionally substituted —NR1—(CH2)n—C(O)u(NR1)v(SO2)w-Aryl, an optionally substituted —NR1—(CH2)n—C(O)u(NR1)v(SO2)w-Heteroaryl or an optionally substituted —NR1—(CH2)n—(C═O)vNR1(SO2)w-Heterocycle, an optionally substituted —XR2′-alkyl group; an optionally substituted —XR2′— Aryl group; an optionally substituted —XR2′— Heteroaryl group; an optionally substituted —XR2′— Heterocycle group; an optionally substituted; R3′ is an optionally substituted alkyl, an optionally substituted —(CH2)n—C(O)u(NR1)v(SO2)w-alkyl, an optionally substituted —(CH2)n—C(O)u(NR1)v(SO2)w—NR1NR2N, an optionally substituted —(CH2)n—C(O)u(NR1)v(SO2)w—NR1C(O)R1N, an optionally substituted —(CH2)n—C(O)u(NR1)v(SO2)w—C(O)NR1R2, an optionally substituted —(CH2)n—C(O)u(NR1)v(SO2)w-Aryl, an optionally substituted —(CH2)n—C(O)(NR1)(SO2)w-Heteroaryl, an optionally substituted —(CH2)n—C(O)(NR1)(SO2)w-Heterocycle, an optionally substituted —NR1—(CH2)n—C(O)u(NR1)v(SO2)w-alkyl, an optionally substituted —NR1—(CH2)n—C(O)u(NR1)v(SO2)w—NR1NR2N, an optionally substituted —NR1—(CH2)n—C(O)u(NR1)v(SO2)w—NR1C(O)R1N, an optionally substituted —NR1—(CH2)n—C(O)(NR1)v(SO2)w-Aryl, an optionally substituted —NR1—(CH2)n—C(O)(NR1)v(SO2)w-Heteroaryl, an optionally substituted —NR1—(CH2)n—C(O)(NR1)v(SO2)w-Heterocycle, an optionally substituted —O—(CH2)n—(C═O)(NR1)v(SO2)w-alkyl, an optionally substituted —O—(CH2)n—(C═O)u(NR1)v(SO2)w—NR1NR2N, an optionally substituted —O—(CH2)n—(C═O)u(NR1)v(SO2)w—NR1C(O)R1N, an optionally substituted —O—(CH2)n—(C═O)u(NR1)v(SO2)w-Aryl, an optionally substituted —O—(CH2)n—(C═O)(NR1)v(SO2)w-Heteroaryl or an optionally substituted —O—(CH2)n—(C═O)u(NR1)v(SO2)w-Heterocycle; —(CH2)n—(V)n′—(CH2)n—(V)n′-alkyl group, an optionally substituted —(CH2)n—(V)n′—(CH2)n—(V)n′-Aryl group, an optionally substituted —(CH2)n—(V)n′—(CH2)n—(V)n′-Heteroaryl group, an optionally substituted —(CH2)n—(V)n—(CH2)n—(V)n′-Heterocycle group, an optionally substituted —(CH2)n—N(R1)(C═O)m′—(V)n′-alkyl group, an optionally substituted —(CH2)n—N(R1)(C═O)m′—(V)n′-Aryl group, an optionally substituted —(CH2)n—N(R1)(C═O)m′—(V)n′-Heteroaryl group, an optionally substituted —(CH2)n—N(R1)(C═O)m′—(V)n′-Heterocycle group, an optionally substituted —XR3′-alkyl group; an optionally substituted —XR3′-Aryl group; an optionally substituted —XR3′-Heteroaryl group; an optionally substituted —XR3′-Heterocycle group; an optionally substituted;
    Where R1N and R2N are each independently H, C1-C6 alkyl which is optionally substituted with one or two hydroxyl groups and up to three halogen groups or an optionally substituted —(CH2)n-Aryl, —(CH2)n-Heteroaryl or —(CH2)n-Heterocycle group;
    • V is O, S or NR1;
  • R1 is the same as above;
    R1 and R1′ are each independently H or a C1-C3 alkyl group;
    XR2′ and XR3′ are each independently an optionally substituted —CH2)n—, —CH2)n—CH(Xv)═CH(Xv)— (cis or trans), —CH2)n—CH≡CH—, —(CH2CH2O)n— or a C3-C6 cycloalkyl group, where Xv is H, a halo or a C1-C3 alkyl group which is optionally substituted;
    Each m is independently 0, 1, 2, 3, 4, 5, 6;
    Each m′ is independently 0 or 1;
    Each n is independently 0, 1, 2, 3, 4, 5, 6;
    Each n′ is independently 0 or 1;
    Each u is independently 0 or 1;
    Each v is independently 0 or 1;
    Each w is independently 0 or 1; and
    wherein any one or more of R1′, R2′, R3′, X and X′ of
    Figure US20190127359A1-20190502-P00001
    is modified to be covalently bonded to the
    Figure US20190127359A1-20190502-P00002
    group through a linker group when
    Figure US20190127359A1-20190502-P00002
    is not,
    Figure US20190127359A1-20190502-P00003
    , or when
    Figure US20190127359A1-20190502-P00002
    is
    Figure US20190127359A1-20190502-P00003
    , any one or more of R1′, R2′, R3′, X and X′ of each of
    Figure US20190127359A1-20190502-P00001
    and
    Figure US20190127359A1-20190502-P00003
    are modified to be covalently bonded to each other directly or through a linker group, or
    a pharmaceutically acceptable salt, stereoisomer, solvate orpolymorph thereof.
  • In alternative aspects of the present invention
    Figure US20190127359A1-20190502-P00001
    and when present,
    Figure US20190127359A1-20190502-P00003
    , are each independently a group according to the chemical structure:
  • Figure US20190127359A1-20190502-C00004
  • Wherein each of R1′, R2′ and R3′ are the same as above and X is C═O, C═S, —S(O) group or a S(O)2 group, more preferably a C═O group, and
    wherein any one or more of R1′, R2′ and R3′ are modified to bind a linker group to which is further covalently bonded to the
    Figure US20190127359A1-20190502-P00002
    group when
    Figure US20190127359A1-20190502-P00002
    is not
    Figure US20190127359A1-20190502-P00003
    , or when
    Figure US20190127359A1-20190502-P00002
    is
    Figure US20190127359A1-20190502-P00003
    , any one or more of R1′, R2′, R3′ of each of
    Figure US20190127359A1-20190502-P00001
    and
    Figure US20190127359A1-20190502-P00003
    are modified to be covalently bonded to each other directly or through a linker group, or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof.
  • In still further preferred aspects of the invention,
    Figure US20190127359A1-20190502-P00001
    , and when present,
    Figure US20190127359A1-20190502-P00003
    , are each independently according to the chemical structure:
  • Figure US20190127359A1-20190502-C00005
  • wherein any one or more of R1′, R2′ and R3′ are modified to bind a linker group to which is further covalently bonded to the
    Figure US20190127359A1-20190502-P00002
    group when
    Figure US20190127359A1-20190502-P00002
    is not
    Figure US20190127359A1-20190502-P00003
    , or when
    Figure US20190127359A1-20190502-P00002
    is
    Figure US20190127359A1-20190502-P00003
    , any one or more of R1′, R2′, R3′ of each of
    Figure US20190127359A1-20190502-P00001
    and
    Figure US20190127359A1-20190502-P00003
    are modified to be covalently bonded to each other directly or through a linker group, or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof.
  • In further preferred aspects of the invention, R1′ is preferably a hydroxyl group or a group which may be metabolized to a hydroxyl or carboxylic group, such that the compound represents a prodrug form of an active compound. Exemplary preferred R1′ groups include, for example, —(CH2)nOH, (CH2)n—O—(C1-C6)alkyl group, —(CH2)nCOOH, —(CH2O)nH, an optionally substituted —(CH2)nOC(O)—(C1-C6 alkyl), or an optionally substituted —(CH2)nC(O)—O—(C1-C6 alkyl), wherein n is 0 or 1. Where R1′ is or contains a carboxylic acid group, a hydroxyl group or an amine group, the hydroxyl group, carboxylic acid group or amine (each of which may be optionally substituted), may be further chemically modified to provide a covalent link to a linker group to which the
    Figure US20190127359A1-20190502-P00002
    group (including a
    Figure US20190127359A1-20190502-P00003
    group) is bonded.
  • X and X′, where present, are preferably a C═O, C═S, —S(O) group or a S(O)2 group, more preferably a C═O group.
  • R2′ is preferably an optionally substituted —NR1-T-Aryl, an optionally substituted —NR1-T-Heteroaryl group or an optionally substituted —NR1-T-Heterocycle, where R1 is H or CH3, preferably H and T is an optionally substituted —(CH2)n— group, wherein each one of the methylene groups may be optionally substituted with one or two substituents, preferably selected from halogen, an amino acid sidechain as otherwise described herein or a C1-C3 alkyl group, preferably one or two methyl groups, which may be optionally substituted; and n is 0 to 6, often 0, 1, 2 or 3, preferably 0 or 1. Alternatively, T may also be a —(CH2O)n— group, a —(OCH2)n— group, a —(CH2CH2O)n— group, a —(OCH2CH2)n— group, all of which groups are optionally substituted.
  • Preferred Aryl groups for R2′ include optionally substituted phenyl or naphthyl groups, preferably phenyl groups, wherein the phenyl group is optionally substituted with a linker group to which is attached a
    Figure US20190127359A1-20190502-P00002
    group (including a
    Figure US20190127359A1-20190502-P00003
    group), a halogen (preferably F or Cl), an amine, monoalkyl- or dialkyl amine (preferably, dimethylamine), F, Cl, OH, COOH, C1-C6 alkyl, preferably CH3, CF3, OMe, OCF3, NO2, or CN group (each of which may be substituted in ortho-, meta- and/or para-positions of the phenyl ring, preferably para-), an optionally substituted phenyl group (the phenyl group itself is preferably substituted with a linker group attached to a
    Figure US20190127359A1-20190502-P00002
    group, including a
    Figure US20190127359A1-20190502-P00003
    group), and/or at least one of F, Cl, OH, COOH, CH3, CF3, OMe, OCF3, NO2, or CN group (in ortho-, meta- and/or para-positions of the phenyl ring, preferably para-), a naphthyl group, which may be optionally substituted, an optionally substituted heteroaryl, preferably an optionally substituted isoxazole including a methylsubstituted isoxazole, an optionally substituted oxazole including a methylsubstituted oxazole, an optionally substituted thiazole including a methyl substituted thiazole, an optionally substituted isothiazole including a methyl substituted isothiazole, an optionally substituted pyrrole including a methylsubstituted pyrrole, an optionally substituted imidazole including a methylimidazole, an optionally substituted benzimidazole or methoxybenzylimidazole, an optionally substituted oximidazole or methyloximidazole, an optionally substituted diazole group, including a methyldiazole group, an optionally substituted triazole group, including a methylsubstituted triazole group, an optionally substituted pyridine group, including a halo- (preferably, F) or methylsubstitutedpyridine group or an oxapyridine group (where the pyridine group is linked to the phenyl group by an oxygen), an optionally substituted furan, an optionally substituted benzofuran, an optionally substituted dihydrobenzofuran, an optionally substituted indole, indolizine or azaindolizine (2, 3, or 4-azaindolizine), an optionally substituted quinoline, an optionally substituted group according to the chemical structure:
  • Figure US20190127359A1-20190502-C00006
  • Where Sc is CHRSS, NRURE, or O;
    RHET is H, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted O(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group —C≡C—Ra where Ra is H or a C1-C6 alkyl group (preferably C1-C3 alkyl);
    RSS is H, CN, NO2, halo (preferably F or Cl), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted O—(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted —C(O)(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
    RURE is H, a C1-C6 alkyl (preferably H or C1-C3 alkyl) or a —C(O)(C1-C6 alkyl) each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted phenyl group, an optionally substituted heteroaryl, or an optionally substituted heterocycle, preferably for example piperidine, morpholine, pyrrolidine, tetrahydrofuran);
    RPRO is H, optionally substituted C1-C6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C1-C3 alkyl group, preferably methyl or a halo group, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine;
    RPRO1 and RPRO2 are each independently H, an optionally substituted C1-C3 alkyl group or together form a keto group; and
    each n is independently 0, 1, 2, 3, 4, 5, or 6 (preferably 0 or 1), or
    an optionally substituted heterocycle, preferably tetrahydrofuran, tetrahydrothiene, piperidine, piperazine or morpholine (each of which groups when substituted, are preferably substituted with a methyl or halo (F, Br, Cl),
    each of which groups may be optionally substituted with a linker group to which is attached a
    Figure US20190127359A1-20190502-P00002
    group (including a
    Figure US20190127359A1-20190502-P00003
    group).
  • In certain preferred aspects,
  • Figure US20190127359A1-20190502-C00007
  • is a
  • Figure US20190127359A1-20190502-C00008
  • group,
    Where RPRO and n are the same as above.
  • Preferred heteroaryl groups for R2′ include an optionally substituted quinoline (which may be attached to the pharmacophore or substituted on any carbon atom within the quinoline ring), an optionally substituted indole, an optionally substituted indolizine, an optionally substituted azaindolizine, an optionally substituted benzofuran, including an optionally substituted benzofuran, an optionally substituted isoxazole, an optionally substituted thiazole, an optionally substituted isothiazole, an optionally substituted thiophene, an optionally substituted pyridine (2-, 3, or 4-pyridine), an optionally substituted imidazole, an optionally substituted pyrrole, an optionally substituted diazole, an optionally substituted triazole, a tetrazole, an optionally substituted oximidazole, or a group according to the chemical structure:
  • Figure US20190127359A1-20190502-C00009
  • Where Sc is CHRSS, NRURE, or O;
    RHET is H, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted O(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group —C≡C—Ra where Ra is H or a C1-C6 alkyl group (preferably C1-C3 alkyl);
    RSS is H, CN, NO2, halo (preferably F or Cl), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted O—(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted —C(O)(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
    RURE is H, a C1-C6 alkyl (preferably H or C1-C3 alkyl) or a —C(O)(C1-C6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and
    YC is N or C—RYC, where RYC is H, OH, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted O(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group —C≡C—Ra where Ra is H or a C1-C6 alkyl group (preferably C1-C3 alkyl), each of which groups may be optionally substituted with a linker group to which is attached a
    Figure US20190127359A1-20190502-P00002
    group (including a
    Figure US20190127359A1-20190502-P00003
    group);
  • Preferred heterocycle groups for R2′ include tetrahydrofuran, tetrahydrothiene, tetrahydroquinoline, piperidine, piperazine, pyrrolidine, morpholine, oxane or thiane, each of which groups may be optionally substituted, or a group according to the chemical structure:
  • Figure US20190127359A1-20190502-C00010
    • Preferably, a
  • Figure US20190127359A1-20190502-C00011
  • group,
    Where RPRO is H, optionally substituted C1-C6 alkyl or an optionally substituted aryl, heteroaryl or heterocyclic group;
    RPRO1 and RPRO2 are each independently H, an optionally subsituted C1-C3 alkyl group or together form a keto group and
    Each n is independently 0, 1, 2, 3, 4, 5, or 6 (often 0 or 1), each of which groups may be optionally substituted with a linker group to which is attached a
    Figure US20190127359A1-20190502-P00002
    group (including a
    Figure US20190127359A1-20190502-P00003
    group).
  • Preferred R2′ substituents for use in the present invention also include specifically (and without limitation to the specific compound disclosed) the R2′ substituents which are found in the identified compounds disclosed herein (which includes the specific compounds which are disclosed in the present specification, and the figures which are attached hereto). Each of these R2′ substituents may be used in conjunction with any number of R3′ substituents which are also disclosed herein.
  • R3′ is preferably an optionally substituted -T-Aryl, an optionally substituted -T-Heteroaryl, an optionally substituted -T-Heterocycle, an optionally substituted —NR1-T-Aryl, an optionally substituted —NR1-T-Heteroaryl or an optionally substituted —NR1-T-Heterocycle, where R1 is H or a C1-C3 alkyl group, preferably H or CH3, T is an optionally substituted —(CH2)n— group, wherein each one of the methylene groups may be optionally substituted with one or two substituents, preferably selected from halogen, a C1-C3 alkyl group or the sidechain of an amino acid as otherwise described herein, preferably methyl, which may be optionally substituted; and n is 0 to 6, often 0, 1, 2, or 3 preferably 0 or 1. Alternatively, T may also be a —(CH2O)n— group, a —(OCH2)n— group, a —(CH2CH2O)n— group, a —(OCH2CH2)n— group, each of which groups is optionally substituted.
  • Preferred aryl groups for R3 include optionally substituted phenyl or naphthyl groups, preferably phenyl groups, wherein the phenyl or naphthyl group s optionally substituted with a linker group to which is attached a
    Figure US20190127359A1-20190502-P00002
    group (including a
    Figure US20190127359A1-20190502-P00003
    group) and/or a halogen (preferably F or Cl), an amine, monoalkyl- or dialkyl amine (preferably, dimethylamine), an amido group (preferably a —(CH2)m—NR1C(O)R2 group where m, R1 and R2 are the same as above), a halo (often F or Cl), OH, CH3, CF3, OMe, OCF3, NO2, CN or a S(O)2RS group (RS is a a C1-C6 alkyl group, an optionally substituted aryl, heteroaryl or heterocycle group or a —(CH2)mNR1R2 group), each of which may be substituted in ortho-, meta- and/or para-positions of the phenyl ring, preferably para-), or an Aryl (preferably phenyl), Heteroaryl or Heterocycle. Preferably said substituent phenyl group is an optionally substituted phenyl group (i.e., the substituent phenyl group itself is preferably substituted with at least one of F, Cl, OH, SH, COOH, CH3, CF3, OMe, OCF3, NO2, CN or a linker group to which is attached a
    Figure US20190127359A1-20190502-P00002
    group (including a
    Figure US20190127359A1-20190502-P00003
    group), wherein the substitution occurs in ortho-, meta- and/or para-positions of the phenyl ring, preferably para-), a naphthyl group, which may be optionally substituted including as described above, an optionally substituted heteroaryl (preferably an optionally substituted isoxazole including a methylsubstituted isoxazole, an optionally substituted oxazole including a methylsubstituted oxazole, an optionally substituted thiazole including a methyl substituted thiazole, an optionally substituted pyrrole including a methylsubstituted pyrrole, an optionally substituted imidazole including a methylimidazole, a benzylimidazole or methoxybenzylimidazole, an oximidazole or methyloximidazole, an optionally substituted diazole group, including a methyldiazole group, an optionally substituted triazole group, including a methylsubstituted triazole group, a pyridine group, including a halo- (preferably, F) or methylsubstitutedpyridine group or an oxapyridine group (where the pyridine group is linked to the phenyl group by an oxygen) or an optionally substituted heterocycle (tetrahydrofuran, tetrahydrothiophene, pyrrolidine, piperidine, morpholine, piperazine, tetrahydroquinoline, oxane or thiane. Each of the aryl, heteroaryl or heterocyclic groups may be optionally substituted with a linker group to which is attached a
    Figure US20190127359A1-20190502-P00002
    group (including a
    Figure US20190127359A1-20190502-P00003
    group).
  • Preferred Heteroaryl groups for R3 include an optionally substituted quinoline (which may be attached to the pharmacophore or substituted on any carbon atom within the quinoline ring), an optionally substituted indole (including dihydroindole), an optionally substituted indolizine, an optionally substituted azaindolizine (2, 3 or 4-azaindolizine) an optionally substituted benzimidazole, benzodiazole, benzoxofuran, an optionally substituted imidazole, an optionally substituted isoxazole, an optionally substituted oxazole (preferably methyl substituted), an optionally substituted diazole, an optionally substituted triazole, a tetrazole, an optionally substituted benzofuran, an optionally substituted thiophene, an optionally substituted thiazole (preferably methyl and/or thiol substituted), an optionally substituted isothiazole, an optionally substituted triazole (preferably a 1,2,3-triazole substituted with a methyl group, a triisopropylsilyl group, an optionally substituted —(CH2)m—O—C1-C6 alkyl group or an optionally substituted —(CH2)m—C(O)—O—C1-C6 alkyl group), an optionally substituted pyridine (2-, 3, or 4-pyridine) or a group according to the chemical structure:
  • Figure US20190127359A1-20190502-C00012
  • Where Sc is CHRSS, NRURE, or O;
    RHET is H, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted O(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group —C≡C—Ra where Ra is H or a C1-C6 alkyl group (preferably C1-C3 alkyl);
    RSS is H, CN, NO2, halo (preferably F or Cl), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted O—(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted —C(O)(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
    RURE is H, a C1-C6 alkyl (preferably H or C1-C3 alkyl) or a —C(O)(C1-C6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and
    YC is N or C—RYC, where RYC is H, OH, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted O(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group —C≡C—Ra where Ra is H or a C1-C6 alkyl group (preferably C1-C3 alkyl). Each of said heteroaryl groups may be optionally substituted with a linker group to which is attached a
    Figure US20190127359A1-20190502-P00002
    group (including a
    Figure US20190127359A1-20190502-P00003
    group).
  • Preferred heterocycle groups for R3′ include tetrahydroquinoline, piperidine, piperazine, pyrrolidine, morpholine, tetrahydrofuran, tetrahydrothiophene, oxane and thiane, each of which groups may be optionally substituted or a group according to the chemical structure:
  • Figure US20190127359A1-20190502-C00013
    • Preferably, a
  • Figure US20190127359A1-20190502-C00014
  • group, Where RPRO is H, optionally substituted C1-C6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C1-C3 alkyl group, preferably methyl or a halo group, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine;
    RPRO1 and RPRO2 are each independently H, an optionally substituted C1-C3 alkyl group or together form a keto group, and
    Each n is 0, 1, 2, 3, 4, 5, or 6 (preferably 0 or 1), wherein each of said Heteocycle groups may be optionally substituted with a linker group to which is attached a
    Figure US20190127359A1-20190502-P00002
    group (including a
    Figure US20190127359A1-20190502-P00003
    group).
  • Preferred R3′ substituents for use in the present invention also include specifically (and without limitation to the specific compound disclosed) the R3′ substituents which are found in the identified compounds disclosed herein (which includes the specific compounds which are disclosed in the present specification, and the figures which are attached hereto). Each of these R3′ substituents may be used in conjunction with any number of R2′ substituents which are also disclosed herein.
  • In certain alternative preferred embodiments, R2′ is an optionally substituted —NR1—XR2′-alkyl group, —NR1—XR2′-Aryl group; an optionally substituted —NR1—XR2′-HET, an optionally substituted —NR1—XR2′-Aryl-HET or an optionally substituted —NR1—XR2′-HET-Aryl,
  • Where R1 is H or a C1-C3 alkyl group (preferably H);
    XR2′ is an optionally substituted —CH2)n—, —CH2)n—CH(Xv)═CH(Xv)— (cis or trans), —CH2)n—CH≡CH—, —(CH2CH2O)n— or a C3-C6 cycloalkyl group;
    where Xv is H, a halo or a C1-C3 alkyl group which is optionally substituted with one or two hydroxyl groups or up to three halogen groups;
    Alkyl is an optionally substituted C1-C10 alkyl (preferably a C1-C6 alkyl) group (in certain preferred embodiments, the alkyl group is end-capped with a halo group, often a Cl or Br); Aryl is an optionally substituted phenyl or naphthyl group (preferably, a phenyl group); and HET is an optionally substituted oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, benzofuran, indole, indolizine, azaindolizine, quinoline (when substituted, each preferably substituted with a C1-C3 alkyl group, preferably methyl or a halo group, preferably F or Cl) or a group according to the chemical structure:
  • Figure US20190127359A1-20190502-C00015
  • Where Sc is CHRSS, NRURE, or O;
    RHET is H, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted O(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group —C≡C—Ra where Ra is H or a C1-C6 alkyl group (preferably C1-C3 alkyl);
    RSS is H, CN, NO2, halo (preferably F or Cl), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted O—(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted —C(O)(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
    RURE is H, a C1-C6 alkyl (preferably H or C1-C3 alkyl) or a —C(O)(C1-C6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and
    YC is N or C—RYC, where RYC is H, OH, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted O(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group —C≡C—Ra where Ra is H or a C1-C6 alkyl group (preferably C1-C3 alkyl);
    RPRO is H, optionally substituted C1-C6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C1-C3 alkyl group, preferably methyl or a halo group, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine;
    RPRO1 and RPRO2 are each independently H, an optionally substituted C1-C3 alkyl group or together form a keto group, and
    Each n is independently 0, 1, 2, 3, 4, 5, or 6 (preferably 0 or 1). Each of said groups may be optionally substituted with a linker group to which is attached a
    Figure US20190127359A1-20190502-P00002
    group (including a
    Figure US20190127359A1-20190502-P00003
    group).
  • In certain alternative preferred embodiments of the present invention, R3′ is an optionally substituted —(CH2)n—(V)n′—(CH2)n—(V)n′—RS3′ group, an optionally substituted —(CH2)n—N(R1′)(C═O)m′—(V)n′—RS3′ group, an optionally substituted —XR3′-alkyl group, an optionally substituted —XR3′-Aryl group; an optionally substituted —XR3′-HET group, an optionally substituted —XR3′-Aryl-HET group or an optionally substituted —XR3′-HET-Aryl group,
  • Where RS3′ is an optionally substituted alkyl group (C1-C10, preferably C1-C6 alkyl), an optionally substituted Aryl group or a HET group;
    R1′ is H or a C1-C3 alkyl group (preferably H);
    • V is O, S or NR1′;
  • XR3′ is —(CH2)n—, —(CH2CH2O)n—, —CH2)n—CH(Xv)═CH(Xv)— (cis or trans), —CH2)n—CH≡CH—, or a C3-C6 cycloalkyl group, all optionally substituted;
    where Xv is H, a halo or a C1-C3 alkyl group which is optionally substituted with one or two hydroxyl groups or up to three halogen groups;
    Alkyl is an optionally substituted C1-C10 alkyl (preferably a C1-C6 alkyl) group (in certain preferred embodiments, the alkyl group is end-capped with a halo group, often a Cl or Br); Aryl is an optionally substituted phenyl or napthyl group (preferably, a phenyl group); and HET is an optionally substituted oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, benzofuran, indole, indolizine, azaindolizine, quinoline (when substituted, each preferably substituted with a C1-C3 alkyl group, preferably methyl or a halo group, preferably F or Cl), or a group according to the chemical structure:
  • Figure US20190127359A1-20190502-C00016
  • Where Sc is CHRSS, NRURE, or O;
    RHET is H, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted O(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group —C≡C—Ra where Ra is H or a C1-C6 alkyl group (preferably C1-C3 alkyl);
    RSS is H, CN, NO2, halo (preferably F or Cl), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted O—(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted —C(O)(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
    RURE is H, a C1-C6 alkyl (preferably H or C1-C3 alkyl) or a —C(O)(C0-C6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and
    YC is N or C—RYC, where RYC is H, OH, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted O(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group —C≡C—Ra where Ra is H or a C1-C6 alkyl group (preferably C1-C3 alkyl);
    RPRO is H, optionally substituted C1-C6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C1-C3 alkyl group, preferably methyl or a halo group, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine;
    RPRO1 and RPRO2 are each independently H, an optionally substituted C1-C3 alkyl group or together form a keto group, and
    Each n is independently 0, 1, 2, 3, 4, 5, or 6 (preferably 0 or 1);
    Each m′ is 0 or 1; and
    Each n′ is 0 or 1,
    Wherein each of said compounds, preferably on the alkyl, Aryl or Het groups, is substituted with a linker group to which is attached a
    Figure US20190127359A1-20190502-P00002
    group (including a
    Figure US20190127359A1-20190502-P00003
    group).
  • In alternative embodiments, R3′ is —(CH2)n-Aryl, —(CH2CH2O)n-Aryl, —(CH2)n-HET or —(CH2CH2O)n—HET;
  • Where Aryl is phenyl which is optionally substituted with one or two substitutents, wherein said substituent(s) is preferably selected from —(CH2)nOH, C1-C6 alkyl which itself is further optionally substituted with CN, halo (up to three halo groups), OH, —(CH2)nO(C1-C6)alkyl, amine, mono- or di-(C1-C6 alkyl) amine wherein the alkyl group on the amine is optionally substituted with 1 or 2 hydroxyl groups or up to three halo (preferably F, Cl) groups, or said Aryl group is substituted with —(CH2)nOH, —(CH2)n—O—(C1-C6)alkyl, —(CH2)n—O—(CH2)n—(C1-C6)alkyl, —(CH2)n—C(O)(C0-C6) alkyl, —(CH2)n—C(O)O(C0-C6)alkyl, —(CH2)n—OC(O)(C0-C6)alkyl, amine, mono- or di-(C1-C6 alkyl) amine wherein the alkyl group on the amine is optionally substituted with 1 or 2 hydroxyl groups or up to three halo (preferably F, Cl) groups, CN, NO2, an optionally substituted —(CH2)n—(V)m′—CH2)n—(V)m′—(C1-C6)alkyl group, a —(V)m′—(CH2CH2O)n—RPEG group where V is O, S or NR1′, R1′ is H or a C1-C3 alkyl group (preferably H) and RPEG is H or a C1-C6 alkyl group which is optionally substituted (including being optionally substituted with a carboxyl group), or said Aryl group is optionally substituted with a heterocycle, including a heteroaryl, selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, benzofuran, indole, indolizine, azaindolizine, (when substituted each preferably substituted with a C1-C3 alkyl group, preferably methyl or a halo group, preferably F or Cl), or a group according to the chemical structure:
  • Figure US20190127359A1-20190502-C00017
  • Where Sc is CHRSS, NRURE, or O;
    RHET is H, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted O(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group —C≡C—Ra where Ra is H or a C1-C6 alkyl group (preferably C1-C3 alkyl);
    RSS is H, CN, NO2, halo (preferably F or Cl), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted O—(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted —C(O)(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
    RURE is H, a C1-C6 alkyl (preferably H or C1-C3 alkyl) or a —C(O)(C0-C6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and
    YC is N or C—RYC, where RYC is H, OH, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted O(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group —C≡C—Ra where Ra is H or a C1-C6 alkyl group (preferably C1-C3 alkyl);
    RPRO is H, optionally substituted C1-C6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C1-C3 alkyl group, preferably methyl or a halo group, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine;
    RPRO1 and RPRO2 are each independently H, an optionally substituted C1-C3 alkyl group or together form a keto group;
    HET is preferably oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C1-C3 alkyl group, preferably methyl or a halo group, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine, or a group according to the chemical structure:
  • Figure US20190127359A1-20190502-C00018
  • Where Sc is CHRSS, NRURE, or O;
    RHET is H, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted O(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group —C≡C—Ra where Ra is H or a C1-C6 alkyl group (preferably C1-C3 alkyl);
    RSS is H, CN, NO2, halo (preferably F or Cl), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted O—(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted —C(O)(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
    RURE is H, a C1-C6 alkyl (preferably H or C1-C3 alkyl) or a —C(O)(C0-C6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and
    YC is N or C—RYC, where RYC is H, OH, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted O(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group —C≡C—Ra where Ra is H or a C1-C6 alkyl group (preferably C1-C3 alkyl);
    RPRO is H, optionally substituted C1-C6 alkyl or an optionally substituted aryl, heteroaryl or heterocyclic group;
    RPRO1 and RPRO2 are each independently H, an optionally substituted C1-C3 alkyl group or together form a keto group,
    Each m′ is independently 0 or 1, and
    Each n is independently 0, 1, 2, 3, 4, 5, or 6 (preferably 0 or 1),
    Wherein each of said compounds, preferably on said Aryl or HET groups, is substituted with a linker group to which is attached a
    Figure US20190127359A1-20190502-P00002
    group (including a
    Figure US20190127359A1-20190502-P00003
    group).
  • In still additional embodiments, preferred compounds include those according to the chemical structure:
  • Figure US20190127359A1-20190502-C00019
  • Where R1′ is OH or a group which is metabolized in a patient or subject to OH;
    R2′ is a —NH—CH2-Aryl-HET (preferably, a phenyl linked directly to a methyl substituted thiazole);
    R3′ is a —CHRCR3′—NH—C(O)—R3P1 group or a —CHRCR3′—R3P2 group;
    Where RCR3′ is a C1-C4 alkyl group, preferably methyl, isopropyl or tert-butyl;
    R3P1 is C1-C3 alkyl (preferably methyl), an optionally substituted oxetane group (preferably methyl substituted, a —(CH2)nOCH3 group where n is 1 or 2 (preferably 2), or a
  • Figure US20190127359A1-20190502-C00020
  • group (the ethyl ether group is preferably meta-substituted on the phenyl moiety), a morpholino grop (linked to the carbonyl at the 2- or 3-position;
    • R3P2 is
  • Figure US20190127359A1-20190502-C00021
  • group,
    Where Aryl is phenyl;
    HET is an optionally substituted thiazole or isothiazole; and
    RHET is H or a halo group (preferably H),
    Or a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof, wherein each of said compounds is substituted with a linker group to which is attached a
    Figure US20190127359A1-20190502-P00002
    group (including a
    Figure US20190127359A1-20190502-P00003
    group)
  • In an alternative embodiment,
    Figure US20190127359A1-20190502-P00001
    groups for inclusion in compounds according to the present invention include:
  • Figure US20190127359A1-20190502-C00022
  • Where X is Cl, F, C1-C3 alkyl (preferably methyl) or heterocycle (preferably an optionally substituted heterocycle, including as defined above for R3′;
    R1 and R2 are each independently H, C1-C3 alkyl (preferably methyl), or phenyl and each of said compounds is substituted with a linker group or a linker group to which is attached a
    Figure US20190127359A1-20190502-P00002
    group, or a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
  • Additional preferred
    Figure US20190127359A1-20190502-P00001
    groups for inclusion in compounds according to the present invention include:
  • Figure US20190127359A1-20190502-C00023
    • Where n is 0 or 1;
  • R is a linker or a linker attached to a
    Figure US20190127359A1-20190502-P00002
    group
    X is H, F, Cl, C1-C3 alkyl (preferably methyl) or heterocycle (preferably an optionally substituted heterocycle, especially including a water soluble heterocycle such as a morpholino group, including as defined above for R3′), or
    a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
  • Additional preferred
    Figure US20190127359A1-20190502-P00001
    groups for inclusion in compounds according to the present invention include for example:
  • Figure US20190127359A1-20190502-C00024
    • Where n is 0 or 1;
  • R is a linker or a linker attached to a
    Figure US20190127359A1-20190502-P00002
    group a linker or a linker attached to a
    Figure US20190127359A1-20190502-P00002
    group linked to the
    Figure US20190127359A1-20190502-P00001
    group through an amide, ester, ether or carbamate group;
    R1 is C1-C3 alkyl (optionally substituted with one or two hydroxyl groups) or —C(O)NR3R4 where R3 and R4 are each independently H, C1-C3 alkyl (preferably methyl), phenyl or heterocycle (including a heterocycle such as a morpholino, piperazine or other group which increases water solubility),
    X is H, F, Cl, C1-C3 alkyl (preferably methyl) or heterocycle (preferably an optionally substituted heterocycle, including a water soluble heterocycle, including as defined above for R3′), or a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
  • Still further preferred
    Figure US20190127359A1-20190502-P00001
    groups for inclusion in compounds according to the present invention include for example:
  • Figure US20190127359A1-20190502-C00025
    • Where n is 0 or 1;
  • R1 is a linker or a linker attached to a
    Figure US20190127359A1-20190502-P00002
    group linked to the
    Figure US20190127359A1-20190502-P00001
    group through an amide, ester, ether, carbamate or heterocyclic group (preferably an optionally substituted heterocycle, including as defined above for R3′);
    R is H, F, Cl, C1-C3 alkyl (optionally substituted with one or two hydroxyl groups, preferably methyl), —O—C(O)NR3R4 or —C(O)NR3R4 wherein each of R3 and R4 is independently H, C1-C3 alkyl (preferably methyl), phenyl or heterocycle, including a water soluble heterocycle, or A pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
  • Yet still further preferred
    Figure US20190127359A1-20190502-P00001
    groups for inclusion in compounds according to the present invention include for example:
  • Figure US20190127359A1-20190502-C00026
    • Where n is 0 or 1;
  • R is a linker or a linker attached to a
    Figure US20190127359A1-20190502-P00002
    group linked to the
    Figure US20190127359A1-20190502-P00001
    group through an amide, ester, ether, carbamate or heterocyclic group; and
    Each X is independently is H, F, Cl, C1-C3 alkyl (optionally substituted with one or two hydroxyl groups, preferably methyl), heterocyle (preferably an optionally substituted heterocycle, including a water soluble heterocycle, and/or as defined above for R3′), —O—C(O)NR3R4 or —C(O)NR3R4 wherein each of R3 and R4 is independently H, C1-C3 alkyl (preferably methyl), or phenyl, or
    a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
  • Yet additional further preferred
    Figure US20190127359A1-20190502-P00001
    groups for inclusion in compounds according to the present invention include for example:
  • Figure US20190127359A1-20190502-C00027
    • Where n is 0 or 1;
  • R is a linker or a linker attached to a
    Figure US20190127359A1-20190502-P00002
    group linked to the
    Figure US20190127359A1-20190502-P00001
    group through an amide, ester, ether, carbamate or heterocyclic group;
    R1 is C1-C3 alkyl, which is optionally substituted with one or two hydroxyl groups, —O—C(O)NR3R4 or —C(O)NR3R4 wherein each of R3 and R4 is independently H, C1-C3 alkyl (preferably methyl), or phenyl; and
    X is independently is H, F, Cl, C1-C3 alkyl (optionally substituted with one or two hydroxyl groups, preferably methyl) or heterocycle (preferably an optionally substituted heterocycle, including a water soluble heterocycle, and/or as defined above for R3′), or a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
  • Yet additional further preferred
    Figure US20190127359A1-20190502-P00001
    groups for inclusion in compounds according to the present invention include for example:
  • Figure US20190127359A1-20190502-C00028
    • Where n is 0 or 1;
  • R is a linker or a linker attached to a
    Figure US20190127359A1-20190502-P00002
    group linked to the
    Figure US20190127359A1-20190502-P00001
    group through an amide, ester, ether, carbamate or heterocyclic group;
    R1 is H, C1-C3 alkyl, which is optionally substituted with one or two hydroxyl groups, —O—C(O)NR3R4 or —C(O)NR3R4 wherein each of R3 and R4 is independently H, C1-C3 alkyl (preferably methyl), or phenyl; and
    Each X is independently is H, F, Cl, C1-C3 alkyl (optionally substituted with one or two hydroxyl groups, preferably methyl) or heterocycle (preferably an optionally substituted heterocycle, including a water soluble heterocycle and/or including as defined above for R3′), or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof.
  • In an additional embodiment, particularly preferred compounds according to the present invention may be identified according to any one or more of the chemical structures as set forth in FIG. 19 hereof:
  • Wherein any one or more of R1PC, R2PC, R3PC, R4PC, R5PC, R6PC, R7PC, R8PC, R9PC, R10PC, R11PC, R12PC, R13PC and R14PC is a
  • Figure US20190127359A1-20190502-C00029
  • group,
    Where L is a linker group and
    Figure US20190127359A1-20190502-P00002
    is a protein targeting moiety, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thererof.
  • In preferred embodiments, no more than two of R1PC, R2PC, R3PC, R4PC, R5PC, R6PC, R7PC, R8PC, R9PC, R10PC, R11PC, R12PC, R13PC and R14PC is a
  • Figure US20190127359A1-20190502-C00030
  • group and the other of groups R1PC, R2PC, R3PC, R4PC, R5PC, R6PC, R7PC, R8PC, R9PC, R10PC, R11PC, R12PC, R13PC and R14PC are independently H or a CH3 group, often H.
  • Certain preferred embodiments are directed to compounds according to the chemical structure:
  • Figure US20190127359A1-20190502-C00031
  • Wherein R7PC and R10PC are each independently a
  • Figure US20190127359A1-20190502-C00032
  • group or H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, either of R7PC Or R10PC is a
  • Figure US20190127359A1-20190502-C00033
  • group and the other R7PC or R10PC is H.
  • In other preferred embodiments, the compound has the chemical structure:
  • Figure US20190127359A1-20190502-C00034
    • Wherein R7PC is a
  • Figure US20190127359A1-20190502-C00035
  • group, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • In still other preferred embodiments, the compound has the chemical structure:
  • Figure US20190127359A1-20190502-C00036
  • Wherein R7PC, R11PC R12PC, R13PC and R14PC are each independently a
  • Figure US20190127359A1-20190502-C00037
  • group or H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, one of R7PC, R11PC, R12PC, R13PC and R14PC is a
  • Figure US20190127359A1-20190502-C00038
  • group and the other groups are H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • In still other preferred embodiments, the compound has the chemical structure:
  • Figure US20190127359A1-20190502-C00039
  • Wherein R4PC, R7PC, R11PC R12PC, R13PC and R14PC are each independently a
  • Figure US20190127359A1-20190502-C00040
  • group or H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, either of R4PC, R7PC or one of R11PC, R12PC, R13PC and R14PC is a
  • Figure US20190127359A1-20190502-C00041
  • group and the other groups are H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • In still other preferred embodiments, the compound has the chemical structure:
  • Figure US20190127359A1-20190502-C00042
  • Wherein R3PC, R7PC R11PC R12PC, R13PC and R14PC are each independently a
  • Figure US20190127359A1-20190502-C00043
  • group or H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, one of R3PC, R7PC, R11PC, R12PC, R13PC and R14PC is a
  • Figure US20190127359A1-20190502-C00044
  • group and the other groups are H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • In still other preferred embodiments, the compound has the chemical structure:
  • Figure US20190127359A1-20190502-C00045
  • Wherein R7PC and R10PC are each independently a
  • Figure US20190127359A1-20190502-C00046
  • group or H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, one of R7PC and R10PC is a
  • Figure US20190127359A1-20190502-C00047
  • group and the other group is H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • In still other preferred embodiments, the compound has the chemical structure:
  • Figure US20190127359A1-20190502-C00048
  • Wherein R7PC and R10PC are each independently a
  • Figure US20190127359A1-20190502-C00049
  • group or H and R8PC is H or CH3, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, one of R7PC and R10PC is a
  • Figure US20190127359A1-20190502-C00050
  • group and the other group is H and R8PC is H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • In still other preferred embodiments, the compound has the chemical structure:
  • Figure US20190127359A1-20190502-C00051
  • Wherein R7PC and R10PC are each independently a
  • Figure US20190127359A1-20190502-C00052
  • group or H and R8PC is H or CH3, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, one of R7PC and R10PC is a
  • Figure US20190127359A1-20190502-C00053
  • group and the other group is H and R8PC is H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
    In still other preferred embodiments, the compound has the chemical structure:
  • Figure US20190127359A1-20190502-C00054
  • Wherein R7PC and R10PC are each independently a
  • Figure US20190127359A1-20190502-C00055
  • group or H and R8PC is H or CH3 or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, one of R7PC and R10PC is a
  • Figure US20190127359A1-20190502-C00056
  • group and the other group is H and R8PC is H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • In still other preferred embodiments, the compound has the chemical structure:
  • Figure US20190127359A1-20190502-C00057
  • Wherein R7PC and R10PC are each independently a
  • Figure US20190127359A1-20190502-C00058
  • group or H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, one of R7PC and R10PC is a
  • Figure US20190127359A1-20190502-C00059
  • group and the other group is H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • In still other preferred embodiments, the compound has the chemical structure:
  • Figure US20190127359A1-20190502-C00060
  • Wherein R7PC and R9PC are each independently a
  • Figure US20190127359A1-20190502-C00061
  • group or H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, one of R7PC and R9PC is a
  • Figure US20190127359A1-20190502-C00062
  • group and the other group is H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • In still other preferred embodiments, the compound has the chemical structure:
  • Figure US20190127359A1-20190502-C00063
  • Wherein R7PC and R14PC are each independently a
  • Figure US20190127359A1-20190502-C00064
  • group or H and each of R12PC and R13PC is H or CH3, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, one of R7PC and R14PC is a
  • Figure US20190127359A1-20190502-C00065
  • group and the other of R7PC and R14PC group is H and each of R12PC and R13PC is H,
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • In still other preferred embodiments, the compound has the chemical structure:
  • Figure US20190127359A1-20190502-C00066
  • Wherein R7PC and R9PC are each independently a
  • Figure US20190127359A1-20190502-C00067
  • group or H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, one of R7PC and R9PC is a
  • Figure US20190127359A1-20190502-C00068
  • group and the other group is H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • In still other preferred embodiments, the compound has the chemical structure:
  • Figure US20190127359A1-20190502-C00069
  • Wherein R7PC and R9PC are each independently a
  • Figure US20190127359A1-20190502-C00070
  • group or H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably,
    one of R7PC and R9PC is a
  • Figure US20190127359A1-20190502-C00071
  • group and the other group is H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • In still other preferred embodiments, the compound has the chemical structure:
  • Figure US20190127359A1-20190502-C00072
  • Wherein R7PC and R10PC are each independently a
  • Figure US20190127359A1-20190502-C00073
  • group or H and R9PC is H or CH3, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, one of R7PC and R10PC is a
  • Figure US20190127359A1-20190502-C00074
  • group and the other group is H and R9PC is H, or
    A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • In the above embodiments, the linker group may be any linker group as described hereinabove, below is preferably a polyethylene glycol group ranging in size from about 1 to about 12 ethylene glycol units, between 1 and about 10 ethylene glycol units, about 2 about 6 ethylene glycol units, between about 2 and 5 ethylene glycol units, between about 2 and 4 ethylene glycole units.
  • In preferred embodiments, the linker group L is a group:
  • Figure US20190127359A1-20190502-C00075
  • Where Z is a group which link
    Figure US20190127359A1-20190502-P00001
    to X; and
    X is a group linking Z to group
    Figure US20190127359A1-20190502-P00002
    (including a
    Figure US20190127359A1-20190502-P00003
    group).
  • In preferred aspects, Z is absent (a bond), —(CH2)i—O, —(CH2)i—S, —(CH2)i—N—R, a (CH2)i—X1Y1 group wherein X1Y1 forms an amide group, or a urethane group, ester or thioester group, or a
  • Figure US20190127359A1-20190502-C00076
  • group
    Each R is H, or a C1-C3 alkyl, an alkanol group or a heterocycle (including a water soluble heterocycle, preferably, a morpholino, piperidine or piperazine group to promote water solubility of the linker group);
    Each Y is independently a bond, O, S or N—R;
    and each i is independently 0 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5;
  • In preferred aspects X is a
  • Figure US20190127359A1-20190502-C00077
  • group
    Where each D is independently a bond absent),
  • Figure US20190127359A1-20190502-C00078
  • j is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5;
    k is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5; preferably k is 1, 2, 3, 4, or 5;
    m′ is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5;
    n is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5;
    X1 is O, S or N—R, preferably O;
    Y is the same as above; and
    Figure US20190127359A1-20190502-P00004
    is a connector group (which may be a bond) which connects Z to X, when present in the linker group.
  • In preferred aspects,
    Figure US20190127359A1-20190502-P00004
    is a bond (absent), a heterocycle including a water soluble heterocycle such as a piperazinyl or other group or a
  • Figure US20190127359A1-20190502-C00079
  • Where X2 is O, S, NR4, S(O), S(O)2, —S(O)2O, —OS(O)2, or OS(O)2O;
    X3 is O, S, CHR4, NR4; and
    R4 is H or a C1-C3 alkyl group optionally substituted with one or two hydroxyl groups, or a pharmaceutically acceptable salt, enantiomer or stereoisomer thereof.
  • In alternative preferred aspects, the linker group is a (poly)ethyleneglycol having between 1 and about 100 ethylene glycol units, between about 1 and about 50 ethylene glycol units, between 1 and about 25 ethylene glycol units, between about 1 and 10 ethylene glycol units, between 1 and about 8 ethylene glycol units and 1 and 6 ethylene glycol units, between 2 and 4 ethylene glycol units.
  • In alternative preferred aspects,
    Figure US20190127359A1-20190502-P00004
    is a
  • Figure US20190127359A1-20190502-C00080
  • group or an amide group.
  • Although the
    Figure US20190127359A1-20190502-P00001
    group and
    Figure US20190127359A1-20190502-P00002
    group (including
    Figure US20190127359A1-20190502-P00003
    group) may be covalently linked to the linker group through any group which is appropriate and stable to the chemistry of the linker, in preferred aspects of the present invention, the linker is independently covalently bonded to the
    Figure US20190127359A1-20190502-P00001
    group and the
    Figure US20190127359A1-20190502-P00002
    group (including a group) preferably through an amide, ester, thioester, keto group, carbamate
    Figure US20190127359A1-20190502-P00005
    (urethane) or ether, each of which groups may be inserted anywhere on the
    Figure US20190127359A1-20190502-P00001
    group and
    Figure US20190127359A1-20190502-P00002
    group (including a
    Figure US20190127359A1-20190502-P00003
    group) to provide maximum binding of the
    Figure US20190127359A1-20190502-P00001
    group on the ubiquitin ligase and the
    Figure US20190127359A1-20190502-P00003
    group on the target protein to be degraded. (It is noted that in certain aspects where the
    Figure US20190127359A1-20190502-P00003
    group is a
    Figure US20190127359A1-20190502-P00003
    group, the target protein for degradation may be the ubiquitin ligase itself). In certain preferred aspects, the linker may be linked to an optionally substituted alkyl, alkylene, alkene or alkyne group, an aryl group or a heterocyclic group on
    Figure US20190127359A1-20190502-P00001
    the and/or
    Figure US20190127359A1-20190502-P00003
    groups.
  • In preferred aspects of the invention, the
    Figure US20190127359A1-20190502-P00003
    group is a
    Figure US20190127359A1-20190502-P00003
    group, which binds to target proteins. Targets of the
    Figure US20190127359A1-20190502-P00003
    group are numerous in kind and are selected from proteins that are expressed in a cell such that at least a portion of the sequences is found in the cell and may bind to a
    Figure US20190127359A1-20190502-P00003
    group. The term “protein” includes oligopeptides and polypeptide sequences of sufficient length that they can bind to a
    Figure US20190127359A1-20190502-P00003
    group according to the present invention. Any protein in a eukaryotic system or a microbial system, including a virus, bacteria or fungus, as otherwise described herein, are targets for ubiquitination mediated by the compounds according to the present invention. Preferably, the target protein is a eukaryotic protein. In certain aspects, the protein binding moiety is a haloalkane (preferably a C1-C10 alkyl group which is substituted with at least one halo group, preferably a halo group at the distil end of the alkyl group (i.e., away from the linker or
    Figure US20190127359A1-20190502-P00001
    group), which may covalently bind to a dehalogenase enzyme in a patient or subject or in a diagnostic assay.
    Figure US20190127359A1-20190502-P00002
    groups according to the present invention include, for example, include any moiety which binds to a protein specifically (binds to a target protein) and includes the following non-limiting examples of small molecule target protein moieties: Hsp90 inhibitors, kinase inhibitors, MDM2 inhibitors, compounds targeting Human BET Bromodomain-containing proteins, HDAC inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR), among numerous others. The compositions described below exemplify some of the members of these nine types of small molecule target protein binding moieties. Such small molecule target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these compositions, as well as other small molecules that may target a protein of interest. These binding moieties are linked to the ubiquitin ligase binding moiety preferably through a linker in order to present a target protein (to which the protein target moiety is bound) in proximity to the ubiquitin ligase for ubiquitination and degradation.
  • Any protein, which can bind to a protein target moiety or
    Figure US20190127359A1-20190502-P00002
    group and acted on or degraded by an ubiquitin ligase is a target protein according to the present invention. In general, target proteins may include, for example, structural proteins, receptors, enzymes, cell surface proteins, proteins pertinent to the integrated function of a cell, including proteins involved in catalytic activity, aromatase activity, motor activity, helicase activity, metabolic processes (anabolism and catrabolism), antioxidant activity, proteolysis, biosynthesis, proteins with kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulator activity, signal transducer activity, structural molecule activity, binding activity (protein, lipid carbohydrate), receptor activity, cell motility, membrane fusion, cell communication, regulation of biological processes, development, cell differentiation, response to stimulus, behavioral proteins, cell adhesion proteins, proteins involved in cell death, proteins involved in transport (including protein transporter activity, nuclear transport, ion transporter activity, channel transporter activity, carrier activity, permease activity, secretion activity, electron transporter activity, pathogenesis, chaperone regulator activity, nucleic acid binding activity, transcription regulator activity, extracellular organization and biogenesis activity, translation regulator activity. Proteins of interest can include proteins from eurkaryotes and prokaryotes including humans as targets for drug therapy, other animals, including domesticated animals, microbials for the determination of targets for antibiotics and other antimicrobials and plants, and even viruses, among numerous others.
  • In still other embodiments, the
    Figure US20190127359A1-20190502-P00002
    group is a haloalkyl group, wherein said alkyl group generally ranges in size from about 1 or 2 carbons to about 12 carbons in length, often about 2 to 10 carbons in length, often about 3 carbons to about 8 carbons in length, more often about 4 carbons to about 6 carbons in length. The haloalkyl groups are generally linear alkyl groups (although branched-chain alkyl groups may also be used) and are end-capped with at least one halogen group, preferably a single halogen group, often a single chloride group. Haloalkyl
    Figure US20190127359A1-20190502-P00002
    groups for use in the present invention are preferably represented by the chemical structure —(CH2)v-Halo where v is any integer from 2 to about 12, often about 3 to about 8, more often about 4 to about 6. Halo may be any halogen, but is preferably Cl or Br, more often Cl.
  • In still other embodiments, the
    Figure US20190127359A1-20190502-P00002
    group is a
  • Figure US20190127359A1-20190502-C00081
  • group, where w is 0 to 3, preferably 1 or 2. This group binds selectively to estrogen receptors and is useful for treating diseases which are modulated through estrogen receptors, and in particular cancers, such as breast cancer, endometrial cancer, ovarian cancer and uterine cancer, among others.
  • The present invention may be used to treat a number of disease states and/or conditions, including any disease state and/or condition in which proteins are dysregulated and where a patient would benefit from the degradation of proteins.
  • In another aspect, the present invention relates to pharmaceutical compositions comprising an effective amount of a compound as set forth hereinabove, in combination with a pharmaceutically acceptable carrier, additive or excipient, and optionally an additional bioactive agent.
  • In alternative aspects, the present invention relates to a method for treating a disease state by degrading a protein or polypeptide through which a disease state or condition is modulated comprising administering to said patient or subject an effective amount of at least one compound as described hereinabove, optionally in combination with an additional bioactive agent. The method according to the present invention may be used to treat a large number of disease states or conditions including cancer, by virtue of the administration of effective amounts of at least one compound described herein.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The following terms are used to describe the present invention. In instances where a term is not specifically defined herein, that term is given an art-recognized meaning by those of ordinary skill applying that term in context to its use in describing the present invention.
  • Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise (such as in the case of a group containing a number of carbon atoms in which case each carbon atom number falling within the range is provided), between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either both of those included limits are also included in the invention.
  • The term “compound”, as used herein, unless otherwise indicated, refers to any specific chemical compound disclosed herein and includes tautomers, regioisomers, geometric isomers, and where applicable, stereoisomers, including optical isomers (enantiomers) and other stereoisomers (diastereomers) thereof, as well as pharmaceutically acceptable salts and derivatives (including prodrug forms) thereof where applicable, in context. Within its use in context, the term compound generally refers to a single compound, but also may include other compounds such as stereoisomers, regioisomers and/or optical isomers (including racemic mixtures) as well as specific enantiomers or enantiomerically enriched mixtures of disclosed compounds. The term also refers, in context to prodrug forms of compounds which have been modified to facilitate the administration and delivery of compounds to a site of activity. It is noted that in describing the present compounds, numerous substituents and variables associated with same, among others, are described. It is understood by those of ordinary skill that molecules which are described herein are stable compounds as generally described hereunder. When the bond
    Figure US20190127359A1-20190502-P00006
    is shown, both a double bond and single bond are represented within the context of the compound shown.
  • The term “patient” or “subject” is used throughout the specification to describe an animal, preferably a human or a domesticated animal, to whom treatment, including prophylactic treatment, with the compositions according to the present invention is provided.
  • For treatment of those infections, conditions or disease states which are specific for a specific animal such as a human patient, the term patient refers to that specific animal, including a domesticated animal such as a dog or cat or a farm animal such as a horse, cow, sheep, etc. In general, in the present invention, the term patient refers to a human patient unless otherwise stated or implied from the context of the use of the term.
  • The term “effective” is used to describe an amount of a compound, composition or component which, when used within the context of its intended use, effects an intended result. The term effective subsumes all other effective amount or effective concentration terms, which are otherwise described or used in the present application.
  • The term “VCB E3 Ubiquitin Ligase”, “Hippel-Lindau E3 Ubiquitin Ligase” or “Ubiquitin Ligase” is used to describe a target enzyme(s) binding site of ubiquitin ligase moieties in the bifunctional (chimeric) compounds according to the present invention. VCB E3 is a protein that in combination with an E2 ubiquitin-conjugating enzyme causes the attachment of ubiquitin to a lysine on a target protein; the E3 ubiquitin ligase targets specific protein substrates for degradation by the proteasome. Thus, E3 ubiquitin ligase alone or in complex with an E2 ubiquitin conjugating enzyme is responsible for the transfer of ubiquitin to targeted proteins. In general, the ubiquitin ligase is involved in polyubiquitination such that a second ubiquitin is attached to the first, a third is attached to the second, and so forth. Polyubiquitination marks proteins for degradation by the proteasome. However, there are some ubiquitination events that are limited to mono-ubiquitination, in which only a single ubiquitin is added by the ubiquitin ligase to a substrate molecule. Mono-ubiquitinated proteins are not targeted to the proteasome for degradation, but may instead be altered in their cellular location or function, for example, via binding other proteins that have domains capable of binding ubiquitin. Further complicating matters, different lysines on ubiquitin can be targeted by an E3 to make chains. The most common lysine is Lys48 on the ubiquitin chain. This is the lysine used to make polyubiquitin, which is recognized by the proteasome.
  • The term “protein target moiety” or PTM is used to describe a small molecule which binds to a target protein or other protein or polypeptide of interest and places/presents that protein or polypeptide in proximity to an ubiquitin ligase such that degradation of the protein or polypeptide by ubiquitin ligase may occur. Non-limiting examples of small molecule target protein binding moieties include Hsp90 inhibitors, kinase inhibitors, MDM2 inhibitors, compounds targeting Human BET Bromodomain-containing proteins, HDAC inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR), among numerous others. The compositions described below exemplify some of the members of these nine types of small molecule target protein.
  • Protein target moieties according to the present invention include, for example, Haloalkane halogenase inhibitors, Hsp90 inhibitors, kinase inhibitors, MDM2 inhibitors, compounds targeting Human BET Bromodomain-containing proteins, HDAC inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR). The compositions described below exemplify some of the members of these types of small molecule target protein binding moieties. Such small molecule target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these compositions, as well as other small molecules that may target a protein of interest. References which are cited hereinbelow are incorporated by reference herein in their entirety.
    • I. Heat Shock Protein 90 (HSP90) Inhibitors:
  • HSP90 inhibitors as used herein include, but are not limited to:
    1. The HSP90 inhibitors identified in Vallee, et al., “Tricyclic Series of Heat Shock Protein 90 (HSP90) Inhibitors Part I: Discovery of Tricyclic Imidazo[4,5-C]Pyridines as Potent Inhibitors of the HSP90 Molecular Chaperone (2011) J. Med. Chem. 54: 7206, including
  • Figure US20190127359A1-20190502-C00082
  • Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00083
  • group is attached via the terminal amide group;
    • 2. The HSP90 Inhibitor p54 (Modified):
  • Figure US20190127359A1-20190502-C00084
  • Where a linker group L or a
  • Figure US20190127359A1-20190502-C00085
  • group is attached via the terminal acetylene group;
    3. The HSP90 inhibitors (modified) identified in Brough, et al., “4,5-Diarylisoxazole HSP90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer”, J. MED. CHEM. vol: 51, page: 196 (2008), including the compound 2GJ (5-[2,4-DIHYDROXY-5-(1-METHYLETHYL)PHENYL]-N-ETHYL-4-[4-(MORPHOLIN-4-YLMETHYL)PHENYL]ISOXAZOLE-3-CARBOXAMIDE) having the structure:
  • Figure US20190127359A1-20190502-C00086
  • Derivatized, where a linker group L or a
  • Figure US20190127359A1-20190502-C00087
  • group is attached via the amide group (at the amine or at the alkyl group on the amine;
    4. The HSP90 inhibitors (modified) identified in Wright, et al., Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 Isoforms, Chem Biol. 2004 June; 11(6):775-85, including the HSP90 inhibitor PU3 having the structure:
  • Figure US20190127359A1-20190502-C00088
  • Where a linker group L or
  • Figure US20190127359A1-20190502-C00089
  • is attached via the butyl group; and
    5. The HSP90 inhibitor Geldanamycin ((4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1](derivatized) or any of its derivatives (e.g. 17-alkylamino-17-desmethoxygeldanamycin (“17-AAG”) or 17-(2-dimethylaminoethyl)amino-17-desmethoxygeldanamycin (“17-DMAG”)) (derivatized, where a linker group L or a
  • Figure US20190127359A1-20190502-C00090
  • group is attached via the amide group).
    • II. Kinase and Phosphatase Inhibitors:
  • Kinase inhibitors as used herein include, but are not limited to:
    • 1. Erlotinib Derivative Tyrosine Kinase Inhibitor
  • Figure US20190127359A1-20190502-C00091
  • Where R is a linker group L or a
  • Figure US20190127359A1-20190502-C00092
  • group attached via the ether group;
    2. The kinase inhibitor Sunitanib (derivatized):
  • Figure US20190127359A1-20190502-C00093
  • (Derivatized where R is a linker group L or a
  • Figure US20190127359A1-20190502-C00094
  • group attached to the pyrrole moiety);
    1
    3. Kinase inhibitor Sorafenib (derivatized)
  • Figure US20190127359A1-20190502-C00095
  • (Derivatized where R is a linker group L or a
  • Figure US20190127359A1-20190502-C00096
  • group attached to the phenyl moiety);
    4. The kinase Inhibitor Desatinib (derivatized)
  • Figure US20190127359A1-20190502-C00097
  • (Derivatized where R is a linker group L or a
  • Figure US20190127359A1-20190502-C00098
  • attached to the pyrimidine);
    5. The kinase inhibitor Lapatinib (derivatized)
  • Figure US20190127359A1-20190502-C00099
  • Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00100
  • group is attached via the terminal methyl of the sulfonyl methyl group;
    6. The kinase inhibitor U09-CX-5279 (Derivatized)
    7.
  • Figure US20190127359A1-20190502-C00101
  • Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00102
  • group is attached via the amine (aniline), carboxylic acid or amine alpha to cyclopropyl group, or cyclopropyl group;
    7. The kinase inhibitors identified in Millan, et al., Design and Synthesis of Inhaled P38 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease, J. MED. CHEM. vol: 54, page: 7797 (2011), including the kinase inhibitors Y1W and Y1X (Derivatized) having the structures:
  • Figure US20190127359A1-20190502-C00103
  • Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00104
  • group is attached preferably via the propyl group;
  • Figure US20190127359A1-20190502-C00105
  • Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00106
  • group is attached preferably via either the propyl group or the butyl group;
    8. The kinase inhibitors identified in Schenkel, et al., Discovery of Potent and Highly Selective Thienopyridine Janus Kinase 2 Inhibitors J. Med. Chem., 2011, 54 (24), pp 8440-8450, including the compounds 6TP and 0TP (Derivatized) having the structures:
  • Figure US20190127359A1-20190502-C00107
  • Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00108
  • group is attached preferably via the terminal methyl group bound to amide moiety;
  • Figure US20190127359A1-20190502-C00109
  • Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00110
  • group is attached preferably via the terminal methyl group bound to the amide moiety;
    9. The kinase inhibitors identified in Van Eis, et al., “2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymes”, Biorg. Med. Chem. Lett. 2011 Dec. 15; 21(24):7367-72, including the kinase inhibitor 07U having the structure:
  • Figure US20190127359A1-20190502-C00111
  • Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00112
  • group is attached preferably via the secondary amine or terminal amino group;
    10. The kinase inhibitors identified in Lountos, et al., “Structural Characterization of Inhibitor Complexes with Checkpoint Kinase 2 (Chk2), a Drug Target for Cancer Therapy”, J. STRUCT. BIOL. vol: 176, page: 292 (2011), including the kinase inhibitor YCF having the structure:
  • Figure US20190127359A1-20190502-C00113
  • Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00114
  • group is attached preferably via either of the terminal hydroxyl groups;
    11. The kinase inhibitors identified in Lountos, et al., “Structural Characterization of Inhibitor Complexes with Checkpoint Kinase 2 (Chk2), a Drug Target for Cancer Therapy”, J. STRUCT. BIOL. vol: 176, page: 292 (2011), including the kinase inhibitors XK9 and NXP (derivatized) having the structures:
  • Figure US20190127359A1-20190502-C00115
  • Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00116
  • group is attached preferably via the terminal hydroxyl group (XK9) or the hydrazone group (NXP);
    12. The kinase inhibitor Afatinib (derivatized) (N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide) (Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00117
  • group is attached preferably via the aliphatic amine group);
    13. The kinase inhibitor Fostamatinib (derivatized) ([6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-pyrido[3,2-b]-1,4-oxazin-4-yl]methyl disodium phosphate hexahydrate) (Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00118
  • group is attached preferably via a methoxy group);
    14. The kinase inhibitor Gefitinib (derivatized) (N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine) (Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00119
  • group is attached preferably via a methoxy or ether group);
  • Figure US20190127359A1-20190502-C00120
  • 15. The kinase inhibitor Lenvatinib (derivatized) (4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide) (Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00121
  • group is attached preferably via the cyclopropyl group);
    16. The kinase inhibitor Vandetanib (derivatized) (N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine) (derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00122
  • group is attached preferably via the methoxy or hydroxyl group); and
    17. The kinase inhibitor Vemurafenib (derivatized) (propane-1-sulfonic acid {3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide) (Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00123
  • group is attached preferably via the sulfonyl propyl group);
    18. The kinase inhibitor Gleevec (derivatized):
  • Figure US20190127359A1-20190502-C00124
  • (Derivatized where R as a linker group L or a
  • Figure US20190127359A1-20190502-C00125
  • group is attached preferably via the amide group or via the aniline amine group);
    19. The kinase inhibitor Pazopanib (derivatized) (VEGFR3 inhibitor):
  • Figure US20190127359A1-20190502-C00126
  • (Derivatized where R is a linker group L or a
  • Figure US20190127359A1-20190502-C00127
  • group preferably attached to the phenyl moiety or via the aniline amine group);
    20. The kinase inhibitor AT-9283 (Derivatized) Aurora Kinase Inhibitor
  • Figure US20190127359A1-20190502-C00128
  • (where R is a linker group L or a
  • Figure US20190127359A1-20190502-C00129
  • group attached preferably to the phenyl moiety);
    21. The kinase inhibitor TAE684 (derivatized) ALK inhibitor
  • Figure US20190127359A1-20190502-C00130
  • (where R is a linker group L or a
  • Figure US20190127359A1-20190502-C00131
  • group attached preferably to the phenyl moiety);
    22. The kinase inhibitor Nilotanib (derivatized) Abl inhibitor:
  • Figure US20190127359A1-20190502-C00132
  • (Derivatized where R is a linker group L or a
  • Figure US20190127359A1-20190502-C00133
  • group attached preferably to the phenyl moiety or the aniline amine group);
    27. Kinase Inhibitor NVP-BSK805 (derivatized) JAK2 Inhibitor
  • Figure US20190127359A1-20190502-C00134
  • (Derivatized where R is a linker group L or a
  • Figure US20190127359A1-20190502-C00135
  • group attached to the phenyl moiety or the diazole group);
    • 28. Kinase Inhibitor Crizotinib Derivatized Alk Inhibitor
  • Figure US20190127359A1-20190502-C00136
  • (Derivatized where R is a linker group L or a
  • Figure US20190127359A1-20190502-C00137
  • group attached to the phenyl moiety or the diazole group);
    29. Kinase Inhibitor JNJ FMS (derivatized) Inhibitor
  • Figure US20190127359A1-20190502-C00138
  • (Derivatized where R is a linker group L or a
  • Figure US20190127359A1-20190502-C00139
  • group attached preferably to the phenyl moiety);
    30. The kinase inhibitor Foretinib (derivatized) Met Inhibitor
  • Figure US20190127359A1-20190502-C00140
  • (Derivatized where R is a linker group L or a
  • Figure US20190127359A1-20190502-C00141
  • group attached to the phenyl moiety or a hydroxyl or ether group on the quinoline moiety);
    31. The allosteric Protein Tyrosine Phosphatase Inhibitor PTP1B (derivatized):
  • Figure US20190127359A1-20190502-C00142
  • Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00143
  • group is preferably attached at R, as indicated.
    32. The inhibitor of SHP-2 Domain of Tyrosine Phosphatase (derivatized):
  • Figure US20190127359A1-20190502-C00144
  • Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00145
  • group is attached preferably at R.
    33. The inhibitor (derivatized) of BRAF (BRAFV600E)/MEK:
  • Figure US20190127359A1-20190502-C00146
  • Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00147
  • group is attached preferably at R.
    34. Inhibitor (derivatized) of Tyrosine Kinase ABL
  • Figure US20190127359A1-20190502-C00148
  • (Derivatized where “R” designates a site for attachment of a linker group L or a
  • Figure US20190127359A1-20190502-C00149
  • group on the piperazine moiety).
    • III. MDM2 Inhibitors:
  • MDM2 inhibitors as used herein include, but are not limited to:
    1. The MDM2 inhibitors identified in Vassilev, et al., In vivo activation of the p53 pathway by small-molecule antagonists of MDM2, SCIENCE vol: 303, page: 844-848 (2004), and Schneekloth, et al., Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics, Bioorg. Med. Chem. Lett. 18 (2008) 5904-5908, including (or additionally) the compounds nutlin-3, nutlin-2, and nutlin-1 (derivatized) as described below, as well as all derivatives and analogs thereof:
  • Figure US20190127359A1-20190502-C00150
  • (Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00151
  • group is attached preferably at the methoxy group or as a hydroxyl group)
  • Figure US20190127359A1-20190502-C00152
  • (Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00153
  • group is attached preferably at the methoxy group or hydroxyl group);
  • Figure US20190127359A1-20190502-C00154
  • (Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00155
  • group is attached via the methoxy group or as a hydroxyl group); and
    • 2. Trans-4-Iodo-4′-Boranyl-Chalcone
  • Figure US20190127359A1-20190502-C00156
  • (Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00157
  • group is attached a linker group L or a
  • Figure US20190127359A1-20190502-C00158
  • group is attached group is attached via a hydroxy group);
    • IV. Compounds Targeting Human BET Bromodomain-Containing Proteins:
  • Compounds targeting Human BET Bromodomain-containing proteins include, but are not limited to the compounds associated with the targets as described below, where “R” designates a site for linker group L or a
  • Figure US20190127359A1-20190502-C00159
  • group attachment: 1.
    • Protein Targets: Brd2, Brd3, Brd4
  • Figure US20190127359A1-20190502-C00160
  • JQ1, Filippakopoulos et al. Selective inhibition of BET bromodomains. Nature (2010)
    2.
  • Figure US20190127359A1-20190502-C00161
  • I-BET, Nicodeme et al. Suppression of inflammation by a synthetic histone mimic. Nature (2010) Chung et al. Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains. Journal of medicinal chemistry (2011)
    3.
  • Figure US20190127359A1-20190502-C00162
  • 4d, Hewings et al. 3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands. J. Med. Chem. (2011) vol. 54 (19) pp. 6761-70
    4.
  • Figure US20190127359A1-20190502-C00163
  • I-BET151, Dawson et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature (2011)
    Where R, in each instance, designates a site for attachment of a linker group L or a
  • Figure US20190127359A1-20190502-C00164
  • group).
    • V. HDAC Inhibitors:
  • HDAC Inhibitors (derivatized) include, but are not limited to:
  • 1.
  • Figure US20190127359A1-20190502-C00165
  • Finnin, M. S. et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401, 188-193 (1999).
    (Derivatized where “R” designates a site for attachment of a linker group L or a
  • Figure US20190127359A1-20190502-C00166
  • group); and
    2. Compounds as defined by formula (I) of PCT WO0222577 (“DEACETYLASE INHIBITORS”) (Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00167
  • group is attached via the hydroxyl group);
    • VI. Human Lysine Methyltransferase Inhibitors:
  • Human Lysine Methyltransferase inhibitors include, but are not limited to:
  • 1.
  • Figure US20190127359A1-20190502-C00168
  • Chang et al. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat Struct Mol Biol (2009) vol. 16 (3) pp. 312-7
    (Derivatized where “R” designates a site for attachment of a linker group L or a
  • Figure US20190127359A1-20190502-C00169
  • group);
  • Figure US20190127359A1-20190502-C00170
  • Liu F, Chen X, Allali-Hassani A, et al. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J Med Chem 2009; 52(24):7950-3
    (Derivatized where “R” designates a potential site for attachment of a linker group L or a
  • Figure US20190127359A1-20190502-C00171
  • group);
    3. Azacitidine (derivatized) (4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one) (Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00172
  • group is attached via the hydroxy or amino groups); and
    4. Decitabine (derivatized) (4-amino-1-(2-deoxy-b-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one) (Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00173
  • group is attached via either of the hydroxy groups or at the amino group).
    • VII. Angiogenesis Inhibitors:
  • Angiogenesis inhibitors include, but are not limited to:
    1. GA-1 (derivatized) and derivatives and analogs thereof, having the structure(s) and binding to linkers as described in Sakamoto, et al., Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation, Mol Cell Proteomics 2003 December; 2(12):1350-8;
    2. Estradiol (derivatized), which may be bound to a linker group L or a
  • Figure US20190127359A1-20190502-C00174
  • group as is generally described in Rodriguez-Gonzalez, et al., Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer, Oncogene (2008) 27, 7201-7211;
    3. Estradiol, testosterone (derivatized) and related derivatives, including but not limited to DHT and derivatives and analogs thereof, having the structure(s) and binding to a linker group L or a
  • Figure US20190127359A1-20190502-C00175
  • group as generally described in Sakamoto, et al., Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation, Mol Cell Proteomics 2003 December; 2(12): 1350-8; and
    4. Ovalicin, fumagillin (derivatized), and derivatives and analogs thereof, having the structure(s) and binding to a linker group L or a
  • Figure US20190127359A1-20190502-C00176
  • group as is generally described in Sakamoto, et al., Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation Proc Natl Acad Sci USA. 2001 Jul. 17; 98(15):8554-9 and U.S. Pat. No. 7,208,157.
    • VIII. Immunosuppressive Compounds:
  • Immunosuppressive compounds include, but are not limited to:
    1. AP21998 (derivatized), having the structure(s) and binding to a linker group L or a
  • Figure US20190127359A1-20190502-C00177
  • group as is generally described in Schneekloth, et al., Chemical Genetic Control of Protein Levels: Selective in Vivo Targeted Degradation, J. AM. CHEM. SOC. 2004, 126, 3748-3754;
    2. Glucocorticoids (e.g., hydrocortisone, prednisone, prednisolone, and methylprednisolone) (Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00178
  • group is to bound, e.g. to any of the hydroxyls) and beclometasone dipropionate (Derivatized where a linker group or a
  • Figure US20190127359A1-20190502-C00179
  • is bound, e.g. to a proprionate);
    3. Methotrexate (Derivatized where a linker group or a
  • Figure US20190127359A1-20190502-C00180
  • group can be bound, e.g. to either of the terminal hydroxyls);
    4. Ciclosporin (Derivatized where a linker group or a
  • Figure US20190127359A1-20190502-C00181
  • group can be bound, e.g. at any of the butyl groups);
    5. Tacrolimus (FK-506) and rapamycin (Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00182
  • group can be bound, e.g. at one of the methoxy groups); and
    6. Actinomycins (Derivatized where a linker group L or a
  • Figure US20190127359A1-20190502-C00183
  • group can be bound, e.g. at one of the isopropyl groups).
    • IX. Compounds Targeting the Aryl Hydrocarbon Receptor (AHR):
  • Compounds targeting the aryl hydrocarbon receptor (AHR) include, but are not limited to:
  • 1. Apigenin (Derivatized in a way which binds to a linker group L or a
  • Figure US20190127359A1-20190502-C00184
  • group as is generally illustrated in Lee, et al., Targeted Degradation of the Aryl Hydrocarbon Receptor by the PROTAC Approach: A Useful Chemical Genetic Tool, ChemBioChem Volume 8, Issue 17, pages 2058-2062, Nov. 23, 2007); and
    2. SR1 and LGC006 (derivatized such that a linker group L or a
  • Figure US20190127359A1-20190502-C00185
  • is bound), as described in Boitano, et al., Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells, Science 10 Sep. 2010: Vol. 329 no. 5997 pp. 1345-1348.
    • X. Compounds Targeting RAF Receptor (Kinase):
  • Figure US20190127359A1-20190502-C00186
  • (Derivatized where “R” designates a site for linker group L or
  • Figure US20190127359A1-20190502-C00187
  • group attachment).
    • XI. Compounds Targeting FKBP
  • Figure US20190127359A1-20190502-C00188
  • (Derivatized where “R” designates a site for a linker group L or a
  • Figure US20190127359A1-20190502-C00189
  • group attachment).
    • XII. Compounds Targeting Androgen Receptor (AR)
  • 1. RU59063 Ligand (derivatized) of Androgen Receptor
  • Figure US20190127359A1-20190502-C00190
  • (Derivatized where “R” designates a site for a linker group L or a
  • Figure US20190127359A1-20190502-C00191
  • group attachment).
    2. SARM Ligand (derivatized) of Androgen Receptor
  • Figure US20190127359A1-20190502-C00192
  • (Derivatized where “R” designates a site for a linker group L or a
  • Figure US20190127359A1-20190502-C00193
  • group attachment).
    3. Androgen Receptor Ligand DHT (derivatized)
  • Figure US20190127359A1-20190502-C00194
  • (Derivatized where “R” designates a site for a linker group L or
  • Figure US20190127359A1-20190502-C00195
  • group attachment).
    • XIII. Compounds Targeting Estrogen Receptor (ER) ICI-182780 1. Estrogen Receptor Ligand
  • Figure US20190127359A1-20190502-C00196
  • (Derivatized where “R” designates a site for linker group L or
  • Figure US20190127359A1-20190502-C00197
  • group attachment).
    • XIV. Compounds Targeting Thyroid Hormone Receptor (TR) 1. Thyroid Hormone Receptor Ligand (Derivatized)
  • Figure US20190127359A1-20190502-C00198
  • (Derivatized where “R” designates a site for linker group L or
  • Figure US20190127359A1-20190502-C00199
  • group attachment and MOMO indicates a methoxymethoxy group).
    XV. Compounds targeting HIV Protease
    • 1. Inhibitor of HIV Protease (Derivatized)
  • Figure US20190127359A1-20190502-C00200
  • (Derivatized where “R” designates a site for linker group L or
  • Figure US20190127359A1-20190502-C00201
  • group attachment). See, J. Med. Chem. 2010, 53, 521-538.
    • 2. Inhibitor of HIV Protease
  • Figure US20190127359A1-20190502-C00202
  • (Derivatized where “R” designates a potential site for linker group L or
  • Figure US20190127359A1-20190502-C00203
  • group attachment). See, J. Med. Chem. 2010, 53, 521-538.
    • XVI. Compounds Targeting HIV Integrase 1. Inhibitor of HIV Integrase (Derivatized)
  • Figure US20190127359A1-20190502-C00204
  • (Derivatized where “R” designates a site for linker group L or
  • Figure US20190127359A1-20190502-C00205
  • group attachment). See, J. Med. Chem. 2010, 53, 6466.
    • 2. Inhibitor of HIV Integrase (Derivatized)
  • Figure US20190127359A1-20190502-C00206
  • (Derivatized where “R” designates a site for linker group L or
  • Figure US20190127359A1-20190502-C00207
  • group attachment). See, J. Med. Chem. 2010, 53, 6466.
    XVII. Compounds targeting HCV Protease
    • 1. Inhibitors of HCV Protease (Derivatized)
  • Figure US20190127359A1-20190502-C00208
  • (Derivatized where “R” designates a site for linker group L or
  • Figure US20190127359A1-20190502-C00209
  • group attachment).
    • XVIII. Compounds Targeting Acyl-Protein Thioesterase-1 and -2 (APT1 and APT2) 1. Inhibitor of APT1 and APT2 (Derivatized)
  • Figure US20190127359A1-20190502-C00210
  • (Derivatized where “R” designates a site for linker group L or
  • Figure US20190127359A1-20190502-C00211
  • group attachment). See, Angew. Chem. Int. Ed. 2011, 50, 9838-9842, where L is a linker group as otherwise described herein and said
    Figure US20190127359A1-20190502-P00007
    group is as otherwise described herein such that
  • Figure US20190127359A1-20190502-C00212
  • binds the
    Figure US20190127359A1-20190502-P00007
    group to a
    Figure US20190127359A1-20190502-P00008
    group as otherwise described herein.
  • The term “target protein” is used to describe a protein or polypeptide, which is a target for binding to a compound according to the present invention and degradation by ubiquitin ligase hereunder. Such small molecule target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these compositions, as well as other small molecules that may target a protein of interest. These binding moieties are linked to
    Figure US20190127359A1-20190502-P00007
    groups through linker groups L.
  • Target proteins which may be bound to the protein target moiety and degraded by the ligase to which the ubiquitin ligase binding moiety is bound include structural proteins, receptors, enzymes, cell surface proteins, proteins pertinent to the integrated function of a cell, including proteins involved in catalytic activity, aromatase activity, motor activity, helicase activity, metabolic processes (anabolism and catrabolism), antioxidant activity, proteolysis, biosynthesis, proteins with kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulator activity, signal transducer activity, structural molecule activity, binding activity (protein, lipid carbohydrate), receptor activity, cell motility, membrane fusion, cell communication, regulation of biological processes, development, cell differentiation, response to stimulus, behavioral proteins, cell adhesion proteins, proteins involved in cell death, proteins involved in transport (including protein transporter activity, nuclear transport, ion transporter activity, channel transporter activity, carrier activity, permease activity, secretion activity, electron transporter activity, pathogenesis, chaperone regulator activity, nucleic acid binding activity, transcription regulator activity, extracellular organization and biogenesis activity, translation regulator activity. Proteins of interest can include proteins from eurkaryotes and prokaryotes, including microbes, viruses, fungi and parasites, including humans, microbes, viruses, fungi and parasites, among numerous others, as targets for drug therapy, other animals, including domesticated animals, microbials for the determination of targets for antibiotics and other antimicrobials and plants, and even viruses, among numerous others
  • More specifically, a number of drug targets for human therapeutics represent protein targets to which protein target moiety may be bound and incorporated into compounds according to the present invention. These include proteins which may be used to restore function in numerous polygenic diseases, including for example B7.1 and B7, TINFRlm, TNFR2, NADPH oxidase, BclIBax and other partners in the apotosis pathway, C5a receptor, HMG-CoA reductase, PDE V phosphodiesterase type, PDE IV phosphodiesterase type 4, PDE I, PDEII, PDEIII, squalene cyclase inhibitor, CXCR1, CXCR2, nitric oxide (NO) synthase, cyclo-oxygenase 1, cyclo-oxygenase 2, 5HT receptors, dopamine receptors, G Proteins, i.e., Gq, histamine receptors, 5-lipoxygenase, tryptase serine protease, thymidylate synthase, purine nucleoside phosphorylase, GAPDH trypanosomal, glycogen phosphorylase, Carbonic anhydrase, chemokine receptors, JAW STAT, RXR and similar, HIV 1 protease, HIV 1 integrase, influenza, neuramimidase, hepatitis B reverse transcriptase, sodium channel, multi drug resistance (MDR), protein P-glycoprotein (and MRP), tyrosine kinases, CD23, CD124, tyrosine kinase p56 lck, CD4, CD5, IL-2 receptor, IL-1 receptor, TNF-alphaR, ICAM1, Cat+ channels, VCAM, VLA-4 integrin, selectins, CD40/CD40L, newokinins and receptors, inosine monophosphate dehydrogenase, p38 MAP Kinase, RaslRaflMEWERK pathway, interleukin-1 converting enzyme, caspase, HCV, NS3 protease, HCV NS3 RNA helicase, glycinamide ribonucleotide formyl transferase, rhinovirus 3C protease, herpes simplex virus-1 (HSV-I), protease, cytomegalovirus (CMV) protease, poly (ADP-ribose) polymerase, cyclin dependent kinases, vascular endothelial growth factor, oxytocin receptor, microsomal transfer protein inhibitor, bile acid transport inhibitor, 5 alpha reductase inhibitors, angiotensin 11, glycine receptor, noradrenaline reuptake receptor, endothelin receptors, neuropeptide Y and receptor, estrogen receptors, androgen receptors, adenosine receptors, adenosine kinase and AMP deaminase, purinergic receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2X1-7), farnesyltransferases, geranylgeranyl transferase, TrkA a receptor for NGF, beta-amyloid, tyrosine kinase Flk-IIKDR, vitronectin receptor, integrin receptor, Her-21 neu, telomerase inhibition, cytosolic phospholipaseA2 and EGF receptor tyrosine kinase. Additional protein targets include, for example, ecdysone 20-monooxygenase, ion channel of the GABA gated chloride channel, acetylcholinesterase, voltage-sensitive sodium channel protein, calcium release channel, and chloride channels. Still further target proteins include Acetyl-CoA carboxylase, adenylosuccinate synthetase, protoporphyrinogen oxidase, and enolpyruvylshikimate-phosphate synthase.
  • Haloalkane dehalogenase enzymes are another target of specific compounds according to the present invention. Compounds according to the present invention which contain chloroalkane peptide binding moieties (C1-C12 often about C2-C10 alkyl halo groups) may be used to inhibit and/or degrade haloalkane dehalogenase enzymes which are used in fusion proteins or related dioagnostic proteins as described in PCT/US 2012/063401 filed Dec. 6, 2011 and published as WO 2012/078559 on Jun. 14, 2012, the contents of which is incorporated by reference herein.
  • These various protein targets may be used in screens that identify compound moieties which bind to the protein and by incorporation of the moiety into compounds according to the present invention, the level of activity of the protein may be altered for therapeutic end result.
  • The term “disease state or condition” is used to describe any disease state or condition wherein protein dysregulation (i.e., the amount of protein expressed in a patient is elevated) occurs and where degradation of one or more proteins in a patient may provide beneficial therapy or relief of symptoms to a patient in need thereof. In certain instances, the disease state or condition may be cured.
  • Disease states of conditions which may be treated using compounds according to the present invention include, for example, asthma, autoimmune diseases such as multiple sclerosis, various cancers, ciliopathies, cleft palate, diabetes, heart disease, hypertension, inflammatory bowel disease, mental retardation, mood disorder, obesity, refractive error, infertility, Angelman syndrome, Canavan disease, Coeliac disease, Charcot-Marie-Tooth disease, Cystic fibrosis, Duchenne muscular dystrophy, Haemochromatosis, Haemophilia, Klinefelter's syndrome, Neurofibromatosis, Phenylketonuria, Polycystic kidney disease, (PKD1) or 4 (PKD2) Prader-Willi syndrome, Sickle-cell disease, Tay-Sachs disease, Turner syndrome.
  • Further disease states or conditions which may be treated by compounds according to the present invention include Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's disease), Anorexia nervosa, Anxiety disorder, Atherosclerosis, Attention deficit hyperactivity disorder, Autism, Bipolar disorder, Chronic fatigue syndrome, Chronic obstructive pulmonary disease, Crohn's disease, Coronary heart disease, Dementia, Depression, Diabetes mellitus type 1, Diabetes mellitus type 2, Epilepsy, Guillain-Barre syndrome, Irritable bowel syndrome, Lupus, Metabolic syndrome, Multiple sclerosis, Myocardial infarction, Obesity, Obsessive-compulsive disorder, Panic disorder, Parkinson's disease, Psoriasis, Rheumatoid arthritis, Sarcoidosis, Schizophrenia, Stroke, Thromboangiitis obliterans, Tourette syndrome, Vasculitis.
  • Still additional disease states or conditions which can be treated by compounds according to the present invention include aceruloplasminemia, Achondrogenesis type II, achondroplasia, Acrocephaly, Gaucher disease type 2, acute intermittent porphyria, Canavan disease, Adenomatous Polyposis Coli, ALA dehydratase deficiency, adenylosuccinate lyase deficiency, Adrenogenital syndrome, Adrenoleukodystrophy, ALA-D porphyria, ALA dehydratase deficiency, Alkaptonuria, Alexander disease, Alkaptonuric ochronosis, alpha 1-antitrypsin deficiency, alpha-1 proteinase inhibitor, emphysema, amyotrophic lateral sclerosis Alstrom syndrome, Alexander disease, Amelogenesis imperfecta, ALA dehydratase deficiency, Anderson-Fabry disease, androgen insensitivity syndrome, Anemia Angiokeratoma Corporis Diffusum, Angiomatosis retinae (von Hippel-Lindau disease) Apert syndrome, Arachnodactyly (Marfan syndrome), Stickler syndrome, Arthrochalasis multiplex congenital (Ehlers-Danlos syndrome#arthrochalasia type) ataxia telangiectasia, Rett syndrome, primary pulmonary hypertension, Sandhoff disease, neurofibromatosis type II, Beare-Stevenson cutis gyrata syndrome, Mediterranean fever, familial, Benjamin syndrome, beta-thalassemia Bilateral Acoustic Neurofibromatosis (neurofibromatosis type II), factor V Leiden thrombophilia, Bloch-Sulzberger syndrome (incontinentia pigmenti), Bloom syndrome, X-linked sideroblastic anemia, Bonnevie-Ullrich syndrome (Turner syndrome), Bourneville disease (tuberous sclerosis), prion disease, Birt-Hogg-Dube syndrome, Brittle bone disease (osteogenesis imperfecta), Broad Thumb-Hallux syndrome (Rubinstein-Taybi syndrome), Bronze Diabetes/Bronzed Cirrhosis (hemochromatosis), Bulbospinal muscular atrophy (Kennedy's disease), Burger-Grutz syndrome (lipoprotein lipase deficiency), CGD Chronic granulomatous disorder, Campomelic dysplasia, biotinidase deficiency, Cardiomyopathy (Noonan syndrome), Cri du chat, CAVD (congenital absence of the vas deferens), Caylor cardiofacial syndrome (CBAVD), CEP (congenital erythropoietic porphyria), cystic fibrosis, congenital hypothyroidism, Chondrodystrophy syndrome (achondroplasia), otospondylomegaepiphyseal dysplasia, Lesch-Nyhan syndrome, galactosemia, Ehlers-Danlos syndrome, Thanatophoric dysplasia, Coffin-Lowry syndrome, Cockayne syndrome, (familial adenomatous polyposis), Congenital erythropoietic porphyria, Congenital heart disease, Methemoglobinemia/Congenital methaemoglobinaemia, achondroplasia, X-linked sideroblastic anemia, Connective tissue disease, Conotruncal anomaly face syndrome, Cooley's Anemia (beta-thalassemia), Copper storage disease (Wilson's disease), Copper transport disease (Menkes disease), hereditary coproporphyria, Cowden syndrome, Craniofacial dysarthrosis (Crouzon syndrome), Creutzfeldt-Jakob disease (prion disease), Cockayne syndrome, Cowden syndrome, Curschmann-Batten-Steinert syndrome (myotonic dystrophy), Beare-Stevenson cutis gyrata syndrome, primary hyperoxaluria, spondyloepimetaphyseal dysplasia (Strudwick type), muscular dystrophy, Duchenne and Becker types (DBMD), Usher syndrome, Degenerative nerve diseases including de Grouchy syndrome and Dejerine-Sottas syndrome, developmental disabilities, distal spinal muscular atrophy, type V, androgen insensitivity syndrome, Diffuse Globoid Body Sclerosis (Krabbe disease), Di George's syndrome, Dihydrotestosterone receptor deficiency, androgen insensitivity syndrome, Down syndrome, Dwarfism, erythropoietic protoporphyria Erythroid 5-aminolevulinate synthetase deficiency, Erythropoietic porphyria, erythropoietic protoporphyria, erythropoietic uroporphyria, Friedreich's ataxia, familial paroxysmal polyserositis, porphyria cutanea tarda, familial pressure sensitive neuropathy, primary pulmonary hypertension (PPH), Fibrocystic disease of the pancreas, fragile X syndrome, galactosemia, genetic brain disorders, Giant cell hepatitis (Neonatal hemochromatosis), Gronblad-Strandberg syndrome (pseudoxanthoma elasticum), Gunther disease (congenital erythropoietic porphyria), haemochromatosis, Hallgren syndrome, sickle cell anemia, hemophilia, hepatoerythropoietic porphyria (HEP), Hippel-Lindau disease (von Hippel-Lindau disease), Huntington's disease, Hutchinson-Gilford progeria syndrome (progeria), Hyperandrogenism, Hypochondroplasia, Hypochromic anemia, Immune system disorders, including X-linked severe combined immunodeficiency, Insley-Astley syndrome, Jackson-Weiss syndrome, Joubert syndrome, Lesch-Nyhan syndrome, Jackson-Weiss syndrome, Kidney diseases, including hyperoxaluria, Klinefelter's syndrome, Kniest dysplasia, Lacunar dementia, Langer-Saldino achondrogenesis, ataxia telangiectasia, Lynch syndrome, Lysyl-hydroxylase deficiency, Machado-Joseph disease, Metabolic disorders, including Kniest dysplasia, Marfan syndrome, Movement disorders, Mowat-Wilson syndrome, cystic fibrosis, Muenke syndrome, Multiple neurofibromatosis, Nance-Insley syndrome, Nance-Sweeney chondrodysplasia, Niemann-Pick disease, Noack syndrome (Pfeiffer syndrome), Osler-Weber-Rendu disease, Peutz-Jeghers syndrome, Polycystic kidney disease, polyostotic fibrous dysplasia (McCune-Albright syndrome), Peutz-Jeghers syndrome, Prader-Labhart-Willi syndrome, hemochromatosis, primary hyperuricemia syndrome (Lesch-Nyhan syndrome), primary pulmonary hypertension, primary senile degenerative dementia, prion disease, progeria (Hutchinson Gilford Progeria Syndrome), progressive chorea, chronic hereditary (Huntington) (Huntington's disease), progressive muscular atrophy, spinal muscular atrophy, propionic acidemia, protoporphyria, proximal myotonic dystrophy, pulmonary arterial hypertension, PXE (pseudoxanthoma elasticum), Rb (retinoblastoma), Recklinghausen disease (neurofibromatosis type I), Recurrent polyserositis, Retinal disorders, Retinoblastoma, Rett syndrome, RFALS type 3, Ricker syndrome, Riley-Day syndrome, Roussy-Levy syndrome, severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), Li-Fraumeni syndrome, sarcoma, breast, leukemia, and adrenal gland (SBLA) syndrome, sclerosis tuberose (tuberous sclerosis), SDAT, SED congenital (spondyloepiphyseal dysplasia congenita), SED Strudwick (spondyloepimetaphyseal dysplasia, Strudwick type), SEDc (spondyloepiphyseal dysplasia congenita) SEMD, Strudwick type (spondyloepimetaphyseal dysplasia, Strudwick type), Shprintzen syndrome, Skin pigmentation disorders, Smith-Lemli-Opitz syndrome, South-African genetic porphyria (variegate porphyria), infantile-onset ascending hereditary spastic paralysis, Speech and communication disorders, sphingolipidosis, Tay-Sachs disease, spinocerebellar ataxia, Stickler syndrome, stroke, androgen insensitivity syndrome, tetrahydrobiopterin deficiency, beta-thalassemia, Thyroid disease Tomaculous neuropathy (hereditary neuropathy with liability to pressure palsies) Treacher Collins syndrome, Triplo X syndrome (triple X syndrome), Trisomy 21 (Down syndrome), Trisomy X, VHL syndrome (von Hippel-Lindau disease), Vision impairment and blindness (Alstrom syndrome), Vrolik disease, Waardenburg syndrome, Warburg Sjo Fledelius Syndrome, Weissenbacher-Zweymuller syndrome, Wolf-Hirschhorn syndrome, Wolff Periodic disease, Weissenbacher-Zweymfiller syndrome and Xeroderma pigmentosum, among others.
  • The term “neoplasia” or “cancer” is used throughout the specification to refer to the pathological process that results in the formation and growth of a cancerous or malignant neoplasm, i.e., abnormal tissue that grows by cellular proliferation, often more rapidly than normal and continues to grow after the stimuli that initiated the new growth cease. Malignant neoplasms show partial or complete lack of structural organization and functional coordination with the normal tissue and most invade surrounding tissues, metastasize to several sites, and are likely to recur after attempted removal and to cause the death of the patient unless adequately treated. As used herein, the term neoplasia is used to describe all cancerous disease states and embraces or encompasses the pathological process associated with malignant hematogenous, ascitic and solid tumors. Exemplary cancers which may be treated by the present compounds either alone or in combination with at least one additional anti-cancer agent include squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the bladder, bowel, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias; benign and malignant lymphomas, particularly Burkitt's lymphoma and Non-Hodgkin's lymphoma; benign and malignant melanomas; myeloproliferative diseases; sarcomas, including Ewing's sarcoma, hemangiosarcoma, Kaposi's sarcoma, liposarcoma, myosarcomas, peripheral neuroepithelioma, synovial sarcoma, gliomas, astrocytomas, oligodendrogliomas, ependymomas, gliobastomas, neuroblastomas, ganglioneuromas, gangliogliomas, medulloblastomas, pineal cell tumors, meningiomas, meningeal sarcomas, neurofibromas, and Schwannomas; bowel cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, esophageal cancer, pancreatic cancer, stomach cancer, liver cancer, colon cancer, melanoma; carcinosarcoma, Hodgkin's disease, Wilms' tumor and teratocarcinomas.
  • Additional cancers which may be treated using compounds according to the present invention include, for example, T-lineage Acute lymphoblastic Leukemia (T-ALL), T-lineage lymphoblastic Lymphoma (T-LL), Peripheral T-cell lymphoma, Adult T-cell Leukemia, Pre-B ALL, Pre-B Lymphomas, Large B-cell Lymphoma, Burkitts Lymphoma, B-cell ALL, Philadelphia chromosome positive ALL and Philadelphia chromosome positive CML, The term “bioactive agent” is used to describe an agent, other than a compound according to the present invention, which is used in combination with the present compounds as an agent with biological activity to assist in effecting an intended therapy, inhibition and/or prevention/prophylaxis for which the present compounds are used. Preferred bioactive agents for use herein include those agents which have pharmacological activity similar to that for which the present compounds are used or administered and include for example, anti-cancer agents, antiviral agents, especially including anti-HIV agents and anti-HCV agents, antimicrobial agents, antifungal agents, etc.
  • The term “additional anti-cancer agent” is used to describe an anti-cancer agent, which may be combined with compounds according to the present invention to treat cancer. These agents include, for example, everolimus, trabectedin, abraxane, TLK 286, AV-299, DN-101, pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD 6244 (ARRY-142886), AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, a FLT-3 inhibitor, a VEGFR inhibitor, an EGFR TK inhibitor, an aurora kinase inhibitor, a PIK-1 modulator, a Bcl-2 inhibitor, an HDAC inhbitor, a c-MET inhibitor, a PARP inhibitor, a Cdk inhibitor, an EGFR TK inhibitor, an IGFR-TK inhibitor, an anti-HGF antibody, a PI3 kinase inhibitors, an AKT inhibitor, a JAK/STAT inhibitor, a checkpoint-1 or 2 inhibitor, a focal adhesion kinase inhibitor, a Map kinase kinase (mek) inhibitor, a VEGF trap antibody, pemetrexed, erlotinib, dasatanib, nilotinib, decatanib, panitumumab, amrubicin, oregovomab, Lep-etu, nolatrexed, azd2171, batabulin, ofatumumab, zanolimumab, edotecarin, tetrandrine, rubitecan, tesmilifene, oblimersen, ticilimumab, ipilimumab, gossypol, Bio 111, 131-I-TM-601, ALT-110, BIO 140, CC 8490, cilengitide, gimatecan, IL13-PE38QQR, INO 1001, IPdR1 KRX-0402, lucanthone, LY317615, neuradiab, vitespan, Rta 744, Sdx 102, talampanel, atrasentan, Xr 311, romidepsin, ADS-100380, sunitinib, 5-fluorouracil, vorinostat, etoposide, gemcitabine, doxorubicin, liposomal doxorubicin, 5′-deoxy-5-fluorouridine, vincristine, temozolomide, ZK-304709, seliciclib; PD0325901, AZD-6244, capecitabine, L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt, heptahydrate, camptothecin, PEG-labeled irinotecan, tamoxifen, toremifene citrate, anastrazole, exemestane, letrozole, DES (diethyl stilbestrol), estradiol, estrogen, conjugated estrogen, bevacizumab, IMC-1C11, CHIR-258); 3-[5-(methylsulfonylpiperadinemethyl)-indolylj-quinolone, vatalanib, AG-013736, AVE-0005, the acetate salt of [D-Ser(Bu t) 6, Azgly 10] (pyro-Glu-His-Trp-Ser-Tyr-D-Ser(Bu t)-Leu-Arg-Pro-Azgly-NH2 acetate [C59H84N18Oi4-(C2H4O2)X where x=1 to 2.4], goserelin acetate, leuprolide acetate, triptorelin pamoate, medroxyprogesterone acetate, hydroxyprogesterone caproate, megestrol acetate, raloxifene, bicalutamide, flutamide, nilutamide, megestrol acetate, CP-724714; TAK-165, HKI-272, erlotinib, lapatanib, canertinib, ABX-EGF antibody, erbitux, EKB-569, PKI-166, GW-572016, lonafarnib, BMS-214662, tipifarnib; amifostine, NVP-LAQ824, suberoyl analide hydroxamic acid, valproic acid, trichostatin A, FK-228, SU11248, sorafenib, KRN951, aminoglutethimide, arnsacrine, anagrelide, L-asparaginase, Bacillus Calmette-Guerin (BCG) vaccine, adriamycin, bleomycin, buserelin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, diethylstilbestrol, epirubicin, fludarabine, fludrocortisone, fluoxymesterone, flutamide, gleevec, gemcitabine, hydroxyurea, idarubicin, ifosfamide, imatinib, leuprolide, levamisole, lomustine, mechlorethamine, melphalan, 6-mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, octreotide, oxaliplatin, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, teniposide, testosterone, thalidomide, thioguanine, thiotepa, tretinoin, vindesine, 13-cis-retinoic acid, phenylalanine mustard, uracil mustard, estramustine, altretamine, floxuridine, 5-deooxyuridine, cytosine arabinoside, 6-mecaptopurine, deoxycoformycin, calcitriol, valrubicin, mithramycin, vinblastine, vinorelbine, topotecan, razoxin, marimastat, COL-3, neovastat, BMS-275291, squalamine, endostatin, SU5416, SU6668, EMD121974, interleukin-12, IM862, angiostatin, vitaxin, droloxifene, idoxyfene, spironolactone, finasteride, cimitidine, trastuzumab, denileukin diftitox, gefitinib, bortezimib, paclitaxel, cremophor-free paclitaxel, docetaxel, epithilone B, BMS-247550, BMS-310705, droloxifene, 4-hydroxytamoxifen, pipendoxifene, ERA-923, arzoxifene, fulvestrant, acolbifene, lasofoxifene, idoxifene, TSE-424, HMR-3339, ZK186619, topotecan, PTK787/ZK 222584, VX-745, PD 184352, rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, temsirolimus, AP-23573, RAD001, ABT-578, BC-210, LY294002, LY292223, LY292696, LY293684, LY293646, wortmannin, ZM336372, L-779,450, PEG-filgrastim, darbepoetin, erythropoietin, granulocyte colony-stimulating factor, zolendronate, prednisone, cetuximab, granulocyte macrophage colony-stimulating factor, histrelin, pegylated interferon alfa-2a, interferon alfa-2a, pegylated interferon alfa-2b, interferon alfa-2b, azacitidine, PEG-L-asparaginase, lenalidomide, gemtuzumab, hydrocortisone, interleukin-11, dexrazoxane, alemtuzumab, all-transretinoic acid, ketoconazole, interleukin-2, megestrol, immune globulin, nitrogen mustard, methylprednisolone, ibritgumomab tiuxetan, androgens, decitabine, hexamethylmelamine, bexarotene, tositumomab, arsenic trioxide, cortisone, editronate, mitotane, cyclosporine, liposomal daunorubicin, Edwina-asparaginase, strontium 89, casopitant, netupitant, an NK-1 receptor antagonist, palonosetron, aprepitant, diphenhydramine, hydroxyzine, metoclopramide, lorazepam, alprazolam, haloperidol, droperidol, dronabinol, dexamethasone, methylprednisolone, prochlorperazine, granisetron, ondansetron, dolasetron, tropisetron, pegfilgrastim, erythropoietin, epoetin alfa, darbepoetin alfa and mixtures thereof.
  • The term “anti-HIV agent” or “additional anti-HIV agent” includes, for example, nucleoside reverse transcriptase inhibitors (NRTI), other non-nucloeoside reverse transcriptase inhibitors (i.e., those which are not representative of the present invention), protease inhibitors, fusion inhibitors, among others, exemplary compounds of which may include, for example, 3TC (Lamivudine), AZT (Zidovudine), (−)-FTC, ddI (Didanosine), ddC (zalcitabine), abacavir (ABC), tenofovir (PMPA), D-D4FC (Reverset), D4T (Stavudine), Racivir, L-FddC, L-FD4C, NVP (Nevirapine), DLV (Delavirdine), EFV (Efavirenz), SQVM (Saquinavir mesylate), RTV (Ritonavir), IDV (Indinavir), SQV (Saquinavir), NFV (Nelfinavir), APV (Amprenavir), LPV (Lopinavir), fusion inhibitors such as T20, among others, fuseon and mixtures thereof, including anti-HIV compounds presently in clinical trials or in development.
  • Other anti-HIV agents which may be used in coadministration with compounds according to the present invention include, for example, other NNRTI's (i.e., other than the NNRTI's according to the present invention) may be selected from the group consisting of nevirapine (BI-R6-587), delavirdine (U-90152S/T), efavirenz (DMP-266), UC-781 (N-[4-chloro-3-(3-methyl-2-butenyloxy)phenyl]-2methyl3-furancarbothiamide), etravirine (TMC125), Trovirdine (Ly300046.HCl), MKC-442 (emivirine, coactinon), HI-236, HI-240, HI-280, HI-281, rilpivirine (TMC-278), MSC-127, HBY 097, DMP266, Baicalin (TJN-151) ADAM-II (Methyl 3′,3′-dichloro-4′,4″-dimethoxy-5′,5″-bis(methoxycarbonyl)-6,6-diphenylhexenoate), Methyl 3-Bromo-5-(1-5-bromo-4-methoxy-3-(methoxycarbonyl)phenyl)hept-1-enyl)-2-methoxybenzoate (Alkenyldiarylmethane analog, Adam analog), 5C13PhS-2Indo1CONH2 (5-chloro-3-(phenylsulfinyl)-2′-indolecarboxamide), AAP-BHAP (U-104489 or PNU-104489), Capravirine (AG-1549, S-1153), atevirdine (U-87201E), aurin tricarboxylic acid (SD-095345), 1-[(6-Cyano-2-indoyly)carbonyl]-4-[3-(isopropylamino)-2-pyridinyl]piperazine (piperazine1 pyridine 4 indolyl derivative), 1-[5-[[N-(methyl)methylsulfonylamino]-2-indolylcarbonyl-4-[3-(isopropylamino)-2-pyridinyl]piperazine (piperazine 1pyridine 5 indolyl derivative), 1-[3-(Ethylamino)-2-[pyridinyl]-4-[(5-hydroxy-2-indolyl)carbonyl]piperazine, 1-[(6-Formyl-2-indoyly)carbonyl]-4-[3-(isopropylamino)-2-pyridinyl]piperazine, 1-[[5-(Methyl sulfonyloxy)-2-indoyly)carbonyl]-4-[3-(isopropylamino)-2-pyridinyl]piperazine, U88204E, Bis(2-nitrophenyl)sulfone (NSC 633001), Calanolide A (NSC675451), Calanolide B, 6-Benzyl-5-methyl-2-(cyclohexyloxy)pyrimidin-4-one (DABO-546), DPC 961, E-EBU, E-EBU-dm, E-EPSeU, E-EPU, Foscarnet (Foscavir), HEPT (1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine), HEPT-M (1-[(2-Hydroxyethoxy)methyl]-6-(3-methylphenyl)thio)thymine), HEPT-S (1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)-2-thiothymine), Inophyllum P, L-737,126, Michellamine A (NSC650898), Michellamine B (NSC649324), Michellamine F, 6-(3,5-Dimethylbenzyl)-1-[(2-hydroxyethoxy)methyl]-5-isopropyluracil, 6-(3,5-Dimethylbenzyl)-1-(ethyoxymethyl)-5-isopropyluracil, NPPS, E-BPTU (NSC 648400), Oltipraz (4-Methyl-5-(pyrazinyl)-3H-1,2-dithiole-3-thione), N-{2-(2-Chloro-6-fluorophenethyl]-N′-(2-thiazolyl)thiourea (PETT Cl, F derivative), N-{2-(2,6-Difluorophenethyl]-N′-[2-(5-bromopyridyl)]thiourea {PETT derivative), N-{2-(2,6-Difluorophenethyl]-N′-[2-(5-methylpyridyl)]hiourea {PETT Pyridyl derivative), N-[2-(3-Fluorofuranyl)ethyl]-N′-[2-(5-chloropyridyl)]thiourea, N-[2-(2-Fluoro-6-ethoxyphenethyl)]-N′-[2-(5-bromopyridyl)]thiourea, N-(2-Phenethyl)-N′-(2-thiazolyl)thiourea (LY-73497), L-697,639, L-697,593, L-697,661, 3-[2-(4,7-Difluorobenzoxazol-2-yl)ethyl}-5-ethyl-6-methyl(pypridin-2(1H)-thione (2-Pyridinone Derivative), 3-[[(2-Methoxy-5,6-dimethyl-3-pyridyl)methyl]amine]-5-ethyl-6-methyl(pypridin-2(1H)-thione (2-Pyridinone 3pyrid 3MeNH Derivative), R82150, R82913, R87232, R88703, R89439 (Loviride), R90385, S-2720, Suramin Sodium, TBZ (Thiazolobenzimidazole, NSC 625487), Thiazoloisoindol-5-one, (+)(R)-9b-(3,5-Dimethylphenyl-2,3-dihydrothiazolo[2,3-a]isoindol-5 (9bH)-one, Tivirapine (R86183), UC-38 and UC-84, among others.
  • The term “pharmaceutically acceptable salt” is used throughout the specification to describe, where applicable, a salt form of one or more of the compounds described herein which are presented to increase the solubility of the compound in the gastic juices of the patient's gastrointestinal tract in order to promote dissolution and the bioavailability of the compounds. Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids, where applicable. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium, magnesium and ammonium salts, among numerous other acids and bases well known in the pharmaceutical art. Sodium and potassium salts are particularly preferred as neutralization salts of the phosphates according to the present invention.
  • The term “pharmaceutically acceptable derivative” is used throughout the specification to describe any pharmaceutically acceptable prodrug form (such as an ester, amide other prodrug group), which, upon administration to a patient, provides directly or indirectly the present compound or an active metabolite of the present compound.
  • The term “independently” is used herein to indicate that the variable, which is independently applied, varies independently from application to application.
  • The term “hydrocarbyl” shall mean a compound which contains carbon and hydrogen and which may be fully saturated, partially unsaturated or aromatic and includes aryl groups, alkyl groups, alkenyl groups and alkynyl groups.
  • The term “alkyl” shall mean within its context a linear, branch-chained or cyclic fully saturated hydrocarbon radical or alkyl group, preferably a C1-C10, more preferably a C1-C6, alternatively a C1-C3 alkyl group, which may be optionally substituted. Examples of alkyl groups are methyl, ethyl, n-butyl, sec-butyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, isopropyl, 2-methylpropyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopentylethyl, cyclohexylethyl and cyclohexyl, among others. In certain preferred embodiments, compounds according to the present invention which may be used to covalently bind to dehalogenase enzymes. These compounds generally contain a side chain (often linked through a polyethylene glycol group) which terminates in an alkyl group which has a halogen substituent (often chlorine or bromine) on its distil end which results in covalent binding of the compound containing such a moiety to the protein. The term “Alkenyl” refers to linear, branch-chained or cyclic C2-C10 (preferably C2-C6) hydrocarbon radicals containing at least one C═C bond. The term “Alkynyl” refers to linear, branch-chained or cyclic C2-C10 (preferably C2-C6) hydrocarbon radicals containing at least one C≡C bond. The term “alkylene” when used, refers to a —(CH2)n— group (n is an integer generally from 0-6), which may be optionally substituted. When substituted, the alkylene group preferably is substituted on one or more of the methylene groups with a C1-C6 alkyl group (including a cyclopropyl group or a t-butyl group), more preferably a methyl group, but may also be substituted with one or more halo groups, preferably from 1 to 3 halo groups or one or two hydroxyl groups, O—(C1-C6 alkyl) groups or amino acid sidechains as otherwise disclosed herein. In certain embodiments, an alkylene group may be substituted with a urethane or alkoxy group (or other group) which is further substituted with a polyethylene glycol chain (of from 1 to 10, preferably 1 to 6, often 1 to 4 ethylene glycol units) to which is substituted (preferably, but not exclusively on the distal end of the polyethylene glycol chain) an alkyl chain substituted with a single halogen group, preferably a chlorine group. In still other embodiments, the alkylene (often, a methylene) group, may be substituted with an amino acid sidechain group such as a sidechain group of a natural or unnatural amino acid, for example, alanine, β-alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamic acid, glutamine, glycine, phenylalanine, histidine, isoleucine, lysine, leucine, methionine, proline, serine, threonine, valine, tryptophan or tyrosine.
  • The term “unsubstituted” shall mean substituted only with hydrogen atoms. A range of carbon atoms which includes C0 means that carbon is absent and is replaced with H. Thus, a range of carbon atoms which is C0-C6 includes carbons atoms of 1, 2, 3, 4, 5 and 6 and for C0, H stands in place of carbon. The term “substituted” or “optionally substituted” shall mean independently (i.e., where more than substituent occurs, each substituent is independent of another substituent) one or more substituents (independently up to five substitutents, preferably up to three substituents, often 1 or 2 substituents on a moiety in a compound according to the present invention and may include substituents which themselves may be further substituted) at a carbon (or nitrogen) position anywhere on a molecule within context, and includes as substituents hydroxyl, thiol, carboxyl, cyano (C≡N), nitro (NO2), halogen (preferably, 1, 2 or 3 halogens, especially on an alkyl, especially a methyl group such as a trifluoromethyl), an alkyl group (preferably, C1-C10, more preferably, C1-C6), aryl (especially phenyl and substituted phenyl for example benzyl or benzoyl), alkoxy group (preferably, C1-C6 alkyl or aryl, including phenyl and substituted phenyl), thioether (C1-C6 alkyl or aryl), acyl (preferably, C1-C6 acyl), ester or thioester (preferably, C1-C6 alkyl or aryl) including alkylene ester (such that attachment is on the alkylene group, rather than at the ester function which is preferably substituted with a C1-C6 alkyl or aryl group), preferably, C1-C6 alkyl or aryl, halogen (preferably, F or Cl), amine (including a five- or six-membered cyclic alkylene amine, further including a C1-C6 alkyl amine or a C1-C6 dialkyl amine which alkyl groups may be substituted with one or two hydroxyl groups) or an optionally substituted —N(C0-C6 alkyl)C(O)(O—C1-C6 alkyl) group (which may be optionally substituted with a polyethylene glycol chain to which is further bound an alkyl group containing a single halogen, preferably chlorine substituent), hydrazine, amido, which is preferably substituted with one or two C1-C6 alkyl groups (including a carboxamide which is optionally substituted with one or two C1-C6 alkyl groups), alkanol (preferably, C1-C6 alkyl or aryl), or alkanoic acid (preferably, C1-C6 alkyl or aryl). Substituents according to the present invention may include, for example —SiR1R2R3 groups where each of R1 and R2 is as otherwise described herein and R3 is H or a C1-C6 alkyl group, preferably R1, R2, R3 in this context is a C1-C3 alkyl group (including an isopropyl or t-butyl group). Each of the above-described groups may be linked directly to the substituted moiety or alternatively, the substituent may be linked to the substituted moiety (preferably in the case of an aryl or heteraryl moiety) through an optionally substituted —(CH2)m— or alternatively an optionally substituted —(OCH2)m—, —(OCH2CH2)m— or —(CH2CH2O)m— group, which may be substituted with any one or more of the above-described substituents. Alkylene groups —(CH2)m— or —(CH2)n— groups or other chains such as ethylene glycol chains, as identified above, may be substituted anywhere on the chain. Preferred substitutents on alkylene groups include halogen or C1-C6 (preferably C1-C3) alkyl groups, which may be optionally substituted with one or two hydroxyl groups, one or two ether groups (0-C1-C6 groups), up to three halo groups (preferably F), or a sideshain of an amino acid as otherwise described herein and optionally substituted amide (preferably carboxamide substituted as described above) or urethane groups (often with one or two C0-C6 alkyl substitutents, which group(s) may be further substituted). In certain embodiments, the alkylene group (often a single methylene group) is substituted with one or two optionally substituted C1-C6 alkyl groups, preferably C1-C4 alkyl group, most often methyl or O-methyl groups or a sidechain of an amino acid as otherwise described herein. In the present invention, a moiety in a molecule may be optionally substituted with up to five substituents, preferably up to three substituents. Most often, in the present invention moieties which are substituted are substituted with one or two substituents.
  • The term “substituted” (each substituent being independent of any other substituent) shall also mean within its context of use C1-C6 alkyl, C1-C6 alkoxy, halogen, amido, carboxamido, sulfone, including sulfonamide, keto, carboxy, C1-C6 ester (oxyester or carbonylester), C1-C6 keto, urethane —O—C(O)—NR1R2 or —N(R1)—C(O)—O—R1, nitro, cyano and amine (especially including a C1-C6 alkylene-NR1R2, a mono- or di-C1-C6 alkyl substituted amines which may be optionally substituted with one or two hydroxyl groups). Each of these groups contain unless otherwise indicated, within context, between 1 and 6 carbon atoms. In certain embodiments, preferred substituents will include for example, —NH—, —NHC(O)—, —O—, ═O, —(CH2)m— (here, m and n are in context, 1, 2, 3, 4, 5 or 6), —S—, —S(O)—, SO2— or —NH—C(O)—NH—, —(CH2)nOH, —(CH2)nSH, —(CH2)nCOOH, C1-C6 alkyl, —(CH2)nO—(C1-C6 alkyl), —(CH2)nC(O)—(C1-C6 alkyl), —(CH2)nOC(O)—(C1-C6 alkyl), —(CH2)nC(O)—(C1-C6 alkyl), —(CH2)nNHC(O)—R1, —(CH2)nC(O)—NR1R2, —(OCH2)nOH, —(CH2O)nCOOH, C1-C6 alkyl, —(OCH2)nO—(C1-C6 alkyl), —(CH2O)nC(O)—(C1-C6 alkyl), —(OCH2)nNHC(O)—R1, —(CH2O)nC(O)—NR1R2, —S(O)2—RS, —S(O)—RS (RS is C1-C6 alkyl or a —(CH2)m—NR1R2 group), NO2, CN or halogen (F, Cl, Br, I, preferably F or Cl), depending on the context of the use of the substituent. R1 and R2 are each, within context, H or a C1-C6 alkyl group (which may be optionally substituted with one or two hydroxyl groups or up to three halogen groups, preferably fluorine). The term “substituted” shall also mean, within the chemical context of the compound defined and substituent used, an optionally substituted aryl or heteroaryl group or an optionally substituted heterocyclic group as otherwise described herein. Alkylene groups may also be substituted as otherwise disclosed herein, preferably with optionally substituted C1-C6 alkyl groups (methyl, ethyl or hydroxymethyl or hydroxyethyl is preferred, thus providing a chiral center), a sidechain of an amino acid group as otherwise described herein, an amido group as described hereinabove, or a urethane group O—C(O)—NR1R2 group where R1 and R2 are as otherwise described herein, although numerous other groups may also be used as substituents. Various optionally substituted moieties may be substituted with 3 or more substituents, preferably no more than 3 substituents and preferably with 1 or 2 substituents. It is noted that in instances where, in a compound at a particular position of the molecule substitution is required (principally, because of valency), but no substitution is indicated, then that substituent is construed or understood to be H, unless the context of the substitution suggests otherwise.
  • The term “aryl” or “aromatic”, in context, refers to a substituted (as otherwise described herein) or unsubstituted monovalent aromatic radical having a single ring (e.g., benzene, phenyl, benzyl) or condensed rings (e.g., naphthyl, anthracenyl, phenanthrenyl, etc.) and can be bound to the compound according to the present invention at any available stable position on the ring(s) or as otherwise indicated in the chemical structure presented. Other examples of aryl groups, in context, may include heterocyclic aromatic ring systems “heteroaryl” groups having one or more nitrogen, oxygen, or sulfur atoms in the ring (moncyclic) such as imidazole, furyl, pyrrole, furanyl, thiene, thiazole, pyridine, pyrimidine, pyrazine, triazole, oxazole or fused ring systems such as indole, quinoline, indolizine, azaindolizine, benzofurazan, etc., among others, which may be optionally substituted as described above. Among the heteroaryl groups which may be mentioned include nitrogen-containing heteroaryl groups such as pyrrole, pyridine, pyridone, pyridazine, pyrimidine, pyrazine, pyrazole, imidazole, triazole, triazine, tetrazole, indole, isoindole, indolizine, azaindolizine, purine, indazole, quinoline, dihydroquinoline, tetrahydroquinoline, isoquinoline, dihydroisoquinoline, tetrahydroisoquinoline, quinolizine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, imidazopyridine, imidazotriazine, pyrazinopyridazine, acridine, phenanthridine, carbazole, carbazoline, perimidine, phenanthroline, phenacene, oxadiazole, benzimidazole, pyrrolopyridine, pyrrolopyrimidine and pyridopyrimidine; sulfur-containing aromatic heterocycles such as thiophene and benzothiophene; oxygen-containing aromatic heterocycles such as furan, pyran, cyclopentapyran, benzofuran and isobenzofuran; and aromatic heterocycles comprising 2 or more hetero atoms selected from among nitrogen, sulfur and oxygen, such as thiazole, thiadizole, isothiazole, benzoxazole, benzothiazole, benzothiadiazole, phenothiazine, isoxazole, furazan, phenoxazine, pyrazoloxazole, imidazothiazole, thienofuran, furopyrrole, pyridoxazine, furopyridine, furopyrimidine, thienopyrimidine and oxazole, among others, all of which may be optionally substituted.
  • The term “heterocycle” refers to a cyclic group which contains at least one heteroatom, i.e., O, N or S, and may be aromatic (heteroaryl) or non-aromatic. Thus, the heteroaryl moieties are subsumed under the definition of heterocycle, depending on the context of its use. Exemplary heteroaryl groups are described hereinabove. Exemplary non-aromatic heterocyclic groups for use in the present invention include, for example, pyrrolidinyl, pyrrolinyl, piperidinyl, piperazinyl, N-methylpiperazinyl, pyrazolidinyl, imidazolidinyl, morpholinyl, tetrahydropyranyl, azetidinyl, oxetanyl, oxathiolanyl, pyridone, 2-pyrrolidone, ethyleneurea, 1,3-dioxolane, 1,3-dioxane, 1,4-dioxane, phthalimide and succinimide, among others, as described herein.
  • The terms “treat”, “treating”, and “treatment”, etc., as used herein, refer to any action providing a benefit to a patient for which the present compounds may be administered, including the treatment of any disease state or condition which is modulated through the protein to which the present compounds bind. Disease states or conditions, including cancer, which may be treated using compounds according to the present invention are set forth hereinabove.
  • The term “coadministration” or “combination therapy” shall mean that at least two compounds or compositions are administered to the patient at the same time, such that effective amounts or concentrations of each of the two or more compounds may be found in the patient at a given point in time. Although compounds according to the present invention may be co-administered to a patient at the same time, the term embraces both administration of two or more agents at the same time or at different times, provided that effective concentrations of all coadministered compounds or compositions are found in the subject at a given time. In certain preferred aspects of the present invention, one or more of the present compounds described above, are coadministered in combination with at least one additional bioactive agent, especially including an anticancer agent. In particularly preferred aspects of the invention, the co-administration of compounds results in synergistic therapeutic, including anticancer therapy.
  • Pharmaceutical compositions comprising combinations of an effective amount of at least one bifunctional compound according to the present invention, and one or more of the compounds otherwise described herein, all in effective amounts, in combination with a pharmaceutically effective amount of a carrier, additive or excipient, represents a further aspect of the present invention.
  • The present invention includes, where applicable, the compositions comprising the pharmaceutically acceptable salts, in particular, acid or base addition salts of compounds of the present invention. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds useful in this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1′-methylene-bis-(2-hydroxy-3 naphthoate)]salts, among numerous others.
  • Pharmaceutically acceptable base addition salts may also be used to produce pharmaceutically acceptable salt forms of the compounds or derivatives according to the present invention. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of the present compounds that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (eg., potassium and sodium) and alkaline earth metal cations (eg, calcium, zinc and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines, among others.
  • The compounds of the present invention may, in accordance with the invention, be administered in single or divided doses by the oral, parenteral or topical routes. Administration of the active compound may range from continuous (intravenous drip) to several oral administrations per day (for example, Q.I.D.) and may include oral, topical, parenteral, intramuscular, intravenous, sub-cutaneous, transdermal (which may include a penetration enhancement agent), buccal, sublingual and suppository administration, among other routes of administration. Enteric coated oral tablets may also be used to enhance bioavailability of the compounds from an oral route of administration. The most effective dosage form will depend upon the pharmacokinetics of the particular agent chosen as well as the severity of disease in the patient. Administration of compounds according to the present invention as sprays, mists, or aerosols for intra-nasal, intra-tracheal or pulmonary administration may also be used. The present invention therefore also is directed to pharmaceutical compositions comprising an effective amount of compound according to the present invention, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient. Compounds according to the present invention may be administered in immediate release, intermediate release or sustained or controlled release forms. Sustained or controlled release forms are preferably administered orally, but also in suppository and transdermal or other topical forms. Intramuscular injections in liposomal form may also be used to control or sustain the release of compound at an injection site.
  • The compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers and may also be administered in controlled-release formulations. Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as prolamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
  • The compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term “parenteral” as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously.
  • Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1, 3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of inj ectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as Ph. Helv or similar alcohol.
  • The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • Alternatively, the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient, which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
  • The pharmaceutical compositions of this invention may also be administered topically. Suitable topical formulations are readily prepared for each of these areas or organs. Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-acceptable transdermal patches may also be used.
  • For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. In certain preferred aspects of the invention, the compounds may be coated onto a stent which is to be surgically implanted into a patient in order to inhibit or reduce the likelihood of occlusion occurring in the stent in the patient.
  • Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
  • The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
  • The amount of compound in a pharmaceutical composition of the instant invention that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host and disease treated, the particular mode of administration. Preferably, the compositions should be formulated to contain between about 0.05 milligram to about 750 milligrams or more, more preferably about 1 milligram to about 600 milligrams, and even more preferably about 10 milligrams to about 500 milligrams of active ingredient, alone or in combination with at least one other compound according to the present invention.
  • It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease or condition being treated.
  • A patient or subject in need of therapy using compounds according to the present invention can be treated by administering to the patient (subject) an effective amount of the compound according to the present invention including pharmaceutically acceptable salts, solvates or polymorphs, thereof optionally in a pharmaceutically acceptable carrier or diluent, either alone, or in combination with other known erythopoiesis stimulating agents as otherwise identified herein.
  • These compounds can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, including transdermally, in liquid, cream, gel, or solid form, or by aerosol form.
  • The active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutically effective amount for the desired indication, without causing serious toxic effects in the patient treated. A preferred dose of the active compound for all of the herein-mentioned conditions is in the range from about 10 ng/kg to 300 mg/kg, preferably 0.1 to 100 mg/kg per day, more generally 0.5 to about 25 mg per kilogram body weight of the recipient/patient per day. A typical topical dosage will range from 0.01-5% wt/wt in a suitable carrier.
  • The compound is conveniently administered in any suitable unit dosage form, including but not limited to one containing less than 1 mg, 1 mg to 3000 mg, preferably 5 to 500 mg of active ingredient per unit dosage form. An oral dosage of about 25-250 mg is often convenient.
  • The active ingredient is preferably administered to achieve peak plasma concentrations of the active compound of about 0.00001-30 mM, preferably about 0.1-30 μM. This may be achieved, for example, by the intravenous injection of a solution or formulation of the active ingredient, optionally in saline, or an aqueous medium or administered as a bolus of the active ingredient. Oral administration is also appropriate to generate effective plasma concentrations of active agent.
  • The concentration of active compound in the drug composition will depend on absorption, distribution, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
  • Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound or its prodrug derivative can be incorporated with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a dispersing agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents.
  • The active compound or pharmaceutically acceptable salt thereof can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
  • The active compound or pharmaceutically acceptable salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as erythropoietin stimulating agents, including EPO and darbapoietin alfa, among others. In certain preferred aspects of the invention, one or more compounds according to the present invention are coadministered with another bioactive agent, such as an erythropoietin stimulating agent or a would healing agent, including an antibiotic, as otherwise described herein.
  • Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • If administered intravenously, preferred carriers are physiological saline or phosphate buffered saline (PBS).
  • In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • Liposomal suspensions may also be pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811 (which is incorporated herein by reference in its entirety). For example, liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound are then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
    • General Synthetic Approaches
  • Generic scheme for the synthesis of ULM derivatives is described here. Briefly, the compounds according to the present invention are synthesized pursuant to the general solution phase synthetic scheme (presented hereinbelow) and/or general scheme I, which is directed to phase synthesis of compounds according to the present invention. Initially a hydroxyl-protected carboxy substituted (and protected) pyrrolidine compound is reacted with a carboxylic acid containing reagent, which introduces a carbonyl group at the amine of the pyrollidine ring to form an amide group. Alternatively, the pyrrolidine amine may be protected and the carboxylic acid moiety may be condensed with a nucleophilic group on a right hand fragment to provide an amide on the right hand portion of the pyrrolidine moiety. The left and right hand fragments to be condensed onto, respectively, the amine and carboxylic acid group of the pyrrolidine moiety are preferably prepared prior to condensing onto the pyrrolidine group, but other approaches may be taken to introduce groups onto the pyrrolidine group. The individual components which are combined to produce a ULM group can be prepared using blocking groups at preferred functional groups on the ULM group which can be removed so as to react with and covalently link a linker group which is prepared to accommodate a PTM moiety to which is already bound a protein binding moiety or PTM group or may be further reacted to form a covalent bound with a PTM group, which may also may comprise a ULM′ group as otherwise described herein. Thus, a carboxylic acid containing left hand fragment may be condensed onto the amine group of the pyrroline, thus forming an amide group with an R1 left hand fragment as depicted below. Onto the carboxyl group, any number of nucleophilic (preferably, amine containing) right hand fragments (pre-synthesized) may be condensed onto the carboxyl group to provide an amide group with an R2 right fragment as depicted below. Formation of the pre-synthesized groups to condense onto the amine and/or the carboxyl moiety of the pyrrolidine proceeds in a facile manner. Virtually any compound can be synthesized readily using this approach. The solid phase synthetic method can also be used and employs similar methods used in the solution phase synthesis, the major difference being that the hydroxyl group may be bound to a solid support as the other steps of the synthesis occur. The general synthetic methods are applicable to virtually all of the compounds of the present invention with facile modifications being made consistent with the state of chemical synthetic art as used directly or adapted from the specific teachings of the examples which follow.
  • Figure US20190127359A1-20190502-C00213
  • Figure US20190127359A1-20190502-C00214
  • Alternative General Method for Solid Phase Synthesis of VHL Ligands according to the present invention (details for which are presented in the second set of examples), set forth herein:
    • Synthetic Approaches for Compound Generation to Screen for Target Protein Binding Elements (PTM) and Ubiquitination Ligand Moieties (ULM) of the Subject Invention
  • Two basic methods which are used in combinatorial chemistry to identify PTM moieties and ULM moieties are solid-phase and solution-phase methods. Using these methods combinatorial compounds are created either by solution-phase synthesis or by producing compounds bound covalently to solid-phase particles. Once their moieties are identified they may be modified using appropriate groups (electrophilic and/or nucleophilic), and condensed onto linker groups to produce bifunctional compounds according to the present invention.
    • Solid Phase Methods
  • Solid Phase Methods rely on the teachings of Fruchtel, et al. 1996, Angew. Chem. Int. Ed. Engl. 35, 17-42; which is incorporated by reference in its entirety herein).
  • Solid-phase synthesis makes it easier to conduct multistep reactions and to drive reactions to completion, because excess reagents can be added and then easily washed away after each reaction step. Another key factor in favor of solid-phase synthesis is that it makes it possible to use split synthesis, a technique developed in 1982. Split synthesis produces large support-bound libraries in which each solid-phase particle holds a single compound, or soluble libraries produced by cleavage of compounds from the solid support. For example in a split synthesis method if you have 3 compound addition steps with 10 compounds used at each step i.e. 10 containers for those compounds. This will generate 103 compounds. Also, if you consider all the reaction steps included in a synthesis 10,000 compounds made via a solid phase methods using a three-step chemistry may only require about 22 containers for the chemistry and about 66 liquid handling steps relative to the 10,000 containers and 30,000 liquid handling steps. When you combine these advantages of solid phase synthesis with split synthesis, a significant level of synergy is achieved.
    • Solution Phase Methods
  • Solution phase chemistry is favored by many for library construction due to the wider range of organic reactions available for solution-phase synthesis, the technology used traditionally by most synthetic organic chemists, and products in solution can be more easily identified in standard drug target assays and characterized. A problem for solution-phase synthesis of one molecule at a time is the final purification that can be both expensive and slow. Chromatography is commonly a first resort since it usually works. In addition, the problems associated with solution chemistry are compounded when attempting to make tens of thousands of compounds to generate a library or a ‘book’ for a library.
  • In the generation of libraries of compounds numerous methods have been devised resulting in the wide spread use of large libraries of chemicals to readily allow the discovery of potential drug candidates. The generation of chemical libraries that are free in solution is typically the goal of most of the pharmaceutical industry. This aim is due to the nature of many of the drug targets and the associated assays. Also the construction and utility of chemical libraries is typically facilitated but the generation of master plates of compounds in solution to form the basis of the chemical library. Thus the general advantages of the solid phase synthesis methods are typically not fully realized in the context of the current drug discovery efforts. The main reason for this is the interest not in binding of the compound to the drug target but to demonstrate that the activity of the drug target is altered, which typically requires compound free in solution. Further concerns with libraries of compounds on a solid phase arise from concerns of the potential influence of the linker and steric effects on the compounds bound to the solid phase.
  • Thus methods for the discovery of compounds, which bind to target molecules is known in the art. Also, the optimization of the initially discovered compound is well known in the art where the affinity is improved by generation of a pool of related compound via a more selective combinatorial chemistry approach.
  • The present invention provides a mechanism to overcome these problems in drug and small molecule discovery.
    • Addition of the Ubiquitin Ligase Binding Moiety (ULM)
  • At this point in the compound discovery path for the subject invention, the target protein-binding element of the compounds of the invention has been identified. These optimal binding molecules are then subjected to further chemistry to add the ubiquitin ligase binding moiety (ULM), pursuant to the disclosure of the present application.
  • An alternative approach to the discovery of the target protein-binding moiety is based on solution phase screening. In such an example compounds (available either via synthesis, natural products or from companies such as ArQule (www.arqule.com), Pharmacopeia (www.pharmacopiea), and Cerep (www.cerep.com) are obtained and added to the target protein of interest and then subjected to size exclusion to remove the unbound compounds. The protein bound fraction is then subjected to GC/MS to identify the molecules. In this way the solution phase screening is made rapid and facile for compounds in solution. There are numerous additional ways to determine ligand binding, including, for example, detecting changes in the Tm of the protein upon the ligand binding, among others.
    • Screening for Target Protein Binding Elements
  • Initially a target protein is selected, for example, an enzyme or protein involved in a particular biological process. Target protein for the subject invention come from numerous fields where small molecules are used to achieve modulation of a biological system in eukaryotic organisms. Examples of such fields are antivirals, antimicrobials, anti-parasitics, or other drug targets in a human patient, which may be rather diverse, etc.
  • The target protein is then either purified from a natural source in order to provide sufficient material for the screen or expressed via recombinant methods to provide sufficient material for the screens.
  • The target protein is then either labeled directly with a detectable species such as a radioactive, electrochemiluminescent, and chemiluminescent or fluorescent label or with an indirectly detectable species such as an enzyme, or particle. Alternatively an antibody or equivalent with binding activity to the target protein is labeled.
  • The next step is to provide a library of compounds for screening. A library of from 1,000 to 1,000,000 is typical of the size that is screened. These are available from a series of companies, which are well known in the art. These libraries of compounds are used to screen for the binding of the target protein. Ideally compounds are bought still bound to the solid phase or are screened for binding directly to immobilized target protein using methods as described below for screening.
  • It is also possible to generate a chemical library of various potential binding molecules bound to a solid phase following conventional methods to give rise to differing potential compounds. The optimal methods for the construction of the chemical library is to employ the methods of split synthesis coupled to the solid phase (as outlined above). The library is generated using a series of solid phase chemistries such as to give rise to various compilations that form the basis of a library. The library is screened in the form of a library or in the form of the compilations. Typically one would take the products from the split synthesis and pool the solid phase and use this as the basis for the screen.
  • To the pool of beads used as the solid phase for the synthesis, a mixture of buffer, detergents, salts and blocking agents such as serum albumin or other proteins are added. This buffer addition step is used to block the beads or solid phase in such a way that any significant non-specific binding of the selected target protein does not occur. Following this blocking step the beads are washed and followed by the addition of the target protein either labeled or not. The beads or solid phase are then incubated to allow the binding of the target protein binding elements to the target protein. Following the incubation of the target molecule to the beads or solid phase the beads are washed and then the binding of the labeled target protein detected directly. In an alternative format, if the target protein is labeled with an indirectly detectable label such as an enzyme, the beads are then placed in to a substrate reaction solution to detect the presence of the enzyme label. In the case of an enzyme label, substrates for these detection methods are based on insoluble chromogenic products. In the case where the target protein is not labeled and an antibody or equivalent is available, the beads are subjected to another binding reaction where the antibody or equivalent, is labeled either directly or indirectly as suggested for the labeling of the target protein. It is also possible at this step to not use a labeled antibody or equivalent and to add a further step where the labeled antibody or equivalent is used. These additional steps can be detected using the same standard methods known in the art as suggested for the directly labeled target protein.
  • Following these steps a series of beads are identified and these beads are selected from the bead population and subject to analysis to determine the structure of the binding molecule that is able to bind the target protein as in this example. This is achieved by the use of GC/MS or via molecular tags used during the construction of the library as described earlier. Alternatively, a pool which was positive is re-made generating a series of sub pools for screening and further re-synthesis and dividing out of the various pooled compounds until a single compound is presented in a single well for analysis allowing the determination of the active compound.
  • This method can be repeated and/or adapted for identifying peptide target binding moieties (PTM) for virtually any target protein.
  • Screening for Binding Molecules from Chemical Libraries
  • The step of screening for specific molecules is made easy in the invention as only binding activity is desired and not specific modulation of the target protein as is required in traditional drug discovery.
  • One can buy a library of compounds for screening. A library of from 1,000 to 1,000,000 is typical of the size that might be screened. These are available from a number of companies. These libraries of compounds are used to screen for the binding of the target protein. Ideally, compounds are purchased still bound to the solid phase or are screened for binding directly to immobilized target protein using methods as described below for screening.
  • It is also possible to generate a library of from 1,000 to 100,000 compounds contained on a solid phase using split synthesis methods as described earlier. The library may be constructed using a series of chemical methods resulting in pools of the solid phase used during synthesis, which form the basis of the entries which make up the library. In addition at the final chemical coupling step used to construct the various entries the solid phase pools are stored in sub-pools in the libraries. These so called entries and sub-pools form the basis for screening as they contain not only pools of compounds but also a known chemical-coupling step used in synthesis.
  • The library can then be screened using two approaches. In both cases the solid phase from the chemical library to be screened is subjected incubation with assay buffers with blocking agents such as for example; proteins (i.e. BSA, gelatin), polyvinylpyrrolidone, ficoll, heparin, detergents (i.e. SDS, Tween, NP40, Triton X-100). This incubation step is to block the non-specific binding sites on the solid phase used in the generation of the library and allow the determination of specific binding events. This initial incubation is an art recognized step in various binding assays such as ELISA, southerns, westerns etc. Following this incubation with blocking agents the protein of interest is then added to a buffer which typically has the same composition as that during the blocking step but can also be modified using lower or no additional blocking agents with the exception of the detergents which are typically always present during a binding reaction.
  • In one of the screening methods the entries following the blocking step are then subjected to binding with the purified target protein. The solid phase from this incubation is then washed and subjected to a second binding step with a labeled reagent which binds to the tag sequence added to the receptor sub-unit during the recombinant engineering for the expression of the receptor sub-unit. Typically an antibody to this tag recognizes the tag sequence; examples that are in common use are the myc, flag, and his epitopes. Following the incubation with the tag specific binding species the presence of the labeled binding species is detected by the presence of the label that is typically an enzyme such as alkaline phosphatase or peroxidase. The detection step typically makes use of an insoluble chromogenic substrate that is readily detected by eye or by image analysis systems.
  • In an alternative method soluble substrates can also be used and screened using ELISA plate readers, eye or other spectrophotometric methods. In its simplest form the various entries from the library are screened by eye to look for beads that have developed a color due to the enzymatic action on the chromogenic substrate. These colored beads indicate that the receptor subunit is binding to one of the compounds within the group of entries the next step is to determine if these so called positive group of entries contain specific binding or if binding is just to the tag binding reagent or some non-specific activation of the chromogenic substrate. To achieve this, the positive entries are screened with out the specific binding step to the receptor sub-unit. If these positive entries now become negative or show significantly reduced signals interms of positive solid phases with in the mixture then these are considered to be real positive hits in the screen. These real positive entries are then subjected to re-synthesis. In this re-synthesis the initial chemical steps to create the specific binding molecule is unknown only the last chemical coupling step in the compound synthesis is know, as this formed the last chemical step which constructed the group of entries. During the re-synthesis of the positive chapter the chemical step prior to the last chemical coupling is carried out as in the initial synthesis but the solid phase is not pooled and split for the final chemical coupling but are maintained as separate pools then subjected to the chemical coupling step know for that chapter. This resynthesis results in the formation of a new series of solid phase compound pools which have the last two chemical coupling steps known. This new series of solid phase compound pools are screened as in the initial screen and positive pools are checked as previously for the binding specificity to identify positive pools. The positive pool(s) now allow the re-synthesis of the pool(s) with the last two steps for the generation of the compound, which specifically binds to the receptor subunit. The positive pools are then subjected to the same cycle of re-synthesis and screening as just described but with the last two chemical coupling steps know the pools are maintained individually prior to the last know step. In this way the synthesis of the specific compound able to bind to the receptor sub-unit is deconvoluted from the chemical library and identified.
  • In an alternative method the positive solid phase is removed from the screen and collected. These are then subjected to the cleavage reaction, which removed the specific chemistry from the solid phase followed by the analysis of the various chemical species using GC to separate the individual compounds followed by MS to determine the molecular weight. This information coupled with the synthesis methods used is used to determine the compound identity. After the determination of these various candidate specific binding molecules they are then re-synthesized and subjected to the binding assay to check if these are the specific compounds that resulted in the positive solid phases.
    • Screening of the Ubiquitin Ligase Binding Moiety
  • This screening effort following methods and protocols known in the art allows the identification of compounds according to the present invention that bind to ubiquitin ligase.
  • These compounds, already identified here, form the basis for the development of compounds of the invention. These compounds are then subjected to further chemistry based on the use of the linker group used in the development of the solid phase chemistry. To this linker group the various ubiquitin ligase binding moieties and/or protein binding moieties are added, generally through condensation reactions or other reactions to couple a ligand to a ubiquitin ligase binding moiety or a protein binding moiety. These reactions are well known in the art. Derivatization of linker groups is well-known in the art and can consist of providing a nucleophilic group (e.g., an alcohol, amine, thiol or other nucleophilic group) or an electrophilic group (e.g., ester, carboxylic acid, acyl halide, halogen, etc.) at either or both ends of the linker group which may be used to condense an appropriately modified ULM group and/or PTM group onto the linker to produce a covalent bond. This final step of chemistry generates the compounds of the invention. The compounds of the invention are then subject to analysis to determine which of the compounds from the chemical library screen with which of the individual ubiquitin ligase binding moiety element is able to function most effectively in the targeted ubiquitination and/or degradation of the target protein. The ubiquitin ligase binding moiety may be determined by the methods as otherwise described in the examples section hereinbelow. In addition, the compounds of the invention can be tested in a mammalian tissue culture system where the target protein either intact or as an engineered fragment is expressed. In such a mammalian tissue culture system, the compounds effect on the target protein's level is determined by making use of the tag sequence which can be engineered into the recombinant expression of the target protein during the construction of the mammalian tissue culture test system. The tag sequence is used to determine the levels of the target protein during the incubation with the potential compounds screened and synthesized as described above. This assay for the tag sequence can take the form of a western blot or via an ELISA, for example. Other tags, which are valuable to use are those based on the green fluorescent protein, which allows the analysis of protein levels in living cells and/or organisms.
  • The compounds that show the optimal activity in the test systems will then form the basis for the next stage of drug development. In this next stage these selected compounds are subjected to the recognized drug development path. The drug development path determines the potential value of the compounds by evaluating a series of factors including bioavailability; toxicology, pharmacology and efficacy in animal models before the compounds are considered for human testing.
    • Protein Level Control
  • This invention also relates to a method for the control of protein levels with a cell. This is based on the use of compounds of the invention, which are known to interact with a specific target protein such that degradation of a target protein in vivo will result in the control of the amount of protein in a biological system, prerferably to a particular therapeutic benefit.
  • The following examples are used to assist in describing the present invention, but should not be seen as limiting the present invention in any way.
    • EXAMPLES First Set
  • The inventors initially hypothesized that small molecule inhibitors of the VHL/HIF-1α interaction could be rationally designed using hydroxyproline (Hyp) as a starting point, since residue Hyp564 on HIF-1α makes key interactions with VHL14 and is crucial for HIF-1α binding15. The inventors used the de-novo design software BOMB to guide the selection of plausible hydroxyproline analogs.16 1 and 2 were synthesized to test a promising design featuring an isoxazole moiety positioned to interact with a crystallographic water observed in the structure of VHL bound to the HIF peptide (549-582)14 and a benzyl group stacked along the side chain of Tyr98. Their ability to bind to VHL was measured by the competition of a fluorescent HIF-1α peptide using fluorescence polarization (FP).17 Both were able to displace the fluorescent peptide albeit at high concentrations (Table 1A). While the smaller 3 was unable to fully displace the fluorescent peptide, the observed binding to VHL through the use of WaterLOGSY and saturation transfer difference (STD) NMR. As no binding was observed with hydroxyproline alone, this suggested that the inventors identified a minimal pharmacophore (see FIG. 2).
  • TABLE 1A
    Binding of Initial Ligands to VHL
    R IC50 (μM)a SEM (μM)
     1 
    Figure US20190127359A1-20190502-C00215
         		  117   10  
    2
    Figure US20190127359A1-20190502-C00216
         		  120.1 7.1
    3 CH3 >250   N/A
    aAverage IC50 values were determined from three independent trials, each in triplicate.
  • Figure US20190127359A1-20190502-C00217
  • Encouraged by these initial results, the inventors sought to increase the affinity of our VHL ligands by modifying the benzylamine moiety of 1 while maintaining the methyl-isoxazole fragment. In order to generate analogs rapidly, we developed a solid phase synthesis that involved the attachment of Fmoc-Hyp-OAllyl to Wang resin.18 Fmoc deprotection, coupling with 3-methyl-5-isoxazoleacetic acid followed by allyl ester deprotection and coupling with various amines and subsequent cleavage with trifluoroacetic acid led to the rapid generation of VHL ligands (Scheme 1).19,20 These ligands were then tested for their ability to bind VHL using the HIF peptide FP displacement assay.
  • Incorporation of various halogenated benzylamines showed that para substitution yielded the highest affinity and that there were only slight differences of affinity between chlorides and bromides, although the corresponding fluoride was less potent. We also found that substitution with electron withdrawing groups such as esters, nitro groups, nitriles, and ketones led to more potent ligands than substitution with the electron donating methoxy and t-butyl substituents. Molecular dynamics simulations suggested that Arg107 is flexible and could accommodate bulkier groups at the para position. Therefore, we considered larger heterocyclic substituents at the para position of the benzylamine moiety and synthesized 15, which was found to bind with a 4.1 μM IC50 value (Table 2, below).
    • Fluorescence Polarization Assay
  • Ability of VHL ligands to compete for the HIF 1α binding site on VCB was determined through a fluorescence polarization competition assay as described in the literature (Buckley et al. JACS, 2012, 134, 4465-4468). VHL ligands were dissolved in DMSO (100 mM), and then diluted 10 fold with VHL buffer. The compounds were then diluted 2 fold with 10% DMSO in buffer (20 uL into uL of 10% DMSO in buffer) 14 times. Aqueous DEALA-Hyp-YIPD was used as a positive control. 278 nM FAM-DEALA-Hyp-YIPD (DMSO) was diluted 1000 fold into VHL buffer. For polarization displacement assays, 9 uL of 1 uM V1-213CB (450 nM final), 2 uL of VHL Ligands (VL) compounds in 10% DMSO (1% DMSO final), and 9 uL of 278 nM FAM-DEALA-Hyp-YIPD were added to a 384 well plate (Corning 3575). The plate was then shaken for 1 minute, and centrifuged for 1 minute, before reading fluorescence polarization on a Perkin Elmer Envision 2101 Multilabel reader (excitation 486 nM, emission 535 nM). Wells containing V1-213CB, DMSO vehicle, FAM-DEALA-Hyp-YIPD served as maximum polarization (or minimum displacement). Wells containing buffer in place of V1-213CB, DMSO vehicle, FAM-DEALA-Hyp-YIPD served as minimum polarization (or maximum displacement). The percent inhibition was determined by normalization to maximum and minimum polarization, and graphed against the log [VL]. IC50 values were then determined using Prism 5 for each replicate (n=9), which were then averaged to determine the average IC50 and the standard error of the mean (SEM). The results for a number of exemplary compounds are presented in Table 2 Affinity Table herein below.
  • TABLE 2
    Affinity Table.
    VHL IC50 (μM) IC50 (μM)
    ligand No. 10% DMSO 1% DMSO Chemical Structure
    VL001 >1000
    Figure US20190127359A1-20190502-C00218
    VL002 241.1 120
    Figure US20190127359A1-20190502-C00219
    VL003 >1000
    Figure US20190127359A1-20190502-C00220
    VL004 123.1 117
    Figure US20190127359A1-20190502-C00221
    VL005 >1000
    Figure US20190127359A1-20190502-C00222
    VL006 Inactive
    Figure US20190127359A1-20190502-C00223
    VL007 Inactive
    Figure US20190127359A1-20190502-C00224
    VL008 >1000
    Figure US20190127359A1-20190502-C00225
    VL009 Inactive
    Figure US20190127359A1-20190502-C00226
    VL010 Inactive
    Figure US20190127359A1-20190502-C00227
    VL011 >1000
    Figure US20190127359A1-20190502-C00228
    VL012 >1000
    Figure US20190127359A1-20190502-C00229
    VL013 240
    Figure US20190127359A1-20190502-C00230
    VL014 4.7
    Figure US20190127359A1-20190502-C00231
    VL015 >1000
    Figure US20190127359A1-20190502-C00232
    VL016 ~730
    Figure US20190127359A1-20190502-C00233
    VL017 ~510
    Figure US20190127359A1-20190502-C00234
    VL018 280
    Figure US20190127359A1-20190502-C00235
    VL019 450.5
    Figure US20190127359A1-20190502-C00236
    VL020 295.4 149
    Figure US20190127359A1-20190502-C00237
    VL021 36 20.5
    Figure US20190127359A1-20190502-C00238
    VL022 ~870
    Figure US20190127359A1-20190502-C00239
    VL023 589
    Figure US20190127359A1-20190502-C00240
    VL024 511
    Figure US20190127359A1-20190502-C00241
    VL025 517
    Figure US20190127359A1-20190502-C00242
    VL026 >1000 >250
    Figure US20190127359A1-20190502-C00243
    VL027 >1000
    Figure US20190127359A1-20190502-C00244
    VL028 210.0 149
    Figure US20190127359A1-20190502-C00245
    VL029 24.9 32
    Figure US20190127359A1-20190502-C00246
    VL030 215
    Figure US20190127359A1-20190502-C00247
    VL031 68.5 >250
    Figure US20190127359A1-20190502-C00248
    VL032 639
    Figure US20190127359A1-20190502-C00249
    VL033 >1000
    Figure US20190127359A1-20190502-C00250
    VL034 130.7 130
    Figure US20190127359A1-20190502-C00251
    VL035 34 39.4
    Figure US20190127359A1-20190502-C00252
    VL036 743.5
    Figure US20190127359A1-20190502-C00253
    VL037 88.8
    Figure US20190127359A1-20190502-C00254
    VL039 >1000
    Figure US20190127359A1-20190502-C00255
    VL043 >1000
    Figure US20190127359A1-20190502-C00256
    VL044 285.8
    Figure US20190127359A1-20190502-C00257
    VL045 145.6
    Figure US20190127359A1-20190502-C00258
    VL046 215.2
    Figure US20190127359A1-20190502-C00259
    VL047 405.7 106
    Figure US20190127359A1-20190502-C00260
    VL048 24.8 16
    Figure US20190127359A1-20190502-C00261
    VL049 15.1
    Figure US20190127359A1-20190502-C00262
    VL050 332.1
    Figure US20190127359A1-20190502-C00263
    VL051 >1000
    Figure US20190127359A1-20190502-C00264
    VL052 >1000
    Figure US20190127359A1-20190502-C00265
    VL053 >1000
    Figure US20190127359A1-20190502-C00266
    VL054 139.6
    Figure US20190127359A1-20190502-C00267
    VL055 910.3
    Figure US20190127359A1-20190502-C00268
    VL056 938.5
    Figure US20190127359A1-20190502-C00269
    VL057 >1000
    Figure US20190127359A1-20190502-C00270
    VL058 >1000
    Figure US20190127359A1-20190502-C00271
    VL059 205.4
    Figure US20190127359A1-20190502-C00272
    VL060 >1000
    Figure US20190127359A1-20190502-C00273
    VL061 419.5
    Figure US20190127359A1-20190502-C00274
    VL062 >1000
    Figure US20190127359A1-20190502-C00275
    VL063 >1000
    Figure US20190127359A1-20190502-C00276
    VL064 110.0
    Figure US20190127359A1-20190502-C00277
    VL065 74.2
    Figure US20190127359A1-20190502-C00278
    VL066 72.4
    Figure US20190127359A1-20190502-C00279
    VL067 70.7
    Figure US20190127359A1-20190502-C00280
    VL068 >1000
    Figure US20190127359A1-20190502-C00281
    VL069 23.8
    Figure US20190127359A1-20190502-C00282
    VL070 38.2
    Figure US20190127359A1-20190502-C00283
    VL071 10.4
    Figure US20190127359A1-20190502-C00284
    VL072 29.5
    Figure US20190127359A1-20190502-C00285
    VL073 39 46
    Figure US20190127359A1-20190502-C00286
    VL074 42.9
    Figure US20190127359A1-20190502-C00287
    VL075 35.5
    Figure US20190127359A1-20190502-C00288
    VL076 19.6
    Figure US20190127359A1-20190502-C00289
    VL077 8.9
    Figure US20190127359A1-20190502-C00290
    VL078 60.2
    Figure US20190127359A1-20190502-C00291
    VL079 26.3
    Figure US20190127359A1-20190502-C00292
    VL080 17.0
    Figure US20190127359A1-20190502-C00293
    VL081 15.5
    Figure US20190127359A1-20190502-C00294
    VL082 29.0
    Figure US20190127359A1-20190502-C00295
    VL083 >1000
    Figure US20190127359A1-20190502-C00296
    VL084 460.3
    Figure US20190127359A1-20190502-C00297
    VL085 27.1
    Figure US20190127359A1-20190502-C00298
    VL086 168.4
    Figure US20190127359A1-20190502-C00299
    VL087 102.6
    Figure US20190127359A1-20190502-C00300
    VL088 18.2 60
    Figure US20190127359A1-20190502-C00301
    VL089 40.8
    Figure US20190127359A1-20190502-C00302
    VL090 45.2
    Figure US20190127359A1-20190502-C00303
    VL091 23.0
    Figure US20190127359A1-20190502-C00304
    VL093 510
    Figure US20190127359A1-20190502-C00305
    VL094 540
    Figure US20190127359A1-20190502-C00306
    VL095 14.8 22.6
    Figure US20190127359A1-20190502-C00307
    VL096 32.5
    Figure US20190127359A1-20190502-C00308
    VL097 49.4
    Figure US20190127359A1-20190502-C00309
    VL098 244.4
    Figure US20190127359A1-20190502-C00310
    VL099 39.6
    Figure US20190127359A1-20190502-C00311
    VL100 63.6
    Figure US20190127359A1-20190502-C00312
    VL101 940
    Figure US20190127359A1-20190502-C00313
    VL102 64.5
    Figure US20190127359A1-20190502-C00314
    VL104 >1000
    Figure US20190127359A1-20190502-C00315
    VL105 >1000
    Figure US20190127359A1-20190502-C00316
    VL106 >1000
    Figure US20190127359A1-20190502-C00317
    VL108 347.2
    Figure US20190127359A1-20190502-C00318
    VL109 349.0
    Figure US20190127359A1-20190502-C00319
    VL110 138.0
    Figure US20190127359A1-20190502-C00320
    VL111 4.1 4.1
    Figure US20190127359A1-20190502-C00321
    VL112 11.3
    Figure US20190127359A1-20190502-C00322
    VL113 Inactive Inactive
    Figure US20190127359A1-20190502-C00323
    VL114 Inactive Inactive
    Figure US20190127359A1-20190502-C00324
    VL115 17.0 19
    Figure US20190127359A1-20190502-C00325
    VL116 2.9 2.9
    Figure US20190127359A1-20190502-C00326
    VL117 5.0 13
    Figure US20190127359A1-20190502-C00327
    VL118 16.4 31
    Figure US20190127359A1-20190502-C00328
    VL119 17.8 33
    Figure US20190127359A1-20190502-C00329
    VL120 >1000 >1000
    Figure US20190127359A1-20190502-C00330
    VL121 >1000 >1000
    Figure US20190127359A1-20190502-C00331
    VL122 102.1 220
    Figure US20190127359A1-20190502-C00332
    VL123 560 404
    Figure US20190127359A1-20190502-C00333
    VL124 990 670
    Figure US20190127359A1-20190502-C00334
    VL125 790 568
    Figure US20190127359A1-20190502-C00335
    VL126 88.1 82
    Figure US20190127359A1-20190502-C00336
    VL127 47.7 73
    Figure US20190127359A1-20190502-C00337
    VL128 57.9 224
    Figure US20190127359A1-20190502-C00338
    VL129 760 493
    Figure US20190127359A1-20190502-C00339
    VL130 >1000 >1000
    Figure US20190127359A1-20190502-C00340
    VL131 8.0 19
    Figure US20190127359A1-20190502-C00341
    VL132 77.7 85
    Figure US20190127359A1-20190502-C00342
    VL133 2.2 7.5
    Figure US20190127359A1-20190502-C00343
    VL134 48.1 54
    Figure US20190127359A1-20190502-C00344
    VL135 Inactive >1000
    Figure US20190127359A1-20190502-C00345
    VL136 28.2 540
    Figure US20190127359A1-20190502-C00346
    VL137 35.6 128
    Figure US20190127359A1-20190502-C00347
    VL138 52.2 70
    Figure US20190127359A1-20190502-C00348
    VL139 24.7 44
    Figure US20190127359A1-20190502-C00349
    VL140 10.3 17
    Figure US20190127359A1-20190502-C00350
    VL141 191.8 220
    Figure US20190127359A1-20190502-C00351
    VL142 780 >1000
    Figure US20190127359A1-20190502-C00352
    VL143 >1000 >1000
    Figure US20190127359A1-20190502-C00353
    VL144 >1000 >1000
    Figure US20190127359A1-20190502-C00354
    VL145 >1000 >1000
    Figure US20190127359A1-20190502-C00355
    VL146 128.9 196
    Figure US20190127359A1-20190502-C00356
    VL147 >1000 >1000
    Figure US20190127359A1-20190502-C00357
    VL148 23.8 113
    Figure US20190127359A1-20190502-C00358
    VL149
    Figure US20190127359A1-20190502-C00359
    VL150 16.0 41
    Figure US20190127359A1-20190502-C00360
    VL151 11 33
    Figure US20190127359A1-20190502-C00361
    VL152 22.8 32
    Figure US20190127359A1-20190502-C00362
    VL153 978.3
    Figure US20190127359A1-20190502-C00363
    VL154 118.3 77
    Figure US20190127359A1-20190502-C00364
    VL155 17.4 14
    Figure US20190127359A1-20190502-C00365
    VL156 >1000 >1000
    Figure US20190127359A1-20190502-C00366
    VL157 371.7 360
    Figure US20190127359A1-20190502-C00367
    VL158 265.8 180
    Figure US20190127359A1-20190502-C00368
    VL159 66.9 54
    Figure US20190127359A1-20190502-C00369
    VL160 12.1 9
    Figure US20190127359A1-20190502-C00370
    VL161 36.4 35
    Figure US20190127359A1-20190502-C00371
    VL162 235.4 250
    Figure US20190127359A1-20190502-C00372
    VL163 507.5 610
    Figure US20190127359A1-20190502-C00373
    VL164 72.9 40
    Figure US20190127359A1-20190502-C00374
    VL165
    Figure US20190127359A1-20190502-C00375
    VL166
    Figure US20190127359A1-20190502-C00376
    VL167
    Figure US20190127359A1-20190502-C00377
    VL168
    Figure US20190127359A1-20190502-C00378
    VL169
    Figure US20190127359A1-20190502-C00379
    VL170
    Figure US20190127359A1-20190502-C00380
    VL171
    Figure US20190127359A1-20190502-C00381
    VL172
    Figure US20190127359A1-20190502-C00382
    VL173
    Figure US20190127359A1-20190502-C00383
    VL174
    Figure US20190127359A1-20190502-C00384
    VL175
    Figure US20190127359A1-20190502-C00385
    VL176
    Figure US20190127359A1-20190502-C00386
    VL177
    Figure US20190127359A1-20190502-C00387
    VL178
    Figure US20190127359A1-20190502-C00388
    VL179
    Figure US20190127359A1-20190502-C00389
    VL180
    Figure US20190127359A1-20190502-C00390
    VL181
    Figure US20190127359A1-20190502-C00391
    VL182
    Figure US20190127359A1-20190502-C00392
    VL183
    Figure US20190127359A1-20190502-C00393
    VL184
    Figure US20190127359A1-20190502-C00394
    VL185
    Figure US20190127359A1-20190502-C00395
    VL186
    Figure US20190127359A1-20190502-C00396
    VL187
    Figure US20190127359A1-20190502-C00397
    VL188
    Figure US20190127359A1-20190502-C00398
    VL189
    Figure US20190127359A1-20190502-C00399
    VL190
    Figure US20190127359A1-20190502-C00400
    VL191
    Figure US20190127359A1-20190502-C00401
    VL192
    Figure US20190127359A1-20190502-C00402
    VL193
    Figure US20190127359A1-20190502-C00403
    VL194
    Figure US20190127359A1-20190502-C00404
    VL195
    Figure US20190127359A1-20190502-C00405
    VL196
    Figure US20190127359A1-20190502-C00406
    VL197
    Figure US20190127359A1-20190502-C00407
    VL198
    Figure US20190127359A1-20190502-C00408
    VL199
    Figure US20190127359A1-20190502-C00409
    VL200
    Figure US20190127359A1-20190502-C00410
    VL201
    Figure US20190127359A1-20190502-C00411
    VL202
    Figure US20190127359A1-20190502-C00412
    VL203
    Figure US20190127359A1-20190502-C00413
    VL204
    Figure US20190127359A1-20190502-C00414
    VL205
    Figure US20190127359A1-20190502-C00415
    VL206
    Figure US20190127359A1-20190502-C00416
    VL207
    Figure US20190127359A1-20190502-C00417
    VL208
    Figure US20190127359A1-20190502-C00418
    VL209
    Figure US20190127359A1-20190502-C00419
    VL210
    Figure US20190127359A1-20190502-C00420
    VL211
    Figure US20190127359A1-20190502-C00421
    VL212
    Figure US20190127359A1-20190502-C00422
    VL213
    Figure US20190127359A1-20190502-C00423
    VL214
    Figure US20190127359A1-20190502-C00424
    VL215
    Figure US20190127359A1-20190502-C00425
    VL216
    Figure US20190127359A1-20190502-C00426
    VL217
    Figure US20190127359A1-20190502-C00427
    VL218
    Figure US20190127359A1-20190502-C00428
    VL219
    Figure US20190127359A1-20190502-C00429
    VL220
    Figure US20190127359A1-20190502-C00430
    VL221
    Figure US20190127359A1-20190502-C00431
    VL222
    Figure US20190127359A1-20190502-C00432
    VL223
    Figure US20190127359A1-20190502-C00433
    VL224
    Figure US20190127359A1-20190502-C00434
    VL225
    Figure US20190127359A1-20190502-C00435
    VL226
    Figure US20190127359A1-20190502-C00436
    VL227
    Figure US20190127359A1-20190502-C00437
    VL228
    Figure US20190127359A1-20190502-C00438
    VL229
    Figure US20190127359A1-20190502-C00439
    VL230
    Figure US20190127359A1-20190502-C00440
    VL231
    Figure US20190127359A1-20190502-C00441
    VL232
    Figure US20190127359A1-20190502-C00442
    VL237
    Figure US20190127359A1-20190502-C00443
    VL238
    Figure US20190127359A1-20190502-C00444
    VL239
    Figure US20190127359A1-20190502-C00445
    VL240
    Figure US20190127359A1-20190502-C00446
    VL241
    Figure US20190127359A1-20190502-C00447
    VL242
    Figure US20190127359A1-20190502-C00448
    VL243
    Figure US20190127359A1-20190502-C00449
    VL244
    Figure US20190127359A1-20190502-C00450
    VL245
    Figure US20190127359A1-20190502-C00451
    VL247
    Figure US20190127359A1-20190502-C00452
    VL248
    Figure US20190127359A1-20190502-C00453
    VL249
    Figure US20190127359A1-20190502-C00454
    VL250
    Figure US20190127359A1-20190502-C00455
    VL251
    Figure US20190127359A1-20190502-C00456
    VL252
    Figure US20190127359A1-20190502-C00457
    VL253
    Figure US20190127359A1-20190502-C00458
    VL254
    Figure US20190127359A1-20190502-C00459
    VL255
    Figure US20190127359A1-20190502-C00460
    VL256
    Figure US20190127359A1-20190502-C00461
    VL257
    Figure US20190127359A1-20190502-C00462
    VL258
    Figure US20190127359A1-20190502-C00463
    VL259
    Figure US20190127359A1-20190502-C00464
    VL260
    Figure US20190127359A1-20190502-C00465
    VL261
    Figure US20190127359A1-20190502-C00466
    VL262
    Figure US20190127359A1-20190502-C00467
    VL263
    Figure US20190127359A1-20190502-C00468
    VL264
    Figure US20190127359A1-20190502-C00469
    VL265
    Figure US20190127359A1-20190502-C00470
    VL266
    Figure US20190127359A1-20190502-C00471
    • Synthetic Methods General Chemistry
  • All reactions were performed in oven-dried or flame-dried glassware fitted with rubber septa under a positive pressure of nitrogen, unless otherwise noted. Air- and moisture-sensitive liquids were transferred via syringe or cannula. THF was distilled from sodium/benzophenone. Dichloromethane was distilled from calcium hydride. Analytical thin layer chromatography (TLC) was performed using glass plates precoated with silica gel (0.25 mm). TLC plates were visualized by exposure to UV light (UV) or KMnO4. Flash column chromatography was performed using silica gel 60 (230-400 mesh, Merck) with the indicated solvents.
  • 1H and 13C spectra were recorded on Bruker Avance DPX-500 or Bruker Avance DPX-400 NMR spectrometers. 1H NMR spectra are represented as follows: chemical shift, multiplicity (s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, br=broad), integration, and coupling constant (J) in Hertz (Hz). 1H NMR chemical shifts are reported relative to CDCl3 (7.26 ppm), d6-DMSO (2.50 ppm) and d4-MeOD (3.31 ppm). 13C NMR was recorded relative to the central line of CDCl3 (77.16 ppm), d6-DMSO (39.52 ppm) and d4-MeOD (49.00 ppm). In most cases, only peaks of the major rotamer are reported. Mass spectra were obtained using a Perkin-Elmer API 150 EX spectrometer. MALDI-TOF analyses of purified samples were performed in a Voyager-DE-PRO 6268 (Applied Biosystems) using cyano-4-hydroxycinnamic acid matrices. Unless otherwise noted, HPLC was performed using a Dynamax SD200 solvent delivery system connected to a Dynamax UV-1 Absorbance Detector with a YMC-Pack ODS-AM preparative column (250×20 mm, 5 m particle size, 12 nm pore size). A linear gradient of MeCN in H2O from 20% to 100% MeCN, with constant 0.1% TFA was run over 40 minutes.
    • General Methods of Chemical Synthesis
  • The following eight (8) general chemical synthetic methods (Methods A through F and Solid Phase Synthesis A and B, described hereinbelow) are provided for synthesizing numerous compounds according to the present invention which are set forth in Table 2 Affinity Table above. Each method is presented with reference to a specific compound, the synthetic details of which are presented hereinabove. All of the compounds numbered may be synthesized relatively easily using the straight-forward methods which are set forth hereinbelow. In certain instances, more synthetic details are provided for certain preferred embodiments in order to present that information such that it may serve as a template for synthesizing a number of other compounds as otherwise disclosed herein.
  • Figure US20190127359A1-20190502-C00472
  • As an example, see the synthesis for compound VL133 of Table II, set forth below.
  • Figure US20190127359A1-20190502-C00473
  • See the general synthesis for VL116 of Table II with protection of the hydroxyl group.
  • Figure US20190127359A1-20190502-C00474
  • See the general synthesis for compound VL 156 of Table II, described below.
  • Figure US20190127359A1-20190502-C00475
  • See the general synthesis for compound VL 217 of Table II, described below.
  • Figure US20190127359A1-20190502-C00476
  • See the general synthesis for VL 219 of Table II, described below.
  • Figure US20190127359A1-20190502-C00477
  • Method F subsumes methods C, D and E and is a general method which proceeds through commercially available amines.
  • Following the general synthetic methods set forth above and as previously described, the following compounds are synthesized by analogy.
  • Figure US20190127359A1-20190502-C00478
    • (2S,4R)-1-((9H-fluoren-9-yl)methyl) 2-allyl 4-(tert-butoxy)pyrrolidine-1,2-dicarboxylate (Fmoc-Hyp(OtBu)-OAllyl)
  • Figure US20190127359A1-20190502-C00479
  • Fmoc-Hyp(OtBu)OH (24.9 g, 60.8 mmol, 1 eq) was dissolved in DMF (300 mL) at room temperature. Sodium bicarbonate (12.8 g, 152 mmol, 2.5 eq) was added, followed by allyl bromide (25.3 mL, 300 mmol, 4.9 eq). The solution was fitted with an air condenser and heated to 50° C. for 20 hours. It was then cooled to room temperature, diluted with EtOAc, washed with aqueous 1 M HCl, saturated sodium bicarbonate, water and brine. The organic layer was dried with sodium sulfate, filtered and condensed.15 Purification by column chromatography (15 to 33% EtOAc/hexanes) gave Fmoc-Hyp(OtBu)OAllyl (23.42 g, 52.1 mmol, 86%) as a faint yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.76 (t, J=6.3 Hz, 2H), 7.63-7.54 (m, 2H), 7.43-7.37 (m, 2H), 7.31 (t, J=7.0 Hz, 2H), 5.99-5.79 (m, 1H), 5.39-5.18 (m, 2H), 4.66 (d, J=5.6 Hz, 1H), 4.63-4.13 (m, 6H), 3.81 (ddd, J=16.6, 10.7, 6.2 Hz, 1H), 3.48-3.33 (m, 1H), 2.31-2.18 (m, 1H), 2.18-2.08 (m, 1H), 1.21 (d, J=11.6 Hz, 9H). 13C NMR (126 MHz, CDCl3) (mixture of rotamers) δ 172.49, 155.01, 154.49, 144.31, 144.18, 144.06, 143.84, 141.44, 141.41, 141.36, 131.91, 131.74, 127.80, 127.76, 127.20, 127.16, 125.31, 125.28, 125.11, 120.08, 120.05, 118.93, 118.61, 74.29, 69.37, 68.48, 67.73, 65.86, 58.09, 57.79, 54.01, 53.52, 47.40, 47.28, 38.90, 37.87, 28.41, 28.37. MS (ESI) 450.5 (M+H).
    • (2S,4R)-1-((9H-fluoren-9-yl)methyl) 2-allyl 4-hydroxypyrrolidine-1,2-dicarboxylate (Fmoc-Hyp(OH)-OAllyl)
  • Figure US20190127359A1-20190502-C00480
  • Fmoc-Hyp(OtBu)-OAllyl (23.42 g, 52.1 mmol) was dissolved in DCM (306 mL) at room temperature. TFA (54 mL, 15% vol/vol) was added and the solution was stirred for 13 hours. The solution was poured into water, neutralized by slow addition of saturated aqueous sodium bicarbonate and extracted twice with DCM and once with EtOAc. The combined organic layers were dried with sodium sulfate, filtered and condensed. Purification by column chromatography (30 to 80% EtOAc/hexanes) gave Fmoc-Hyp(OH)-OAllyl as a yellowish oil (16.7 g, 42.4 mmol, 81%). 1H and 13C NMR spectra matched those reported in the literature.16
  • Figure US20190127359A1-20190502-C00481
    • Fmoc-Hyp(OWang)-OAllyl
  • Figure US20190127359A1-20190502-C00482
  • Wang Resin (12.1 g, 1.1 mmol/g loading, 13.3 mmol, 1 eq) was swelled with DCM (90 mL) in a glass reaction vessel and cooled to 4° C. Trichloroacetonitirle (20 mL, 200 mmol, 15 eq) was added, followed by the addition of DBU (3 mL, 20 mmol, 1.5 eq) in 3 portions over 3 minutes, manually shaking the reaction vessel in between additions. The reaction vessel was nutated at 4° C. for 1 hour, then washed with DCM, DMSO, THF, then twice with DCM at room temperature.17 A solution of Fmoc-Hyp(OH)-OAllyl (26.15 g, 66.5 mmol, 5 eq) in DCM (40 mL) and THF (40 mL) was then added, and shaken for 30 minutes and then washed twice with DCM, thrice with DCM and then twice with MeOH followed by DCM. The initial DCM washes were condensed, and purified by column chromatography (33% to 80% EtOAc) to recover the Fmoc-Hyp(OH)-OAllyl starting material (21.51 g, 54.67 mmol, 82%). The resin was dried in air, then dried under vacuum to give 15.5 g of Fmoc-Hyp(OWang)-OAllyl.18 The loading of the resin was estimated to be 0.53 mmol/g based upon the increase in mass.
  • Figure US20190127359A1-20190502-C00483
    • Solid Phase Synthesis General Method A
  • Fmoc-Hyp(OWang)-OAllyl resin (1 eq) was swelled DMF, then reacted with 20% piperidine in DMF for 30 minutes. The resin was then washed once with piperidine, and reacted again with 20% piperidine for 30 minutes to ensure complete deprotection. The resin was then washed twice with DMF and once with MeOH followed by DCM. The resulting free amine was then coupled with 3-methyl-5-isoxazoleacetic acid (4 eq), PyBOP (4 eq) HOBt (4 eq) and DIPEA (7 eq) in DMF for 4 hours. The resin was then washed thrice with DMF and twice with MeOH followed by DCM. The resin was then swelled with freshly distilled DCM, and reacted with Pd(PPh3)4(0.1 eq) and PhSiH3 (10 eq) for 30 minutes. The resin was then washed once with DCM, and reacted again with Pd(PPh3)4(0.1 eq) and PhSiH3 (10 eq) in distilled DCM for 30 minutes, after which the resin was washed twice with DMF and once with MeOH followed by DCM. The resulting carboxylic acid was then coupled with the appropriate amine (or a salt of the appropriate amine), RNH2 (4 eq) with PyBOP (4 eq), HOBt (4 eq) and DIPEA (7 eq for free amines, 8 eq for amine salts) in DMF for 4 hours. The resin was then washed 5 times with DMF, thrice with MeOH and 5 times with DCM. The resin was then reacted with 20% TFA in DCM for 2 hours. The reaction mixture was then drained and the resin was washed with DCM. Condensation under reduced pressure, and purification by column chromatography (1% to 10% 0.5M NH3 in MeOH/DCM or 1% to 10% MeOH in DCM) gave the desired VHL ligand.
  • Figure US20190127359A1-20190502-C00484
    • Solid Phase Synthesis General Method B
  • Briefly, Fmoc-Hyp-(OWang)-OAllyl resin (1 eq) was swelled with freshly distilled DCM, and reacted with Pd(PPh3)4(0.1 eq) and PhSiH3 (10 eq) for 30 minutes. The resin was then washed once with DCM, and reacted again with Pd(PPh3)4(0.1 eq) and PhSiH3 (10 eq) in distilled DCM for 30 minutes, after which the resin was washed twice with DMF and once with MeOH followed by DCM. The resulting carboxylic acid was then coupled with 4-chlorobenzylamine (4 eq), PyBOP (4 eq), HOBt (4 eq) and DIPEA (7 eq) in DMF for 4 hours. The resin was then reacted with 20% piperidine in DMF for 30 minutes. The resin was then washed once with DMF, and reacted again with 20% piperidine for 30 minutes to ensure complete deprotection. The resin was then coupled with the appropriate carboxylic acid (RCO2H, 4 eq), PyBOP (4 eq), HOBt (4 eq) and DIPEA (7 eq) in DMF for 4 hours. The resin was then washed 4 times with DMF and twice with methanol followed by DCM. The resin was then reacted with 20% TFA in DCM for 2 hours. The reaction mixture was then drained and the resin was washed with DCM. Condensation under reduced pressure, and purification by column chromatography (1% to 10% 0.5M NH3 in MeOH/DCM or 1% to 10% MeOH in DCM) gave the desired VHL ligand. Yields are based upon the loading of the resin, which was estimated based upon its change in mass.
  • Figure US20190127359A1-20190502-C00485
    • tert-Butyl 4-(methoxy(methyl)carbamoyl)benzylcarbamate (Boc-Amb-N(OMe)Me)
  • Figure US20190127359A1-20190502-C00486
  • Boc-Amb-OH (2.55 g, 10.16 mmol, 1 eq) was dissolved in DCM (68 mL) and cooled to 4° C. in an ice bath. EDC (2.34 g, 12.2 mmol, 1.2 eq), HOBt (1.65 g, 12.2 mmol, 1.2 eq) and DIPEA (6.2 mL, 35.6 mmol, 3.5 eq) were added. The solution was stirred for 30 minutes and then N,O-Dimethylhydroxylamine hydrochloride (1.09 g, 11.2 mmol, 1.1 eq) was added. The solution warmed slowly to room temperature and after 21 hours was poured into brine, with a small amount of chloroform to break the resulting emulsion. After separation, the aqueous layer was extracted twice with EtOAc. The combined organic layer was dried over sodium sulfate, filtered and condensed. Purification by column chromatography (40 to 75% EtOAc/hexanes) gave a colorless oil (2.45 g, 8.33 mmol, 82%). 1H NMR (500 MHz, CDCl3) δ 7.65 (d, J=8.2 Hz, 2H), 7.31 (d, J=8.1 Hz, 2H), 4.88 (s, 1H), 4.36 (d, J=5.1 Hz, 2H), 3.55 (s, 3H), 3.35 (d, J=4.7 Hz, 3H), 1.47 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 169.77, 156.04, 141.79, 133.21, 128.76, 127.03, 79.87, 61.20, 44.50, 33.88, 28.55. MS (ESI) 295.2 (M+H).
    • tert-Butyl 4-formylbenzylcarbamate (Boc-Amb-H)
  • Figure US20190127359A1-20190502-C00487
  • Boc-Amb-N(OMe)Me (2.45 g, 8.33 mmol, 1 eq) was dissolved in THF (83 mL) and cooled to −78° C. in a dry ice/acetone bath. Lithium aluminum hydride (0.41 g, 10.83 mmol, 1.3 eq) was added in 2 portions over 5 minutes. After 50 minutes, the suspension was warmed to 4° C. in an ice bath. After 3.5 hours, the reaction was deemed complete by TLC (mini workup in 10% potassium bisulfate and EtOAc, 50% EtOAc/hexanes) and the reaction was quenched by the slow addition of 10% potassium bisulfate at 4° C. The mixture was warmed to room temperature, and stirred for 30 minutes. Most of the THF was removed under reduced pressure and mixture was diluted with water and extracted thrice with EtOAc. The combined organic layer was washed once with brine, dried over sodium sulfate, filtered and condensed. Purification by column chromatography (40 to 50% EtOAc/hexanes) gave Boc-Amb-H as a white solid (1.66 g, 7.1 mmol, 85%). 1H NMR (500 MHz, CDCl3) δ 9.96 (s, 1H), 7.81 (d, J=8.2 Hz, 2H), 7.41 (d, J=8.0 Hz, 2H), 5.12 (s, 1H), 4.37 (d, J=5.6 Hz, 2H), 1.44 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 191.94, 156.03, 146.30, 135.62, 130.14, 127.78, 79.92, 44.44, 28.46. MS (ESI) 235.9 (M+H), 180.2 (M-tBu).
    • tert-Butyl 4-(oxazol-5-yl)benzylcarbamate
  • Figure US20190127359A1-20190502-C00488
  • Potassium carbonate (0.13 g, 0.94 mmol, 1.2 eq) and toluenesulfonylmethyl isocyanide (0.184 g, 0.94 mmol, 1.2 eq) were added to MeOH (7.8 mL) at room temperature. The round bottom was fitted with a reflux condenser and heated to 45° C. After 15 minutes, Boc-Amb-H (0.1835 g, 0.78 mmol, 1 eq) was added and the mixture was heated to 75° C. for 3 hours and then cooled to room temperature. The MeOH was removed under reduced pressure and the crude material was resuspended in EtOAc and 1:2 mixture of saturated sodium carbonate to water and separated. The aqueous layer was then extracted once with EtOAc. The combined organic layer was dried over sodium sulfate, filtered and condensed. Purification by column chromatography (20 to 35% EtOAc/hexanes) gave a white solid. 1H NMR (400 MHz, CDCl3) δ 7.91 (s, 1H), 7.62 (d, J=8.3 Hz, 2H), 7.35 (ob d, 2H), 7.34 (ob s, 1), 4.88 (s, 1H), 1.47 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 156.02, 151.40, 150.47, 139.78, 128.01, 126.84, 124.67, 121.47, 79.68, 44.38, 28.47. MS (ESI) 275.5 (M+H).
    • (4-(Oxazol-5-yl)phenyl)methanamine trifluoroacetate salt
  • Figure US20190127359A1-20190502-C00489
  • To a solution of tert-butyl 4-(oxazol-5-yl)benzylcarbamate (1.09 g) in DCM (40 mL), TFA (4 mL) was added at room temperature. The solution was stirred for 16 hours and concentrated under reduced pressure to yield the trifluoroacetate salt of (4-(oxazol-5-yl)phenyl)methanamine (1.984 g) as a cream colored solid, which was used without further purification. 1H NMR (400 MHz, MeOD) δ 8.29 (s, 1H), 7.83 (d, J=8.4 Hz, 2H), 7.60 (s, 1H), 7.56 (d, J=8.5 Hz, 2H), 4.16 (s, 2H). MS (ESI) 175.3 (M-CF3CO2 −).
    • (2S,4R)—N-(3-chlorobenzyl)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxamide (VL4)
  • Figure US20190127359A1-20190502-C00490
  • VL4 was synthesized according to General Method F as a white solid. 1H NMR (500 MHz, MeOD): δ8.684 (1H, s); 7.33-7.23 (4H, m); 6.24 (1H, s); 4.56-4.53 (1H, t, J=8 Hz); 4.51-4.50 (1H, m); 4.39-4.37 (2H, m); 3.96-3.92 (2H, m); 3.81-3.3.78 (1H, dd, J=9 Hz, 4 Hz); 3.64-3.62 (1H, m); 2.28-2.24 (4H, m); 2.09-2.04 (1H, m).13C NMR (125 MHz, MeOD): δ174.56, 168.67, 167.68, 161.58, 142.25, 135.35, 131.04, 128.43, 128.19, 126.76, 105.37, 70.86, 60.78, 56.96, 43.60, 39.33, 33.90, 11.21. MS (ESI) 378.2 (M+H).
    • (2S,4R)-4-hydroxy-N-(4-hydroxyphenethyl)-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxamide (VL2)
  • Figure US20190127359A1-20190502-C00491
  • VL2 was synthesized according to General Method F. 1H NMR (500 MHz, MeOD) δ 8.33 & 8.13 (due to the rotamers, both s, 1H), 7.02 (d, J=8.3 Hz, 2H), 6.69 & 6.65 (due to the rotamers, both d, J=8.3 Hz, 2H), 6.22 & 6.10 (due to the rotamers, both s, 1H), 4.43 (d, J=7.7 Hz, 2H), 3.89 (d, J=4.7 Hz, 2H), 3.74 (dd, J=11.0, 4.3 Hz, 1H), 3.57 (d, J=11.0 Hz, 1H), 3.42-3.36 (m, 2H), 2.73-2.63 (m, 2H), 2.25 (s, 3H), 2.16-2.12 (m, 1H), 1.96-1.91 (m, 1H). 13C NMR (asterisk denotes the signals of the minor rotamer, 125 MHz, MeOD) δ 174.2, 174.1, *173.9, *173.8, *169.0, 168.6, 167.6, *167.4, 161.6, *161.5, *157.0, 156.9, *131.2, 130.8, *116.2, 116.1, *105.6, 105.4, 70.7, *69.2, *61.0, *60.9, 60.7, 60.6, 56.9, *56.2, 42.4, 42.3, *42.0, *41.9, 41.5, 39.3, 35.5, *35.3, 33.9, *32.9, 11.2. MS (ESI) [M+H] 374.1, [2M+Na] 769.6.
    • (2S,4R)-4-hydroxy-N-methyl-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxamide (VL26)
  • Figure US20190127359A1-20190502-C00492
  • VL26 was synthesized according to General Method F and was isolated as a colorless oil (28 mg, 0.105 mmol, 80%). 1H NMR (500 MHz, MeOD) δ 6.23 (s, 1H), 4.47 (dt, J=16.3, 5.2 Hz, 2H), 3.91 (d, J=5.7 Hz, 2H), 3.78 (dd, J=10.9, 4.2 Hz, 1H), 3.61 (dd, J=11.0, 1.8 Hz, 1H), 2.73 (s, 3H), 2.26-2.18 (m, 4H), 2.05 (dd, J=8.3, 4.7 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 174.82, 168.66, 167.67, 161.58, 105.40, 70.79, 60.67, 56.91, 39.30, 33.89, 26.35, 11.20. MS (ESI) 291.1 (M+Na), 268.7 (M+H).
  • Figure US20190127359A1-20190502-C00493
  • VL34 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.3 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (14.7 mg). 1H NMR (400 MHz, MeOD) δ 7.31 (dd, J=5.9, 5.1 Hz, 4H), 7.27-7.17 (m, 1H), 6.23 (s, 1H), 4.55 (t, J=8.0 Hz, 1H), 4.50 (s, 1H), 4.39 (s, 2H), 3.92 (d, J=1.8 Hz, 2H), 3.80 (dd, J=10.9, 4.3 Hz, 1H), 3.61 (dd, J=7.3, 5.5 Hz, 1H), 2.33-2.19 (m, 4H), 2.12-2.03 (m, 1H). 13C NMR (101 MHz, MeOD) δ 174.29, 168.68, 167.68, 161.60, 139.73, 129.51, 128.40, 128.14, 105.36, 70.84, 60.73, 56.97, 44.05, 39.36, 33.95, 11.21. MS (ESI) 344.3 (M+H), 366.2 (M+Na).
  • Figure US20190127359A1-20190502-C00494
  • VL28 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.3 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a yellow solid (19.1 mg). 1H NMR (500 MHz, MeOD) δ 8.66 (t, J=5.5 Hz, 1H), 7.48-7.34 (m, 2H), 7.31-7.21 (m, 2H), 6.23 (s, 1H), 4.58 (t, J=8.0 Hz, 1H), 4.48 (qd, J=15.8, 5.9 Hz, 3H), 3.99-3.87 (m, 2H), 3.80 (dd, J=10.9, 4.3 Hz, 1H), 3.66-3.60 (m, 1H), 2.31-2.22 (m, 4H), 2.09 (ddd, J=13.0, 8.2, 4.7 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 174.60, 168.72, 167.65, 161.59, 136.79, 134.01, 130.29, 130.08, 129.67, 128.21, 105.37, 70.84, 60.74, 56.96, 42.08, 39.34, 33.95, 11.22. MS (ESI) 378.3 (M+H).
  • Figure US20190127359A1-20190502-C00495
  • VL21 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.2 mmol) using Solid Phase Synthesis General Method A. It was isolated as a white solid (15.9 mg). 1H NMR (500 MHz, MeOD) δ 8.65 (s, 1H), 7.32-7.26 (m, 4H), 6.22 (s, 1H), 4.58-4.47 (m, 2H), 4.43-4.32 (m, 2H), 3.92 (d, J=4.2 Hz, 2H), 3.80 (dd, J=10.9, 4.3 Hz, 1H), 3.66-3.58 (m, 1H), 2.30-2.22 (m, 4H), 2.08 (dd, J=8.3, 4.7 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 174.48, 168.71, 167.66, 161.60, 138.67, 133.85, 129.99, 129.53, 105.37, 70.85, 60.80, 56.99, 43.45, 39.33, 33.95, 11.20. MS (ESI) 378.4 (M+H).
  • Figure US20190127359A1-20190502-C00496
  • VL20 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.15 mmol) using Solid Phase Synthesis General Method A. It was isolated as a white solid (9.9 mg). 1H NMR (400 MHz, MeOD) δ 8.64 (t, J=5.6 Hz, 1H), 7.37-7.26 (m, 2H), 7.07-6.99 (m, 2H), 6.23 (s, 1H), 4.57-4.47 (m, 2H), 4.37 (dd, J=8.4, 5.8 Hz, 2H), 3.93 (d, J=3.0 Hz, 2H), 3.80 (dd, J=11.0, 4.2 Hz, 1H), 3.66-3.58 (m, 1H), 2.28-2.22 (m, 4H), 2.08 (dd, J=8.3, 4.7 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 174.31, 168.69, 167.67, 163.44 (d, J=243.5 Hz), 161.60, 135.78, 130.27 (d, J=8.1 Hz), 116.09 (d, J=21.6 Hz), 105.37, 70.85, 60.75, 56.99, 43.32, 39.33, 33.95, 11.20. MS (ESI) 362.3 (M+H).
  • Figure US20190127359A1-20190502-C00497
  • VL29 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.3 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a light yellow solid (16.4 mg). 1H NMR (400 MHz, MeOD) δ 7.45 (dq, J=9.0, 2.2 Hz, 2H), 7.23 (d, J=8.5 Hz, 2H), 6.22 (s, 1H), 4.58-4.47 (m, 2H), 4.35 (dt, J=18.9, 15.4 Hz, 2H), 3.92 (d, J=2.6 Hz, 2H), 3.80 (dd, J=10.9, 4.2 Hz, 1H), 3.63 (d, J=11.0 Hz, 1H), 2.30-2.21 (m, 4H), 2.11-2.02 (m, 1H). 13C NMR (101 MHz, MeOD) δ 174.41, 168.71, 167.66, 161.61, 139.15, 132.55, 130.32, 121.77, 105.37, 70.85, 60.75, 56.99, 43.37, 39.33, 33.94, 11.22. MS (ESI) 424.1 (M+H).
  • Figure US20190127359A1-20190502-C00498
  • VL31 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.3 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (19.8 mg). 1H NMR (500 MHz, MeOD) δ 8.56 (s, 1H), 7.35 (d, J=8.2 Hz, 2H), 7.22 (d, J=8.2 Hz, 2H), 6.24 (s, 1H), 4.53 (dd, J=18.3, 10.3 Hz, 2H), 4.36 (d, J=5.7 Hz, 2H), 3.92 (d, J=3.0 Hz, 2H), 3.80 (dd, J=10.9, 4.2 Hz, 1H), 3.62 (d, J=11.1 Hz, 1H), 2.29-2.21 (m, 4H), 2.12-2.02 (m, 1H), 1.29 (d, J=7.9 Hz, 9H). 13C NMR (126 MHz, MeOD) δ 174.29, 168.67, 167.68, 161.59, 151.18, 136.67, 128.19, 126.39, 105.38, 70.83, 60.77, 56.97, 43.88, 39.37, 35.28, 33.95, 31.79, 31.74, 11.23. MS (ESI) 400.5 (M+H).
  • Figure US20190127359A1-20190502-C00499
  • VL47 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.156 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (9.1 mg). 1H NMR (500 MHz, MeOD) δ 7.22 (dd, J=8.4, 3.9 Hz, 2H), 6.86 (dd, J=8.8, 2.2 Hz, 2H), 6.22 (s, 1H), 4.63-4.45 (m, 2H), 4.37-4.26 (m, 2H), 3.92 (d, J=2.6 Hz, 2H), 3.83-3.70 (m, 4H), 3.61 (d, J=11.2 Hz, 1H), 2.28-2.20 (m, 4H), 2.06 (ddd, J=13.0, 8.1, 4.7 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 174.13, 168.66, 167.68, 161.60, 160.39, 131.67, 129.76, 114.89, 105.37, 70.83, 60.74, 56.97, 55.67, 43.57, 39.34, 33.95, 11.21. MS (ESI) 374.5 (M+H).
  • Figure US20190127359A1-20190502-C00500
  • VL35 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.156 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (14.1 mg). 1H NMR (500 MHz, DMSO) δ 7.90-7.85 (m, 2H), 7.39 (d, J=8.4 Hz, 2H), 6.23 (s, 1H), 5.17 (s, 1H), 4.37 (dd, J=17.9, 10.4 Hz, 4H), 3.88 (s, 2H), 3.84 (s, 3H), 3.70 (dd, J=10.5, 4.6 Hz, 1H), 3.47 (dd, J=10.4, 2.5 Hz, 1H), 2.20 (d, J=10.2 Hz, 3H), 2.11-2.03 (m, 1H), 1.92 (ddd, J=12.5, 7.2, 4.9 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 171.66, 166.66, 166.10, 165.66, 159.35, 145.22, 129.08, 127.99, 127.06, 103.94, 68.62, 58.76, 55.20, 52.02, 41.49, 38.17, 32.73, 10.95. MS (ESI) 402.6 (M+H).
  • Figure US20190127359A1-20190502-C00501
  • VL48 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.156 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (11.4 mg). 1H NMR (400 MHz, MeOD) δ 8.28-8.05 (m, 2H), 7.55 (d, J=8.8 Hz, 2H), 6.23 (s, 1H), 4.64-4.36 (m, 4H), 3.94 (d, J=3.8 Hz, 2H), 3.81 (dd, J=10.9, 4.2 Hz, 1H), 3.65 (dt, J=11.0, 1.7 Hz, 1H), 2.34-2.21 (m, 4H), 2.09 (td, J=8.5, 4.2 Hz, 1H). 13C NMR (101 MHz, MeOD) δ 174.70, 168.79, 167.65, 161.63, 148.48, 147.72, 129.13, 124.56, 105.40, 70.88, 60.79, 57.03, 43.41, 39.32, 33.94, 11.20. MS (ESI) 389.3 (M+H), 411.4 (M+Na).
  • Figure US20190127359A1-20190502-C00502
  • VL88 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.156 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a clear oil (8.0 mg). 1H NMR (500 MHz, MeOD) δ 8.77 (s, 1H), 7.58 (dd, J=88.0, 8.1 Hz, 4H), 6.23 (d, J=4.4 Hz, 1H), 4.61-4.33 (m, 4H), 3.93 (d, J=9.7 Hz, 2H), 3.83-3.74 (m, 1H), 3.63 (dd, J=10.4, 9.0 Hz, 1H), 2.33-2.27 (m, 1H), 2.26 (d, J=3.7 Hz, 3H), 2.15-2.03 (m, 1H). 13C NMR (126 MHz, MeOD) δ 175.33, 168.76, 167.64, 161.61, 145.83, 133.39, 129.12, 119.74, 111.79, 105.28, 70.87, 70.87, 59.32, 57.02, 43.61, 38.79, 33.94, 11.21, 11.19. MS (ESI) 391.2 (M+Na).
  • Figure US20190127359A1-20190502-C00503
  • VL95 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.156 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (23 mg). 1H NMR (400 MHz, MeOD) δ 8.71 (s, 1H), 7.96-7.91 (m, 2H), 7.43 (d, J=8.5 Hz, 2H), 6.22 (s, 1H), 4.56 (t, J=8.0 Hz, 1H), 4.49 (ddd, J=18.6, 8.6, 4.1 Hz, 3H), 3.91 (s, 2H), 3.80 (dd, J=10.9, 4.2 Hz, 1H), 3.65-3.58 (m, 1H), 2.58 (d, J=1.6 Hz, 3H), 2.28-2.22 (m, 4H), 2.10 (dd, J=8.3, 4.7 Hz, 1H). 13C NMR (101 MHz, MeOD) δ 200.08, 174.34, 168.43, 167.36, 161.39, 145.50, 136.96, 129.62, 128.28, 105.26, 70.65, 60.57, 56.83, 43.72, 39.14, 33.87, 26.73, 11.30. MS (ESI) 386.0 (M+H).
  • Figure US20190127359A1-20190502-C00504
  • VL111 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.2 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (18.2 mg). 1H NMR (500 MHz, MeOD) δ 8.23 (s, 1H), 7.68 (d, J=8.1 Hz, 2H), 7.49 (s, 1H), 7.41 (d, J=8.1 Hz, 2H), 6.23 (s, 1H), 4.59-4.37 (m, 4H), 3.93 (d, J=3.4 Hz, 2H), 3.81 (dd, J=10.9, 4.1 Hz, 1H), 3.63 (d, J=11.0 Hz, 1H), 2.32-2.17 (m, 4H), 2.09 (ddd, J=13.0, 8.0, 4.6 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 174.43, 168.72, 167.67, 161.60, 153.14, 152.75, 140.78, 129.06, 127.74, 125.61, 121.81, 105.37, 70.86, 60.78, 57.00, 43.72, 39.35, 33.96, 11.20. MS (ESI) 411.3 (M+H).
    • VL116 Right Hand Fragment (Representative Method B Synthesis)
  • Figure US20190127359A1-20190502-C00505
    • 2-(trimethylsilyl)ethyl 4-bromobenzylcarbamate
  • Figure US20190127359A1-20190502-C00506
  • 4-Bromobenzylamine hydrochloride (354 mg, 1.59 mmol, 1 eq) was dissolved in DMF (6.4 mL) and water (2.1 mL) and stirred at room temperature. Triethylamine (0.33 mL, 2.39 mmol, 1.5 eq) and TeocOSu (454 mg, 1.75 mmol, 1.1 eq) were then added. After 12 hours, the mixture was diluted with EtOAc, washed with 1M HCl, saturated sodium bicarbonate, water and brine. The organic layer was then dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification by column chromatography (10 to 20% EtOAc/hexanes) gave a colorless oil (0.4158 g, 1.26 mmol, 79%). 1H NMR (500 MHz, CDCl3) δ 7.48-7.43 (m, 2H), 7.17 (d, J=8.1 Hz, 2H), 4.94 (s, 1H), 4.31 (d, J=6.0 Hz, 2H), 4.23-4.15 (m, 2H), 1.04-0.93 (m, 2H), 0.04 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 156.91, 137.95, 131.88, 129.32, 121.43, 63.53, 44.53, 17.92, −1.32. MS (ESI) 354.1 (M+H).
    • 2-(trimethylsilyl)ethyl 4-(4-methylthiazol-5-yl)benzylcarbamate
  • Figure US20190127359A1-20190502-C00507
  • 2-(trimethylsilyl)ethyl 4-bromobenzylcarbamate (132 mg, 0.4 mmol, 1 eq), 4-methylthiazole-5-carboxylic acid (114.5 mg, 0.8 mmol, 2 eq), tetrabutylammonium chloride hydrate (118 mg, 0.4 mmol, 1 eq), cesium carbonate (196 mg, 0.6 mmol, 1.5 eq) and Pd(P(tBu)3)2 (40.8 mg, 0.08 mmol, 0.2 eq) were dissolved in DMF (4 mL).1 The reaction was heated to 170° C. in a microwave reactor for 16 minutes. The mixture was then cooled to room temperature, diluted with EtOAc and washed thrice with brine, once with saturated sodium bicarbonate, water, and then brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by coulm chromatography (10 to 35% EtOAc/hexanes) gave a colorless oil (61.7 mg, 0.177 mmol, 44%). 1H NMR (400 MHz, CDCl3) δ 8.67 (s, 1H), 7.43-7.37 (m, 2H), 7.34 (d, J=8.1 Hz, 2H), 5.09 (s, 1H), 4.39 (d, J=6.0 Hz, 2H), 4.28-4.02 (m, 2H), 2.52 (s, 3H), 1.10-0.90 (m, 2H), 0.14-−0.09 (m, 9H). 13C NMR (101 MHz, CDCl3) δ 156.98, 150.42, 148.66, 138.76, 131.67, 131.18, 129.66, 127.89, 63.46, 44.71, 17.90, 16.18, −1.34. MS (ESI) 349.0 (M+H).
    • (4-(4-methylthiazol-5-yl)phenyl)methanamine
  • Figure US20190127359A1-20190502-C00508
  • 2-(trimethylsilyl)ethyl 4-(4-methylthiazol-5-yl)benzylcarbamate (51.8 mg, 0.149 mmol, 1 eq) was dissolvd in acetonittile (6 mL) at room temperature. A one molar solution of tetrabutylammonium fluoride in THF (0.45 mL, 0.45 mmol, 3 eq) was added and the solution was stirred for 24 hours. The mixture was concentrated under reduced pressure. Purification by column chromatography (0.5 to 4% 0.5N NH3 (MeOH)/DCM) gave a light yellow oil (27.2 mg, 0.133 mmol, 89%). 1H NMR (500 MHz, MeOD) δ 8.87 (s, 1H), 7.44 (s, 4H), 3.85 (s, 2H), 2.47 (s, 3H). 13C NMR (126 MHz, MeOD) δ 152.77, 149.07, 143.63, 133.42, 131.46, 130.49, 129.05, 46.23, 15.79. MS (ESI) 205.0 (M+H).
    • Alternate Route:
  • 4-bromobenzonitrile (5.1 g, 28 mmol, 1 eq), 4-methylthiazole (5.56 g, 56 mmol, 2 eq) potassium acetate (5.5 g, 56 mmol, 2 eq), palladium (II) acetate (63 mg, 0.28 mmol, 1 mol %) were dissolved in dimethylacetamide and stirred under argon. (CITE JOC, 2009, 74, 1179) The mixture was heated to 150° C. and stirred for 19 hours, then diluted with 500 mL EtOAc, and washed 4 times with 300 mL water. The first wash was then back extracted with 300 mL EtOAc, and then washed 4 times with 100 mL water. The combined organic layer was dried over sodium sulfate, filtered and concentrated under vacuum to give a beige solid (5.55 g, 27.7 mmol, 99%) that matched the reported spectral data.[8] The solid was then dissolved in MeOH (280 mL) and cooled to 4° C. Cobalt chloride (9.9 g, 41.6 mmol, 1.5 eq) was added, followed by the slow, portionwise addition of sodium borohydride (5.2 g, 139 mmol, 5 eq), which was accompanied by vigorous bubbling. After 90 minutes, the reaction was quenched by the addition of water and ammonium hydroxide. The mixture was extracted 4 times with chloroform, and purified by column chromatography (10 to 30% 0.5M NH3 (MeOH)/DCM) to give a darker oil (4.12 g, 20.2 mmol, 73%).
    • General Solution Phase Synthesis (2S,4R)-allyl 4-(tert-butoxy)pyrrolidine-2-carboxylate
  • Figure US20190127359A1-20190502-C00509
  • (2S,4R)-1-((9H-fluoren-9-yl)methyl) 2-allyl 4-(tert-butoxy)pyrrolidine-1,2-dicarboxylate (7.0 g, 15.57 mmol, 1 eq) was dissolved in DCM (156 mL) and cooled to 4° C. Tris(2-aminoethyl)amine (5.8 mL, 38.9 mmol, 2.5 eq) was added, and the solution was stirred for 1 hour at 4° C. and 4.5 hours at room temperature. The mixture was then mixed with silica gel (roughly 20 g), and concentrated under reduced pressure, and purified by column chromatography (1 to 5% 0.5N NH3 (MeOH)/DCM) to give an opaque oil (3.44 g, 15.1 mmol, 97%). 1H NMR (400 MHz, MeOH) δ 6.03-5.88 (m, 1H), 5.25 (dq, J=17.2, 1.8 Hz, 1H), 5.09 (dq, J=10.5, 1.6 Hz, 1H), 4.33-4.23 (m, 1H), 4.06 (dt, J=5.1, 1.6 Hz, 2H), 3.86 (t, J=8.0 Hz, 1H), 3.18 (dd, J=11.4, 5.7 Hz, 1H), 2.70 (dd, J=11.4, 3.8 Hz, 1H), 2.00 (dd, J=8.0, 5.0 Hz, 2H), 1.19 (s, 9H). 13C NMR (101 MHz, MeOH) δ 175.89, 138.93, 114.88, 74.93, 72.93, 63.97, 59.77, 55.44, 40.18, 28.65. MS (ESI) 228.0 (M+H).
    • (2S,4R)-allyl 4-(tert-butoxy)-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylate
  • Figure US20190127359A1-20190502-C00510
  • (2S,4R)-allyl 4-(tert-butoxy)pyrrolidine-2-carboxylate (0.148 g, 0.65 mmol, 1 eq) was dissolved in DMF (6.5 mL) and cooled to 4° C. 2-(3-methylisoxazol-5-yl)acetic acid (0.12 g, 0.85 mmol, 1.3 eq), EDC (0.163 g, 0.85 mmol, 1.3 eq), HOBt (0.123 g, 0.91 mmol, 1.4 eq), and DIPEA (0.283 mL, 1.63 mmol, 2.5 eq) were added, and the solution was allowed to warm slowly to room temperature. After 12 hours, the mixture was poured into brine and extracted four times with EtOAc. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (1 to 3% MeOH/DCM) gave a light yellow oil (0.2008 g, 0.573 mmol, 88%). 1H NMR (500 MHz, CDCl3) δ 6.17 (s, 1H), 5.95-5.85 (m, 1H), 5.29 (ddd, J=13.8, 11.7, 1.3 Hz, 2H), 4.69-4.55 (m, 3H), 4.40-4.32 (m, 1H), 3.84-3.75 (m, 3H), 3.37 (dd, J=10.0, 4.7 Hz, 1H), 2.27 (s, 3H), 2.15 (ddd, J=18.5, 12.0, 5.9 Hz, 2H), 1.18 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 171.87, 165.94, 165.63, 160.30, 131.84, 118.72, 104.04, 74.53, 69.55, 65.98, 57.96, 54.53, 37.31, 33.58, 28.35, 11.62. MS (ESI) 351.5 (M+H).
    • (2S,4R)-4-(tert-butoxy)-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylic acid
  • Figure US20190127359A1-20190502-C00511
  • (2 S,4R)-allyl 4-(tert-butoxy)-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylate (1.67 g, 4.77 mmol, 1 eq) was dissolved in THE (48 mL) at room temperature. Pd(PPh3)4 (0.55 g, 0.48 mmol, 0.1 eq) and morpholine (4.2 mL, 48 mmol, 10 eq) were then added. After 35 minutes, the solution was concentrated under reduced pressure, redissolved in DCM, and washed four times with 1M HCl (aq). The aqueous layer was then back extracted once with DCM. The combined organic layer was then dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (1 to 20% MeOH/DCM) gave a yellow solid (1.27 g, 4.1 mmol, 86%). 1H NMR (500 MHz, MeOH) δ 6.23 (s, 1H), 4.47 (t, J=6.0 Hz, 2H), 3.94-3.80 (m, 3H), 3.48 (dd, J=10.6, 3.8 Hz, 1H), 2.28-2.11 (m, 5H), 1.21 (s, 9H). 13C NMR (126 MHz, MeOH) δ 175.53, 168.41, 167.68, 161.59, 105.25, 75.57, 71.00, 59.36, 55.81, 38.49, 33.88, 28.48, 11.20. MS (ESI) 311.2 (M+H).
  • General Method B Representative Procedure (with hydroxyl group protection): VL116
    • (2S,4R)-4-(tert-butoxy)-1-(2-(3-methylisoxazol-5-yl)acetyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00512
  • (2S,4R)-4-(tert-butoxy)-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylic acid (53.7 mg, 0.173 mmol, 1.3 eq), (4-(4-methylthiazol-5-yl)phenyl)methanamine (27.2 mg, 0.133 mmol, 1 eq), EDC (33.2 mg, 0.173 mmol, 1.3 eq), and HOBt (23.4 mg, 0.173 mmol, 1.3 eq) were dissolved in DMF (3.5 mL) at 4° C. DIPEA (0.07 mL, 0.4 mmol, 3 eq) was added, and the solution was allowed to slowly warm to room temperature. After 19 hours, the mixture was poured into brine and extracted four times with EtOAc. The organic layer was dried with sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (1 to 5% MeOH/DCM) gave a colorless oil (58.1 mg, 0.117 mmol, 88%). 1H NMR (400 MHz, CDCl3) δ 8.67 (s, 1H), 7.42-7.27 (m, 5H), 6.06 (s, 1H), 4.69 (dd, J=8.4, 2.6 Hz, 1H), 4.59-4.35 (m, 3H), 3.82-3.71 (m, 3H), 3.34 (dd, J=9.9, 6.3 Hz, 1H), 2.59-2.46 (m, 4H), 2.25 (s, 3H), 1.91 (dd, J=8.2, 4.4 Hz, 1H), 1.25-1.14 (m, 9H). 13C NMR (101 MHz, CDCl3) δ 170.70, 167.35, 165.30, 160.24, 150.42, 148.59, 138.09, 131.74, 131.05, 129.66, 127.85, 104.19, 74.48, 70.02, 59.12, 54.20, 43.25, 35.59, 33.49, 28.38, 16.19, 11.57. MS (ESI) 497.4 (M+H).
    • (2S,4R)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VL116)
  • Figure US20190127359A1-20190502-C00513
  • (2 S,4R)-4-(tert-butoxy)-1-(2-(3-methylisoxazol-5-yl)acetyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (58.1 mg, 0.117 mmol) was dissolved in DCM (8 mL). TFA (2 mL, 20% vol/vol) was added and the solution was stirred for 12 hours at room temperature, after which it was concentrated under reduced pressure. Purification by column chromatography (1 to 10% 0.5N NH3 (MeOH)/DCM) gave a colorless oil (28.4 mg, 0.065 mmol, 56%). 1H NMR (400 MHz, MeOH) δ 8.87 (d, J=2.1 Hz, 1H), 7.50-7.34 (m, 4H), 6.23 (s, 1H), 4.57 (t, J=8.0 Hz, 1H), 4.54-4.38 (m, 3H), 3.93 (d, J=2.4 Hz, 2H), 3.81 (dd, J=10.9, 4.3 Hz, 1H), 3.63 (dd, J=7.2, 5.5 Hz, 1H), 2.46 (d, J=8.8 Hz, 3H), 2.33-2.20 (m, 4H), 2.10 (ddd, J=13.1, 8.2, 4.7 Hz, 1H). 13C NMR (101 MHz, MeOH) δ 174.43, 168.71, 167.66, 161.58, 152.83, 149.04, 140.14, 133.39, 131.56, 130.43, 128.88, 105.39, 70.86, 60.78, 57.00, 43.65, 39.36, 33.96, 15.81, 11.22. MS (ESI) 441.3 (M+H).
    • General Method A Representative Procedure: VL133 (2S,4R)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylic acid
  • Figure US20190127359A1-20190502-C00514
  • (2S,4R)-4-(tert-butoxy)-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylic acid (124.9 mg, 0.4 mmol, 1 eq) was dissolved in DCM (18 mL) at room temperature. TFA (2 mL, 10%) was added, and the solution was stirred for 12 hours. It was then concentrated under reduced pressure and purified by column chromatography (4 to 20% MeOH/DCM) to give a yellow oil (99.7 mg, 0.39 mmol, 98%). 1H NMR (500 MHz, MeOD) δ 6.24 (s, 1H), 4.55-4.46 (m, 2H), 3.89 (d, J=28.3 Hz, 2H), 3.77 (dd, J=10.9, 4.3 Hz, 1H), 3.62 (d, J=11.0 Hz, 1H), 2.36-2.22 (m, 4H), 2.10 (ddd, J=13.1, 8.0, 4.8 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 175.33, 168.51, 167.61, 161.61, 105.28, 70.86, 59.33, 56.60, 38.78, 33.85, 11.20. MS (ESI) 255.1 (M+H).
    • (2S,4R)—N-(4-(1H-pyrrol-3-yl)benzyl)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxamide (VL133)
  • Figure US20190127359A1-20190502-C00515
  • (2S,4R)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylic acid (52.6 mg, 0.207 mmol, 1.3 eq), (4-(1H-pyrrol-3-yl)phenyl)methanamine (27.3 mg, 0.159 mmol, 1 eq), EDC (39.7 mg, 0.207 mmol, 1.3 eq) and HOBt (28 mg, 0.207 mmol, 1.3 eq) were dissolved in DMF (4.1 mL) and cooled to 4° C. DIPEA (0.083 mL, 0.477 mmol, 3 eq) was added and the solution was allowed to slowly warm to room temperature. After 16 hours, the mixture was poured into half saturated sodium chloride (aqueous) and extracted 3 times with EtOAc. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (1 to 10% 0.5N NH3 (MeOH)/DCM) gave an off white solid (41.5 mg, 0.102 mmol, 64%). 1H NMR (400 MHz, DMSO) δ 8.40 (d, J=6.0 Hz, 1H), 7.52-7.39 (m, 2H), 7.22-7.12 (m, 3H), 6.82-6.72 (m, 1H), 6.41 (d, J=1.7 Hz, 1H), 6.24 (s, 1H), 5.17 (d, J=3.9 Hz, 1H), 4.31 (ddd, J=17.1, 13.7, 6.4 Hz, 4H), 3.88 (s, 2H), 3.75-3.65 (m, 1H), 3.52-3.41 (m, 1H), 2.18 (d, J=18.0 Hz, 3H), 2.12-1.99 (m, 1H), 1.94-1.85 (m, 1H). 13C NMR (101 MHz, DMSO) δ 171.36, 166.69, 165.54, 159.38, 135.66, 134.68, 127.20, 124.21, 123.00, 118.86, 114.71, 105.22, 103.99, 68.61, 58.76, 55.18, 41.63, 38.27, 32.78, 11.00. MS (ESI) 431.5 (M+Na).
  • For further reference see the following articles and the references cited therein:
    • (1) Buckley D L et al. J. Am. Chem. Soc 2012, 134, 4465-4468.
    • (2) Van Molle I et al. A Chemistry & Biology 2012, 19, 1300-1312
    • (3) Buckley, D Angew. Chem. Int. Ed., 2012, 51, 11463-11467
    • (4) Buckley, D. L et al. Angew. Chem. 2012, 124, 11630-11634.
    Examples Second Set
  • Figure US20190127359A1-20190502-C00516
  • VL50 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (29.8 mg, 0.084 mmol, 54%). 1H NMR (400 MHz, CD3OD): δ7.34-7.27 (m, 4H); 5.43-5.35 (m, 4H); 3.81-3.78 (dd, J=8 Hz, 4 Hz, 1H); 3.61-3.57 (m, 1H); 2.65-2.61 (m, 2H); 2.57-2.51 (m, 2H); 2.28-2.21 (m, 1H); 2.08-2.02 (m, 1H). 13C NMR (100 MHz, CD3OD): δ 177.53, 174.74, 173.76, 138.75, 133.76, 129.96, 129.49, 70.71, 60.55, 56.47, 43.25, 39.33, 30.97, 30.64. MS (ESI) 354.2 (M+H).
  • Figure US20190127359A1-20190502-C00517
  • VL52 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to the Solid Phase Synthesis General Method B. It was isolated as a white solid (7.7 mg, 0.021 mmol, 14%). 1H NMR (500 MHz, CD3OD): δ7.41 (d, J=2 Hz, 1H); 7.30 (s, 4H); 6.35-6.34 (dd, J=3 Hz, 2 Hz, 1H); 6.26-6.25 (d, J=3 Hz, 1H); 4.49-4.32 (m, 4H); 3.82-3.73 (m, 3H); 3.65-2.62 (m, 1H); 2.23-2.22 (m, 1H); 2.09-2.06 (m, 1H).13C NMR (125 MHz, CD3OD): δ174.54, 170.58, 149.67, 143.24, 138.68, 133.84, 129.98, 129.53, 111.50, 108.98, 70.88, 60.75, 56.95, 43.31, 39.24, 35.58. MS (ESI) 365.2 (M+H), 385.3 (M+Na).
  • Figure US20190127359A1-20190502-C00518
  • VL73 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a clear oil (38.9 mg, 0.099 mmol, 55%).1H NMR (500 MHz, CD3OD ) δ 7.51-6.99 (m, 8H), 4.72 (t, J=8.2, 1H), 4.55-4.33 (m, 3H), 3.60 (dd, J=3.7, 11.3, 1H), 3.19 (dd, J=1.5, 11.3, 1H), 2.36-2.25 (m, 1H), 2.21-2.03 (m, 1H).3C NMR (126 MHz, CD3OD) δ 174.03, 169.66, 138.62, 137.31, 133.87, 132.12, 130.92, 130.48, 129.98, 129.56, 129.16, 128.53, 70.64, 60.38, 43.39, 39.25, 24.21. MS (ESI) 395.3 (M+H).
  • Figure US20190127359A1-20190502-C00519
  • VL64 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to the Solid Phase Synthesis General Method B. It was isolated as a white solid (27.5 mg, 0.077 mmol, 49%). 1H NMR (500 MHz, CD3OD) δ 7.66-7.59 (m, 2H), 7.54-7.22 (m, 7H), 4.75 (t, J=8.6, 1H), 4.55-4.33 (m, 3H), 3.85 (dd, J=3.0, 11.5, 1H), 3.43 (d, J=11.5, 1H), 2.38-2.26 (m, 1H), 2.14-2.05 (m, 1H).13C NMR (126 MHz, CD3OD) δ 174.72, 172.78, 138.73, 137.14, 133.83, 131.74, 129.93, 129.55, 129.49, 128.56, 71.04, 60.85, 59.80, 43.34, 39.28. MS (ESI) 359.1 (M+H).
  • Figure US20190127359A1-20190502-C00520
  • VL69 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (26.1 mg, 0.62 mmol, 40%). 1H NMR (500 MHz, DMSO) δ 7.30 (dt, J=8.2, 25.1, 4H), 7.20 (dd, J=1.7, 8.3, 1H), 7.13 (d, J=1.7, 1H), 7.01 (d, J=8.4, 1H), 4.98 (s, 1H), 4.56 (t, J=8.6, 1H), 4.29 (d, J=2.6, 2H), 3.76 (dd, J=15.5, 30.6, 7H), 3.36 (d, J=11.1, 1H), 2.14 (dd, J=7.7, 12.8, 1H), 1.96-1.83 (m, 1H). 3C NMR (126 MHz, DMSO) δ 171.91, 168.82, 150.39, 148.08, 138.70, 131.10, 128.68, 128.09, 121.00, 111.44, 110.75, 99.56, 68.90, 59.33, 59.30, 58.68, 55.57, 41.17, 38.01. MS (ESI) 418.8 (M+H).
  • Figure US20190127359A1-20190502-C00521
  • VL70 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a colorless oil (31.1 mg, 0.083 mmol, 53%).1H NMR (500 MHz, CD3OD) δ 7.38-7.17 (m, 6H), 6.85-6.73 (m, 2H), 4.76 (t, J=8.5, 1H), 4.53-4.31 (m, 3H), 3.85 (dd, J=3.2, 11.6, 1H), 3.37 (d, J=11.6, 1H), 2.50-2.24 (m, 1H), 2.08 (ddd, J=4.3, 9.1, 13.3, 1H).13C NMR (126 MHz, CD3OD) δ 174.72, 172.14, 145.18, 138.67, 133.87, 132.18, 129.97, 129.56, 128.80, 122.39, 118.87, 117.94, 71.01, 60.29, 58.54, 43.40, 39.40. MS (ESI) 374.5 (M+H).
  • Figure US20190127359A1-20190502-C00522
  • VL71 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to the Solid Phase Synthesis General Method B. It was isolated as a colorless oil (31.1 mg, 0.080 mmol, 51%). 1H NMR (500 MHz, CD3OD) δ 7.40-7.32 (m, 4H), 7.24 (t, J=7.6, 1H), 7.09 (d, J=7.9, 1H), 7.03 (d, J=7.1, 1H), 4.74 (t, J=8.2, 1H), 4.59-4.33 (m, 3H), 3.54 (d, J=11.0, 1H), 3.20 (d, J=11.2, 1H), 2.35 (dd, J=8.7, 12.4, 1H), 2.26 (s, 3H), 2.14 (dd, J=4.3, 9.3, 1H). 13C NMR (126 MHz, CD3OD) δ 174.37, 172.44, 140.91, 139.29, 138.69, 133.84, 129.93, 129.55, 128.37, 124.30, 121.45, 120.64, 70.73, 60.11, 43.36, 39.44, 13.89. MS (ESI) 388.1, 390.3 (M+H).
  • Figure US20190127359A1-20190502-C00523
  • VL72 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a yellow oil (31.3 mg, 0.084 mmol, 54%). 1H NMR (500 MHz, CD3OD) δ 7.48 (d, J=8.3, 2H), 7.30 (s, 4H), 6.79 (d, J=8.3, 2H), 4.79-4.69 (m, 1H), 4.53-4.29 (m, 3H), 3.95-3.83 (m, 1H), 3.54 (d, J=11.4, 1H), 2.35-2.24 (m, 1H), 2.07 (ddd, J=3.9, 10.1, 13.5, 1H). 13C NMR (126 MHz, CD3OD) δ 175.03, 173.02, 149.95, 138.75, 133.80, 130.79, 129.91, 129.54, 126.23, 115.89, 71.16, 61.03, 60.12, 43.31, 39.16. MS (ESI) 375.0 (M+H).
  • Figure US20190127359A1-20190502-C00524
  • VL74 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (36.3 mg, 0.092 mmol, 51%). 1H NMR (500 MHz, CD3OD) δ 7.67-7.56 (m, 2H), 7.52-7.44 (m, 2H), 7.34-7.28 (m, 4H), 4.74 (dd, J=7.7, 9.6, 1H), 4.55-4.30 (m, 3H), 3.85 (dd, J=3.5, 11.4, 1H), 3.42 (d, J=11.4, 1H), 2.37-2.28 (m, 1H), 2.15-2.05 (m, 1H). 13C NMR (126 MHz, CD3OD) δ 174.59, 171.54, 138.69, 137.75, 135.66, 133.84, 130.38, 129.92, 129.70, 129.55, 71.04, 60.92, 59.75, 43.34, 39.29. MS (ESI) 394.6 (M+H).
  • Figure US20190127359A1-20190502-C00525
  • VL75 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (25.0 mg, 0.066 mmol, 37%). 1H NMR (500 MHz, CD30OD) δ 7.64-6.87 (m, 8H), 4.73 (dd, J=7.7, 9.6, 1H), 4.54-4.31 (m, 3H), 3.84 (dd, J=3.5, 11.5, 1H), 3.42 (d, J=11.4, 1H), 2.33 (ddd, J=1.6, 7.6, 13.0, 1H), 2.13-2.05 (m, 1H). 3C NMR (126 MHz, CD30OD) δ 174.64, 171.20, 163.83 (d, J=246.5), 139.35, 138.72, 133.86, 131.60, 129.94, 129.56, 124.51, 118.51 (d, J=21.3), 115.56 (d, J=23.4), 71.02, 60.94, 59.70, 43.47, 39.31. MS (ESI) 377.4 (M+H).
  • Figure US20190127359A1-20190502-C00526
  • VL76 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (29.6 mg, 0.067 mmol, 38%). 1H NMR (400 MHz, CD3OD) δ 7.82 (s, 1H), 7.70-7.58 (m, 2H), 7.40 (t, J=7.9, 1H), 7.36-7.18 (m, 4H), 4.73 (dd, J=7.9, 9.4, 1H), 4.53-4.31 (m, 3H), 3.82 (dt, J=5.2, 10.4, 1H), 3.40 (d, J=11.4, 1H), 2.33 (dd, J=7.6, 13.2, 1H), 2.09 (ddd, J=4.1, 9.7, 13.7, 1H). 13C NMR (101 MHz, CD3OD) δ 174.53, 170.95, 139.22, 138.68, 134.68, 133.85, 131.56, 131.44, 129.92, 129.56, 127.31, 123.35, 71.02, 60.90, 59.70, 43.33, 39.31. MS (ESI) 439.4 (M+H).
  • Figure US20190127359A1-20190502-C00527
  • VL77 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (31.0 mg, 0.081 mmol, 45%). 1H NMR (500 MHz, DMSO) δ 8.07 (t, J=1.4, 1H), 8.01-7.95 (m, 1H), 7.93-7.88 (m, 1H), 7.69 (t, J=7.8, 1H), 7.40-7.23 (m, 4H), 4.56 (dd, J=8.3, 16.4, 1H), 4.30 (dd, J=8.1, 15.4, 3H), 3.79 (dd, J=3.6, 11.0, 1H), 3.24 (d, J=11.0, 1H), 2.23-2.15 (m, 1H), 1.92 (ddd, J=4.2, 9.3, 13.2, 1H). 3C NMR (126 MHz, DMSO) δ 171.51, 167.29, 138.64, 137.27, 133.88, 132.29, 131.16, 131.08, 129.73, 128.68, 128.15, 118.25, 111.40, 68.82, 59.39, 59.36, 58.28, 38.19. MS (ESI) 383.8 (M+H).
  • Figure US20190127359A1-20190502-C00528
  • VL79 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (34.9 mg, 0.090 mmol, 50%). 1H NMR (500 MHz, CD3OD) δ 7.41-7.15 (m, 6H), 7.08-6.90 (m, 2H), 4.73 (dd, J=7.7, 9.6, 1H), 4.54-4.31 (m, 3H), 3.87-3.74 (m, 4H), 3.43 (d, J=11.5, 1H), 2.37-2.27 (m, 1H), 2.14-2.05 (m, 1H). 3C NMR (126 MHz, CD3OD) δ 174.72, 172.59, 161.07, 138.72, 138.40, 133.83, 130.67, 129.93, 129.56, 120.58, 117.52, 113.77, 71.01, 60.82, 59.80, 55.87, 43.33, 39.29. MS (ESI) 389.0 (M+H).
  • Figure US20190127359A1-20190502-C00529
  • VL80 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (41.2 mg, 0.110 mmol, 61%). 1H NMR (500 MHz, CD3OD) δ 7.36-6.76 (m, 8H), 4.72 (dd, J=7.8, 9.4, 1H), 4.53-4.31 (m, 3H), 3.82 (dd, J=3.5, 11.6, 1H), 3.45 (d, J=11.6, 1H), 2.34-2.27 (m, 1H), 2.14-2.03 (m, 1H). 13C NMR (126 MHz, CD3OD) δ 174.81, 172.77, 158.73, 138.74, 138.36, 133.83, 130.64, 129.93, 129.56, 119.39, 118.62, 115.26, 71.01, 60.81, 59.80, 43.46, 39.24. MS (ESI) 375.4 (M+H).
  • Figure US20190127359A1-20190502-C00530
  • VL81 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a colorless oil (42.9 mg, 0.091 mmol, 50%). 1H NMR (500 MHz, CD3OD) δ 7.77-7.27 (m, 6H), 7.04 (d, J=8.3, 1H), 4.71 (t, J=8.2, 1H), 4.56-4.30 (m, 3H), 3.59 (dd, J=3.7, 11.2, 1H), 3.17 (d, J=11.3, 1H), 2.37-2.25 (m, 1H), 2.19-2.09 (m, 1H). 13C NMR (126 MHz, CD3OD) δ 173.87, 169.41, 138.18, 137.15, 133.71, 130.60, 130.36, 130.00, 129.69, 129.56, 129.40, 120.48, 70.62, 69.41, 60.48, 43.53, 39.23. MS (ESI) 472.1 (M+H).
  • Figure US20190127359A1-20190502-C00531
  • VL96 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.155 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a light yellow oil (36.6 mg, 0.102 mmol, 66%). 1H NMR (500 MHz, CD3OD) δ 8.81 (s, 1H), 8.66 (dd, J=4.6, 1.5 Hz, 2H), 7.60 (dd, J=4.5, 1.6 Hz, 2H), 7.32-7.25 (m, 4H), 4.70 (dd, J=9.3, 7.9 Hz, 1H), 4.46 (dd, J=15.3, 6.3 Hz, 1H), 4.39 (s, 1H), 4.33 (dd, J=15.4, 5.5 Hz, 1H), 3.78 (dd, J=11.4, 3.5 Hz, 1H), 3.27 (dt, J=3.2, 1.6 Hz, 1H), 2.31 (dd, J=13.2, 7.6 Hz, 1H), 2.08 (ddd, J=13.5, 9.6, 4.2 Hz, 1H). 13C NMR (126 MHz, CD3OD) δ 174.32, 169.63, 150.65, 145.83, 138.68, 133.88, 129.96, 129.56, 123.32, 70.99, 60.88, 59.33, 43.49, 39.33. MS (ESI) 360.5 (M+H).
  • Figure US20190127359A1-20190502-C00532
  • VL112 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.2 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a cream colored solid (22.6 mg, 0.055 mmol, 28%). 1H NMR (500 MHz, CD3OD) δ 7.98 (d, J=7.1 Hz, 3H), 7.46 (d, J=8.0 Hz, 2H), 7.28 (s, 1H), 6.23 (s, 1H), 4.62-4.39 (m, 4H), 3.93 (d, J=2.9 Hz, 2H), 3.81 (dd, J=10.9, 4.1 Hz, 1H), 3.64 (d, J=11.0 Hz, 1H), 2.33-2.17 (m, 4H), 2.15-2.04 (m, 1H). 13C NMR (126 MHz, CD3OD) δ 174.50, 168.72, 167.68, 163.41, 161.60, 142.96, 140.75, 129.45, 128.96, 127.53, 127.15, 105.36, 70.87, 60.78, 56.99, 43.72, 39.36, 33.95, 11.20. MS (ESI) 410.9 (M+H).
  • Figure US20190127359A1-20190502-C00533
  • VL115 was synthesized according to General Method B. 1H NMR (500 MHz, CD3OD) δ 8.87 (s, 1H), 7.46-7.40 (m, 2H), 7.36 (dd, J=8.8, 4.3 Hz, 2H), 6.20 (s, 1H), 4.55 (t, J=8.0 Hz, 1H), 4.50 (d, J=6.3 Hz, 1H), 4.48-4.42 (m, 2H), 3.92 (d, J=4.5 Hz, 2H), 3.80 (dd, J=10.9, 4.3 Hz, 1H), 3.62 (d, J=11.0 Hz, 1H), 2.48 (d, J=10.2 Hz, 3H), 2.31-2.21 (m, 4H), 2.08 (ddd, J=13.0, 8.2, 4.7 Hz, 1H). 13C NMR (126 MHz, CD3OD) δ 174.48, 168.60, 167.70, 161.57, 152.92, 149.26, 140.81, 133.50, 133.09, 130.13, 129.24, 129.09, 128.34, 105.35, 70.86, 60.75, 56.95, 43.81, 39.38, 33.92, 15.87, 11.23. MS (ESI) 441.4 (M+H).
  • Figure US20190127359A1-20190502-C00534
  • VL154 was synthesized according to General Method B. 1H NMR (500 MHz, CD3OD) δ 8.95 (s, 1H), 8.44 (t, J=5.6, 1H), 7.84 (d, J=8.2, 2H), 7.70 (d, J=1.9, 1H), 7.35 (d, J=8.2, 2H), 6.19 (s, 1H), 4.56 (t, J=7.9, 1H), 4.51 (s, 1H), 4.43 (d, J=5.7, 2H), 3.87 (s, 2H), 3.78 (dd, J=10.9, 4.3, 1H), 3.58 (d, J=10.8, 1H), 2.24 (obscured s, 4H), 2.16-2.07 (m, 1H); 13C NMR (126 MHz, CD3OD) δ 176.66, 170.98, 169.94, 164.15, 159.72, 157.62, 142.33, 136.89, 131.58, 130.33, 117.00, 108.05, 73.36, 63.27, 59.60, 46.75, 41.78, 36.80, 14.39; TLC: (EtOAC) Rf=0.5; LRMS (ESI) 427.6 (M+H)+.
  • Figure US20190127359A1-20190502-C00535
  • VL155 was synthesized according to General Method B. 1H NMR (500 MHz, CD3OD) δ 8.87 (d, J=5.2, 1H), 8.54 (t, J=5.7, 1H), 8.07 (s, 1H), 7.56 (d, J=8.2, 2H), 7.36 (d, J=8.2, 2H), 6.20 (s, 1H), 4.56 (t, J=8.0, 1H), 4.51 (s, 1H), 4.42 (qd, J=5.5, 15.5, 2H), 3.78 (dt, J=9.2, 18.5, 1H), 3.60 (d, J=11.1, 1H), 2.28-2.21 (m, 4H), 2.10 (ddd, J=4.7, 8.0, 13.0, 1H); 13C NMR (126 MHz, CD3OD) δ 176.72, 171.03, 169.98, 164.12, 142.98, 142.96, 133.45, 132.34 131.86, 130.07, 108.02, 100.0, 73.37, 63.29, 59.60, 46.52, 41.81, 36.74, 14.27. TLC: (EtOAC) Rf=0.5; LRMS (ESI) 427.4 (M+H)+.
  • Figure US20190127359A1-20190502-C00536
  • VL118 was synthesized according to General Method A. 1H NMR (500 MHz, CD3OD) δ 7.37-7.31 (m, 2H), 7.27 (d, J=7.7 Hz, 1H), 7.22 (d, J=7.5 Hz, 1H), 6.74-6.68 (m, 1H), 6.20 (s, 1H), 6.14 (dd, J=3.5, 1.8 Hz, 1H), 6.10-6.05 (m, 1H), 4.55 (t, J=8.0 Hz, 1H), 4.49 (s, 1H), 4.45-4.39 (m, 2H), 3.89 (t, J=8.4 Hz, 1H), 3.79 (dd, J=10.9, 4.3 Hz, 1H), 3.67-3.55 (m, 5H), 2.26-2.22 (m, 4H), 2.07 (ddd, J=13.0, 8.1, 4.7 Hz, 1H). 13C NMR (126 MHz, CD3OD) δ 174.35, 168.57, 167.66, 161.57, 139.94, 135.44, 135.24, 129.58, 128.35, 128.22, 126.62, 124.93, 109.56, 108.54, 105.37, 70.84, 60.72, 56.91, 44.04, 39.36, 35.34, 33.88, 11.23. MS (ESI) 422.8 (M+H).
  • Figure US20190127359A1-20190502-C00537
  • VL119 was synthesized according to General Method A. 1H NMR (500 MHz, CD3OD) δ 7.38-7.30 (m, 4H), 6.76-6.67 (m, 1H), 6.23 (s, 1H), 6.10 (dd, J=3.5, 1.8 Hz, 1H), 6.09-6.05 (m, 1H), 4.56 (t, J=8.1 Hz, 1H), 4.51 (s, 1H), 4.47-4.39 (m, 2H), 3.93 (d, J=3.0 Hz, 2H), 3.81 (dd, J=10.9, 4.3 Hz, 1H), 3.63 (q, J=5.8 Hz, 4H), 2.31-2.22 (m, 4H), 2.10 (ddd, J=13.0, 8.1, 4.7 Hz, 1H). 13C NMR (101 MHz, ˜1:1 CD3OD:CDCl3) δ 172.63, 167.39, 166.19, 160.68, 136.80, 132.70, 129.06, 128.99, 127.75, 124.09, 108.75, 107.93, 104.62, 69.88, 59.64, 56.15, 43.36, 37.98, 35.19, 33.53, 11.37. MS (ESI) 423.6 (M+H).
  • Figure US20190127359A1-20190502-C00538
  • VL131 was synthesized according to General Method B. 1H NMR (400 MHz, CD3OD) δ 9.02 (d, J=5.2 Hz, 1H), 8.02 (d, J=8.4 Hz, 2H), 7.41 (d, J=8.4 Hz, 2H), 6.17 (s, 1H), 4.52-4.38 (m, 4H), 3.84 (s, 2H), 3.76 (dd, J=10.8, 4.3 Hz, 1H), 3.56 (d, J=9.5 Hz, 1H), 2.30-2.18 (m, 4H), 2.14 (td, J=8.1, 3.9 Hz, 1H). 13C NMR (101 MHz, CD3OD) δ 173.25, 167.86, 167.57, 166.44, 166.18, 160.85, 142.53, 128.33, 128.14, 125.56, 104.77, 70.04, 59.87, 56.31, 43.52, 38.30, 33.60, 11.39. MS (ESI) 413.3 (M+H).
  • Figure US20190127359A1-20190502-C00539
  • VL138 was synthesized according to General Method B. 1H NMR (400 MHz, CD3OD) δ 7.42 (d, J=8.2 Hz, 2H), 7.32-7.24 (m, 2H), 6.24 (s, 1H), 4.69-4.33 (m, 5H), 3.94 (d, J=3.0 Hz, 1H), 3.82 (dd, J=10.9, 4.3 Hz, 1H), 3.64 (d, J=11.1 Hz, 1H), 2.38 (s, 3H), 2.31-2.24 (m, 4H), 2.23 (s, 3H), 2.10 (ddd, J=13.1, 8.2, 4.7 Hz, 1H). 3C NMR (126 MHz, CD3OD) δ 174.41, 168.72, 167.67, 166.87, 161.59, 160.02, 139.46, 130.38, 129.37, 128.89, 117.72, 105.38, 70.87, 60.78, 57.01, 43.74, 39.37, 33.97, 11.38, 11.20, 10.66. MS (ESI) 438.6 (M+H).
  • Figure US20190127359A1-20190502-C00540
  • VL139 was synthesized according to General Method B. 1H NMR (400 MHz, ˜1:1 CD3OD:CDCl3) δ 7.89 (s, 2H), 7.49 (d, J=8.1 Hz, 2H), 7.28 (d, J=7.9 Hz, 2H), 6.20 (s, 1H), 4.54 (dd, J=17.4, 9.5 Hz, 2H), 4.39 (d, J=5.3 Hz, 2H), 3.93-3.46 (m, 4H), 2.32-2.16 (m, 4H), 2.16-2.05 (m, 1H). 3C NMR (126 MHz, ˜1:1 CD3OD:CDCl3) δ 173.80, 168.23, 167.21, 161.29, 137.35, 132.66, 129.24, 128.77, 126.60, 126.48, 105.16, 70.53, 60.42, 56.73, 43.71, 39.00, 33.85, 11.30. MS (ESI) 410.0 (M+H).
  • Figure US20190127359A1-20190502-C00541
  • VL152 was synthesized according to General Method B. 1H NMR (400 MHz, CD3OD) δ 7.38 (d, J=8.2 Hz, 2H), 7.25 (d, J=8.2 Hz, 2H), 6.17 (d, J=55.2 Hz, 1H), 4.65-4.30 (m, 4H), 4.05-3.72 (m, 3H), 3.64 (d, J=11.1 Hz, 1H), 2.32-2.19 (m, 10H), 2.10 (ddd, J=13.1, 8.2, 4.7 Hz, 1H). 13C NMR (101 MHz, CD3OD) δ 174.37, 168.72, 167.67, 161.59, 143.18, 138.27, 132.85, 130.54, 129.12, 128.64, 105.40, 70.86, 60.78, 57.01, 43.80, 39.38, 33.96, 11.21, 11.07. MS (ESI) 438.5 (M+H).
  • Figure US20190127359A1-20190502-C00542
  • VL158 was synthesized according to General Method B. 1H NMR (500 MHz, CD3OD) δ 8.03 (s, 1H), 7.62 (t, J=8.7 Hz, 2H), 7.43 (d, J=6.6 Hz, 1H), 7.33 (t, J=6.5 Hz, 2H), 6.19 (s, 1H), 4.62-4.48 (m, 2H), 4.48-4.32 (m, 2H), 3.93-3.68 (m, 3H), 3.58 (s, 1H), 2.29-2.19 (m, 4H), 2.11 (ddd, J=13.0, 8.0, 4.8 Hz, 1H). 13C NMR (126 MHz, CD3OD) δ 173.59, 168.01, 166.92, 161.11, 138.84, 135.95, 130.48, 129.06, 128.64, 125.89, 116.23, 105.04, 70.35, 60.24, 56.60, 43.56, 38.76, 33.78, 11.33. MS (ESI) 410.1 (M+H).
  • Figure US20190127359A1-20190502-C00543
  • VL160 was synthesized according to General Method B. 1H NMR (500 MHz, CD3OD) δ 7.68 (d, J=8.1 Hz, 2H), 7.63 (s, 1H), 7.33 (d, J=8.0 Hz, 2H), 6.63 (s, 1H), 6.19 (s, 1H), 4.54 (t, J=8.0 Hz, 1H), 4.47 (s, 1H), 4.38 (d, J=4.6 Hz, 2H), 3.89 (d, J=3.1 Hz, 2H), 3.78 (dd, J=10.9, 4.3 Hz, 1H), 3.60 (d, J=11.1 Hz, 1H), 2.28-2.14 (m, 4H), 2.06 (ddd, J=13.0, 8.1, 4.7 Hz, 1H). 13C NMR (126 MHz, CD3OD) δ 174.32, 168.69, 167.67, 161.61, 139.59, 132.31, 129.33, 128.86, 127.00, 126.87, 105.49, 105.38, 70.84, 60.78, 56.97, 43.80, 39.35, 33.95, 11.19. MS (ESI) 409.2 (M+H), 431.8 (M+Na).
    • (2S,4R)-(9H-fluoren-9-yl)methyl 4-(tert-butoxy)-2-((4-chlorobenzyl)carbamoyl)pyrrolidine-1-carboxylate
  • Figure US20190127359A1-20190502-C00544
  • Fmoc-Hyp(OtBu)-OH (1.23 g, 3 mmol, 1 eq) was dissolved in DCM (15 mL) and cooled to 4° C. EDC (0.69 g, 3.6 mmol, 1.2 eq) and HOBt (0.49 g, 3.6 mmol, 1.2 eq) were then added. After 20 minutes, 4-chlorobenzylamine (0.48 mL, 3.9 mmol, 1.3 eq) was added and the solution was allowed to warm slowly to room temperature. After 15 hours, the mixture was diluted with EtOAc and washed with 1M HCl, sodium bicarbonate, water and brine. The organic layer was dried with sodium sulfate, filtered and condensed. Purification by column chromatography (25 to 100% EtOAc/hexanes) gave a white foam (1.42 g, 2.66 mmol, 89%). 1H NMR (400 MHz, CDCl3) δ 7.77 (d, J=7.2 Hz, 2H), 7.57 (s, 2H), 7.40 (t, J=7.3 Hz, 2H), 7.31 (t, J=7.3 Hz, 2H), 7.17 (dd, J=27.2, 19.5 Hz, 4H), 4.58-3.94 (m, 7H), 3.60 (d, J=6.7 Hz, 1H), 3.31 (d, J=6.6 Hz, 1H), 2.50 (s, 1H), 1.96 (s, 1H), 1.28-1.10 (m, 9H). 13C NMR (101 MHz, CDCl3) δ 171.54, 156.13, 143.74, 141.32, 136.81, 133.02, 128.79, 128.71, 127.83, 127.12, 125.04, 120.07, 74.15, 69.63, 67.87, 59.17, 53.26, 47.10, 42.72, 36.34, 28.31. MS (ESI) 534.8 (M+H).
    • (2S,4R)-4-(tert-butoxy)-N-(4-chlorobenzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00545
  • (2S,4R)-(9H-fluoren-9-yl)methyl 4-(tert-butoxy)-2-((4-chlorobenzyl)carbamoyl)pyrrolidine-1-carboxylate (0.5 g, 0.94 mmol, 1 eq) was dissolved in DCM (15 mL) and cooled to 4° C. Tris(2-aminoethyl)amine (0.35 mL, 2.34 mmol, 2.5 eq) was added slowly, dropwise. After 30 minutes, the reaction was warmed to room temperature and stirred for an additional 14 hours. It was loaded directly onto a silica column, and purified by column chromatography (1 to 7% 0.5N methanolic ammonia/DCM) to give a white solid (0.2871 g, 0.92 mmol, 98%). 1H NMR (400 MHz, CD30OD) δ 7.27 (dd, J=20.1, 8.4 Hz, 4H), 4.35 (s, 2H), 4.22 (s, 1H), 3.84 (t, J=8.0 Hz, 1H), 3.08 (dd, J=11.4, 5.1 Hz, 1H), 2.76 (dd, J=11.4, 2.8 Hz, 1H), 2.14-1.98 (m, 1H), 1.97-1.81 (m, 1H), 1.17 (s, 9H). 13C NMR (126 MHz, CD30OD) δ 176.48, 138.81, 133.83, 130.00, 129.52, 74.76, 73.37, 60.80, 55.61, 43.04, 40.76, 28.67.
    • General Method C: Representative Procedure: VL156
  • Figure US20190127359A1-20190502-C00546
  • Figure US20190127359A1-20190502-C00547
  • 1H-Imidazol-1-ylacetic acid (20.6 mg, 0.163 mmol, 1.3 eq), EDC (31.2 mg, 0.163 mmol, 1.3 eq) and HOBt (22 mg, 0.163 mmol, 1.3 eq) were dissolved in DCM (2.5 mL) and DMF (0.4 mL) at room temperature in a 1 dram vial. After stirring for 15 minutes, DIPEA (0.055 mL, 0.313 mmol, 2.5 eq) was added, followed by (2S,4R)-4-(tert-butoxy)-N-(4-chlorobenzyl)pyrrolidine-2-carboxamide (38.9 mg, 0.125 mmol, 1 eq) after an additional 30 minutes. The mixture was stirred for 14 hours, then diluted with EtOAc and washed with brine. The organic layer was dried over sodium sulfate, filtered and condensed. Purification by column chromatography (1 to 10% MeOH/DCM) gave a white solid, which was used directly in the following step. 1H NMR (400 MHz, CD3OD) δ 7.65 (s, 1H), 7.28 (td, J=10.9, 8.4 Hz, 4H), 7.06 (d, J=43.6 Hz, 2H), 4.99 (dd, J=38.1, 17.1 Hz, 2H), 4.51 (t, J=6.6 Hz, 2H), 4.35 (q, J=15.4 Hz, 2H), 3.86 (dd, J=10.2, 5.6 Hz, 1H), 3.45 (dd, J=10.3, 4.1 Hz, 1H), 2.22-2.02 (m, 2H), 1.21 (d, J=13.8 Hz, 9H). MS (ESI) 419.7 (M+H).
  • The white solid was dissolved in DCM (9 mL) at room temperature. TFA (1 mL) was added and the mixture was stirred for 12 hours and condensed. Purification by column chromatography (1 to 20% 0.5 N methanolic ammonia/DCM) gave a white solid (39.8 mg, 0.11 mmol, 88% over 2 steps. 1H NMR (400 MHz, CD3OD) δ 8.73 (s, 1H), 7.47 (d, J=16.9 Hz, 2H), 7.26 (s, 4H), 5.25 (dd, J=37.5, 16.9 Hz, 2H), 4.56 (t, J=7.9 Hz, 2H), 4.44-4.27 (m, 2H), 3.82 (dd, J=10.8, 4.1 Hz, 1H), 3.63 (d, J=10.8 Hz, 1H), 2.36-2.22 (m, 1H), 2.07 (ddd, J=13.1, 8.3, 4.6 Hz, 1H). 13C NMR (126 MHz, CD3OD) δ 174.14, 166.34, 138.56, 138.20, 133.87, 129.97, 129.49, 124.55, 121.47, 70.94, 61.00, 55.75, 51.33, 43.35, 39.21. MS (ESI) 364.8 (M+H).
  • Figure US20190127359A1-20190502-C00548
  • VL120 was synthesized according to General Method C. 1H NMR (500 MHz, CD3OD) δ 8.67 (d, J=1.2 Hz, 1H), 7.36 (s, 1H), 7.29 (d, J=9.2 Hz, 4H), 4.62-4.47 (m, 2H), 4.47-4.24 (m, 2H), 3.87 (ddd, J=18.3, 15.1, 10.8 Hz, 3H), 3.66 (d, J=11.0 Hz, 1H), 2.37-2.20 (m, 1H), 2.07 (ddd, J=13.1, 8.4, 4.6 Hz, 1H). 13C NMR (126 MHz, CD3OD) δ 174.56, 169.45, 138.62, 135.15, 133.89, 129.98, 129.72, 129.52, 118.80, 70.89, 60.70, 56.84, 43.35, 39.46, 31.70. MS (ESI) 362.3 (M+H).
  • Figure US20190127359A1-20190502-C00549
  • VL157 was synthesized according to General Method C. 1H NMR (500 MHz, CD3OD) δ 7.49 (s, 1H), 7.39 (s, 1H), 7.34-7.22 (m, 4H), 4.52 (t, J=8.1 Hz, 1H), 4.50-4.45 (m, 1H), 4.37 (dt, J=22.8, 15.4 Hz, 2H), 3.87-3.80 (m, 3H), 3.77 (dd, J=11.0, 4.2 Hz, 1H), 3.66-3.52 (m, 3H), 2.30-2.18 (m, 1H), 2.04 (ddd, J=13.1, 8.3, 4.7 Hz, 1H). 13C NMR (126 MHz, CD3OD) δ 174.67, 172.70, 140.18, 138.71, 133.81, 131.62, 129.95, 129.51, 115.17, 70.91, 60.65, 56.93, 43.29, 39.28, 38.76, 31.51. MS (ESI) 377.0 (M+H).
  • Figure US20190127359A1-20190502-C00550
  • VL173 was synthesized according to General Method C. 1H NMR (400 MHz, CDCl3/CD3OD) δ 7.63-7.53 (m, 3H); 7.49 (d, J=7.6 Hz, 1H); 7.26 (q, J=8.3 Hz, 4H); 4.60-4.51 (m, 2H); 4.42-4.32 (m, 2H); 3.84-3.75 (m, 3H); 3.59 (d, J=11.3 Hz, 1H); 3.42-3.32 (m, 1H); 2.29-2.19 (m, 1H); 2.17-2.08 (m, 1H). 13C NMR (100 MHz, CDCl3/CD3OD) δ 173.4, 170.7, 137.4, 136.8, 134.8, 133.6, 131.1, 129.9, 129.3, 129.0, 119.2, 112.7, 70.1, 59.8, 56.3, 43.0, 41.1, 38.4. TLC (10% MeOH in CH2Cl2), Rf 0.38 (UV, CAM), MS (ESI+): calculated for C21H21N3O3Cl [M+H]+ 398.1, found 398.2.
  • Figure US20190127359A1-20190502-C00551
    • Azidoacetic Acid
  • Figure US20190127359A1-20190502-C00552
  • To a solution of ethyl azidoacetate (530 mg, 4.107 mmol) in THF-H2O (12 mL/12 mL) at rt was added LiOH.H2O (345 mg, 8.214 mmol). The reaction mixture was stirred at rt for 17 h, evaporated, and diluted with H2O (10 mL), cooled to 0° C., and adjusted to pH 4 with 1N—HCl.
  • The resulting mixture was extracted twice with diethyl ether, washed with brine, dried over anhydrous Na2SO4, and evaporated. The concentrate was purified by short column chromatography (eluting with 100% hexane initially, grading to 2% ethyl acetate in hexane) on silica gel to give azidoacetic acid 1 (372 mg, 89%) as a pale-yellow oil. 1H NMR (500 MHz, CDCl3) δ 9.73 (brs, 1H), 3.97 (s, 2H). 13C NMR (125 MHz, CD3OD) δ 174.2, 50.0.
    • (2S,4R)-1-(2-azidoacetyl)-4-(tert-butoxy)-N-(4-chlorobenzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00553
  • To a solution of azidoacetic acid (32 mg, 0.315 mmol) in CH2Cl2-DMF (1.5 mL/1.5 mL)) at room temperature were added (2S,4R)-4-(tert-butoxy)-N-(4-chlorobenzyl)pyrrolidine-2-carboxamide (93 mg, 0.300 mmol), DIPEA (0.19 mL, 1.080 mmol), and HOBt (48 mg, 0.360 mmol). The mixture was cooled to 0° C., and then EDC (69 mg, 0.360 mmol) was added to the mixture at 0° C. The reaction mixture was allowed to warm to rt, stirred at rt for 17 h, and cooled to 0° C. The resulting mixture was quenched with H2O (5 mL) and extracted twice with ethylacetate. The combined extracts were washed with brine, dried over anhydrous Na2SO4, filtered, and evaporated. The concentrate was purified by column chromatography (eluting with 5% ethyl acetate in hexane initially, grading to 40% ethyl acetate in hexane) on silica gel to afford the coupled product (110 mg, 93%). 1H NMR (400 MHz, CDCl3) δ 7.31 (brs, 1H), 7.27 (d, J=8.5 Hz, 2H), 7.18 (d, J=8.5 Hz, 2H), 4.66 (dd, J=8.4, 2.2 Hz, 1H), 4.58-4.52 (m, 1H), 4.41 (dd, J=15.1, 6.1 Hz, 1H), 4.30 (dd, J=15.1, 5.8 Hz, 1H), 3.87 (dd, J=16.0, 16.0 Hz, 1H), 3.84 (dd, J=16.0, 16.0 Hz, 1H), 3.61 (dd, J=9.8, 7.0 Hz, 1H), 3.14 (dd, J=9.8, 6.4 Hz, 1H), 2.50 (ddd, J=12.6, 6.3, 2.3 Hz, 1H), 1.86 (dt, J=12.6, 8.2 Hz, 1H), 1.19 (s, 9H). 13C NMR, 100 MHz, CDCl3) δ 170.3, 167.4, 162.5, 136.5, 133.1, 128.8, 128.7, 74.3, 69.9, 59.0, 52.7, 50.9, 42.8, 36.4, 35.1, 31.4, 28.2. MS (ESI) [M+H]+ 394.3.
    • (2S,4R)-4-(tert-butoxy)-N-(4-chlorobenzyl)-1-(2-(4-(methoxymethyl)-1H-1,2,3-triazol-1-yl)acetyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00554
  • To a solution of methyl propargyl ether (7 mg, 0.067 mmol) and (2S,4R)-1-(2-azidoacetyl)-4-(tert-butoxy)-N-(4-chlorobenzyl)pyrrolidine-2-carboxamide (25 mg, 0.0636 mmol) in t-BuOH-H2O (1:1, 1 mL) and THF (1 mL) at rt were added CuSO4.5H2O (1.5 mg, 0.006 mmol) and sodium ascorbate (1.0 M in H2O, 2 drops). The reaction mixture was stirred at rt for 19 h and evaporated. The residue was diluted with H2O (5 mL) and the mixture was extracted three times with ethyl acetate. The combined extracts were washed with brine, dried over Na2SO4, filtered, and concentrated. The crude residue was purified by flash chromatography on silica gel to give the desired triazole (25 mg, 85%). 1H NMR (500 MHz, CD3OD) δ 7.91 (s, 1H), 7.30-7.22 (m, 4H), 5.43 (d, J=16.8 Hz, 1H), 5.34 (d, J=16.7 Hz, 1H), 4.54 (s, 2H), 4.53-4.49 (m, 2H), 4.37 (d, J=15.4 Hz, 1H), 4.31 (d, J=15.4 Hz, 1H), 3.90 (dd, J=10.3, 5.6 Hz, 1H), 3.49 (dd, J=10.4, 4.3 Hz, 1H), 3.37 (s, 3H), 2.19-2.13 (m, 1H), 2.11-2.07 (m, 1H), 1.22 (s, 9H). 13C NMR (asterisk denotes the signals of the minor rotamer, 125 MHz, CD3OD) δ 174.1, *173.4, *166.9, 166.7, 145.7, *138.6, 138.5, *134.2, 133.8, *130.4, 129.9, *129.7, 129.5, 126.7, 75.6, *75.5, 71.1, *69.2, 66.3, *66.2, 60.8, *60.3, 58.4, *58.3, *55.5, 54.8, 52.6, *51.9, *43.7, 43.3, *41.1, 38.7, 28.5. MS (ESI) [M+H]+ 464.2.
  • Figure US20190127359A1-20190502-C00555
  • To a stirred solution of the corresponding t-butyl ether (22 mg, 0.0475 mmol) in CH2Cl2 (1.5 mL) at 0° C. was added TFA (0.2 mL). The reaction mixture was stirred at rt for 12 h and concentrated. The residue was chromatographed (eluting with 100% CH2Cl2 initially, grading to 7% CH3OH in CH2Cl2) on silica gel to provide 5 (18.5 mg, 96%). 1H NMR (500 MHz, CD3OD/CDCl3=2:1) d 8.83 & 8.46 (due to the rotamers, both t, J=5.7 Hz, 1H), 7.85 & 7.76 (due to the rotamers, both s, 1H), 7.23 (d, J=8.5 Hz, 2H), 7.18 (d, J=8.5 Hz, 2H), 5.36 (d, J=16.6 Hz, 1H), 5.27 (d, J=16.6 Hz, 1H), 4.54 (s, 2H), 4.54-4.50 (m, 2H), 4.33 & 4.32 (due to the rotamers, both s, 2H), 3.77 (dd, J=10.8, 4.2 Hz, 1H), 3.60 (d, J=10.8 Hz, 1H), 3.37 & 3.36 (due to the rotamers, both s, 3H), 2.26-2.21 (m, 1H), 2.09-2.04 (m, 1H). 13C NMR (asterisk denotes the signals of the minor rotamer, 125 MHz, CD3OD/CDCl3=2:1) d *173.4, 173.3, *166.2, 165.9, 145.2, 137.5, *133.9, 133.5, 129.9, 129.4, 129.1, 126.0, *125.9, 70.4, *68.5, 66.0, *65.9, *60.4, 60.3, 58.4, *58.3, *56.1, 55.4, 52.2, *51.5, *43.2, 43.1, *41.1, 38.4. MS (ESI) [M+H]+ 408.3. TLC (10% MeOH in CH2Cl2), Rf 0.48 (UV, CAM).
  • Figure US20190127359A1-20190502-C00556
  • VL167 was synthesized according to General Method C. 1H NMR (500 MHz, CDCl3) δ 7.86 (s, 1H), 7.71 (d, J=9.5 Hz, 1H), 7.61 (d, J=7.4 Hz, 2H), 7.56 (d, J=7.6 Hz, 1H), 7.51 (d, J=7.6 Hz, 1H), 7.42 (dd, J=7.4, 7.4 Hz, 2H), 7.38-7.30 (m, 2H), 7.30-7.26 (m, 3H), 4.66-4.42 (m, 2H), 4.42-4.27 (m, 2H), 3.85 (dd, J=11.4, 3.5 Hz, 1H), 3.49 (d, J=11.4 Hz, 1H), 2.33-2.29 (m, 1H), 2.15-2.09 (m, 1H). 13C NMR (asterisk denotes the signals of the minor rotamer, 125 MHz, CDCl3) δ 172.5, 170.6, 162.7, 140.7, 139.3, 136.4, 135.6, 131.9, 128.2, *128.1, 128.0, 127.9, 127.6, *127.5, 126.8, 126.1, *126.0, 125.2, 125.1, 68.9, *67.4, *60.2, 58.7, 57.8, 41.5, *39.5, 37.2, 35.2, 30.0. MS (ESI) [M+H]+ 435.5.
  • Figure US20190127359A1-20190502-C00557
  • VL216 was synthesized according to General Method C.
  • Figure US20190127359A1-20190502-C00558
    • (2S,4R)-(9H-fluoren-9-yl)methyl 4-(tert-butoxy)-2-((4-(oxazol-5-yl)benzyl)carbamoyl) pyrrolidine-1-carboxylate
  • Figure US20190127359A1-20190502-C00559
  • To a round bottom flask with stir bar was charged (2S,4R)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-4-(tert-butoxy)pyrrolidine-2-carboxylic acid (0.587, 1.4 mmol 1.0 equiv)′ EDC (380 mg, 2.0 mmol, 1.4 equiv), HOBt (310 mg, 2.0 mmol, 1.4 equiv) and (4-(oxazol-5-yl)phenyl)methanamine (250 mg, 1.4 mmol, 1.0 equiv). Upon stirring for 18 h the reaction was diluted with 25 ml DCM, and washed with citric acid (2×50 mL), and saturated NaHCO3 (2×50 mL). The organic layer was dried with Na2SO4, concentrated down then purified via silica gel chromatography (DCM to 2% MeOH (0.5 N NH3) to yield 515 mg (65% yield) of product as a viscous oil 1H NMR (400 MHz, CDCl3) δ 7.89 (s, 1H), 7.85-7.70 (m, 2H), 7.68-7.49 (m, 4H), 7.47-7.37 (m, 2H), 7.35-7.20 (m, 5H), 4.54-4.35 (m, 4H), 4.35-4.14 (m, 2H), 3.72-3.58 (m, 1H), 3.49-3.27 (m, 1H), 2.53 (s, 1H), 2.00 (dd, J=8.1, 20.2, 1H), 1.25 (s, 9H); TLC: (9:1 DCM:MeOH (0.5 N NH3)) Rf=0.5; LRMS (ESI) 565.9 (M+H)+.
    • (2S,4R)-1-(3-ethoxybenzoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00560
  • To (2S,4R)-(9H-fluoren-9-yl)methyl 4-(tert-butoxy)-2-((4-(oxazol-5-yl)benzyl)carbamoyl) pyrrolidine-1-carboxylate (2.5 g, 3.61 mmol, 1.0 equiv) in 36 mL DCM was charged tris(2-aminoethyl)amine mol, 9.0 mmol, 2.5 equiv). □(400 upon stirring for 3 h the cloudy mixture was diluted with silica gel and concentrated down. The material was then dry loaded to a silica gel column and purified (DCM to 5% MeOH (0.5 N NH3) in DCM) to yield 820 mg (67% yield) as a white solid. 1H NMR (501 MHz, CDCl3) δ 8.02 (s, 1H), 7.90 (s, 1H), 7.60 (d, J=8.1, 2H), 7.33-7.29 (m, 3H), 4.44 (d, J=6.1, 2H), 4.21-4.07 (m, 1H), 3.97 (dd, J=7.2, 8.7, 1H), 2.87 (d, J=11.6, 1H), 2.80 (dd, J=4.3, 11.6, 1H), 2.17 (dd, J=10.2, 12.4, 1H), 2.11-1.94 (m, 1H), 1.16 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 174.88, 151.27, 150.40, 139.33, 128.07, 126.79, 124.63, 121.43, 73.65, 72.30, 59.95, 54.97, 42.51, 39.27, 28.38; TLC: (9:1 DCM:MeOH (0.5 N NH3)) Rf=0.42; LRMS (ESI) 344.2 (M+H)+.
  • 1H NMR (400 MHz, CD3OD) δ 7.42-7.28 (m, 4H), 7.28-7.12 (m, 2H), 7.10-6.77 (m, 2H), 4.71 (dt, J=30.7, 15.3 Hz, 1H), 4.58-4.30 (m, 3H), 4.18-3.92 (m, 2H), 3.87-3.77 (m, 1H), 3.44 (d, J=11.4 Hz, 1H), 2.38-2.24 (m, 1H), 2.15-2.03 (m, 1H), 1.55-1.23 (m, 3H). 13C NMR (126 MHz, CD3OD) δ 174.72, 172.63, 160.34, 138.72, 138.35, 133.82, 130.65, 130.11, 129.92, 129.55, 120.47, 118.08, 114.27, 113.89, 71.01, 64.71, 60.81, 59.80, 43.33, 39.29, 15.09. MS (ESI) 403.2 (M+H).
    • General Method D: Representative Procedure: VL217
  • Figure US20190127359A1-20190502-C00561
    • (2S,4R)-4-(tert-butoxy)-1-(3-ethoxybenzoyl)-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00562
  • 3-Ethoxybenzoic acid (13.3 mg, 0.08 mmol, 1 eq), EDC (16.9 mg, 0.088 mmol, 1.1 eq) and HOBt (11.9 mg, 0.88 mmol, 1.1 eq) were dissolved in DCM (0.8 mL) at room temperature. DIPEA (0.0279 mL, 0.16 mmol, 2 eq) was added, followed by (2S,4R)-4-(tert-butoxy)-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide (33.0 mg, 0.096 mmol, 1.2 eq). The solution was stirred for 21 hours then diluted with EtOAc and washed with 10% citric acid, saturated sodium bicarbonate and brine. The organic layer was dried over sodium sulfate, filtered and condensed. Purification by column chromatography (1 to 5% MeOH/DCM) gave a colorless oil (36.1 mg, 0.073 mmol, 92%). 1H NMR (400 MHz, CDCl3) δ 7.90 (s, 1H), 7.61 (dd, J=16.6, 6.9 Hz, 3H), 7.38-7.27 (m, 4H), 6.98 (dd, J=16.0, 6.4 Hz, 3H), 4.92 (dd, J=8.3, 4.7 Hz, 1H), 4.48 (d, J=6.0 Hz, 2H), 4.43-4.31 (m, 1H), 4.03 (q, J=7.0 Hz, 2H), 3.61 (dd, J=10.9, 5.7 Hz, 1H), 3.31 (dd, J=10.9, 4.4 Hz, 1H), 2.73-2.55 (m, 1H), 2.05-1.92 (m, 1H), 1.40 (t, J=7.0 Hz, 3H), 1.13 (s, 9H). MS (ESI) 492.4 (M+H).
  • Figure US20190127359A1-20190502-C00563
  • (2S,4R)-4-(tert-butoxy)-1-(3-ethoxybenzoyl)-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide (36.1 mg, 0.073 mmol, 1 eq) was dissolved in DCM (9 mL) at room temperature. TFA (1 mL) was added and the solution was stirred for 13 hours, then condensed. Purification by column chromatography (1 to 10% MeOH/DCM) gave a colorless oil (22.9 mg, 0.053 mmol, 72%). 1H NMR (400 MHz, CD3OD) δ 8.24 (d, J=12.0 Hz, 1H), 7.65 (dd, J=28.0, 8.3 Hz, 2H), 7.47 (dd, J=18.8, 10.6 Hz, 3H), 7.23 (ddd, J=9.4, 4.6, 4.1 Hz, 3H), 7.09-6.87 (m, 2H), 4.75 (dd, J=9.6, 7.7 Hz, 1H), 4.48 (dd, J=49.7, 15.5 Hz, 3H), 4.06 (q, J=7.0 Hz, 2H), 3.84 (dd, J=11.5, 3.5 Hz, 1H), 3.44 (d, J=11.5 Hz, 1H), 2.42-2.29 (m, 1H), 2.21-2.05 (m, 1H), 1.36 (dt, J=24.0, 7.0 Hz, 3H). 13C NMR (101 MHz, CD3OD) δ 174.78, 172.66, 160.35, 153.14, 152.74, 140.85, 138.38, 130.66, 129.00, 127.71, 125.62, 121.77, 120.50, 118.08, 114.30, 71.02, 64.71, 60.85, 59.82, 43.72, 39.32,
  • Figure US20190127359A1-20190502-C00564
    • (2S,4R)-tert-butyl 4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl) pyrrolidine-1-carboxylate
  • Figure US20190127359A1-20190502-C00565
  • (2S,4R)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (366 mg, 1.58 mmol, 1 equiv.) was dissolved in 15 mL DMF and charged with EDC (380 mg, 2.0 mmol 1.3 equiv.), and HOBt (310 mg, 2.0 mmol, 1.5 equiv) after 5 minutes of stirring (4-(4-methylthiazol-5-yl)phenyl)methanamine (325 mg, 1.58 mmol, 1 equiv) was added. Upon stirring for 15 h the reaction was diluted with 25 mL EtOAc, and washed with 25 mL brine (2×), followed by 25 mL Sat. NaHCO3 (2×). The organic layer was concentrated down to yield 650 mg (98% yield) of the product as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.67 (s, 1H), 7.43-7.29 (m, 4H), 4.49 (d, J=16.7 Hz, 4H), 3.51 (dd, J=11.0, 4.7 Hz, 2H), 2.61-2.45 (m, 4H), 2.03 (d, J=7.4 Hz, 2H), 1.42 (s, 9H). TLC: (9:1 DCM:MeOH (0.5 N NH3)) Rf=0.20; MS (ESI) 417.5 (M+H)+.
    • (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00566
  • To (2S,4R)-tert-butyl 4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl) pyrrolidine-1-carboxylate (650 mg, 1.40 mmol, 1 equiv) in a round bottom flask was charged 9 mL 4M HCL in dioxanes (36 mmol, 26 equiv). The reaction was left to stir for 1 h upon which time N2 was bubbled through for 1 h and the volatiles were removed by vacuum. The resulting viscous oil was washed dissolved in water and washed with 50 mL EtOAC. The aqueous layer was then basified to pH 12 with 1 M NaOH, and then extracted with 50 mL EtOAC (3×). The organic layer was dried and concentrated down to yield 250 mg (79% yield) of product as a brown viscous oil. 1H NMR (501 MHz, CDCl3) δ 8.66 (s, 1H), 8.18 (t, J=6.0, 1H), 7.38 (d, J=8.1, 2H), 7.30 (d, J=8.1, 2H), 4.48-4.37 (m, 3H), 4.08 (t, J=8.4, 1H), 3.02 (d, J=13.3, 1H), 2.79 (dd, J=3.2, 12.3, 1H), 2.51 (s, 3H), 2.33 (dd, J=8.6, 13.9, 1H), 2.03-1.87 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 174.89, 150.35, 148.46, 138.30, 131.54, 130.95, 129.51, 127.92, 72.90, 59.72, 55.35, 42.53, 39.98, 16.06; TLC: (9:1 DCM:MeOH) Rf=0.1; LRMS (ESI) 317.4 (M+H)+.
    • General Method E: Representative Procedure: VL219
  • Figure US20190127359A1-20190502-C00567
  • Figure US20190127359A1-20190502-C00568
  • 3-ethoxybenzoic acid (17 mg, 0.1 mmol, 1 equiv.) was dissolved in 1 mL 10:1 DCM:DMF and charged with EDC (25 mg, 0.13 mmol 1.3 equiv.), and HOBt (21 mg, 0.13 mmol, 1.3 equiv). After 5 minutes of stirring (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (31 mg, 0.095 mmol, 1 equiv) was added. Upon stirring for 18 h the reaction was diluted with 15 mL EtOAc and washed with 25 mL 10% aqueous citric acid and 25 mL saturated NaHCO3. The organic layer was dried with Na2SO4 and concentrated by vacuum. The resultant oil was purified by silica gel chromatography (DCM to 9% MeOH (0.5 N NH3) in DCM) to yield 25 mg (56% yield) of the product as a white solid. 1H NMR (501 MHz, CD3OD) δ 8.87 (s, 1H), 7.51-7.42 (m, 4H), 7.37 (t, J=8.1, 1H), 7.23-7.14 (m, 2H), 7.05 (dd, J=2.2, 8.4, 1H), 4.79 (dd, J=7.7, 9.5, 1H), 4.63-4.40 (m, 3H), 4.08 (q, J=7.0, 2H), 3.86 (dt, J=3.8, 7.6, 1H), 3.47 (d, J=11.5, 1H), 2.47 (s, 3H) 2.36 (dd, J=7.6, 13.2, 1H), 2.14 (ddd, J=5.3, 10.2, 16.4, 1H), 1.41 (t, J=7.0, 3H); 13C NMR (126 MHz, CD3OD) δ 174.74, 172.64, 160.34, 152.78, 149.05, 140.21, 138.40, 133.39, 131.55, 130.65, 130.44, 128.83, 120.49, 118.07, 114.32, 71.02, 64.71, 60.83, 59.81, 43.67, 39.30, 15.79, 15.06; TLC: (9:1 DCM:MeOH (0.5 N NH3)) Rf=0.25; LRMS (ESI) 466.1 (M+H)+.
  • Figure US20190127359A1-20190502-C00569
  • VL210 was synthesized according to General Method D. 1H NMR (500 MHz, CD3OD) δ 8.23 (s, 1H), 7.82 (t, J=1.7, 1H), 7.73-7.58 (m, 4H), 7.49-7.33 (m, 4H), 4.76 (dd, J=7.6, 9.6, 1H), 4.59-4.32 (m, 3H), 3.84 (dd, J=3.5, 11.4, 1H), 3.41 (d, J=11.3, 1H), 2.43-2.30 (m, 1H), 2.18-2.07 (m, 1H); 13C NMR (126 MHz, CD3OD) δ 173.14, 169.54, 151.35, 139.41, 137.87, 133.28, 130.18, 130.01, 127.92, 127.61, 126.31, 125.93, 124.23, 121.93, 120.36, 69.62, 59.53, 58.30, 42.31, 37.95; LRMS (ESI) 471.5 (M+H)+.
  • Figure US20190127359A1-20190502-C00570
  • VL224 was synthesized according to General Method E. 1H NMR (501 MHz, CD3OD) δ 8.87 (s, 1H), 7.83 (d, J=1.5, 1H), 7.67 (d, J=7.1, 1H), 7.61 (d, J=6.7, 1H), 7.48-7.36 (m, 5H), 4.77 (t, J=8.5, 1H), 4.60-4.39 (obscured m, 3H), 3.90-3.78 (m, 1H), 3.42 (d, J=11.4, 1H), 2.47 (s, 3H), 2.41-2.30 (m, 1H), 2.19-2.06 (m, 1H); 13C NMR (126 MHz, CD3OD) δ 173.15, 169.55, 151.41, 147.64, 138.77, 137.85, 133.26, 132.78, 131.98, 130.16, 130.02, 129.05, 127.43, 125.91, 121.93, 69.64, 59.53, 58.32, 42.27, 37.94, 14.41; TLC: (9:1 DCM:MeOH (0.5 N NH3)) Rf=0.7; LRMS (ESI) 499.8 (M+H)+.
  • Figure US20190127359A1-20190502-C00571
  • VL215 was synthesized according to General Method D. 1H NMR (501 MHz, CD3OD) δ 8.24 (dd, J=13.4, 7.1 Hz, 1H), 7.87-7.58 (m, 3H), 7.58-7.31 (m, 4H), 7.16 (s, 1H), 4.73 (d, J=7.8 Hz, 1H), 4.63-4.50 (m, 1H), 4.49-4.29 (m, 2H), 3.80 (d, J=10.5 Hz, 1H), 3.60 (s, 1H), 2.31 (s, 1H), 2.17 (s, 1H). 13C NMR (126 MHz, CD3OD) δ 179.37, 169.61, 153.12, 152.75, 140.72, 138.21, 137.16, 133.72, 130.38, 129.70, 129.40, 129.08, 127.76, 125.63, 121.80, 70.64, 60.46, 58.42, 43.80, 39.27. MS (ESI) 504.2 (M+H).
  • Figure US20190127359A1-20190502-C00572
  • VL228 was synthesized according to General Method E. NMR (400 MHz, CD3OD) δ 8.88 (d, J=9.3 Hz, 1H), 7.75 (d, J=1.9 Hz, 1H), 7.48 (ddd, J=13.9, 8.4, 4.1 Hz, 5H), 7.17 (d, J=8.3 Hz, 1H), 4.74 (t, J=8.2 Hz, 1H), 4.63-4.33 (m, 3H), 3.61 (dd, J=11.3, 3.8 Hz, 1H), 3.18 (d, J=11.3 Hz, 1H), 2.49 (d, J=9.6 Hz, 3H), 2.33 (ddd, J=7.8, 4.8, 2.1 Hz, 1H), 2.19 (ddd, J=11.9, 7.8, 4.6 Hz, 1H). 13C NMR (126 MHz, CD3OD) δ 173.93, 169.45, 152.84, 149.07, 140.11, 138.21, 137.17, 133.73, 131.62, 130.53, 130.48, 130.39, 129.52, 129.41, 128.93, 70.65, 60.48, 58.39, 43.75, 39.26, 15.81. MS (ESI) 534.4 (M+H).
  • Figure US20190127359A1-20190502-C00573
  • VL177 was synthesized according to General Method D. 1H NMR (500 MHz, CDCl3/CD3OD) δ 7.89 (s, 1H); 7.84 (s, 1H); 7.80-7.75 (m, 2H); 7.69 (d, J=7.8 Hz, 1H); 7.57-7.48 (m, 3H); 7.31 (d, J=8.1 Hz, 2H); 4.76 (t, J=8.3 Hz, 1H); 4.49-4.39 (m, 3H); 3.72 (dd, J=11.2, 3.5 Hz, 1H); 3.36 (d, J=11.2 Hz, 1H); 2.93 (s, 1H); 2.31 (ddd, J=13.2, 8.8, 4.4 Hz, 1H); 2.21 (dd, J=13.5, 7.8 Hz, 1H). 13C NMR (125 MHz, CDCl3/CD3OD) δ 171.8, 169.0, 151.5, 150.6, 138.9, 137.0, 133.9, 131.9, 131.3, 129.5, 128.1, 126.7, 124.7, 121.1, 117.9, 112.7, 69.9, 59.3, 58.5, 43.3, 37.4. TLC (10% MeOH in CH2Cl2), Rf 0.17 (UV, CAM), MS (ESI+): calculated for C23H21N4O4 [M+H]+ 417.2, found 417.1.
  • Figure US20190127359A1-20190502-C00574
  • VL226 was synthesized according to General Method E. 1H NMR (500 MHz, CDCl3/CD3OD) δ 8.65 (s, 1H); 7.84 (s, 1H); 7.74 (dd, J=13.3, 7.8 Hz, 2H); 7.53 (t, J=7.8 Hz, 1H); 7.40-7.28 (m, 5H); 4.92 (t, J=8.1 Hz, 1H); 4.53 (s, 1H); 4.48 (d, J=5.9 Hz, 2H); 3.72 (dd, J=11.3, 3.5 Hz, 1H); 3.52-3.44 (m, 1H); 2.85 (br s, 1H); 2.67-2.56 (m, 1H); 2.48 (s, 3H); 2.21 (dd, J=13.5, 7.8 Hz, 1H). 13C NMR (125 MHz, CDCl3/CD3OD) δ 170.8, 169.4, 150.5, 148.6, 138.0, 137.0, 134.1, 131.9, 131.4, 129.7, 129.6, 127.0, 118.0, 113.0, 70.4, 59.1, 58.6, 43.5, 36.8, 16.2. TLC (10% MeOH in CH2Cl2), Rf 0.32 (UV, CAM), MS (ESI+): calculated for C24H23N4O3S [M+H]+ 447.2, found 447.0.
  • Figure US20190127359A1-20190502-C00575
  • VL211 was synthesized according to General Method D. 1H NMR (500 MHz, CD3OD) δ 8.11 (s, 1H), 7.58 (dd, J=2.3, 8.2, 2H), 7.42-7.30 (m, 3H), 7.16 (t, J=7.9, 1H), 6.96 (d, J=7.7, 1H), 6.92 (s, 1H), 6.80 (dd, J=2.3, 8.1, 1H), 4.65 (t, J=8.6, 1H), 4.47-4.26 (m, 3H), 3.71 (dt, J=4.0, 8.0, 1H), 3.36 (d, J=11.6, 1H), 2.32-2.16 (m, 1H), 2.08-1.94 (m, 1H); 13C NMR (126 MHz, CD3OD) δ 174.74, 172.77, 158.71, 153.14, 152.70, 140.83, 138.38, 130.62, 128.98, 127.69, 125.62, 121.75, 119.39, 118.61, 115.27, 71.01, 60.77, 59.79, 43.73, 39.25; TLC: (9:1 DCM:MeOH R=0.15; LRMS (ESI) 408.3 (M+H)+.
  • Figure US20190127359A1-20190502-C00576
  • Vl225 was synthesized according to General Method E. 1H NMR (501 MHz, CD3OD) δ 8.86 (s, 1H), 7.49-7.34 (m, 4H), 7.27 (t, J=7.8, 1H), 7.11-7.00 (m, 2H), 6.93-6.84 (m, 1H), 4.77 (t, J=8.5, 1H), 4.57-4.38 (m, 3H), 3.84 (dd, J=3.3, 11.5, 1H), 3.47 (d, J=11.5, 1H), 2.46 (S, 3H) 2.34 (dd, J=7.1, 12.5, 1H), 2.18-2.06 (m, 1H); 13C NMR (126 MHz, CD3OD) δ 173.35, 171.36, 157.31, 151.39, 147.62, 138.81, 136.95, 130.12, 129.21, 129.04, 127.62, 127.41, 117.97, 117.19, 113.84, 69.61, 59.37, 58.41, 42.24, 37.85, 14.37; TLC: (9:1 DCM:MeOH) R=0.3; LRMS (ESI) 437.0 (M+H)+.
  • Figure US20190127359A1-20190502-C00577
  • VL178 was synthesized according to General Method D. 1H NMR (400 MHz, CD3OD) δ 8.84 (t, J=5.9, 1H), 8.26 (d, J=5.9, 1H), 7.73 (d, J=8.3, 2H), 7.55-7.45 (m, 3H), 7.06 (t, J=7.8, 1H), 6.86-6.76 (m, 1H), 6.68 (d, J=7.3, 1H), 4.75 (t, J=8.4, 1H), 4.66-4.35 (m, 3H), 3.55 (dd, J=3.5, 11.6, 1H), 3.24 (d, J=11.4, 1H), 2.41-2.26 (m, 1H), 2.21-2.10 (m, 4H); 13C NMR (126 MHz, CD3OD) δ 173.21, 172.03, 151.32, 145.03, 139.46, 137.30, 130.95, 127.61, 126.53, 126.29, 124.22, 123.96, 120.35, 116.31, 115.97, 74.46, 69.35, 58.72, 42.46, 38.02, 23.61; LRMS (ESI) 420.4 (M+H)+.
  • Figure US20190127359A1-20190502-C00578
  • (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (24 mg, 0.0756 mmol, 1 eq), 3-amino-2-methylbenzoic acid (13 mg, 0.083 mmol, 1.1 eq), EDC (16 mg, 0.083 mmol, 1.1 eq) and HOBt (11 mg, 0.083 mmol, 1.1 eq) were dissolved in DMF (0.76 mL) at room temperature. DIPEA (0.02 mL, 0.113 mmol, 1.5 eq) was added, and the solution was stirred for 17 hours. The solution was then partitioned between 1M NaOH and EtOAc, separated, and extracted twice more with EtOAc. The combined organic layer was dried over sodium sulfate, filtered and condensed. Purification by column chromatography (1 to 10% 0.5N methanolic ammonia/DCM) gave a white solid (20.5 mg, 0.045 mmol, 60%). 1H NMR (501 MHz, CD3OD) δ 8.87 (t, J=6.6 Hz, 1H), 7.45 (dt, J=20.5, 7.7 Hz, 4H), 7.03 (t, J=7.6 Hz, 1H), 6.78 (d, J=7.8 Hz, 1H), 6.65 (s, 1H), 4.74 (t, J=8.1 Hz, 1H), 4.67-4.34 (m, 3H), 3.53 (d, J=11.3 Hz, 1H), 3.21 (d, J=9.3 Hz, 1H), 2.48 (d, J=3.1 Hz, 3H), 2.32 (d, J=7.6 Hz, 1H), 2.14 (dd, J=31.4, 20.5 Hz, 4H). 13C NMR (126 MHz, CD3OD) δ 174.56, 173.67, 152.89, 152.81, 149.04, 147.80, 140.23, 138.57, 133.44, 131.54, 130.46, 128.86, 127.83, 117.01, 116.36, 70.77, 69.66, 60.09, 43.70, 39.41, 15.81, 13.92. MS (ESI) 450.6 (M+H), 473.4 (M+Na).
  • For further reference see the following articles and the references cited therein:
    • (1) Buckley D L et al. J. Am. Chem. Soc 2012, 134, 4465-4468.
    • (2) Van Molle I et al. A Chemistry & Biology 2012, 19, 1300-1312
    • (3) Buckley, D Angew. Chem. Int. Ed., 2012, 51, 11463-11467
    • (4) Buckley, D. L et al. Angew. Chem. 2012, 124, 11630-11634.
    Examples—Compounds 165-266 of Affinity Table II
  • The following compounds were synthesized according to the stated General Method, were purified by standard chromatographic methods and had 1H and 13C NMR and MS data consistent with the desired structure.
  • Figure US20190127359A1-20190502-C00579
  • VL165 was synthesized according to General Method B.
    • VL168 & 169
  • The chiral RHS amine fragment was synthesized using the procedure from Surya Prakash, G. K.; Mandal, M.; Olah, G. A. Angew. Chem. Int. Ed. 2001, 40, 589-690.
  • Figure US20190127359A1-20190502-C00580
    • VL168 was Synthesized According to General Method F
  • Figure US20190127359A1-20190502-C00581
    • VL169 was Synthesized According to General Method F
  • Figure US20190127359A1-20190502-C00582
    • VL175: General Method C
  • Figure US20190127359A1-20190502-C00583
    Figure US20190127359A1-20190502-C00584
    Figure US20190127359A1-20190502-C00585
    • VL192-VL205: Solid Phase Synthesis General Method B
  • Figure US20190127359A1-20190502-C00586
    Figure US20190127359A1-20190502-C00587
    Figure US20190127359A1-20190502-C00588
    Figure US20190127359A1-20190502-C00589
    Figure US20190127359A1-20190502-C00590
  • 3-hydroxy-2-methylbenzoic acid (26.3 mg, 0.173 mmol, 1.1 eq), EDC (33.2 mg) and HOBt (23.4 mg) were dissolved in DCM (0.8 mL) and DMF (0.1 mL) at 4° C. After 10 minutes, (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (0.5 mL of a 100 mg/mL solution in DCM) was added and the mixture was warmed to room temperature. After 21 hours, the mixture was diluted with 10 mL of half saturated sodium chloride and extracted thrice with 10 mL of EtOAc. The combined organic layer was dried over sodium sulfate, filtered and condensed. Purification by column chromatography (1 to 10% MeOH/DCM) gave a white solid (29.2 mg, 0.0647, 41%). 1H NMR (400 MHz, MeOD) δ 8.93-8.82 (m, 1H), 7.55-7.36 (m, 4H), 7.10 (t, J=7.8 Hz, 1H), 6.83 (dd, J=10.3, 7.9 Hz, 2H), 4.76 (t, J=8.4 Hz, 1H), 4.66-4.38 (m, 3H), 3.56 (dd, J=11.6, 3.6 Hz, 1H), 3.22 (d, J=11.6 Hz, 1H), 2.54-2.47 (m, 3H), 2.41-2.31 (m, 1H), 2.19 (dt, J=11.3, 10.9 Hz, 4H). 13C NMR (126 MHz, MeOD) δ 174.50, 173.09, 157.22, 152.89, 152.80, 149.01, 140.21, 139.18, 133.42, 131.52, 130.44, 128.85, 127.94, 117.84, 116.42, 70.73, 69.62, 60.12, 43.69, 39.38, 15.79, 12.70. MS (ESI) 452.5 (M+H).
  • Figure US20190127359A1-20190502-C00591
    Figure US20190127359A1-20190502-C00592
    Figure US20190127359A1-20190502-C00593
    Figure US20190127359A1-20190502-C00594
    • VL251 (2S,4R)-1-((S)-2-((S)-2-acetamido-4-methylpentanamido)propanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00595
    • tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-1-oxopropan-2-yl)carbamate
  • Figure US20190127359A1-20190502-C00596
  • Boc-Ala-OH (189 mg, 1.0-mmol) was dissolved in 10 mL DCM and charged with EDC (248 mg, 1.2 mmol), and HOBt (202 mg, 1.3 mmol) after 5 minutes of stirring (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carb-oxamide (317 mg, 1.0 mmol) was added. Upon stirring for 18 h the reaction was diluted with 10 mL DCM and washed with 10 mL 10% aqueous citric acid followed by 5 mL saturated NaHCO3. The mixture was concentrated down and purified by silica gel chromatography (DCM/MeOH gradient) to yield 210 mg (43% yield) of the product as a white solid. 1H NMR (501 MHz, CDCl3) δ 8.65 (s, 1H), 7.58 (s, 1H), 7.31 (d, J=8.1, 2H), 7.26 (d, J=8.0, 2H), 5.44 (d, J=7.4, 1H), 4.66 (t, J=7.6, 1H), 4.52 (s, 1H), 4.39 (m, 3H), 3.78 (d, J=10.9, 1H), 3.59 (d, J=7.0, 1H), 2.47 (s, 3H), 2.30 (s, 1H), 2.10 (s, 1H), 1.54-1.31 (m, 9H), 1.26 (d, J=6.9, 3H); 13C NMR (126 MHz, CDCl3) δ 173.1, 171.2, 155.5, 150.5, 148.2, 138.2, 130.7, 129.4, 127.6, 80.1, 70.1, 58.8, 55.2, 48.0, 42.3, 36.5, 28.3, 18.0, 16.0; LRMS (ESI) 489.4 (M+H)+.
    • VL251 (2S,4R)-1-((S)-2-((S)-2-acetamido-4-methylpentanamido)propanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00597
  • Boc-Ala-Hyp-benzyl thiazole (116 mg, 0.225 mmol) was dissolved in 1 mL DCM and charged with 2.3 mL 4M HCL in dioxanes. Upon stirring for one hour Nitrogen gas was sparged through the mixture for 15 minutes and the remaining volatiles removed by roto vap.
  • The resultant foam was then dissolved in 5 mL 1:1 DCM: DMF and charged with EDC (56 mg, 0.29 mmol), HOBt (45 mg, 0.29 mmol), and Ac-Leu-OH (43 mg, 0.25 mmol) were added. After stirring for 5 minutes triethyl amine was added. Upon stirring for 18 h the reaction was diluted with 10 mL EtOAc and washed with 10 mL 10% aqueous citric acid followed by 5 mL saturated NaHCO3 The aqueous layer was then back extracted 2×10 mL DCM. The organic layers were combined and the mixture was concentrated down and purified by silica gel chromatography (DCM/MeOH gradient) to yield 35 mg (29% yield) of the product as a white solid. 1H NMR (501 MHz, CDCl3) δ 8.68 (s, 1H), 8.05 (s, 1H), 7.70 (s, 1H), 7.36 (d, J=7.3, 2H), 7.28 (d, J=8.6, 2H), 6.50 (s, 1H), 4.85-4.73 (m, 2H), 4.68 (s, 1H), 4.59 (s, 1H), 4.40 (d, J=32.4, 2H), 3.84 (d, J=10.7, 1H), 3.70 (d, J=10.5, 1H), 2.51 (s, 3H), 2.30 (s, 1H), 2.21 (s, 1H), 1.85 (s, 3H), 1.59 (s, 1H), 1.50 (s, 2H), 1.34 (d, J=6.7, 3H), 0.86 (t, J=6.7, 6H); 13C NMR (126 MHz, CDCl3) δ 172.1, 172.0, 171.2, 170.8, 150.4, 148.4, 138.1, 129.5, 129.4, 127.8, 110.0, 70.36, 58.9, 55.5, 51.8, 46.9, 43.1, 41.8, 36.9, 24.7, 23.2, 23.1, 21.8, 17.9, 16.0; LRMS (ESI) 545.1 (M+H)+.
    • VL252 (2S,4R)-1-((S)-2-((S)-2-amino-4-methylpentanamido)propanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00598
  • Boc-Ala-Hyp-benzyl thiazole (116 mg, 0.225 mmol) was dissolved in 1 mL DCM and charged with 2.3 mL 4M HCL in dioxanes. Upon stirring for one hour Nitrogen gas was sparged through the mixture for 15 minutes and the remaining volatiles removed by roto vap. The resultant foam was then dissolved in 5 mL 1:1 DCM: DMF and charged with EDC (56 mg, 0.29 mmol), HOBt (45 mg, 0.29 mmol), and Boc-Leu-OH (62 mg, 0.25 mmol) were added. After stirring for 5 minutes triethyl amine was added. Upon stirring for 18 h the reaction was diluted with 10 mL EtOAc and washed with 10 mL 10% aqueous citric acid followed by 5 mL saturated NaHCO3. The organic layers were combined and the mixture was concentrated to yield 55 mg (40% yield) of the product as a white solid. LRMS (ESI) 602.0 (M+H)+. Upon confirmation by mass spec the product was dissolved in 2 mL 1:1 DCM:MeOH and charged with 3 mL 4M HCl in dioxanes. Upon stirring for 45 minutes the reaction was quenched with 5 ml 0.5 N ammonia in methanol. The solvents were evaporated down and purified by silica gel chromatography (gradient of DCM/MeOH (0.5 N NH3) to yield 50 mg of pure product as a white solid. 1H NMR (501 MHz, CDCl3) δ 8.25 (s, 1H), 6.91 (dd, J=7.3, 18.0, 4H), 4.17 (d, J=7.5, 2H), 4.06 (d, J=22.4, 2H), 3.95 (d, J=15.3, 1H), 3.56-3.42 (m, 2H), 3.24 (d, J=7.8, 1H), 2.05 (s, 3H), 1.86-1.77 (m, 1H), 1.77-1.65 (m, 1H), 1.35-1.19 (m, 2H), 1.13 (s, 1H), 0.93 (d, J=6.8, 3H), 0.50 (dd, J=6.3, 9.8, 6H); 13C NMR (126 MHz, CDCl3) δ 171.6, 171.5, 150.3, 147.7, 137.9, 131.4, 130.1, 129.0, 127.3, 109.9, 69.7, 58.6, 55.11, 46.9, 42.5, 36.7, 24.1, 22.4, 22.2, 16.2, 15.3; LRMS (ESI) 502.0 (M+H)+.
  • Figure US20190127359A1-20190502-C00599
    Figure US20190127359A1-20190502-C00600
    Figure US20190127359A1-20190502-C00601
    • Examples for Compounds of FIG. 15
  • The following procedures were used to synthesize and/or characterize compounds according to the present invention as indicated
    • LCMS Method:
  • The analysis was conducted on an Acquity UPLC BEH C18 column (50 mm×2.1 mm internal diameter 1.7 μm packing diameter) at 40° C.
  • The solvents employed were:
  • A=0.1% v/v solution of formic acid in water.
    B=0.1% v/v solution of formic acid in acetonitrile.
  • The gradient employed was as follows:
  • Time Flow Rate
    (minutes) (mL/min) % A % B
    0 1 97 3
    1.5 1 0 100
    1.9 1 0 100
    2.0 1 97 3
  • The UV detection was an averaged signal from wavelength of 210 nm to 350 nm and mass spectra were recorded on a mass spectrometer using alternate-scan positive and negative mode electrospray ionization.
  • The following illustrates the mobile phases and gradients used when compounds underwent purification by mass-directed autopreparative HPLC.
  • Mass-Directed Autopreparative HPLC (Formic Acid Modifier)
  • The HPLC analysis was conducted on a Sunfire C18 column (150 mm×30 mm internal diameter, 5 m packing diameter) at ambient temperature.
  • The solvents employed were:
  • A=0.1% v/v solution of formic acid in water.
    B=0.1% v/v solution of formic acid in acetonitrile.
  • Mass-Directed Autopreparative HPLC (Trifluoroacetic Acid Modifier)
  • The HPLC analysis was conducted on a Sunfire C18 column (150 mm×30 mm internal diameter, 5 m packing diameter) at ambient temperature.
  • The solvents employed were:
  • A=0.1% v/v solution of trifluoroacetic acid in water.
    B=0.1% v/v solution of trifluoroacetic acid in acetonitrile.
  • Mass-Directed Autopreparative HPLC (Ammonium Bicarbonate Modifier) The HPLC analysis was conducted on an XBridge C18 column (150 mm×30 mm internal diameter, 5 m packing diameter) at ambient temperature.
  • The solvents employed were:
  • A=10 mM ammonium bicarbonate in water adjusted to pH 10 with ammonia solution.
    B=acetonitrile.
  • For each of the mass-directed autopreparative purifications, irrespective of the modifier used, the gradient employed was dependent upon the retention time of the particular compound undergoing purification as recorded in the analytical LCMS, and was as follows:
  • For compounds with an analytical LCMS retention time below 0.6 minutes the following gradient was used:
  • Time Flow Rate
    (minutes) (mL/min) % A % B
    0 40 99 1
    1 40 99 1
    10 40 70 30
    11 40 1 99
    15 40 1 99
  • For compounds with an analytical LCMS retention time between 0.6 and 0.9 minutes the following gradient was used:
  • Time Flow Rate
    (minutes) (mL/min) % A % B
    0 40 85 15
    1 40 85 15
    10 40 45 55
    11 40 1 99
    15 40 1 99
  • For compounds with an analytical LCMS retention time between 0.9 and 1.2 minutes the following gradient was used:
  • Time Flow Rate
    (minutes) (mL/min) % A % B
    0 40 70 30
    1 40 70 30
    10 40 15 85
    11 40 1 99
    15 40 1 99
  • For compounds with an analytical LCMS retention time between 1.2 and 1.4 minutes the following gradient was used:
  • Time Flow Rate
    (minutes) (mL/min) % A % B
    0 40 50 50
    1 40 50 50
    10 40 1 99
    11 40 1 99
    15 40 1 99
  • The UV detection was an averaged signal from wavelength of 210 nm to 350 nm and mass spectra were recorded on a mass spectrometer using alternate-scan positive and negative mode electrospray ionization.
  • The chemical names were generated using ACD Name Pro version 6.02 from Advanced Chemistry Development, Inc.
    • EXAMPLES (2S,4R)-1-(2-ethoxybenzoyl)-4-hydroxy-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00602
  • A solution of 2-ethoxybenzoic acid (commercially available from for example Aldrich) (29 mg, 0.17 mmol), (2S,4R)-4-hydroxy-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide (50 mg, 0.17 mmol) and DIPEA (0.061 mL, 0.35 mmol) in DMF (1 mL) was treated with HATU (80 mg, 0.21 mmol) and the mixture was stirred at ambient temperature for 2 hours. The product was then subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (38 mg, 0.087 mmol, 50% yield). LCMS RT=0.72 min, ES+ve m/z 436 [M+H]+.
  • Using a method analogous to that for (2S,4R)-1-(2-ethoxybenzoyl)-4-hydroxy-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide, the following compounds were prepared:
  • Name Structure Yield RT [M + H]+
    (2S,4R)-1-benzoyl-4-hydroxy- N-(4-(oxazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00603
         		82% 0.65 min 392
    (2S,4R)-4-hydroxy-1-(3- methoxybenzoyl)-N-(4- (oxazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00604
         		66% 0.67 min 422
    (2S,4R)-1-(3-ethoxybenzoyl)- 4-hydroxy-N-(4-(-oxazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00605
         		54% 0.72 min 436
    (2S,4R)-1-(4-ethoxybenzoyl)- 4-hydroxy-N-(4-(oxazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00606
         		46% 0.71 min 436
    (2S,4R)-1-(3-cyanobenzoyl)- 4-hydroxy-N-(4-(oxazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00607
         		57% 0.64 min 417
    (2S,4R)-4-hydroxy-1-(3- isopropoxybenzoyl)-N-(4- (oxazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00608
         		53% 0.78 min 450
    (2S,4R)-1-(3-acetylbenzoyl)- 4-hydroxy-N-(4-(oxazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00609
         		47% 0.63 min 434
    (2S,4R)-4-hydroxy-1-(3- morpholinobenzoyl)-N-(4- (oxazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00610
         		63% 0.66 min 477
    (2S,4R)-4-hydroxy-1-(3- isopropylbenzoyl)-N-(4- (oxazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00611
         		69% 0.82 min 434
    (2S,4R)-1-(3-chlorobenzoyl)- 4-hydroxy-N-(4-(oxazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00612
         		65% 0.73 min 426
    (2S,4R)-1-(3-bromobenzoyl)- 4-hydroxy-N-(4-(oxazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00613
         		66% 0.75 min 470, 472
    (2S,4R)-1-(3-ethylbenzoyl)-4- hydroxy-N-(4-(oxazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00614
         		55% 0.77 min 420
    (2S,4R)-1-(3,5- diethoxybenzoyl)-4-hydroxy- N-(4-(oxazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00615
         		65% 0.81 min 480
    (2S,4R)-4-hydroxy-N-(4- (oxazol-5-yl)benzyl)-1-(3- propoxybenzoyl)pyrrolidine- 2-carboxamide
    Figure US20190127359A1-20190502-C00616
         		52% 0.80 min 450
    • (S)-1-((2S,4R)-4-hydroxy-2-((4-(oxazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-1-oxopropan-2-yl acetate and (2S,4R)-4-hydroxy-1-((S)-2-hydroxypropanoyl)-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00617
  • A stirred mixture of (2S,4R)-4-hydroxy-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (60 mg, 0.19 mmol) and (S)-2-acetoxypropanoic acid (commercially available from for example Aldrich) (25 mg, 0.19 mmol) in DMF (1.2 mL) was treated with DIPEA (0.13 mL, 0.74 mmol) and then with HATU (85 mg, 0.22 mmol) and the mixture was stirred at ambient temperature for 30 minutes. Half of the reaction mixture was then subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford (S)-1-((2 S,4R)-4-hydroxy-2-((4-(oxazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-1-oxopropan-2-yl acetate (21 mg, 0.052 mmol, 28% yield). LCMS RT=0.58 min, ES+ve m/z 402 [M+H]+.
  • The remaining half of the reaction mixture was treated with ammonia (2M solution in methanol) (2 mL), sealed and allowed to stand for 1 day. The solution was then evaporated to dryness and the product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford (2S,4R)-4-hydroxy-1-((S)-2-hydroxypropanoyl)-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide (18 mg, 0.050 mmol, 27% yield). LCMS RT=0.53 min, ES+ve m/z 360 [M+H]+.
    • (2S,4R)-benzyl 4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylate
  • Figure US20190127359A1-20190502-C00618
  • An ice-cooled mixture of 2-(3-methylisoxazol-5-yl)acetic acid (commercially available from for example Aldrich) (0.91 g, 6.4 mmol) and (2S,4R)-benzyl 4-hydroxypyrrolidine-2-carboxylate, hydrochloride (1.67 g, 6.5 mmol) in DMF (9 mL) was treated with DIPEA (3.4 mL, 19 mmol) and then with HATU (2.56 g, 6.7 mmol) over 20 minutes. The mixture was stirred with cooling for 30 minutes and then overnight at ambient temperature. The mixture was then treated with saturated aqueous sodium bicarbonate (50 mL), extracted with dichloromethane (4×60 mL) and the combined organic phase was filtered through a hydrophobic frit and evaporated to dryness. The product was purified by flash chromatography (100 g cartridge) using a gradient elution from 0% to 15% methanol in dichloromethane to afford the title compound (2.3 g, 6.7 mmol, quantitative). LCMS RT=0.75 min, ES+ve m/z 345 [M+H]+.
    • (2S,4R)—N-((3,4-dihydro-2H-benzo [b][1,4]oxazin-2-yl)methyl)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00619
  • A solution of (2S,4R)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylic acid (90 mg, 0.35 mmol), (3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methanamine (commercially available from for example Fluorochem) (58 mg, 0.35 mmol) and DIPEA (0.155 mL, 0.89 mmol) in DMF (2 mL) was treated with HATU (139 mg, 0.37 mmol) and stirred for 1 hour. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (84 mg, 0.21 mmol, 60% yield) LCMS RT=0.61 min, ES+ve m/z 401 [M+H]+.
    • (2S,4R)—N-(4-chlorobenzyl)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00620
  • A solution of (4-chlorophenyl)methanamine (commercially available from for example Aldrich) (0.021 mL, 0.17 mmol) and (2S,4R)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylic acid (40 mg, 0.16 mmol) in DMF (1 mL) was treated with DIPEA (0.082 mL, 0.47 mmol) then with HATU (66 mg, 0.17 mmol) and the mixture was stirred at ambient temperature for 2 hours. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (24 mg, 0.064 mmol, 40% yield). LCMS RT=0.73 min, ES+ve m/z 378 [M+H]+.
    • (2S,4R)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)-N-(4-(2-oxo-2,3-dihydrobenzo [d]oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00621
  • A mixture of (2S,4R)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylic acid (60 mg, 0.24 mmol) and 5-(4-(aminomethyl)phenyl)benzo[d]oxazol-2(3H)-one, hydrochloride (65 mg, 0.24 mmol) in DMF (1.6 mL) was treated with DIPEA (0.124 mL, 0.71 mmol) and HATU (99 mg, 0.26 mmol) and the mixture was stirred for 30 minutes. The product was then subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (64 mg, 0.13 mmol, 57% yield). LCMS RT=0.70 min, ES+ve m/z 477 [M+H]+.
    • (2S,4R)—N-(1-(benzofuran-2-yl)ethyl)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00622
  • A stirred solution of (2S,4R)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylic acid (90 mg, 0.35 mmol), 1-(benzofuran-2-yl)ethanamine (commercially available from for example Enamine) (57 mg, 0.35 mmol) and DIPEA (0.155 mL, 0.89 mmol) in DMF (2 mL) was treated with HATU (139 mg, 0.37 mmol). After 1 hour the product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (91 mg, 0.21 mmol, 65% yield) LCMS RT=0.79 min, ES+ve m/z 398 [M+H]+.
    • (2S,4R)—N-([1,1′-biphenyl]-4-ylmethyl)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00623
  • A stirred mixture of (2S,4R)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylic acid (30 mg, 0.12 mmol) and [1,1′-biphenyl]-4-ylmethanamine (commercially available from for example Aldrich) (22 mg, 0.12 mmol) in DMF (0.8 mL) was treated with DIPEA (0.08 mL, 0.47 mmol) and then with HATU (49 mg, 0.13 mmol) and the mixture was stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (40 mg, 81% yield). LCMS RT=0.86 min, ES+ve m/z 420 [M+H]+.
  • Using a method analogous to that for (2S,4R)—N-([1,1′-biphenyl]-4-ylmethyl)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxamide the following compounds were prepared:
  • Name Structure Yield RT [M + H]+
    (2S,4R)-N- benzyl-4- hydroxy-1-(2-(3- methylisoxazol-5- yl)acetyl)pyrrolidine- 2-carboxamide
    Figure US20190127359A1-20190502-C00624
         		61% 0.62 min 344
    (2S,4R)-4- hydroxy-N-((1- methyl-1H- pyrazol-3- yl)methyl)-1-(2- (3- methylisoxazol-5- yl)acetyl)pyrrolidine- 2-carboxamide
    Figure US20190127359A1-20190502-C00625
         		75% 0.40 min 348
    (2S,4R)-4- hydroxy-1-(2-(3- methylisoxazol-5- yl)acetyl)-N-((6- phenylpyridin-3- yl)methyl)pyrro- lidine-2- carboxamide
    Figure US20190127359A1-20190502-C00626
         		41% 0.57 min 421
    (2S,4R)-4- hydroxy-1-(2-(3- methylisoxazol-5- yl)acetyl)-N-((2- oxo-2,3-dihydro- 1H- benzo[d]imidazol- 5- yl)methyl)pyrro- lidine-2- carboxamide
    Figure US20190127359A1-20190502-C00627
         		24% 0.42 min 400
    (2S,4R)-4- hydroxy-1-(2-(3- methylisoxazol-5- yl)acetyl)-N- (quinolin-7- ylmethyl)pyrrolidine- 2-carboxamide
    Figure US20190127359A1-20190502-C00628
         		19% 0.39 min 395
    (2S,4R)-4- hydroxy-1-(2-(3- methylisoxazol-5- yl)acetyl)-N-((4- phenylthiazol-2- yl)methyl)pyrro- lidine-2- carboxamide
    Figure US20190127359A1-20190502-C00629
         		34% 0.72 min 427
    (2S,4R)-4- hydroxy-1-(2-(3- methylisoxazol-5- yl)acetyl)-N-((1- phenylpyrrolidin- 3- yl)methyl)pyrro- lidine-2- carboxamide
    Figure US20190127359A1-20190502-C00630
         		35 0.72 min 413
    (2S,4R)-4- hydroxy-1-(2-(3- methylisoxazol-5- yl)acetyl)-N-((5- phenyl-1,2,4- oxadiazol-3- yl)methyl)pyrro- lidine-2- carboxamide
    Figure US20190127359A1-20190502-C00631
         		31% 0.67 min 412
    (2S,4R)-4- hydroxy-1-(2-(3- methylisoxazol-5- yl)acetyl)-N-((3- (p-tolyl)isoxazol- 5- yl)methyl)pyrro- lidine-2- carboxamide
    Figure US20190127359A1-20190502-C00632
         		56% 0.78 min 426
    (2S,4R)-N-((S)-1- (4- chlorophenyl)eth- yl)-4-hydroxy-1- (2-(3- methylisoxazol-5- yl)acetyl)pyrrolidine- 2-carboxamide
    Figure US20190127359A1-20190502-C00633
         		58% 0.78 min 392
    (2S,4R)-N-((3-(4- chlorophenyl)- 1,2,4-oxadiazol-5- yl)methyl)-4- hydroxy-1-(2-(3- methylisoxazol-5- yl)acetyl)pyrrolidine- 2-carboxamide
    Figure US20190127359A1-20190502-C00634
         		57% 0.81 min 446
    (2S,4R)-4- hydroxy-1-(2-(3- methylisoxazol-5- yl)acetyl)-N-((5- phenylisoxazol-3- yl)methyl)pyrro- lidine-2- carboxamide
    Figure US20190127359A1-20190502-C00635
         		66% 0.72 min 411
    (2S,4R)-4- hydroxy-1-(2-(3- methylisoxazol-5- yl)acetyl)-N-(4- (pyrrolidin-1- yl)benzyl)pyrro- lidine-2- carboxamide
    Figure US20190127359A1-20190502-C00636
         		43% 0.60 min 413
    • (2S,4R)-1-((S)-2-acetamidopropanoyl)-4-hydroxy-N-phenethylpyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00637
  • A stirred mixture of (2S,4R)-1-((S)-2-acetamidopropanoyl)-4-hydroxypyrrolidine-2-carboxylic acid (24 mg, 0.10 mmol) and 2-phenylethanamine (commercially available from for example Aldrich) (0.012 mL, 0.10 mmol) in DMF (0.8 mL) was treated with DIPEA (0.07 mL, 0.39 mmol) and then with HATU (45 mg, 0.12 mmol), and the mixture was stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (25 mg, 72% yield). LCMS RT=0.56 min, ES+ve m/z 348 [M+H]+.
  • Using a method analogous to that for (2S,4R)-1-((S)-2-acetamidopropanoyl)-4-hydroxy-N-phenethylpyrrolidine-2-carboxamide the following compounds were prepared:
  • [M +
    Name Structure Yield RT H]+
    (2S,4R)-1-((S)-2- acetamidopropanoyl)-4-hydroxy- N-((6-phenylpyridin-3- yl)methyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00638
         		10% 0.49 min 411
    (2S,4R)-N-([1,1′-biphenyl]-4- ylmethyl)-1-((S)-2- acetamidopropanoyl)-4- hydroxypyrrolidine-2-carboxamide
    Figure US20190127359A1-20190502-C00639
         		40% 0.79 min 411
    (2S,4R)-1-((S)-2- acetamidopropanoyl)-N-benzyl-4- hydroxypyrrolidine-2-carboxamide
    Figure US20190127359A1-20190502-C00640
         		12% 0.51 min 334
    (2S,4R)-1-((S)-2- acetamidopropanoyl)-4-hydroxy- N-((3-(p-tolyl)isoxazol-5- yl)methyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00641
         		70% 0.70 min 415
    (2S,4R)-1-((S)-2- acetamidopropanoyl)-N-cinnamyl- 4-hydroxypyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00642
         		50% 0.64 min 360
    (2S,4R)-1-((S)-2- acetamidopropanoyl)-N-(2- (benzyl(methyl)amino)-2- oxoethyl)-4-hydroxypyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00643
         		27% 0.56 min 405
    (2S,4R)-1-((S)-2- acetamidopropanoyl)-4-hydroxy- N-(2-((3- methoxybenzyl)(methyl)amino)-2- oxoethyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00644
         		28% 0.58 min 435
    (2S,4R)-1-((S)-2- acetamidopropanoyl)-4-hydroxy- N-((1S,2R)-2- phenylcyclopropyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00645
         		44% 0.62 min 360
    (2S,4R)-1-((S)-2- acetamidopropanoyl)-N-((R)-1- benzyl-2-oxopyrrolidin-3-yl)-4- hydroxypyrrolidine-2-carboxamide
    Figure US20190127359A1-20190502-C00646
         		76% 0.58 min 417
    • (S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-1-oxopropan-2-yl acetate & (2S,4R)-1-acetyl-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00647
  • An ice-cooled mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (31 mg, 0.088 mmol) and (S)-2-acetoxypropanoic acid (commercially available from for example Aldrich) (8 μL, 0.09 mmol) in DMF (0.8 mL) was treated with DIPEA (0.074 mL, 0.42 mmol). HATU (34 mg, 0.088 mmol) was then added portion-wise over 10 minutes and the mixture was stirred at ambient temperature for 1 hour. The products were separated and purified by mass-directed automated preparative HPLC (formic acid modifier) to afford (S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-1-oxopropan-2-yl acetate (15 mg, 0.035 mmol, 41% yield) LCMS RT=0.64 min, ES+ve m/z 432 [M+H]+ and (2S,4R)-1-acetyl-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (9 mg, 0.025 mmol, 30% yield) LCMS RT=0.57 min, ES+ve m/z 360 [M+H]+.
    • (2S,4R)-1-(2-(cyanomethyl)benzoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00648
  • A stirred mixture of (2S,4R)-4-hydroxy-N-(4-(thiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (50 mg, 0.17 mmol) and 2-(cyanomethyl)benzoic acid (commercially available from for example Aldrich) (29 mg, 0.18 mmol) in DMF (0.7 mL) was treated with DIPEA (0.086 mL, 0.49 mmol) and then with HATU (69 mg, 0.18 mmol) and the mixture was stirred at ambient temperature for 10 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (31 mg, 0.067 mmol, 41% yield). LCMS RT=0.73 min, ES+ve m/z 461 [M+H]+.
  • Using a method analogous to that for (2S,4R)-1-(2-(cyanomethyl)benzoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide the following compounds were prepared:
  • Stereo-
    chemistry [M +
    Name Structure Comment Yield RT H]+
    (2S,4R)-4-hydroxy-1-(2-(2- methoxyethoxy)acetyl)-N-(4- (4-methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00649
         		59% 0.57 min 434
    (2S,4R)-1-((S)-2- acetamidopropanoyl)-4- hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00650
         		71% 0.56 min 431
    (2S,4R)-1-((S)-1- acetylpyrrolidine-2-carbonyl)- 4-hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00651
         		57% 0.54 min 457
    (2S,4R)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)-1- ((S)-5-oxopyrrolidine-2- carbonyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00652
         		58% 0.53 min 429
    (2S,4R)-1- (cyclohexanecarbonyl)-4- hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00653
         		61% 0.76 min 428
    (2S,4R)-1-(4-ethoxybenzoyl)- 4-hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00654
         		73% 0.78 min 466
    (2S,4R)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)-1- (5-oxopyrrolidine-3- carbonyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00655
         		85% 0.53 min 429
    (2S,4R)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)-1- (2- morpholinoacetyl)pyrrolidine- 2-carboxamide
    Figure US20190127359A1-20190502-C00656
         		40% 0.48 min 445
    (2S,4R)-4-hydroxy-1-(2- methoxyacetyl)-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00657
         		68% 0.55 min 390
    (2S,4R)-4-hydroxy-1-((S)-2- methoxypropanoyl)-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00658
         		69% 0.57 min 404
    (2S,4R)-4-hydroxy-1-(3- methoxybenzoyl)-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00659
         		67% 0.71 min 452
    (2S,4R)-4-hydroxy-1-(2- methylbenzoyl)-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00660
         		77% 0.74 min 436
    (2S,4R)-4-hydroxy-1-(3- methoxy-2-methylbenzoyl)-N- (4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00661
         		61% 0.76 min 466
    (2S,4R)-1-(3-chloro-5- methoxybenzoyl)-4-hydroxy- N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00662
         		69% 0.80 min 486
    (2S,4R)-4-hydroxy-1-(3- hydroxy-2-methylbenzoyl)-N- (4-(4-methyithiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00663
         		84% 0.64 min 452
    (2S,4R)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)-1- (2-(3- oxomorpholino)propanoyl) pyrrolidine-2-carboxamide
    Figure US20190127359A1-20190502-C00664
         		Single enantiomer, stereo- chemistry unknown at the unspecified chiral centre, eluted first during HPLC purification (formic acid modifier) 32% 0.59 min 473
    (2S,4R)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)-1- ((S)-2-(1-oxoisoindolin-2- yl)pentanoyl)pyrrolidine-2- carboxaniide
    Figure US20190127359A1-20190502-C00665
         		69% 0.84 min 533
    (2S,4R)-4-hydroxy-1-(2-(6- methoxy-1-oxoisoindolin-2- yl)-3-methylbutanoyl)-N-(4- (4-methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00666
         		Single enantiomer, stereo- chemistry unknown at the unspecified chiral centre, eluted first during HPLC purification (formic acid modifier) 35% 0.84 min 563
    (2S,4R)-4-hydroxy-1-(2-(6- methoxy-1-oxoisoindolin-2- yl)-3-methylbutanoyl)-N-(4- (4-methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00667
         		Single enantiomer, stereo- chemistry unknown at the unspecified chiral centre, eluted first during HPLC purification (formic acid modifier) 34% 0.85 min 563
    (2S,4R)-4-hydroxy-1-(2-(5- methoxy-1-oxoisoindolin-2- yl)-3-methylbutanoyl)-N-(4- (4-methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00668
         		Single enantiomer, stereo- chemistry unknown at the unspecified chiral centre, eluted first during HPLC purification (formic acid modifier) 28% 0.84 min 536
    (2S,4R)-1-(2-(7-chloro-1- oxoisoindolin-2-yl)-3- methylbutanoyl)-4-hydroxy- N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00669
         		Single enantiomer, stereo- chemistry unknown at the unspecified chiral centre, eluted first during HPLC purification (formic acid modifier) 35% 0.93 min 567, 569
    (2S,4R)-1-((S)-2-acetamido-4- methylpentanoyl)-4-hydroxy- N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00670
         		71% 0.71 min 473
    (2S,4R)-1-((S)-2-acetamido-3- phenylpropanoyl)-4-hydroxy- N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00671
         		77% 0.75 min 507
    (2S,4R)-4-hydroxy-1-((S)-3- methyl-2-(3-methyl-2,5-dioxo- 2,5-dihydro-1H-pyrrol-1- yl)butanoyl)-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00672
         		17% 0.80 min 511
    (2S,4R)-1-benzoyl-4-hydroxy- N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00673
         		57% 0.69 min 422
    (2S,4R)-1-(3- (cyanomethyl)benzoyl)-4- hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00674
         		74% 0.68 min 461
    (2S,4R)-1-(1-(cyanomethyl)- 1H-indole-2-carbonyl)-4- hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00675
         		62% 0.82 min 500
    (2S,4R)-1-(4- ethoxycyclohexanecarbonyl)- 4-hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00676
         		74% 0.74 min 472
    (2S,4R)-1-(2- cyclopentylpropanoyl)-4- hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00677
         		Mixture of diastereo- isomers 67% 0.82 min 442
    (2S,4R)-4-hvdroxy-N-(4-(4- methylthiazol-5-yl)benzyl)-1- (2- morpholinopropanoyl) pyrrolidine-2-carboxamide
    Figure US20190127359A1-20190502-C00678
         		Mixture of diastereo- isomers 53% 0.68 min 459
    (2S,4R)-4-hydroxy-1- (indoline-2-carbonyl)-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00679
         		Single enantiomer, stereo- chemistry unknown at the undefined chiral centre, eluted first during 64% 0.70 min 463
    HPLC
    purification
    (formic acid
    modifier)
    (2S,4R)-1-(2-(4-chloro-1H- pyrazol-1-yl)propanoyl)-4- hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00680
         		Single enantiomer, stereo- chemistry unknown at the undefined chiral centre, eluted first during HPLC 39% 0.74 min 474
    purification
    (formic acid
    modifier)
    (2S,4R)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)-1- (2-(1-oxoisoindolin-2- yl)propanoyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00681
         		Mixture of diastereo- isomers 51% 0.73 min 505
    (2S,4R)-1-(2-(3- (difluoromethyl)-5-methyl- 1H-pyrazol-1-yl)propanoyl)- hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00682
         		Single enantiomer, stereo- chemistry unknown at the undefined chiral centre, eluted first during HPLC purification 31% 0.76 min 504
    (formic acid
    modifier)
    (2S,4R)-4-hydroxy-1-(1H- indole-2-carbonyl)-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00683
         		65% 0.78 min 461
    (2S,4R)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)-1- (2-(pyrazolo[1,5-a]pyridin-3- yl)acetyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00684
         		51% 0.65 min 476
    (2S,4R)-1-(2- cyclohexylpropanoyl)-4- hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00685
         		Mixture of diastereo- isomers 68% 0.87 min 456
    (2S,4R)-1-(2-((4- fluorophenyl)amino)propanoyl)- 4-hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00686
         		Mixture of diastereo- isomers 41% 0.77 min 483
    (2S,4R)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)-1- (2-(1-oxoisoindolin-2- yl)acetyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00687
         		49% 0.69 min 491
    (2S,4R)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)-1- (2-(pyrazolo[1,5-a]pyridin-3- yl)propanoyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00688
         		Mixture of diastereo- isomers 61% 0.70 min 490
    (2S,4R)-1-(2-(3- cyanophenyl)propanoyl)-4- hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00689
         		Mixture of diastereo- isomers 54% 0.77 min 475
    (2S,4R)-4-hydroxy-1-(2- methyl-4-oxo-4- phenylbutanoyl)-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00690
         		Single enantiomer, stereo- chemistry unknown at the undefined chiral centre, eluted first during HPLC 35% 0.80 min 492
    purification
    (formic acid
    modifier)
    (2S,4R)-4-hydroxy-1-(2- methyl-4-oxo-4- phenylbutanoyl)-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00691
         		Single enantiomer, stereo- chemistry unknown at the undefined chiral centre, eluted first during 26% 0.82 min 492
    HPLC
    purification
    (formic acid
    modifier)
    (2S,4R)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)-1- (2- phenylpropanoyl)pyrrolidine- 2-carboxamide
    Figure US20190127359A1-20190502-C00692
         		Single enantiomer, stereo- chemistry unknown at the undefined chiral centre, eluted first during HPLC purification 44% 0.78 min 450
    (formic acid
    modifier)
    (2S,4R)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)-1- (2- phenylpropanoyl)pvrrolidine- 2-carboxamide
    Figure US20190127359A1-20190502-C00693
         		Single enantiomer, stereo- chemistry unknown at the undefined chiral centre, eluted first during HPLC purification (formic acid modifier) 41% 0.80 min 450
    (2S,4R)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)-1- (2-(2-oxopyridin-1(2H)- yl)propanoyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00694
         		Single enantiomer, stereo- chemistry unknown at the undefined chiral centre, eluted first during HPLC purification 33% 0.62 min 467
    (formic acid
    modifier)
    (2S,4R)-4-hydroxy-1-(2- (indolin-1-yl)propanoyl)-N-(4- (4-methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00695
         		Single enantiomer, stereo- chemistry unknown at the undefined chiral centre, eluted first during HPLC 35% 0.86 min 491
    purification
    (formic acid
    modifier)
    (2S,4R)-4-hydroxy-1-(2- (indolin-1-yl)propanoyl)-N-(4- (4-methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00696
         		Single enantiomer, stereo- chemistry unknown at the undefined chiral centre, eluted first during HPLC 40% 0.88 min 491
    purification
    (formic acid
    modifier)
    (2S,4R)-4-hydroxy-1-(2- methyl-3- morpholinopropanoyl)-N-(4- (4-methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00697
         		Mixture of diastereo- isomers 57% 0.52 min 472
    (2S,4R)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)-1- (pyrazolo[1,5-a]pyridine-2- carbonyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00698
         		64% 0.68 min 463
    (2S,4R)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)-1- (2-(4-oxoquinazolin-3(4H)- yl)propanoyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00699
         		Mixture of diastereo- isomers 49% 0.71 min 518
    (2S,4R)-1-(2-(2,5- dioxopyrrolidin-1- yl)propanoyl)-4-hydroxy-N- (4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00700
         		Single enantiomer, stereo- chemistry unknown at the undefined chiral centre, eluted first during HPLC purification 27% 0.60 min 472
    (formic acid
    modifier)
    (2S,4R)-1-(2-(1H-tetrazol-1- yl)acetyl)-4-hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00701
         		73% 0.58 min 428
    (2S,4R)-1-(2-(1H-1,2,4- triazol-1-yl)propanoyl)-4- hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00702
         		Single enantiomer, stereo- chemistry unknown at the undefined chiral centre, eluted first during HPLC 35% 0.58 min 441
    purification
    (formic acid
    modifier)
    (2S,4R)-4-hydroxy-1-(2- methyl-3-(1H-1,2,4-triazol-1- yl)propanoyl)-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00703
         		Mixture of diastereo- isomers 53% 0.60 min 455
    (2S,4R)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)-1- ((S)-2-(1-oxoisoindolin-2- yl)propanoyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00704
         		Single enantiomer 65% 0.74 min 505
    (2S,4R)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)-1- ((S)-2-(1-oxoisoindolin-2- yl)propanoyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00705
         		Single enantiomer 80% 0.76 min 549
    (2S,4R)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)-1- ((S)-2-(1-oxoisoindolin-2- yl)butanoyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00706
         		Single enantiomer 57% 0.67 min 519
    (2S,4R)-1-((S)-2-cyclopropyl- 2-(1-oxoisoindolin-2- yl)acetyl)-4-hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00707
         		Single enantiomer 62% 0.80 min 531
    (2S,4R)-4-hydroxy-1-((S)-3- methyl-2-(1-oxoisoindolin-2- yl)butanoyl)-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00708
         		Single enantiomer 58% 0.83 min 533
    (2S,4R)-1-((S)-3,3-dimethyl- 2-(1-oxoisoindolin-2- yl)butanoyl)-4-hydroxy-N-(4- (4-methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00709
         		Single enantiomer 52% 0.91 min 547
    • 3-(2-(2-(2-(3-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)phenoxy)ethoxy)ethoxy)ethoxy)propanoic acid
  • Figure US20190127359A1-20190502-C00710
  • An ice-cooled mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (682 mg, 2.2 mmol), 3-((14,14-dimethyl-12-oxo-3,6,9,13-tetraoxapentadecyl)oxy)benzoic acid (778 mg, 2.0 mmol), DIPEA (1.36 mL, 7.8 mmol) in DMF (12 mL) was treated with HATU (817 mg, 2.2 mmol). The mixture was allowed to warm to ambient temperature and stirred for 30 minutes then treated with water (70 mL) and extracted with ethyl acetate (3×70 mL). The combined organic phase was washed with saturated aqueous sodium bicarbonate (100 mL), water (100 mL), brine (100 mL), dried over magnesium sulfate, filtered and evaporated to dryness. The crude product was dissolved in dichloromethane (6 mL) and treated with TFA (2.0 mL). After 1 hour, the reaction mixture was evaporated to dryness and the product was purified by flash chromatography (60 g C18 cartridge) using a gradient elution from 10 to 95% acetonitrile (+0.1% formic acid) in water (+0.1% formic acid) to afford the title compound (568 mg, 45% yield). LCMS RT=0.73 min, ES+ve m/z 642 [M+H]+.
    • (2S,4R)-4-hydroxy-1-(3-(2-methoxyethoxy)benzoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00711
  • A mixture of (2 S,4R)-4-hydroxy-1-(3-hydroxybenzoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (55 mg, 0.13 mmol) and potassium carbonate (55 mg, 0.40 mmol) in DMF (0.8 mL) was treated with 1-bromo-2-methoxyethane (commercially available from for example Aldrich) (0.024 mL, 0.25 mmol) and stirred at 50° C. for 2.5 hours. Additional 1-bromo-2-methoxyethane (0.024 mL, 0.25 mmol) was added and the mixture stirred at 50° C. overnight. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (41 mg, 0.083 mmol, 66% yield) LCMS RT=0.74 min, ES+ve m/z 496 [M+H]+
    • (2S,4R)-4-hydroxy-1-(3-(2-(2-methoxyethoxy)ethoxy)benzoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00712
  • A mixture of (2 S,4R)-4-hydroxy-1-(3-hydroxybenzoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (55 mg, 0.13 mmol) and potassium carbonate (55 mg, 0.40 mmol) in DMF (0.8 mL) was treated with 1-bromo-2-(2-methoxyethoxy)ethane (commercially available from for example Aldrich) (0.034 mL, 0.25 mmol) and the reaction stirred at 50° C. for 2.5 hours. Additional 1-bromo-2-(2-methoxyethoxy)ethane (0.034 mL, 0.25 mmol) was added and the mixture stirred at 50° C. overnight. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (40 mg, 0.074 mmol, 59% yield) LCMS RT=0.74 min, ES+ve m/z 540 [M+H]+.
    • (2S,4R)-1-((S)-2-((S)-2-acetamido-4-methylpentanamido)propanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00713
  • A stirred mixture of (2S,4R)-1-((S)-2-aminopropanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (50 mg, 0.12 mmol) and (S)-2-acetamido-4-methylpentanoic acid (commercially available from for example Aldrich) (22 mg, 0.12 mmol) in DMF (0.7 mL) was treated with DIPEA (0.062 mL, 0.35 mmol) and then with HATU (49 mg, 0.13 mmol) and the mixture was stirred at ambient temperature for 10 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (42 mg, 0.077 mmol, 66% yield). LCMS RT=0.68 min, ES+ve m/z 544 [M+H]+.
    • (2S,4R)-1-((S)-2-acetamido-3-methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00714
  • A solution of tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate (120 mg, 0.23 mmol) in dichloromethane (2 mL) and treated with 4 M hydrochloric acid in 1,4-dioxane (1 mL). The mixture was stirred at ambient temperature for 30 minutes and was then evaporated to dryness. The residue was dissolved in DMF (1 mL) and treated with triethylamine (0.08 mL, 0.58 mmol), followed by acetic anhydride (0.02 mL, 0.21 mmol) and the mixture was stirred at ambient temperature for 1 hour. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (53 mg, 49% yield). LCMS RT=0.65 min, ES+ve m/z 460 [M+H]+.
  • Using a method analogous to that for (2S,4R)-1-((S)-2-acetamido-3-methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, the following compounds were prepared:
  • Name Structure Yield RT [M + H]+
    (2S,4R)-1-((S)-1- acetylpiperidine-2- carbonyl)-4-hydroxy-N- (4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00715
         		49% 0.67 min 471
    (2S,4R)-1-((S)-4- acetylmorpholine-3- carbonyl)-4-hydroxy-N- (4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2 carboxamide
    Figure US20190127359A1-20190502-C00716
         		57% 0.59 min 473
    (2S,4R)-1-((S)-2- acetamidobutanoyl)-4- hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00717
         		82% 0.61 min 445
    (2S,4R)-1-((S)-2- acetamido-3,3- dimethylbutanoyl)-4- hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00718
         		68% 0.71 min 473
    (2S,4R)-1-((S)-2- acetamido-2- cyclopropylacetyl)-4- hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00719
         		67% 0.62 min 457
    • (2S,4R)-1-((S)-2-(3-ethoxy-N-methylbenzamido)propanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00720
  • A mixture of (2 S,4R)-4-hydroxy-1-((S)-2-(methyl amino)propanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (20 mg, 0.05 mmol), DIPEA (0.043 mL, 0.25 mmol) and 3-ethoxybenzoic acid (commercially available from for example Aldrich) (8 mg, 0.05 mmol) in DMF (1 mL) was treated with HATU (19 mg, 0.05 mmol) and the mixture was stirred for 20 minutes. The product was purified by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (14 mg, 0.025 mmol, 50% yield). LCMS RT=0.82 min, ES+ve m/z 551 [M+H]+.
    • (2S,4R)-4-hydroxy-1-((S)-2-(3-methoxypropanamido)propanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00721
  • A solution of a mixture of (2S,4R)-1-((S)-2-aminopropanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (107 mg, 0.25 mmol), 3-methoxypropionic acid (commercially available from for example Aldrich) (0.028 mL, 0.30 mmol) and DIPEA (0.2 mL, 1.15 mmol) in dry DMF (3 mL) was treated with HATU (115 mg, 0.30 mmol). The mixture was stirred at ambient temperature for 30 minutes. The mixture was loaded onto a methanol-preconditioned aminopropyl solid-phase extraction cartridge (2 g), which was eluted with methanol (3 column volumes). The resulting eluant was evaporated to dryness and the product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (57 mg, 0.12 mmol, 48% yield). LCMS RT=0.62 min, ES+ve m/z 475 [M+H]+.
    • (2S,4R)-4-hydroxy-1-(2-(3-methoxypropanamido)-2-methylpropanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00722
  • A solution of a mixture of (2S,4R)-1-(2-amino-2-methylpropanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (95 mg, 0.24 mmol), 3-methoxypropionic acid (0.028 mL, 0.30 mmol) and DIPEA (0.2 mL, 1.15 mmol) in dry DMF (3 mL) was treated with HATU (115 mg, 0.30 mmol) and the mixture was stirred at ambient temperature for 30 minutes. The mixture was loaded onto a methanol-preconditioned aminopropyl solid-phase extraction cartridge (NH2) which was eluted with methanol (3 column volumes). The resulting eluant was evaporated to dryness and the product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (45 mg, 0.09 mmol, 37% yield). LCMS RT=0.68 min, ES+ve m/z 489 [M+H]+.
    • (2S,4R)-4-hydroxy-1-((S)-2-(2-methoxyacetamido)-3-methylbutanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00723
  • A mixture of (2S,4R)-1-((S)-2-amino-3-methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (20 mg, 0.044 mmol), 2-methoxyacetic acid (3 μL, 0.039 mmol) and DIPEA (0.035 mL, 0.20 mmol) in DMF (1 mL) was treated with HATU (18 mg, 0.047 mmol) and stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (14 mg, 0.029 mmol, 73% yield). LCMS RT=0.70 min, ES+ve m/z 489 [M+H]+.
    • (2S,4R)-4-hydroxy-1-((S)-2-(2-methoxy-N-methylacetamido)-3-methylbutanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00724
  • A mixture of (2S,4R)-4-hydroxy-1-((S)-3-methyl-2-(methylamino)butanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (19 mg, 0.041 mmol), 2-methoxyacetic acid (3 μL, 0.039 mmol) and DIPEA (0.035 mL, 0.20 mmol) in DMF (1 mL) was treated with HATU (18 mg, 0.047 mmol) and stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (16 mg, 0.032 mmol, 81% yield).
  • LCMS RT=0.70 min, ES+ve m/z 503 [M+H]+.
    • (2S,4R)-1-((S)-2-(N,3-dimethyloxetane-3-carboxamido)propanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00725
  • A mixture of (2S,4R)-4-hydroxy-1-((S)-2-(methyl amino)propanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (15 mg, 0.037 mmol), DIPEA (0.032 mL, 0.18 mmol) and 3-methyloxetane-3-carboxylic acid (commercially available from for example Fluorochem) (3 μL, 0.037 mmol) in DMF (1 mL) was treated with HATU (14 mg, 0.037 mmol) and the mixture was stirred for 1 hour. The product was purified by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (9 mg, 0.019 mmol, 51% yield). LCMS RT=0.62 min, ES+ve m/z 501 [M+H]+.
    • (2S,4R)-4-hydroxy-1-((S)-2-(3-methyloxetane-3-carboxamido)propanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00726
  • A stirred mixture of (2S,4R)-1-((S)-2-aminopropanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (21 mg, 0.043 mmol), DIPEA (0.043 mL, 0.25 mmol) and 3-methyloxetane-3-carboxylic acid (commercially available from for example Fluorochem) (6 mg, 0.05 mmol) in DMF (2 mL) was treated with HATU (19 mg, 0.05 mmol) and stirred for 30 minutes. The product was purified by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (14 mg, 0.029 mmol, 60% yield). LCMS RT=0.59 min, ES+ve m/z 487 [M+H]+.
    • (2S,4R)-1-((S)-2-(3-ethoxybenzamido)propanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00727
  • A stirred mixture of 3-ethoxybenzoic acid (commercially available from for example Aldrich) (20 mg, 0.12 mmol) and (2S,4R)-1-((S)-2-aminopropanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (56 mg, 0.13 mmol) in DMF (3.2 mL) was treated with DIPEA (0.063 mL, 0.36 mmol) and then with HATU (50 mg, 0.13 mmol) and the mixture was stirred at ambient temperature for 30 minutes. The product was then subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (36 mg, 0.067 mmol, 56% yield). LCMS RT=0.80 min, ES+ve m/z 537 [M+H]+.
    • (2S,4R)—N-((1H-indol-3-yl)methyl)-4-hydroxy-1-((S)-2-(1-oxoisoindolin-2-yl)propanoyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00728
  • A solution of (2S,4R)-4-hydroxy-1-((S)-2-(1-oxoisoindolin-2-yl)propanoyl)pyrrolidine-2-carboxylic acid (10 mg, 0.031 mmol), DIPEA (0.038 mL, 0.22 mmol) and (1H-indol-3-yl)methanamine (commercially available from for example Fluorochem) (6 mg, 0.041 mmol) in DMF (0.8 mL) was treated with HATU (15 mg, 0.039 mmol) and stirred for 1 hour. The product was purified by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (3.1 mg, 6.9 μmol, 22% yield). LCMS RT=0.75 min, ES+ve m/z 447 [M+H]+.
    • (2S,4R)—N—((R)-2,3-dihydrobenzofuran-3-yl)-4-hydroxy-1-((S)-2-(1-oxoisoindolin-2-yl)propanoyl)pyrrolidine-2-carboxamide & (2S,4R)—N—((S)-2,3-dihydrobenzofuran-3-yl)-4-hydroxy-1-((S)-2-(1-oxoisoindolin-2-yl)propanoyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00729
  • A mixture of 2,3-dihydrobenzofuran-3-amine (commercially available from for example Chem-Impex International, Inc.) (13 mg, 0.094 mmol) and (2S,4R)-4-hydroxy-1-((S)-2-(1-oxoisoindolin-2-yl)propanoyl)pyrrolidine-2-carboxylic acid (25 mg, 0.079 mmol) in DMF (0.8 mL) was treated with DIPEA (0.055 mL, 0.31 mmol) and then HATU (33 mg, 0.086 mmol) and the mixture was stirred at ambient temperature for 30 minutes. The product mixture was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compounds: Isomer 1 (first-eluting) (12 mg, 0.027 mmol, 35% yield). LCMS RT=0.73 min, ES+ve m/z 436 [M+H]+. Isomer 2 (second-eluting) (13 mg, 0.030 mmol, 38% yield). LCMS RT=0.74 min, ES+ve m/z 436 [M+H]+.
  • Using a method analogous to that for the two diastereoisomers of (2S,4R)—N-(2,3-dihydrobenzofuran-3-yl)-4-hydroxy-1-((S)-2-(1-oxoisoindolin-2-yl)propanoyl)pyrrolidine-2-carboxamide, the following compounds were prepared:
  • Name Structure Yield RT [M + H]+
    (2S,4R)-N-((S)-1-(4- chlorophenyl)ethyl)-1-(3- ethoxybenzoyl)-4- hydroxypyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00730
         		56% 0.92 min 417
    (2S,4R)-N-benzyl-1-(3- ethoxybenzoyl)-4- hydroxypyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00731
         		64% 0.76 min 369
    (2S,4R)-1-(3- ethoxybenzoyl)-4-hydroxy- N-((S)-2-oxopyrrolidin-3- yl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00732
         		77% 0.50 min 362
    (2S,4R)-1-(3- ethoxybenzoyl)-4-hydroxy- N-((2-methylthiazol-5- yl)methyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00733
         		69% 0.57 min 390
    (2S,4R)-1-(3- ethoxybenzoyl)-4-hydroxy- N-((1-methyl-1H-pyrazol-4- yl)methyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00734
         		70% 0.55 min 375
    (2S,4R)-N-([1,1′-biphenyl]- 4-ylmethyl)-1-(3- ethoxybenzoyl)-4- hydroxypyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00735
         		55% 0.98 min 445
    (2S,4R)-1-(3- ethoxybenzoyl)-4-hydroxy- N-((5-phenyl-1,2,4- oxadiazol-3- yl)methyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00736
         		60% 0.82 min 437
    (2S,4R)-N-((3-(4- chlorophenyl)-1,2,4- oxadiazol-5-yl)methyl)-1- (3-ethoxybenzoyl)-4- hydroxypyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00737
         		47% 0.95 min 471
    (2S,4R)-1-(3- ethoxybenzoyl)-4-hydroxy- N-((5-phenylisoxazol-3- yl)methyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00738
         		60% 0.86 min 436
    (2S,4R)-1-(3- ethoxybenzoyl)-4-hydroxy- N-((1-methyl-1,2,3,4- tetrahydroquinolin-6- yl)methyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00739
         		30% 0.67 min 438
    • (2S,4R)-4-hydroxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00740
  • A mixture of (2S,4R)-4-hydroxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (125 mg, 0.34 mmol) and (S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoic acid (83 mg, 0.36 mmol) in DMF (1.6 mL) was treated with DIPEA (0.24 mL, 1.4 mmol) and HATU (140 mg, 0.37 mmol) and the mixture was stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (120 mg, 0.22 mmol, 65% yield). LCMS RT=0.81 min, ES+ve m/z 549 [M+H]+.
    • (2S,4R)-4-hydroxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)-1-((R)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00741
  • A mixture of (2S,4R)-4-hydroxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (65 mg, 0.18 mmol) and (R)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoic acid (43 mg, 0.19 mmol) in DMF (1.6 mL) was treated with DIPEA (0.123 mL, 0.70 mmol) and HATU (74 mg, 0.19 mmol) and the mixture was stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (64 mg, 0.12 mmol, 66% yield). LCMS RT=0.80 min, ES+ve m/z 549 [M+H]+.
    • tert-butyl ((S)-1-((2R,4S)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-1-oxopropan-2-yl)(methyl)carbamate
  • Figure US20190127359A1-20190502-C00742
  • A stirred mixture of (S)-2-((tert-butoxycarbonyl)(methyl)amino)propanoic acid (115 mg, 0.57 mmol) and (2R,4S)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (200 mg, 0.57 mmol) in DMF (0.7 mL) was treated with DIPEA (0.4 mL, 2.3 mmol) and then with HATU (215 mg, 0.57 mmol) and the mixture was stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (146 mg, 0.29 mmol, 51% yield). LCMS RT=0.84 min, ES+ve m/z 503 [M+H]+.
    • (2S,4R)-4-hydroxy-1-((S)-2-(3-methoxy-N-methylpropanamido)propanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00743
  • A stirred mixture of (2S,4R)-4-hydroxy-1-((S)-2-(methylamino)propanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (50 mg, 0.12 mmol) and 3-methoxypropanoic acid (commercially available from for example Aldrich) (0.013 mL, 0.14 mmol) in DMF (0.8 mL) was treated with DIPEA (0.087 mL, 0.50 mmol) and then with HATU (52 mg, 0.14 mmol). The mixture was stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (43 mg, 71% yield). LCMS RT=0.61 min, ES+ve m/z 489 [M+H]+.
    • (2S,4R)-4-hydroxy-1-((S)-2-((2-methoxyethyl)(methyl)amino)propanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00744
  • A stirred mixture of 1-bromo-2-methoxyethane (commercially available from for example Aldrich) (0.013 mL, 0.14 mmol) and (2S,4R)-4-hydroxy-1-((S)-2-(methylamino)propanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (50 mg, 0.12 mmol) in DMF (0.8 mL) was treated with DIPEA (0.054 mL, 0.31 mmol) and the mixture was stirred at 85° C. for 18 hours. The reaction mixture was cooled and the product was subj ected to purification by mass-directed automated preparative HPLC (ammonium bicarbonate modifier) to afford the title compound (44 mg, 77% yield). LCMS RT=0.51 min, ES+ve m/z 461 [M+H]+.
    • (2S,4R)-4-hydroxy-1-((S)-4-(2-methoxyacetyl)morpholine-3-carbonyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00745
  • A mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)-1-((S)-morpholine-3-carbonyl)pyrrolidine-2-carboxamide, hydrochloride (19 mg, 0.041 mmol), 2-methoxyacetic acid (3 μL, 0.039 mmol) and DIPEA (0.035 mL, 0.20 mmol) in DMF (1 mL) was treated with HATU (18 mg, 0.047 mmol) and stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (13 mg, 0.026 mmol, 66% yield). LCMS RT=0.60 min, ES+ve m/z 503 [M+H]+.
    • (2S,4R)—N-(4-(2,4-dimethylthiazol-5-yl)benzyl)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00746
  • A stirred mixture of (2S,4R)—N-(4-(2,4-dimethylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2-carboxamide (30 mg, 0.09 mmol) and 2-(3-methylisoxazol-5-yl)acetic acid (commercially available from for example Aldrich) (13 mg, 0.09 mmol) in DMF (0.8 mL) was treated with DIPEA (0.063 mL, 0.36 mmol) and then with HATU (41 mg, 0.11 mmol) and stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (26 mg, 63% yield). LCMS RT=0.66 min, ES+ve m/z 455 [M+H]+.
    • (2S,4R)-1-((S)-2-acetamidopropanoyl)-N-(4-(2,4-dimethylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00747
  • A stirred mixture of (2S,4R)—N-(4-(2,4-dimethylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2-carboxamide (30 mg, 0.09 mmol) and (S)-2-acetamidopropanoic acid (commercially available from for example Aldrich) (12 mg, 0.09 mmol) in DMF (0.8 mL) was treated with DIPEA (0.063 mL, 0.36 mmol) and then with HATU (41 mg, 0.11 mmol), and the mixture was stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (30 mg, 75% yield). LCMS RT=0.58 min, ES+ve m/z 445 [M+H]+.
    • (2S,4R)—N-(4-bromobenzyl)-1-(3-ethoxybenzoyl)-4-hydroxypyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00748
  • An ice-cooled mixture of (2S,4R)-1-(3-ethoxybenzoyl)-4-hydroxypyrrolidine-2-carboxylic acid (73 mg, 0.26 mmol) and (4-bromophenyl)methanamine, hydrochloride (commercially available from for example Aldrich) (58 mg, 0.26 mmol) in DMF (0.5 mL) was treated with a solution of DIPEA (0.145 mL, 0.83 mmol) in DMF (1 mL) and then with HATU (105 mg, 0.28 mmol) and stirred overnight at ambient temperature. The product was then subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (62 mg, 53% yield). LCMS RT=0.90 min, ES+ve m/z 447,449 [M+H]+.
    • (2S,4R)—N-([1,1′-biphenyl]-4-ylmethyl)-1-(3-ethoxybenzoyl)-4-hydroxypyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00749
  • A mixture of (2 S,4R)-1-(3-ethoxybenzoyl)-4-hydroxypyrrolidine-2-carboxylic acid (30 mg, 0.11 mmol) and [1,1′-biphenyl]-4-ylmethanamine (commercially available from for example Aldrich) (20 mg, 0.11 mmol) in DMF (0.8 mL) was treated with DIPEA (0.075 mL, 0.43 mmol) and then with HATU (45 mg, 0.12 mmol) and stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (26 mg, 55% yield). LCMS RT=0.98 min, ES+ve m/z 445 [M+H]+.
  • Using a method analogous to that for 2S,4R)—N-([1,1′-biphenyl]-4-ylmethyl)-1-(3-ethoxybenzoyl)-4-hydroxypyrrolidine-2-carboxamide, the following compounds were prepared:
  • Name Structure Yield RT [M + H]+
    (2S,4R)-N-((S)-1-(4- chlorophenyl)ethyl)-1-(3- ethoxybenzoyl)-4- hydroxypyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00750
         		56% 0.92 min 417
    (2S,4R)-N-benzyl-1-(3- ethoxybenzoyl)-4- hydroxypyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00751
         		64% 0.76 min 369
    (2S,4R)-1-(3- ethoxybenzoyl)-4- hydroxy-N-((S)-2- oxopyrrolidin-3- yl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00752
         		77% 0.50 min 362
    (2S,4R)-1-(3- ethoxybenzoyl)-4- hydroxy-N-((2- methylthiazol-5- yl)methyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00753
         		69% 0.57 min 390
    (2S,4R)-1-(3- ethoxybenzoyl)-4- hydroxy-N-((1-methyl- 1H-pyrazol-4- yl)methyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00754
         		70% 0.55 min 375
    (2S,4R)-N-([1,1′- biphenyl]-4-ylmethyl)-1- (3-ethoxybenzoyl)-4- hydroxypyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00755
         		55% 0.98 min 445
    (2S,4R)-1-(3- ethoxybenzoyl)-4- hydroxy-N-((5-phenyl- 1,2,4-oxadiazol-3- yl)methyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00756
         		60% 0.82 min 437
    (2S,4R)-N-((3-(4- chlorophenyl)-1,2,4- oxadiazol-5-yl)methyl)-1- (3-ethoxybenzoyl)-4- hydroxypyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00757
         		47% 0.95 min 471
    (2S,4R)-1-(3- ethoxybenzoyl)-4- hydroxy-N-((5- phenylisoxazol-3- yl)methyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00758
         		60% 0.86 min 436
    (2S,4R)-1-(3- ethoxybenzoyl)-4- hydroxy-N-((1-methyl- 1,2,3,4- tetrahydroquinolin-6- yl)methyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00759
         		30% 0.67 min 438
    • (2S,4R)-4-hydroxy-1-(2-(3-methoxypropanamido)acetyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00760
  • A mixture of (2S,4R)-1-(2-aminoacetyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (134 mg, 0.33 mmol) and 3-methoxypropanoic acid (commercially available from for example Aldrich) (37 mg, 0.36 mmol) in DMF (0.8 mL) was treated with DIPEA (0.23 mL, 1.3 mmol) and then with HATU (136 mg, 0.36 mmol) and stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (36 mg, 24% yield). LCMS RT=0.56 min, ES+ve m/z 461 [M+H]+.
    • (2S,4R)-1-((S)-3,3-dimethyl-2-(3-methyloxetane-3-carboxamido)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00761
  • A stirred mixture of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (20 mg, 0.04 mmol) and 3-methyloxetane-3-carboxylic acid (commercially available from for example Chemgenx) (5 mg, 0.04 mmol) in DMF (0.6 mL) was treated with DIPEA (0.03 mL, 0.17 mmol) and then with HATU (20 mg, 0.05 mmol), and the mixture was stirred at ambient temperature for 1 hour. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to give the title compound (18 mg, 80% yield). LCMS RT=0.76 min, ES+ve m/z 529 [M+H]+.
  • Using a method analogous to that for (2S,4R)-1-((S)-3,3-dimethyl-2-(3-methyloxetane-3-carboxamido)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, the following compounds were prepared:
  • Name Structure Yield RT [M + H]+
    (2S,4R)-1-((S)-3,3- dimethyl-2-(oxetane-3- carboxamido)butanoyl)-4- hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00762
         		41% 0.72 min 515
    (2S,4R)-1-((S)-2- (cyclopentanecarboxamido)- 3,3-dimethylbutanoyl)- 4-hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00763
         		58% 0.89 min 527
    (2S,4R)-1-((S)-3,3- dimethyl-2-(tetrahydro- 2H-pyran-4- carboxamido)butanoyl)-4- hydroxy-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00764
         		52% 0.76 min 543
    • (S)—N—((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)morpholine-3-carboxamide, hydrochloride
  • Figure US20190127359A1-20190502-C00765
  • A mixture of (2 S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (40 mg, 0.086 mmol) and (S)-4-(tert-butoxycarbonyl)morpholine-3-carboxylic acid (commercially available from for example Astatech, Inc.) (20 mg, 0.086 mmol) in DMF (0.6 mL) was treated with DIPEA (0.06 mL, 0.35 mmol) and then with HATU (40 mg, 0.10 mmol) and stirred at ambient temperature for 1 hour. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to give the intermediate Boc-protected product. The intermediate was then dissolved in a mixture of dichloromethane (1 mL) and methanol (0.5 mL) and treated with 4M hydrochloric acid in 1,4-dioxane (0.4 mL, 1.6 mmol), After stirring at ambient temperature for 1 hour, the mixture was evaporated to dryness to afford the title compound (31 mg, 62% yield). LCMS RT=0.60 min, ES+ve m/z 544 [M+H]+.
  • Using a method analogous to that for (S)—N—((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)morpholine-3-carboxamide, hydrochloride, the following compounds were prepared:
  •
    (R)-N-((S)-1-((2S,4R)-4- hydroxy-2-((4-(4- methylthiazol-5- yl)benzyl)carbamoyl) pyrrolidin- 1-yl)-3,3-dimethyl-1- oxobutan-2-yl)morpholine-3- carboxamide, hydrochloride
    Figure US20190127359A1-20190502-C00766
         		58% 0.63 min 544
    (S)-N-((S)-1-((2S,4R)-4- hydroxy-2-((4-(4- methylthiazol-5- yl)benzyl)carbamoyl) pyrrolidin- 1-yl)-3,3-dimethyl-1- oxobutan-2-yl)morpholine-2- carboxamide, hydrochloride
    Figure US20190127359A1-20190502-C00767
         		54% 0.62 min 544
    N-((S)-1-((2S,4R)-4-hydroxy- 2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl) pyrrolidin- 1-yl)-3,3-dimethyl-1- oxobutan-2-yl)morpholine-2- carboxamide, hydrochloride
    Figure US20190127359A1-20190502-C00768
         		52%  0.62- 0.64 min 544
    • tert-butyl 4-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-1-oxopropan-2-yl)piperazine-1-carboxylate & tert-butyl 4-((R)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-1-oxopropan-2-yl)piperazine-1-carboxylate
  • Figure US20190127359A1-20190502-C00769
  • A stirred mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (100 mg, 0.28 mmol) and 2-(4-(tert-butoxycarbonyl)-2-oxopiperazin-1-yl)propanoic acid (85 mg, 0.31 mmol) in DMF (0.8 mL) was treated with DIPEA (0.20 mL, 1.13 mmol) and then with HATU (129 mg, 0.34 mmol) and then stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (ammonium bicarbonate modifier) to afford the title compounds: Isomer 1 (first-eluting) (48 mg, 30% yield). LCMS RT=0.85 min, ES+ve m/z 572 [M+H]+. Isomer 2 (second-eluting) (51 mg, 32% yield). LCMS RT=0.86 min, ES+ve m/z 572 [M+H]+.
    • (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(piperazin-1-yl)propanoyl)pyrrolidine-2-carboxamide, hydrochloride & (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)-1-((R)-2-(piperazin-1-yl)propanoyl)pyrrolidine-2-carboxamide, hydrochloride
  • Figure US20190127359A1-20190502-C00770
  • Isomer 1 and isomer 2 of tert-butyl 4-(1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-1-oxopropan-2-yl)piperazine-1-carboxylate (48 mg, 0.08 mmol) were separately dissolved in a mixture of dichloromethane (0.3 mL) and methanol (0.1 mL) and treated with 4M hydrochloric acid in 1,4-dioxane (0.3 mL, 1.2 mmol) respectively. After stirring at ambient temperature for 1 hour, the reaction mixtures were evaporated to dryness to afford the title compounds as hydrochloride salts. Isomer 1 (42 mg, 99% yield). LCMS RT=0.62 min, ES+ve m/z 472 [M+H]+. Isomer 2 (42 mg, 99% yield). LCMS RT=0.60 min, ES+ve m/z 472 [M+H]+.
    • (S)—N—((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-4-(2-methoxyethyl)morpholine-2-carboxamide
  • Figure US20190127359A1-20190502-C00771
  • A mixture of 1-bromo-2-methoxyethane (4 μL, 0.04 mmol), (S)—N—((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)morpholine-2-carboxamide, hydrochloride (20 mg, 0.04 mmol) and DIPEA (0.019 mL, 0.11 mmol) in DMF (0.5 mL) was stirred at 85° C. for 6 hours. The cooled product was subjected to purification by mass-directed automated preparative HPLC (ammonium bicarbonate modifier) to afford the title compound (9 mg, 41% yield). LCMS RT=0.88 min, ES+ve m/z 602 [M+H]+.
  • Using a method analogous to that for (S)—N—((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-4-(2-methoxyethyl)morpholine-2-carboxamide the following compounds were prepared:
  • Stereo-
    chemistry [M +
    Name Structure Comments Yield RT H]+
    (2S,4R)-4-hydroxy-1-(2-(4- (2-methoxyethyl)-2- oxopiperazin-1- yl)propanoyl)-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00772
         		Single enantiomer, stereo- chemistry unknown at the unspecified chiral centre 20% 0.68 min 530
    (2S,4R)-4-hydroxy-1-(2-(4- (2-methoxyethyl)-2- oxopiperazin-1- yl)propanovl)-N-(4-(4- methylthiazol-5- yl)benzyl)pyrrolidine-2- carboxamide
    Figure US20190127359A1-20190502-C00773
         		Single enantiomer, stereo- chemistry unknown at the unspecified chiral centre 32% 0.69 min 530
    (S)-N-((S)-1-((2S,4R)-4- hydroxy-2-((4-(4- methylthiazol-5- yl)benzyl)carbamoyl) pyrrolidin-1-yl)-3,3-dimethyl- 1-oxobutan-2-yl)-4-(2- methoxyethyl)morpholine- 3-carboxamide
    Figure US20190127359A1-20190502-C00774
         		41% 0.86 min 602
    (R)-N-((S)-1-((2S,4R)-4- hydroxy-2-((4-(4- methylthiazol-5- yl)benzyl)carbamoyl) pyrrolidin-1-yl)-3,3-dimethyl- 1-oxobutan-2-yl)-4-(2- methoxyethyl)morpholine- 3-carboxamide
    Figure US20190127359A1-20190502-C00775
         		45% 0.86 min 602
    • Methyl 4-(((S)-1-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-1-oxopropan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-4-oxobutanoate
  • Figure US20190127359A1-20190502-C00776
  • A mixture of (2S,4R)-1-((S)-2-((S)-2-amino-4-methylpentanamido)propanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (102 mg, 0.19 mmol), DIPEA (0.165 mL, 0.95 mmol) and 4-methoxy-4-oxobutanoic acid (commercially available from for example Aldrich) (25 mg, 0.19 mmol) in DMF (2 mL) was treated with HATU (64 mg, 0.17 mmol) and the mixture was stirred at ambient temperature for 20 minutes. Brine (10 mL) was added and the product was extracted with ethyl acetate (20 mL). The organic phase was washed with brine (2×20 mL), dried using a hydrophobic frit and evaporated to dryness. The product was purified by chromatography on reverse phase silica using a gradient elution from 5% to 70% acetonitrile (+0.1% formic acid) in water (+0.1% formic acid) to afford the title compound (73 mg, 0.12 mmol, 63% yield). LCMS RT=0.74 min, ES+ve m/z 616 [M+H]+.
    • 4-(3-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)phenoxy)butanoic acid (
  • Figure US20190127359A1-20190502-C00777
  • A solution of tert-butyl 4-(3-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)phenoxy)butanoate (130 mg, 0.22 mmol) in dichloromethane (3 mL) was treated with TFA (0.5 mL, 6.5 mmol) and stirred at ambient temperature for 5 hours. The solvent was evaporated to dryness and the product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (65 mg, 0.12 mmol, 55% yield). LCMS RT=0.70 min, ES+ve m/z 524 [M+H]+.
    • 4-(((S)-1-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-1-oxopropan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-4-oxobutanoic acid
  • Figure US20190127359A1-20190502-C00778
  • A solution of methyl 4-(((S)-1-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-1-oxopropan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-4-oxobutanoate (73 mg, 0.12 mmol) in methanol (3 mL) was treated with aqueous sodium hydroxide (2M, 0.6 mL, 1.2 mmol) and the mixture was stirred at ambient temperature for 2 hours. The mixture was evaporated to dryness and the product was purified by chromatography on reverse phase silica using a gradient elution from 5% to 60% acetonitrile (+0.1% formic acid) in water (+0.1% formic acid) to afford the title compound (53 mg, 0.088 mmol, 74% yield). LCMS RT=0.69 min, ES+ve m/z 602 [M+H]+.
    • (2S,4R)-4-hydroxy-1-((S)-2-((S)-2-(2-methoxyacetamido)-4-methylpentanamido)propanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00779
  • A mixture of (2S,4R)-1-((S)-2-((S)-2-amino-4-methylpentanamido)propanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (30 mg, 0.056 mmol), 2-methoxyacetic acid (commercially available from for example Aldrich) (4.3 uL, 0.056 mmol) and DIPEA (0.05 mL, 0.29 mmol) in DMF (1 mL) was treated with HATU (25 mg, 0.066 mmol) and stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (18 mg, 0.031 mmol, 56% yield). LCMS RT=0.73 min, ES+ve m/z 574 [M+H]+.
    • (2S,4R)-4-hydroxy-1-((S)-2-((S)-2-(3-methoxypropanamido)-4-methylpentanamido)propanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxaide
  • Figure US20190127359A1-20190502-C00780
  • A mixture of (2S,4R)-1-((S)-2-((S)-2-amino-4-methylpentanamido)propanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (30 mg, 0.056 mmol), 3-methoxypropanoic acid (commercially available from for example Aldrich) (5.2 uL, 0.056 mmol) and DIPEA (0.05 mL, 0.29 mmol) in DMF (1 mL) and stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (20 mg, 0.034 mmol, 61% yield). LCMS RT=0.72 min, ES+ve m/z 588 [M+H]+.
    • (2S,4R)-1-(6-cyanopyridin-2-yl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00781
  • A mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (58 mg, 0.16 mmol) and 6-fluoropicolinonitrile (commercially available from for example Aldrich) (20 mg, 0.16 mmol) in DMSO (1 mL) was treated with DIPEA (0.10 mL, 0.57 mmol), sealed and heated in a Biotage “Initiator” microwave at 100° C. for 60 minutes. The product was purified by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (23 mg, 0.055 mmol, 34% yield). LCMS RT=0.74 min, ES+ve m/z 420 [M+H]+.
    • Intermediates 4-(oxazol-5-yl)benzonitrile
  • Figure US20190127359A1-20190502-C00782
  • A mixture of 4-formylbenzonitrile (commercially available from for example Aldrich) (5.32 g, 41 mmol), 1-((isocyanomethyl)sulfonyl)-4-methylbenzene (commercially available from for example Aldrich) (8.83 g, 45 mmol) and potassium carbonate (7.3 g, 53 mmol) in methanol (200 mL) was stirred at ambient temperature for 80 minutes. The mixture was then evaporated to dryness; the residue was treated with saturated aqueous sodium bicarbonate (100 mL) and extracted with dichloromethane (3×100 mL). The combined organics were washed with brine (75 mL), passed through a hydrophobic frit and then evaporated to dryness to afford the title compound (7.19 g, 42 mmol, quantitative). LCMS RT=0.48 min, ES+ve m/z 171 [M+H]+.
    • (4-(oxazol-5-yl)phenyl)methanamine
  • Figure US20190127359A1-20190502-C00783
  • Under an atmosphere of nitrogen, an ice-cooled mixture of 4-(oxazol-5-yl)benzonitrile (900 mg, 5.29 mmol) and cobalt(II) chloride hexahydrate (commercially available from for example Aldrich) (1.8 g, 7.9 mmol) in methanol (50 mL) was treated portion-wise over 5 minutes with sodium borohydride (1 g, 26 mmol). The mixture was stirred for 30 minutes and then treated with water (50 mL) and concentrated aqueous ammonia (20 mL). The mixture was extracted with chloroform (3×150 mL), the combined organics were evaporated to dryness and the product was purified by chromatography on silica using a gradient elution from 0% to 30% methanol in dichloromethane (+0.1% triethylamine) to afford the title compound (580 mg, 3.3 mmol, 63% yield). LCMS RT=0.35 min, ES+ve m/z 175 [M+H]+.
    • (2S,4R)-tert-butyl 4-hydroxy-2-((4-(oxazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carboxylate
  • Figure US20190127359A1-20190502-C00784
  • To a stirred solution of (2S,4R)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (0.66 g, 2.9 mmol) in dry DMF (20 mL) were added (4-(oxazol-5-yl)phenyl)methanamine (0.5 g, 2.87 mmol) and DIPEA (1 mL, 5.7 mmol). This solution was then ice-cooled and HATU (1.09 g, 2.9 mmol) was added. The reaction mixture was stirred with cooling for an additional hour then treated with water (30 mL) and extracted with ethyl acetate (3×100 mL). The combined organic phase was washed with saturated aqueous sodium bicarbonate (60 mL), brine (60 mL), dried over magnesium sulfate, filtered and evaporated to dryness. The product was purified by chromatography on silica using a gradient elution from 0% to 25% methanol in dichloromethane to afford the title compound (758 mg, 1.96 mmol, 68% yield). LCMS RT=0.73 min, ES+ve m/z 388 [M+H]+.
    • (2S,4R)-4-hydroxy-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride
  • Figure US20190127359A1-20190502-C00785
  • A solution of (2S,4R)-tert-butyl 4-hydroxy-2-((4-(oxazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carboxylate (2.74 g, 7.1 mmol) in methanol (10 mL) and dichloromethane (15 mL) was treated with hydrochloric acid (4 M in 1,4-dioxane) (8.8 mL, 35 mmol) and the mixture was stirred at ambient temperature for 24 hours. The mixture was evaporated to dryness. The residue was suspended in methanol, filtered and dried under vacuum to afford the title compound (2.24 g, 6.9 mmol, 98% yield). LCMS RT=0.44 min, ES+ve m/z 288 [M+H]+.
    • (2S,4R)-tert-butyl 2-((4-bromobenzyl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate
  • Figure US20190127359A1-20190502-C00786
  • An ice-cooled mixture of (2S,4R)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (commercially available from for example Aldrich) (7.95 g, 34 mmol) and (4-bromophenyl)methanamine (commercially available from for example Fluorochem) (6.4 g, 34 mmol) in DMF (200 mL) was treated with DIPEA (18 mL, 103 mmol) and then with HATU (14.4 g, 38 mmol) and the mixture was stirred at ambient temperature for 30 minutes. The mixture was treated with water (200 mL) and extracted with ethyl acetate (2×200 mL). The combined organic phase was washed with saturated aqueous sodium bicarbonate (2×300 mL), water (100 mL), brine (200 mL), dried over magnesium sulfate and evaporated to dryness. The product was purified by flash chromatography (750 g silica cartridge) using a gradient elution from 0% to 10% methanol in dichloromethane to afford the title compound (12.9 g, 94% yield). LCMS RT=0.87 min, ES+ve m/z 401 [M+H]+.
    • (2S,4R)-tert-butyl 4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carboxylate
  • Figure US20190127359A1-20190502-C00787
  • Under an atmosphere of nitrogen, a mixture of (2S,4R)-tert-butyl 2-((4-bromobenzyl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate (12.9 g, 32 mmol), 4-methylthiazole (commercially available from for example Aldrich) (5.9 mL, 65 mmol), palladium(II) acetate (commercially available from for example Aldrich) (0.145 g, 0.65 mmol) and potassium acetate (6.34 g, 65 mmol) in N-methyl-2-pyrrolidone (80 mL) was stirred at 120° C. for 18 hours. After cooling to ambient temperature, water (100 ml) was added and the product was extracted with ethyl acetate (4×300 mL). The combined organic phase was washed with brine (5×200 mL), dried over magnesium sulfate and evaporated to dryness. The product was purified by flash chromatography (750 g silica cartridge) using a gradient elution from 0% to 10% methanol in dichloromethane to afford the title compound (8.0 g, 59% yield). LCMS RT=0.75 min, ES+ve m/z 418 [M+H]+.
    • (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride
  • Figure US20190127359A1-20190502-C00788
  • A solution of (2S,4R)-tert-butyl 4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carboxylate (8 g, 19 mmol) in a mixture of methanol (30 mL) and dichloromethane (20 mL) was treated with 4M hydrochloric acid in 1,4-dioxane (8 mL, 32 mmol). The mixture was stirred at ambient temperature for 2 hours. The solvent was evaporated to dryness and the residue was triturated in dichloromethane, filtered and dried under vacuum to afford the title compound (6.7 g, 99% yield). LCMS RT=0.51 min, ES+ve m/z 318 [M+H]+.
    • (2S,4R)-1-(3-ethoxybenzoyl)-4-hydroxypyrrolidine-2-carboxylic acid
  • Figure US20190127359A1-20190502-C00789
  • 3-Ethoxybenzoic acid (commercially available from for example Aldrich) (4 g, 24 mmol) was dissolved in thionyl chloride (24 mL, 329 mmol) and stirred at 60° C. for 1 hour and then at 50° C. for 18 hours. After cooling to ambient temperature the mixture was evaporated to dryness and the residue was treated with diethyl ether (5 mL). The mixture was then ice-cooled and treated with a solution of (2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid, hydrochloride (commercially available from for example Aldrich) (4.44 g, 27 mmol) in 1M aqueous sodium hydroxide (27 mL, 27 mmol). The reaction was warmed to ambient temperature and stirred for 18 hours. The mixture was separated; the aqueous phase was washed with diethyl ether and then acidified with 2M aqueous hydrochloric acid. The product was extracted in diethyl ether (2×70 mL) and the combined ethereal phase was evaporated to dryness. The product was purified by flash chromatography (340 g C18 cartridge), using a gradient elution from 10 to 30% acetonitrile (+0.1% formic acid) in water (+0.1% formic acid) to afford the title compound (3.5 g, 52% yield). LCMS RT=0.55 min, ES+ve m/z 280 [M+H]+.
    • (2S,4R)-benzyl 1-((S)-2-acetamidopropanoyl)-4-hydroxypyrrolidine-2-carboxylate
  • Figure US20190127359A1-20190502-C00790
  • An ice-cooled mixture of (S)-2-acetamidopropanoic acid (commercially available from for example Aldrich) (2.80 g, 21 mmol) and (2S,4R)-benzyl 4-hydroxypyrrolidine-2-carboxylate, hydrochloride (commercially available from for example Aldrich) (5 g, 19 mmol) in DMF (5 mL) was treated with DIPEA (14 mL, 78 mmol), followed by HATU (8.11 g, 21 mmol) over 10 min. The mixture was warmed to ambient temperature and stirred for 1 hour then treated with saturated aqueous sodium bicarbonate (30 mL) and stirred for 5 min. The mixture was then extracted with ethyl acetate (3×100 mL) and the combined organic phase was washed with water (100 mL), brine (100 mL), dried over magnesium sulfate and evaporated to dryness. The product was purified by flash chromatography (330 g silica cartridge) using a gradient elution from 0 to 10% methanol in dichloromethane to afford the title compound (2.0 g, 31% yield). LCMS RT=0.63 min, ES+ve m/z 335 [M+H]+.
    • (2S,4R)-1-((S)-2-acetamidopropanoyl)-4-hydroxypyrrolidine-2-carboxylic acid
  • Figure US20190127359A1-20190502-C00791
  • A solution of (2S,4R)-benzyl-1-((S)-2-acetamidopropanoyl)-4-hydroxypyrrolidine-2-carboxylate (2 g, 6.0 mmol) in ethanol (10 mL) was added to a flask containing palladium on carbon (1.27 g, 1.2 mmol) (10%, Degussa type) under an atmosphere of nitrogen. The flask was filled with hydrogen and the solution was stirred at ambient temperature for 2 hours. The catalyst was removed by filtration through celite and the filtrate was evaporated under reduced pressure to afford the title compound (1.37 g, 94% yield). LCMS RT=0.28 min, ES+ve m/z 244 [M+H]+.
    • (2S,4R)-4-hydroxy-1-(2-3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylic acid
  • Figure US20190127359A1-20190502-C00792
  • Under an atmosphere of nitrogen, a solution of (2S,4R)-benzyl 4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylate (2.3 g, 6.7 mmol) in ethanol (60 mL) was added to palladium on carbon (0.071 g, 0.67 mmol) (10%, Degussa type) and then stirred under an atmosphere of hydrogen. After 2 hours, the mixture was filtered through celite. The filtrate was evaporated to dryness and the residue was triturated with cyclohexane and dried under vacuum to afford a white solid. The product was purified by mass-directed automated preparative HPLC (TFA modifier) to afford the title compound (650 mg, 2.6 mmol, 38% yield). LCMS RT=0.38 min, ES+ve m/z 255 [M+H]+.
    • (2S,4R)-methyl 4-hydroxy-1-((S)-2-(1-oxoisoindolin-2-yl)propanoyl)pyrrolidine-2-carboxylate
  • Figure US20190127359A1-20190502-C00793
  • A mixture of (2S,4R)-methyl 4-hydroxypyrrolidine-2-carboxylate, hydrochloride (commercially available from for example Aldrich) (1.77 g, 9.8 mmol) and (S)-2-(1-oxoisoindolin-2-yl)propanoic acid (2 g, 9.8 mmol) in DMF (4 mL) was treated with DIPEA (5.11 mL, 29 mmol) and then with HATU (4.08 g, 10.7 mmol), and stirred at ambient temperature for 30 minutes. The mixture was treated with saturated aqueous sodium bicarbonate (100 mL) and extracted with ethyl acetate (2×200 mL). The combined organic phase was washed with water (100 mL), brine (100 mL), dried over magnesium sulfate and evaporated to dryness. The product was purified by flash chromatography (120 g C18 cartridge), using a gradient elution from 10% to 50% acetonitrile (+0.1% formic acid) in water (+0.1% formic acid) to afford the title compound (1.0 g, 31% yield). LCMS RT=0.60 min, ES+ve m/z 333 [M+H]+.
    • (2S,4R)-4-hydroxy-1-((S)-2-(1-oxoisoindolin-2-yl)propanoyl)pyrrolidine-2-carboxylic acid
  • Figure US20190127359A1-20190502-C00794
  • A solution of (2S,4R)-methyl 4-hydroxy-1-((S)-2-(1-oxoisoindolin-2-yl)propanoyl)pyrrolidine-2-carboxylate (1 g, 3.0 mmol) in methanol (2 mL) was treated with 2M aqueous sodium hydroxide (5 mL, 10 mmol) and the mixture was stirred at ambient temperature for 2 hours then acidified with 2M aqueous hydrochloric acid (6 mL). The mixture was then evaporated to about one half of the original volume and then ice-cooled. The resulting precipitate was filtered off and dried under vacuum to afford the title compound (615 mg, 64% yield). LCMS RT=0.51 min, ES+ve m/z 319 [M+H]+.
    • Methyl 3-(4-(tert-butoxy)-4-oxobutoxy)benzoate
  • Figure US20190127359A1-20190502-C00795
  • A solution of methyl 3-hydroxybenzoate (commercially available from for example Aldrich) (1 g, 6.6 mmol) and K2CO3 (1.82 g, 13.2 mmol) in DMF (10 mL) was treated with tert-butyl 4-bromobutanoate (commercially available from for example Aldrich) (2.2 g, 9.9 mmol) and the mixture was stirred at 60° C. for 16 hours. A further aliquot of K2CO3 (1.82 g, 13.2 mmol) and tert-butyl 4-bromobutanoate (2.2 g, 9.9 mmol) were added and the mixture was heated at 60° C. for further 6 hours. The mixture was cooled to ambient temperature and partitioned between ethyl acetate (50 mL) and water (50 mL). The organic phase was washed with brine (2×50 mL), dried (hydrophobic frit) and evaporated to dryness. The product was purified by chromatography on silica using a gradient elution from 0% to 100% methyl tert-butyl ether in cyclohexane to afford the title compound (1.4 g, 4.8 mmol, 72% yield). LCMS RT=1.26 min, ES+ve m/z 312 [M+H]+.
    • 3-(4-(Tert-butoxy)-4-oxobutoxy)benzoic acid
  • Figure US20190127359A1-20190502-C00796
  • A mixture of methyl 3-(4-(tert-butoxy)-4-oxobutoxy)benzoate (1.4 g, 4.8 mmol) and aqueous sodium hydroxide (2M, 4.8 mL, 9.6 mmol) in methanol (10 mL) was stirred at ambient temperature for 5 hours. The methanol was removed under reduced pressure (no heat) and the aqueous phase was acidified to pH 3 with saturated aqueous citric acid. The product was extracted with ethyl acetate (60 mL) and the organic extract was washed with brine (20 mL), dried using a hydrophobic frit and evaporated to dryness. The product was purified by chromatography on silica using a gradient elution from 0% to 25% methanol in dichloromethane to afford the title compound (625 mg, 2.2 mmol, 47% yield). LCMS RT=1.06 min, ES+ve m/z 279 [M−H]+.
    • Methyl 3-((14,14-dimethyl-12-oxo-3,6,9,13-tetraoxapentadecyl)oxy)benzoate
  • Figure US20190127359A1-20190502-C00797
  • An ice-cooled mixture of tert-butyl 3-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)propanoate (commercially available from for example Aldrich) (2.0 g, 7.2 mmol), triphenylphosphine (2.3 g, 8.6 mmol) and methyl 3-hydroxybenzoate (commercially available from for example Aldrich) (1.2 g, 7.9 mmol) in THF (40 mL) was treated dropwise over 5 minutes with diisopropyl azodicarboxylate (1.68 mL, 8.6 mmol). The mixture was warmed to ambient temperature and stirred for 18 hours. The mixture was then evaporated to dryness and purified by flash column chromatography (100 g silica cartridge) using a gradient elution from 0 to 100% methyl tert-butyl ether in cyclohexane over 40 minutes to afford the title compound (2.53 g, 85% yield). LCMS RT=1.14 min, ES+ve m/z 430 [M+NH4]+.
    • 3-((14,14-dimethyl-12-oxo-3,6,9,13-tetraoxapentadecyl)oxy)benzoic acid (
  • Figure US20190127359A1-20190502-C00798
  • A solution of methyl 3-((14,14-dimethyl-12-oxo-3,6,9,13-tetraoxapentadecyl)oxy)benzoate (2.53 g, 4.9 mmol) in methanol (25 mL) was treated with 1M aqueous sodium hydroxide (0.3 g, 7.6 mmol) in water (7 mL), and the mixture was stirred at ambient temperature for 1 hour. Acetic acid (0.45 mL, 7.9 mmol) was slowly added and the mixture was evaporated to dryness and purified by flash chromatography (100 g silica cartridge) using a gradient elution from 0% to 15% methanol in dichloromethane (+1% triethylamine) to afford the title compound (1.37 g, 70% yield). LCMS RT=0.99 min, ES+ve m/z 399 [M+H]+.
    • tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate
  • Figure US20190127359A1-20190502-C00799
  • A stirred mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (125 mg, 0.35 mmol) and (S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanoic acid (commercially available from for example Aldrich) (77 mg, 0.35 mmol) in DMF (0.9 mL) was treated with DIPEA (0.22 mL, 1.3 mmol) and then with HATU (134 mg, 0.35 mmol) and the mixture was stirred at ambient temperature for 1 hour. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (120 mg, 72% yield). LCMS RT=0.87 min, ES+ve m/z 517 [M+H]+.
  • Using a method analogous to that for tert-butyl-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carb amate, the following compounds were prepared:
  • Name Structure Yield RT [M + H]+
    (S)-tert-butyl 2-((2S,4R)- 4-hydroxy-2-((4-(4- methylthiazol-5- yl)benzyl)carbamoyl) pyrrolidine-1- carbonyl)piperidine-1- carboxylate
    Figure US20190127359A1-20190502-C00800
         		67% 0.88 min 529
    (S)-tert-butyl 3-((2S,4R)- 4-hydroxy-2-((4-(4- methylthiazol-5- yl)benzyl)carbamoyl) pyrrolidine-1- carbonyl)morpholine-4- carboxylate
    Figure US20190127359A1-20190502-C00801
         		67% 0.78 min 531
    tert-butyl ((S)-1-((2S,4R)- 4-hydroxy-2-((4-(4- methylthiazol-5- yl)benzyl)carbamoyl) pyrrolidin-1-yl)-1- oxobutan-2-yl)carbamate
    Figure US20190127359A1-20190502-C00802
         		85% 0.81 min 503
    tert-butyl ((S)-1-((2S,4R)- 4-hydroxy-2-((4-(4- methylthiazol-5- yl)benzyl)carbamoyl) pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2- yl)carbamate
    Figure US20190127359A1-20190502-C00803
         		85% 0.94 min 531
    tert-butyl ((S)-1- cyclopropyl-2-((2S,4R)-4- hydroxy-2-((4-(4- methylthiazol-5- yl)benzyl)carbamoyl) pyrrolidin-1-yl)-2- oxoethyl)carbamate
    Figure US20190127359A1-20190502-C00804
         		82% 0.83 min 515
    • (2S,4R)-1-(2-aminoacetyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00805
  • A stirred mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (100 mg, 0.28 mmol) and 2-((tert-butoxycarbonyl)amino)acetic acid (commercially available from for example Aldrich) (49 mg, 0.28 mmol) in DMF (3 mL) was treated with DIPEA (0.20 mL, 1.1 mmol) and then with HATU (118 mg, 0.31 mmol) and the mixture was stirred at ambient temperature for 30 minutes. Water (20 ml) was added and the product was extracted with ethyl acetate (3×20 mL). The combined organic phase was washed with saturated aqueous sodium bicarbonate (20 mL), water (20 mL), brine (20 mL) filtered through a hydrophobic frit and evaporated to dryness. The residue was then dissolved in dichloromethane (3 mL) and treated with TFA (1 mL, 13 mmol). After stirring at ambient temperature for 10 minutes, the reaction mixture was evaporated to dryness. The residue was dissolved in the minimum amount of methanol and then loaded onto a pre-conditioned (methanol) aminopropyl solid-phase extraction cartridge (5 g). The column was eluted with methanol (3 volumes) and the product-containing fractions were evaporated to dryness to afford the title compound (104 mg, 99% yield). LCMS RT=0.44 min, ES+ve m/z 375 [M+H]+.
    • (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)-1-((S)-morpholine-3-carbonyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00806
  • A solution of (S)-tert-butyl 3-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)morpholine-4-carboxylate (115 mg, 0.22 mmol) in dichloromethane (0.5 mL) was treated with TFA (0.5 mL) and the reaction mixture was stirred at ambient temperature for 1 hour. The mixture was evaporated to dryness and the residue was then dissolved in the minimum amount of a mixture of methanol:dichloromethane (1:1), and loaded onto a pre-conditioned (methanol) aminopropyl solid-phase extraction cartridge (2 g). The column was eluted with methanol (3 volumes) and the product-containing fractions were evaporated under reduced pressure to afford the title compound (89 mg, 94% yield). LCMS RT=0.47 min, ES+ve m/z 431 [M+H]+.
    • (2S,4R)-4-hydroxy-1-((S)-3-methyl-2-(methylamino)butanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride
  • Figure US20190127359A1-20190502-C00807
  • A mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (100 mg, 0.28 mmol), (S)-2-((tert-butoxycarbonyl)(methyl)amino)-3-methylbutanoic acid (commercially available from for example Aldrich) (65 mg, 0.28 mmol) and DIPEA (0.247 mL, 1.41 mmol) in DMF (2 mL) was treated with HATU (118 mg, 0.31 mmol) and stirred at ambient temperature for 30 minutes. The Boc protected intermediate was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier). The purified intermediate was dissolved in methanol:dichloromethane (1:1, 3 mL), treated with hydrochloric acid in 1,4-dioxane (4M, 3 mL, 12 mmol) and allowed to stand for 1 hour. The mixture was then evaporated to dryness to afford the title compound (107 mg, 0.23 mmol, 81% yield). LCMS RT=0.55 min, ES+ve m/z 431 [M+H]+.
    • (2S,4R)-1-((S)-2-amino-3-methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride
  • Figure US20190127359A1-20190502-C00808
  • A solution of tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate (287 mg, 0.56 mmol) in THF (5 mL) and treated with 4M hydrochloric acid in 1,4-dioxan (10 mL) and stirred at ambient temperature for 2 hours. The mixture was evaporated to dryness to afford the title compound (224 mg, 0.49 mmol, quantitative). LCMS RT=0.55 min, ES+ve m/z 417 [M+H]+.
    • (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride
  • Figure US20190127359A1-20190502-C00809
  • A stirred mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (70 mg, 0.20 mmol) and (S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoic acid (commercially available from for example Fluka) (50 mg, 0.22 mmol) in DMF (1 mL) was treated with DIPEA (0.14 mL, 0.79 mmol) and then with HATU (90 mg, 0.24 mmol), and stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to give the intermediate boc-protected product. The intermediate was then dissolved in a mixture of dichloromethane (0.5 mL) and methanol (0.1 mL) and treated with 4M hydrochloric acid in 1,4-dioxane (0.25 mL, 1.0 mmol), After stirring at ambient temperature for 1 hour, the reaction mixture was evaporated to dryness and the residue triturated to a solid with dichloromethane and dried under vacuum to afford the title compound (76 mg, 82% yield). LCMS RT=0.58 min, ES+ve m/z 431 [M+H]+.
    • (2S,4R)-1-((S)-2-((S)-2-amino-4-methylpentanamido)propanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride
  • Figure US20190127359A1-20190502-C00810
  • A solution of a mixture of (2S,4R)-1-((S)-2-aminopropanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (507 mg, 1.2 mmol), DIPEA (0.868 mL, 4.97 mmol) and (S)-2-((tert-butoxycarbonyl)amino)-4-methylpentanoic acid (commercially available from for example Aldrich) (230 mg, 0.99 mmol) in DMF (5 mL) was treated with HATU (416 mg, 1.1 mmol) and stirred at ambient temperature for 2 hours. Water (50 mL) was added and the product was extracted with ethyl acetate (50 mL). The organic phase was washed with brine (2×50 mL), dried using a hydrophobic frit and evaporated to dryness. The residue was dissolved in methanol:dichloromethane (1:1, 15 mL), treated with hydrochloric acid in 1,4-dioxane (4M, 5 mL, 20 mmol) and stirred at ambient temperature for 3 hours. The mixture was evaporated to dryness and the residue was suspended in dichloromethane (10 mL), sonicated, filtered and dried under vacuum to afford the title compound (280 mg, 0.56 mmol, 56% yield). LCMS RT=0.55 min, ES+ve m/z 502 [M+H]+.
    • (2S,4R)-tert-butyl 2-((4-(2,4-dimethylthiazol-5-yl)benzyl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate
  • Figure US20190127359A1-20190502-C00811
  • Under an atmosphere of nitrogen, a mixture of (2S,4R)-tert-butyl 2-((4-bromobenzyl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate (200 mg, 0.50 mmol), 2,4-dimethylthiazole (commercially available from for example Avocado) (113 mg, 1.0 mmol), palladium(II) acetate (commercially available from for example Aldrich) (2 mg, 10 μmol) and potassium acetate (98 mg, 1.0 mmol) in N-methyl-2-pyrrolidone (2 mL) was stirred at 120° C. for 18 hours. The cooled mixture was treated with water (25 ml) and the product was extracted with ethyl acetate (4×30 mL). The combined organic phase was washed with brine (5×20 mL), filtered through a hydrophobic frit and evaporated to dryness. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (142 mg, 66% yield). LCMS RT=0.77 min, ES+ve m/z 432 [M+H]+.
    • (2S,4R)—N-(4-(2,4-dimethylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2-carboxamide, hydrochloride
  • Figure US20190127359A1-20190502-C00812
  • A solution of (2S,4R)-tert-butyl 2-((4-(2,4-dimethylthiazol-5-yl)benzyl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate (142 mg, 0.33 mmol) in a mixture of methanol (0.5 mL) and dichloromethane (1.5 mL) was treated with 4M hydrochloric acid in 1,4-dioxane (0.63 mL, 2.5 mmol) and stirred at ambient temperature for 2 hours. The solvent was evaporated to dryness and the residue was triturated to a solid with diethyl ether and dried under vacuum to afford the title compound (120 mg, 99% yield). LCMS RT=0.49 min, ES+ve m/z 332 [M+H]+.
    • (S)-3-methyl-2-(3-methyl-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanoic acid
  • Figure US20190127359A1-20190502-C00813
  • A mixture of 3-methylfuran-2,5-dione (commercially available from for example Aldrich) (0.12 mL, 1.3 mmol) and (S)-2-amino-3-methylbutanoic acid (commercially available from for example Apollo Scientific) (150 mg, 1.3 mmol). in acetic acid (1 mL) was sealed and heated in a Biotage “Initiator” microwave at 120° C. for 1 hour. The mixture was evaporated to dryness to afford the title compound (253 mg, 94% yield). LCMS RT=0.75 min, ES+ve m/z 212 [M+H]+
    • benzyl 2-(3-oxomorpholino)propanoate
  • Figure US20190127359A1-20190502-C00814
  • Under an atmosphere of nitrogen, an ice-cooled solution of morpholin-3-one (commercially available from for example Aldrich) (100 mg, 1.0 mmol) in DMF (2 mL) was treated with sodium hydride (60% w/w in mineral oil) (40 mg, 1.0 mmol). After 5 minutes, benzyl 2-bromopropanoate (commercially available from for example Aldrich) (240 mg, 1.0 mmol) was added and the mixture was stirred with cooling for 30 minutes and then at ambient temperature for a further 18 hours. The reaction mixture was cautiously treated with saturated aqueous sodium bicarbonate (10 mL) and then extracted with ethyl acetate (2×40 mL). The combined organic phase was washed with brine (25 mL), filtered through a hydrophobic frit, and evaporated to dryness. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to give the title compound (105 mg, 40% yield). LCMS RT=0.80 min, ES+ve m/z 264 [M+H]+.
    • 2-(3-oxomorpholino)propanoic acid
  • Figure US20190127359A1-20190502-C00815
  • Under an atmosphere of nitrogen, a solution of benzyl 2-(3-oxomorpholino)propanoate (90 mg, 0.34 mmol) in ethanol (3 mL) was added to a flask containing palladium on carbon (36 mg, 0.034 mmol) (10%, Degussa type). The flask was then filled with hydrogen and the mixture was stirred at ambient temperature for 1 hour. The catalyst was removed by filtration through celite and the filtrate was evaporated under reduced pressure to afford the title compound (55 mg, 93% yield). LCMS RT=0.33 min, ES+ve m/z 174 [M+H]+. tert-butyl 4-(1-(benzyloxy)-1-oxopropan-2-yl)-3-oxopiperazine-1-carboxylate
  • Figure US20190127359A1-20190502-C00816
  • Under an atmosphere of nitrogen, an ice-cooled solution of tert-butyl 3-oxopiperazine-1-carboxylate (commercially available from for example Aldrich) (200 mg, 1.0 mmol) in DMF (4 mL) was treated with sodium hydride (60% w/w in mineral oil) (44 mg, 1.1 mmol). After 5 minutes, benzyl 2-bromopropanoate (commercially available from for example Aldrich) (255 mg, 1.05 mmol) was added. The mixture was stirred at 0° C. for 30 minutes and then at ambient temperature for a further 18 hours. The mixture was cautiously treated with saturated aqueous sodium bicarbonate (20 mL) and then extracted with ethyl acetate (2×40 mL). The combined organic phase was washed with brine (25 mL), filtered through a hydrophobic frit, and evaporated to dryness. The product was purified by flash column chromatography (20 g silica cartridge) using a gradient elution from 0% to 100% ethyl acetate in cyclohexane to afford the title compound (230 mg, 64% yield). LCMS RT=1.05 min, ES+ve m/z 363 [M+H]+.
    • 2-(4-(tert-butoxycarbonyl)-2-oxopiperazin-1-yl)propanoic acid
  • Figure US20190127359A1-20190502-C00817
  • Under an atmosphere of nitrogen, a solution of tert-butyl 4-(1-(benzyloxy)-1-oxopropan-2-yl)-3-oxopiperazine-1-carboxylate (230 mg, 0.64 mmol) in ethanol (3 mL) was added to a flask containing palladium on carbon (68 mg, 0.063 mmol) (10%, Degussa type). The flask was filled with hydrogen and the mixture was stirred at ambient temperature for 1 hour. The catalyst was removed by filtration through celite and the filtrate was evaporated under reduced pressure to afford the title compound (171 mg, 99% yield). LCMS RT=0.62 min, ES+ve m/z 290 [M+H]+.
    • tert-butyl 4-(2-oxo-2,3-dihydrobenzo [d]oxazol-5-yl)benzylcarbamate
  • Figure US20190127359A1-20190502-C00818
  • Under an atmosphere of nitrogen, a mixture of (4-(((tert-butoxycarbonyl)amino)methyl)phenyl)boronic acid (commercially available from for example Aldrich) (387 mg, 1.54 mmol), 5-bromobenzo[d]oxazol-2(3H)-one (commercially available from for example Aldrich) (300 mg, 1.40 mmol) and sodium carbonate (446 mg, 4.21 mmol) in DMF (4 mL) was treated with dicholoro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) (commercially available from for example Aldrich) (72 mg, 0.098 mmol) then sealed and heated in a Biotage “Initiator” microwave at 110° C. for 1 hr. The cooled product mixture was treated with dichloromethane (50 mL) and water (10 mL). The mixture was separated and the organic fraction was evaporated to dryness. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (178 mg, 0.52 mmol, 37% yield). LCMS RT=1.03 min, ES+ve m/z 341 [M+H]+.
    • 5-(4-(aminomethyl)phenyl)benzo[d]oxazol-2(3H)-one, hydrochloride
  • Figure US20190127359A1-20190502-C00819
  • A solution of tert-butyl 4-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)benzylcarbamate (130 mg, 0.38 mmol) in THF (10 mL) was treated with hydrochloric acid (4M in 1,4-dioxan) (1 mL, 4 mmol) and the mixture was stirred at ambient temperature overnight. The mixture was treated with diethyl ether (40 mL); the resulting precipitate was filtered off and dried under vacuum to afford the title compound (87 mg, 0.31 mmol, 82% yield). LCMS RT=0.49 min, ES+ve m/z 241 [M+H]+.
    • (2S,4R)-4-hydroxy-1-(3-hydroxybenzoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00820
  • An ice-cooled solution of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (217 mg, 0.61 mmol), 3-hydroxybenzoic acid (85 mg, 0.61 mmol) and DIPEA (0.321 mL, 1.84 mmol) in DMF (4 mL) was treated portion-wise with HATU (240 mg, 0.63 mmol) over 1 minute and then stirred at ambient temperature for 1 hour. The mixture was treated with saturated aqueous sodium bicarbonate (20 mL) and extracted with ethyl acetate (3×20 mL). The combined organic phase was washed with brine (3×30 mL), filtered through a hydrophobic frit and then evaporated to dryness. The product was purified by flash chromatography (50 g silica cartridge) using a gradient elution from 0 to 25% methanol in dichloromethane to afford the title compound (234 mg, 0.53 mmol, 87% yield). LCMS RT=0.49 min, ES+ve m/z 241 [M+H]+.
    • (S)-2-(1-oxoisoindolin-2-yl)propanoic acid
  • Figure US20190127359A1-20190502-C00821
  • A mixture of phthalaldehyde (commercially available from for example Aldrich) (4 g, 30 mmol) and (S)-2-aminopropanoic acid (commercially available from for example Aldrich) (2.39 g, 27 mmol) in acetonitrile (150 mL) was heated at reflux for 5 hr then allowed to cool to ambient temperature and stood overnight. The resulting crystalline precipitate was filtered off, washed with acetonitrile and dried under vacuum to afford the title compound (4.46 g, 22 mmol, 73% yield). LCMS RT=0.59 min, ES+ve m/z 206 [M+H]+.
  • Using a method analogous to that for (S)-2-(1-oxoisoindolin-2-yl)propanoic acid, the following compounds were prepared:
  • Name Structure Yield RT [M + H]+
    (S)-4-methoxy-2-(1- oxoisoindolin-2- yl)butanoic acid
    Figure US20190127359A1-20190502-C00822
         		46% 0.62 min 250
    (S)-2-(1-oxoisoindolin-2- yl)buanoic acid
    Figure US20190127359A1-20190502-C00823
         		60% 0.67 min 220
    (S)-2-(1-oxoisoindolin-2- yl)pentanoic acid
    Figure US20190127359A1-20190502-C00824
         		60% 0.77 min 234
    (S)-2-cyclopropyl-2-(1- oxoisoindolin-2-yl)acetic acid
    Figure US20190127359A1-20190502-C00825
         		54% 0.69 min 232
    (S)-3-methyl-2-(1- oxoisoindolin-2- yl)butanoic acid
    Figure US20190127359A1-20190502-C00826
         		59% 0.74 min 234
    (S)-3,3-dimethyl-2-(1- oxoisoindolin-2- yl)butanoic acid
    Figure US20190127359A1-20190502-C00827
         		69% 0.82 min 248
    • Ethyl 2-(5-methoxy-1-oxoisoindolin-2-yl)-3-methylbutanoate
  • Figure US20190127359A1-20190502-C00828
  • Under an atmosphere of nitrogen, an ice-cooled solution of 5-methoxyisoindolin-1-one (commercially available from for example Chem Impex) (105 mg, 0.64 mmol) in DMF (2.5 mL) was treated with sodium hydride (60% w/w in mineral oil) (31 mg, 0.77 mmol). The mixture was warmed to ambient temperature, treated with ethyl 2-bromo-3-methylbutanoate (commercially available from for example Alfa Aesar) (135 mg, 0.64 mmol), stirred at ambient temperature for 2 hours and then heated to 70° C. for a further 18 hours. The mixture was then ice-cooled and treated with additional sodium hydride (60% w/w in mineral oil) (31 mg, 0.77 mmol), followed by ethyl 2-bromo-3-methylbutanoate (135 mg, 0.64 mmol) and stirred at 70° C. for a further 24 hours. The cooled mixture was then cautiously treated with saturated aqueous ammonium chloride (20 mL) and the product was extracted with ethyl acetate (2×25 mL). The combined organic phase was washed with water (20 mL), brine (20 mL), filtered through a hydrophobic frit and evaporated to dryness. The product was purified by flash chromatography (20 g silica cartridge) using a gradient elution from 0% to 50% ethyl acetate in cyclohexane to afford the title compound (44 mg, 23% yield). LCMS RT=1.01 min, ES+ve m/z 292 [M+H]+
    • Ethyl 2-(6-methoxy-1-oxoisoindolin-2-yl)-3-methylbutanoate
  • Figure US20190127359A1-20190502-C00829
  • Under an atmosphere of nitrogen, an ice-cooled solution of 6-methoxyisoindolin-1-one (commercially available from for example Astatech) (105 mg, 0.64 mmol) in DMF (2.5 mL) was treated with sodium hydride (60% w/w in mineral oil) (31 mg, 0.77 mmol) and the mixture was allowed to warm to ambient temperature. The mixture was then treated with ethyl 2-bromo-3-methylbutanoate (commercially available from for example Alfa Aesar) (135 mg, 0.64 mmol) and the mixture was stirred for 18 hours then cautiously treated with saturated aqueous ammonium chloride (20 mL). The product was extracted with ethyl acetate (2×25 mL) and the combined organic phase was washed with water (20 mL), brine (20 mL), filtered through a hydrophobic frit and evaporated to dryness. The product was purified by flash chromatography (20 g silica cartridge) using a gradient elution from 0 to 50% ethyl acetate in cyclohexane to afford the title compound (40 mg, 21% yield). LCMS RT=1.03 min, ES+ve m/z 292 [M+H]+
    • 2-(6-methoxy-1-oxoisoindolin-2-yl)-3-methylbutanoic acid
  • Figure US20190127359A1-20190502-C00830
  • A solution of ethyl 2-(6-methoxy-1-oxoisoindolin-2-yl)-3-methylbutanoate (40 mg, 0.14 mmol) in ethanol (0.4 mL) was treated with 2M aqueous sodium hydroxide (0.20 mL, 0.41 mmol) and the mixture was stirred at ambient temperature for 2 hours. The reaction mixture was evaporated to dryness, treated with water (10 mL) and acidified to pH 3 using 2M aqueous hydrochloric acid. The product was extracted with ethyl acetate (2×10 mL), and the combined organic phase was filtered through a hydrophobic frit and evaporated to dryness to afford the title compound (34 mg, 94% yield). LCMS RT=0.80 min, ES+ve m/z 264 [M+H]+.
    • 2-(5-methoxy-1-oxoisoindolin-2-yl)-3-methylbutanoic acid
  • Figure US20190127359A1-20190502-C00831
  • A solution of ethyl 2-(5-methoxy-1l-oxoisoindolin-2-yl)-3-methylbutanoate (40 mg, 0.14 mmol) in ethanol (0.4 mL) was treated with 2M aqueous sodium hydroxide (0.20 mL, 0.41 mmol) and the mixture was stirred at ambient temperature for 2 hours. The mixture was then evaporated to dryness; the residue was treated with water (10 mL) and acidified to pH 3 using 2M aqueous hydrochloric acid. The product was extracted with ethyl acetate (2×10 mL), and the combined organic phase was filtered through a hydrophobic frit and evaporated to dryness to afford the title compound (33 mg, 93% yield). LCMS RT=0.76 min, ES+ve m/z 264 [M+H]+.
    • Ethyl 2-(7-chloro-1-oxoisoindolin-2-yl)-3-methylbutanoate
  • Figure US20190127359A1-20190502-C00832
  • Under a nitrogen atmosphere, an ice-cooled solution of 7-chloroisoindolin-1-one (commercially available from for example JW Pharm) (150 mg, 0.90 mmol) in DMF (2.5 mL) was treated with sodium hydride (60% w/w in mineral oil) (50 mg, 1.25 mmol). The mixture was allowed to warm to ambient temperature, then treated with ethyl 2-bromo-3-methylbutanoate (commercially available from for example Alfa Aesar) (187 mg, 0.90 mmol) and stirred for 5 hours. The mixture was then ice-cooled, treated with additional sodium hydride (60% w/w in mineral oil) (50 mg, 1.25 mmol) and ethyl 2-bromo-3-methylbutanoate (187 mg, 0.90 mmol) and the mixture was stirred at ambient temperature for a further 24 hours. The mixture was then cautiously treated with saturated aqueous ammonium chloride (20 mL), and the product was extracted with ethyl acetate (2×25 mL). The combined organic phase was washed with water (20 mL), brine (20 mL), filtered through a hydrophobic frit and evaporated to dryness. The product was purified by flash chromatography (20 g silica cartridge) using a gradient elution from 0 to 50% ethyl acetate in cyclohexane to afford the title compound (40 mg, 15% yield). LCMS RT=1.07 min, ES+ve m/z 296 [M+H]+.
    • 2-(7-chloro-1-oxoisoindolin-2-yl)-3-methylbutanoic acid
  • Figure US20190127359A1-20190502-C00833
  • A solution of ethyl 2-(7-chloro-1-oxoisoindolin-2-yl)-3-methylbutanoate (40 mg, 0.14 mmol) in ethanol (0.4 mL) was treated with 2M aqueous sodium hydroxide (0.22 mL, 0.45 mmol) and the mixture was stirred at ambient temperature for 2 hours. The mixture was then evaporated to dryness, treated with water (10 mL) and then acidified to pH 3 using 2M aqueous hydrochloric acid. The product was extracted with ethyl acetate (2 xl0 mL) and the combined organic phase was filtered through a hydrophobic frit and evaporated to dryness to afford the title compound (34 mg, 94% yield). LCMS RT=0.82 min, ES+ve m/z 268 [M+H]+.
    • 2-Hydroxy-4-(4-methylthiazol-5-yl)benzonitrile
  • Figure US20190127359A1-20190502-C00834
  • Under an atmosphere of nitrogen, a mixture of 4-bromo-2-hydroxybenzonitrile (commercially available from for example Fluorochem) (15 g, 76 mmol), 4-methylthiazole (commercially available from for example Aldrich) (14 mL, 152 mmol), potassium acetate (14.9 g, 152 mmol) and palladium(II) acetate (0.34 g, 1.52 mmol) in 1-methyl-2-pyrrolidone (125 mL) was heated at 110° C. for 3 hours. The mixture was then cooled to 50° C., poured into water (300 mL) and extracted with ethyl acetate (3×350 mL). The combined organic fraction was filtered and the filtrate was then washed with brine (3×400 mL), filtered through a hydrophobic frit and evaporated to dryness. The residue was re-evaporated from toluene then from diethyl ether and then slurried in methanol to precipitate a yellow solid which was filtered off. The filtrate was evaporated to dryness and slurried in ice-cooled methanol to afford a second batch of yellow solid. The combined solid was dried under vacuum to afford the title compound (12 g, 56 mmol, 73% yield). LCMS RT=0.75 min, ES+ve m/z 217 [M+H]+.
    • 2-(Aminomethyl)-5-(4-methylthiazol-5-yl)phenol
  • Figure US20190127359A1-20190502-C00835
  • An ice-cooled solution of 2-hydroxy-4-(4-methylthiazol-5-yl)benzonitrile (12 g, 56 mmol) in THF (550 mL) was treated dropwise with lithium aluminium hydride (1M in THF, 140 mL, 140 mmol) over 5 minutes. The resulting mixture was then heated at 50° C. for 30 minutes and additional lithium aluminium hydride (1M in THF, 20 mL, 20 mmol) was added. After a further 30 minutes the mixture was cooled in an ice bath and treated cautiously with water (14 mL), followed by aqueous sodium hydroxide (4M, 42 mL, 168 mmol) and finally water (14 mL). After standing for 3 days, the mixture was filtered and the filtered solid was washed with THF. The combined filtrate was evaporated to dryness and the residue was slurried in dichloromethane:methanol (4:1) with Celite (about 20 g) and filtered. The filtered solid was washed three times with dichloromethane/methanol (4:1) and the combined filtrate was evaporated to dryness. The product was purified by flash chromatography (330 g silica cartridge) using a gradient elution from 0 to 15% methanol in dichloromethane (+1% triethylamine) to afford the title compound (6.2 g, 28 mmol, 51% yield). LCMS RT=0.41 min, ES+ve m/z 221 [M+H]+.
    • (2S,4R)-tert-Butyl 4-hydroxy-2-((2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carboxylate
  • Figure US20190127359A1-20190502-C00836
  • An ice-cooled solution of 2-(aminomethyl)-5-(4-methylthiazol-5-yl)phenol (3.05 g, 13.8 mmol) and (2S,4R)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (2.94 mL, 13.8 mmol) in DMF (35 mL) was treated with DIPEA (7.25 mL, 42 mmol) followed by HATU (5.79 g, 15.2 mmol) and the mixture was stirred at ambient temperature for 1 hour. The mixture was treated with saturated aqueous sodium bicarbonate (50 mL) and extracted with ethyl acetate (3×80 mL). The combined organic phase was washed with brine (60 mL), filtered through a hydrophobic frit and evaporated to dryness. The product was purified by flash chromatography (330 g silica cartridge) using a gradient from 0 to 15% methanol in dichloromethane to afford the title product (4.8 g, 11 mmol, 80% yield). LCMS RT=0.76 min, ES+ve m/z 434 [M+H]+.
    • (2S,4R)-4-Hydroxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride
  • Figure US20190127359A1-20190502-C00837
  • A solution of (2S,4R)-tert-butyl 4-hydroxy-2-((2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carboxylate (4.8 g, 11 mmol) in dichloromethane:methanol 20:1 (50 mL) was treated with hydrochloric acid (4M in 1,4-dioxane) (35 mL, 140 mmol) and the mixture was stirred overnight at ambient temperature. The mixture was then evaporated to dryness and the residual solid was suspended in dichloromethane and filtered. The filtered solid was washed with further dichloromethane and dried under vacuum to afford the title compound (4 g, 10.8 mmol, 98% yield). LCMS RT=0.46 min, ES+ve m/z 334 [M+H]+.
    • (2S,4R)-1-((S)-2-Aminopropanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride
  • Figure US20190127359A1-20190502-C00838
  • A stirred mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (100 mg, 0.28 mmol), (S)-2-((tert-butoxycarbonyl)amino)propanoic acid (commercially available from for example Aldrich) (64 mg, 0.34 mmol) and DIPEA (0.197 mL, 1.13 mmol) in dry DMF (3 mL) was treated with HATU (129 mg, 0.34 mmol and stirred at ambient temperature for 30 minutes. The mixture was then partitioned between ethyl acetate (30 mL) and water (30 mL) and the organic phase was washed with brine (30 mL), dried (hydrophobic frit) and evaporated to dryness. The residue was dissolved in methanol and added to a methanol-preconditioned aminopropyl solid-phase extraction cartridge (2 g) eluting with methanol (3 column volumes). The resulting eluant was evaporated to dryness and the residue was dissolved in dichloromethane:methanol (1:1, 8 mL) and treated with hydrochloric acid, (4M in 1,4-dioxane) (1 mL, 4 mmol). The mixture was stirred at ambient temperature for 16 hours and then evaporated to dryness to afford the title compound (107 mg, 0.25 mmol, 89% yield). LCMS RT=0.51 min, ES+ve m/z 389 [M+H]+.
    • (2S,4R)-1-(2-Amino-2-methylpropanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00839
  • A solution of a mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (100 mg, 0.28 mmol), 2-((tert-butoxycarbonyl)amino)-2-methylpropanoic acid (commercially available from for example Aldrich) (69 mg, 0.34 mmol) and DIPEA (0.197 mL, 1.13 mmol) in dry DMF (3 mL) was treated with HATU (129 mg, 0.34 mmol, stirred at ambient temperature for 30 minutes and then partitioned between ethyl acetate (30 mL) and water (30 mL). The organic phase was washed with brine (30 mL), dried (hydrophobic frit) and evaporated to dryness. The residue was dissolved in methanol and added to a methanol-preconditioned aminopropyl solid-phase extraction cartridge (2 g) eluting with methanol. The resulting eluant was evaporated to dryness and the residue was dissolved in dichloromethane:methanol (1:1, 8 mL) and treated with hydrochloric acid, 4M in 1,4-dioxane (1 mL, 4 mmol). The reaction mixture was stirred at ambient temperature for 16 hours and then evaporated to dryness. The residue was suspended in dichloromethane (4 mL) and treated with TFA (1 mL) and the mixture was stirred at ambient temperature for 4 hours.
  • The mixture was evaporated to dryness and the residue was dissolved in methanol and added to a methanol-preconditioned sulfonic acid solid-phase extraction cartridge (2 g) and eluted with methanol (3 column volumes) and then with ammonia in methanol (2M, 3 column volumes). The product-containing fractions were evaporated to dryness to afford the title compound (95 mg, 0.24 mmol, 84% yield). LCMS RT=0.53 min, ES+ve m/z 403 [M+H]+.
    • (2S,4R)-4-Hydroxy-1-((S)-2-(methylamino)propanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00840
  • A stirred mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (120 mg, 0.34 mmol) and (S)-2-((tert-butoxycarbonyl)(methyl)amino)propanoic acid (commercially available from for example Aldrich) (76 mg, 0.37 mmol) in DMF (2 mL) was treated with DIPEA (0.24 mL, 1.36 mmol) and then with HATU (155 mg, 0.41 mmol), and the mixture was stirred at ambient temperature for 30 minutes. The crude product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to give the intermediate Boc-protected product. The intermediate was suspended in dichloromethane (0.5 mL) and treated with TFA (0.5 mL). The mixture was stirred at ambient temperature for 1 hour and was then evaporated to dryness. The residue was dissolved in the minimum amount of a mixture of methanol:dichloromethane (1:1), and then loaded onto a pre-conditioned (methanol) aminopropyl solid-phase extraction cartridge (5 g). The column was eluted with methanol (3 volumes) and the product-containing fractions were combined and evaporated to dryness to afford the title compound (103 mg, 75% yield). LCMS RT=0.47 min, ES+ve m/z 403 [M+H]+.
    • (2S,4R)-4-Hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)-1-((S)-morpholine-3-carbonyl)pyrrolidine-2-carboxamide, hydrochloride
  • Figure US20190127359A1-20190502-C00841
  • A mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (100 mg, 0.28 mmol), (S)-4-(tert-butoxycarbonyl)morpholine-3-carboxylic acid (commercially available from for example Astatech) (65 mg, 0.28 mmol) and DIPEA (0.247 mL, 1.41 mmol) in DMF (2 mL) was treated with HATU (118 mg, 0.311 mmol) and stirred at ambient temperature for 30 minutes. The Boc protected intermediate was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier). The intermediate was dissolved in methanol:dichloromethane (1:1, 3 mL), treated with hydrochloric acid in 1,4-dioxane (4M, 3 mL, 12 mmol) and allowed to stand for 1 hour. The mixture was evaporated to dryness to afford the title compound (110 mg, 0.24 mmol, 83% yield). LCMS RT=0.50 min, ES+ve m/z 431/432 [M+H]+.
    • Tert-butyl 4-(3-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)phenoxy)butanoate
  • Figure US20190127359A1-20190502-C00842
  • A solution of a mixture of 3-(4-(tert-butoxy)-4-oxobutoxy)benzoic acid (95 mg, 0.34 mmol), (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (100 mg, 0.28 mmol) and DIPEA (0.2 mL, 1.15 mmol) in dry DMF (3 mL) was treated with HATU (129 mg, 0.34 mmol) and the mixture was stirred at ambient temperature for 30 minutes. The mixture was added to an aminopropyl solid-phase extraction cartridge and eluted with methanol (3 column volumes). The resulting eluant was evaporated to dryness and the product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (130 mg, 0.22 mmol, 79% yield). LCMS RT=0.98 min, ES+ve m/z 580 [M+H]+.
    • Example—VHL Protac Which Binds Estrogen Receptor (Estrogen Protacts) Abbreviations
    • DCM: dichloromethane.
    • DIPEA: N,N-diisopropylethylamine.
    • DMF: N,N-dimethylformamide.
    • HATU: 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate.
    • HPLC: high-performance liquid chromatography.
    • LCMS: liquid chromatography-mass spectrometry
    • Min: minutes.
    • RT: retention time.
    • tBu: tert-butoxide.
    • TFA: trifluoroacetic acid.
    • THF: tetrahydrofuran.
    LCMS Method:
  • The analysis was conducted on an Acquity UPLC BEH C18 column (50 mm×2.1 mm internal diameter 1.7 μm packing diameter) at 40° C.
  • The solvents employed were:
  • A=0.1% v/v solution of formic acid in water.
    B=0.1% v/v solution of formic acid in acetonitrile.
  • The gradient employed was as follows:
  • Time Flow Rate
    (minutes) (mL/min) % A % B
    0 1 97 3
    1.5 1 0 100
    1.9 1 0 100
    2.0 1 97 3
  • The UV detection was an averaged signal from wavelength of 210 nm to 350 nm and mass spectra were recorded on a mass spectrometer using alternate-scan positive and negative mode electrospray ionization.
  • The following illustrates the mobile phases and gradients used when compounds underwent purification by mass-directed autopreparative HPLC.
    • Mass-Directed Autopreparative HPLC (Formic Acid Modifier)
  • The HPLC analysis was conducted on a Sunfire C18 column (150 mm×30 mm internal diameter, 5 m packing diameter) at ambient temperature.
  • The solvents employed were:
  • A=0.1% v/v solution of formic acid in water.
    B=0.1% v/v solution of formic acid in acetonitrile.
    • Mass-Directed Autopreparative HPLC (Trifluoroacetic Acid Modifier)
  • The HPLC analysis was conducted on a Sunfire C18 column (150 mm×30 mm internal diameter, 5 m packing diameter) at ambient temperature.
  • The solvents employed were:
  • A=0.1% v/v solution of trifluoroacetic acid in water.
    B=0.1% v/v solution of trifluoroacetic acid in acetonitrile.
    • Mass-Directed Autopreparative HPLC (Ammonium Bicarbonate Modifier)
  • The HPLC analysis was conducted on an XBridge C18 column (150 mm×30 mm internal diameter, 5 m packing diameter) at ambient temperature.
  • The solvents employed were:
  • A=10 mM ammonium bicarbonate in water adjusted to pH 10 with ammonia solution.
    B=acetonitrile.
  • For each of the mass-directed autopreparative purifications, irrespective of the modifier used, the gradient employed was dependent upon the retention time of the particular compound undergoing purification as recorded in the analytical LCMS, and was as follows:
  • For compounds with an analytical LCMS retention time below 0.6 minutes the following gradient was used:
  • Time Flow Rate
    (minutes) (mL/min) % A % B
    0 40 99 1
    1 40 99 1
    10 40 70 30
    11 40 1 99
    15 40 1 99
  • For compounds with an analytical LCMS retention time between 0.6 and 0.9 minutes the following gradient was used:
  • Time Flow Rate
    (minutes) (mL/min) % A % B
    0 40 85 15
    1 40 85 15
    10 40 45 55
    11 40 1 99
    15 40 1 99
  • For compounds with an analytical LCMS retention time between 0.9 and 1.2 minutes the following gradient was used:
  • Time Flow Rate
    (minutes) (mL/min) % A % B
     0 40 70 30
     1 40 70 30
    10 40 15 85
    11 40 1 99
    15 40 1 99
  • For compounds with an analytical LCMS retention time between 1.2 and 1.4 minutes the following gradient was used:
  • Time Flow Rate
    (minutes) (mL/min) % A % B
    0 40 50 50
    1 40 50 50
    10 40 1 99
    11 40 1 99
    15 40 1 99
  • For compounds with an analytical LCMS retention time greater than 1.4 minutes (LCMS method A) or greater than 3.6 minutes (LCMS method B) the following gradient was used:
  • Time Flow Rate
    (minutes) (mL/min) % A % B
    0 40 20 80
    1 40 20 80
    10 40 1 99
    11 40 1 99
    15 40 1 99
  • The UV detection was an averaged signal from wavelength of 210 nm to 350 nm and mass spectra were recorded on a mass spectrometer using alternate-scan positive and negative mode electrospray ionization.
  • The chemical names were generated using ACD Name Pro version 6.02 from Advanced Chemistry Development, Inc.
    • 8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one
  • Figure US20190127359A1-20190502-C00843
  • (8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one can be prepared according to the process described by Xiang-Rong Jiang, J. Walter Sowell, Bao Ting Zhu, Steroids, 2006, 71, 334-342. (doi:10.1016/j.steroids. 2005.11.008).
    • 15-Bromo-1-phenyl-2,5,8,11-tetraoxapentadecane
  • Figure US20190127359A1-20190502-C00844
  • To a suspension of sodium hydride, 60% w/w in mineral oil (0.250 g, 6.24 mmol) in DMF (2 mL) was added a solution of 2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethanol (1 g, 4.16 mmol) (commercially available from for example Fluorochem) in DMF (2 mL) at 0° C. After stirring for 25 minutes, 1,4-dibromobutane (commercially available from for example Aldrich) (4.04 g, 18.73 mmol) dissolved in DMF (2 mL) was added dropwise to the mixture. The reaction was stirred under an atmosphere of nitrogen for 2.5 hours. A further aliquot of sodium hydride, 60% w/w in mineral oil (0.250 g, 6.24 mmol) was added and the reaction was stirred at 0° C. for 30 minutes. The reaction was warmed to room temperature and stirred for 30 minutes. A final aliquot of sodium hydride, 60% w/w in mineral oil (0.250 g, 6.24 mmol) was added and the reaction stirred at room temperature for 2 hours then left standing over the weekend. The reaction mixture was filtered through celite and the solid washed with DCM. The filtrate was partitioned between DCM (30 mL) and water (30 mL). The organic extract was washed with brine (2×30 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% methyl tert-butyl ether in cyclohexane to afford the title compound (711 mg, 1.89 mmol, 46% yield). LCMS RT=1.16 min, ES+ve m/z 375.2/377.1 [M+H]+.
    • 15-Iodo-1-phenyl-2,5,8,11-tetraoxapentadecane
  • Figure US20190127359A1-20190502-C00845
  • A mixture of 15-bromo-1-phenyl-2,5,8,11-tetraoxapentadecane (711 mg, 1.894 mmol) and sodium iodide (568 mg, 3.79 mmol) in acetone (10 mL) was heated under reflux conditions for 4 hours. The reaction was cooled to room temperature. The mixture was filtered through celite and the solid washed with acetone. The solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate (30 mL) and washed with water (30 mL) and brine (2×30 mL). The organic extract was dried using a hydrophobic frit and concentrated under reduced pressure to afford the title compound (759 mg, 1.797 mmol, 95% yield). LCMS RT=1.23 min, ES+ve m/z 440.0 [M+NH4]+.
    • (7S,8R,9S,13S,14S,17S)-3,17-Bis(methoxymethoxy)-13-methyl-7-(1-phenyl-2,5,8,11-tetraoxapentadecan-15-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one
  • Figure US20190127359A1-20190502-C00846
  • A solution of KOtBu in THF (1M, 1.282 mL, 1.282 mmol) was added to a cooled solution (0° C.) of (8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one (240 mg, 0.641 mmol) in anhydrous THF (2 mL). The reaction mixture was stirred at 0° C. for 45 minutes and then cooled to −78° C. A solution of 15-iodo-1-phenyl-2,5,8,11-tetraoxapentadecane (789 mg, 1.868 mmol) in THF (1 mL) was added dropwise. The solution was stirred at −78° C. for 2 minutes, allowed to warm to 0° C. and stirred for 1.5 hours at that temperature. The reaction was partitioned between water (30 mL) and ethyl acetate (30 mL). The organic extract was dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% ethyl acetate in cyclohexane to afford the title compound (234 mg, 0.350 mmol, 55% yield). LCMS RT=1.48 min, ES+ve m/z 669.3 [M+H]+, 686.4 [M+NH4]+.
    • (7S,8R,9S,13S,14S,17S)-3,17-Dihydroxy-13-methyl-7-(1-phenyl-2,5,8,11-tetraoxapentadecan-15-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one
  • Figure US20190127359A1-20190502-C00847
  • A solution of aqueous HCl (6M, 2.3 mL, 13.80 mmol) was added to a solution of (7S,8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7-(1-phenyl-2,5,8,11-tetraoxapentadecan-15-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one (234 mg, 0.350 mmol) in THF (2.3 mL). The reaction mixture was stirred at room temperature for 16 hours. Water (30 mL) was added and the product was extracted with ethyl acetate (50 mL). The organic extract was washed with brine (2×30 mL), dried using a hydrophobic frit and concentrated under reduced pressure to afford the title compound (200 mg, 0.344 mmol, 98% yield). LCMS RT=1.07 min, ES+ve m/z 581.3 [M+H]+, 598.3 [M+NH4]+.
    • (7R,8R,9S,13S,14S,17S)-13-Methyl-7-(1-phenyl-2,5,8,11-tetraoxapentadecan-15-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
  • Figure US20190127359A1-20190502-C00848
  • Triethylsilane (commercially available from for example Aldrich) (0.550 mL, 3.44 mmol) was added to a solution of (7S,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7-(1-phenyl-2,5,8,11-tetraoxapentadecan-15-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one (200 mg, 0.344 mmol) in TFA (2 mL, 26.0 mmol). The reaction was stirred at room temperature under an atmosphere of nitrogen for 16 hours. The mixture was partitioned between ethyl acetate (30 mL) and brine (30 mL). The organic extract was washed with brine (2×30 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The residue was dissolved in MeOH (5 mL) and treated with aqueous NaOH (2M, 5 mL, 10.00 mmol). The reaction mixture was stirred at room temperature for 3 hours. The solvent was removed under reduced pressure. The residue was partitioned between ethyl acetate (30 mL) and a 10% citric acid solution (30 mL). The organic extract was washed with brine (30 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by reverse phase chromatography using a gradient elution from 5% to 95% acetonitrile (+0.1% formic acid) in water (+0.1% formic acid) to afford the title compound (150 mg, 0.265 mmol, 77% yield). LCMS RT=1.18 min, ES+ve m/z 567.3 [M+H]+, 584.3 [M+NH4]+.
    • 15-((7R,8R,9S,13S,14S,17S)-3,17-Bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-1-phenyl-2,5,8,11-tetraoxapentadecane
  • Figure US20190127359A1-20190502-C00849
  • A vial was charged with (7R,8R,9S,13S,14S,17S)-13-methyl-7-(1-phenyl-2,5,8,11-tetraoxapentadecan-15-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol (150 mg, 0.265 mmol) and DIPEA (0.555 mL, 3.18 mmol) in THF (10 mL). The vial was sealed, the solution was cooled to 0° C. and chloro(methoxy)methane (commercially available from for example Aldrich) (0.2 mL, 2.63 mmol) was added. The reaction mixture was warmed to room temperature, stirred for 1 hour and heated at 70° C. for 40 hours. The reaction was cooled to room temperature. The reaction was partitioned between ethyl acetate (100 mL) and water (100 mL). The organic extract was washed with brine (2×50 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% methyl tert-butyl ether in cyclohexane to afford the title compound (122 mg, 0.186 mmol, 70% yield). LCMS RT=1.60 min, ES+ve m/z 672.5 [M+NH4]+.
    • 2-(2-(2-(4-((7R,8R,9S,13S,14S,17S)-3,17-Bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)butoxy)ethoxy)ethoxy)ethanol
  • Figure US20190127359A1-20190502-C00850
  • A mixture of 15-((7R,8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-1-phenyl-2,5,8,11-tetraoxapentadecane (115 mg, 0.176 mmol) and 10% w/w palladium on carbon (100 mg, 0.094 mmol) in ethanol (4 mL) was stirred at room temperature under an atmosphere of hydrogen for 1.5 hours. The palladium on carbon was filtered through celite and the filtrate evaporated under reduced pressure. The residue was partitioned between ethyl acetate (15 mL) and brine (15 mL). The organic extract was dried using a hydrophobic frit and concentrated under reduced pressure to afford the title compound (81 mg, 0.143 mmol, 82% yield). LCMS RT=1.36 min, ES+ve m/z 582.4 [M+NH4]+.
    • Tert-butyl 16-((7R,8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3,6,9,12-tetraoxahexadecan-1-oate
  • Figure US20190127359A1-20190502-C00851
  • Sodium hydride, 60% w/w in mineral oil (10 mg, 0.250 mmol) was added to a cooled solution (0° C.) of 2-(2-(2-(4-((7R,8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)butoxy)ethoxy)ethoxy)ethanol (81 mg, 0.143 mmol) in DMF (2 mL). The reaction was stirred at that temperature for 10 minutes and tert-butyl 2-bromoacetate (commercially available from for example Aldrich) (32 μL, 0.217 mmol) was added. The reaction was stirred at 0° C. for 1 hour and at room temperature for further 2 hours. The reaction mixture was partitioned between ethyl acetate (30 mL) and water (30 mL). The organic layer was washed with brine (30 mL), dried (hydrophobic frit) and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% methyl tert-butyl ether in cyclohexane to afford the title compound (60 mg, 0.088 mmol, 62% yield). LCMS RT=1.57 min, ES+ve m/z 696.5 [M+NH4]+.
    • 16-((7R,8R,9S,13S,14S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3,6,9,12-tetraoxahexadecan-1-oic acid
  • Figure US20190127359A1-20190502-C00852
  • Tert-butyl 16-((7R,8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3,6,9,12-tetraoxahexadecan-1-oate (133 mg, 0.196 mmol) was dissolved in THF (1.5 mL) and treated with aqueous HCl (6M, 1.5 mL, 9.00 mmol). The reaction mixture was stirred at room temperature for 8 hours. The reaction mixture was subjected directly to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (60 mg, 0.112 mmol, 57% yield). LCMS RT=0.89 min, ES+ve m/z 535.3 [M+H]+, 552.3 [M+NH4]+.
    • (2S,4R)-1-((S)-19-((7R,8R,9S,13S,14S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-2-isopropyl-4-oxo-6,9,12,15-tetraoxa-3-azanonadecan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00853
  • HATU (16 mg, 0.042 mmol) was added to a mixture of (2S,4R)-1-((S)-2-amino-3-methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (25 mg, 0.055 mmol), 16-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3,6,9,12-tetraoxahexadecan-1-oic acid (15 mg, 0.028 mmol) and DIPEA (0.05 mL, 0.286 mmol) in DMF (1 mL). The reaction was stirred at room temperature for 30 minutes. The reaction mixture was subjected directly to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (20 mg, 0.021 mmol, 76% yield). LCMS RT=0.99 min, ES+ve m/z 933.3 [M+H]+.
    • (2S,4R)-1-((S)-2-(Tert-butyl)-19-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-1-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-4-oxo-6,9,12,15-tetraoxa-3-azanonadecan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00854
  • HATU (22 mg, 0.058 mmol) was added to a mixture of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (25 mg, 0.054 mmol), 16-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3,6,9,12-tetraoxahexadecan-1-oic acid (23 mg, 0.043 mmol) and DIPEA (0.040 mL, 0.229 mmol) in DMF (1 mL). The reaction was stirred at room temperature for 10 minutes. The reaction mixture was subjected directly to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (26 mg, 0.027 mmol, 64% yield). LCMS RT=1.02 min, ES+ve m/z 947.8 [M+H]+.
    • ((2-(2-(4-Bromobutoxy)ethoxy)ethoxy)methyl)benzene
  • Figure US20190127359A1-20190502-C00855
  • To a suspension of sodium hydride, 60% w/w in mineral oil (0.92 g, 22.9 mmol) in DMF (5 mL) was added a solution of 2-(2-(benzyloxy)ethoxy)ethanol (commercially available from for example Aldrich) (2.74 mL, 15.29 mmol) in DMF (5 mL) at 0° C. After stirring for 25 min, 1,4-dibromobutane (commercially available from for example Aldrich) (14.9 g, 68.8 mmol) dissolved in DMF (5 mL) was added dropwise to the mixture. The reaction was warmed to ambient temperature and stirred under an atmosphere of nitrogen for 2.5 hours. A further aliquot of sodium hydride, 60% w/w in mineral oil (0.92 g, 22.9 mmol) was added and the reaction was stirred at 0° C. for 30 minutes and at ambient temperature for 30 minutes. A final aliquot of sodium hydride, 60% w/w in mineral oil (0.92 g, 22.9 mmol) was added and the reaction stirred at ambient temperature for 2 hours then left standing overnight. The reaction mixture was filtered through celite and the solid washed with DCM. The filtrate was partitioned between DCM (30 mL) and water (30 mL). The organic extract was washed with brine (2×30 mL), dried using a hydrophobic frit, and concentrated under reduced pressure. The product was purified by chromatography on silica using a using a gradient elution from 0% to 80% methyl tert-butyl ether in cyclohexane to afford the title compound (3 g, 9.06 mmol, 59% yield). LCMS RT=1.19 min, ES+ve m/z 331.2/333.2 [M+H]+.
    • ((2-(2-(4-Iodobutoxy)ethoxy)ethoxy)methyl)benzene
  • Figure US20190127359A1-20190502-C00856
  • A mixture of ((2-(2-(4-bromobutoxy)ethoxy)ethoxy)methyl)benzene (3 g, 9.06 mmol) and sodium iodide (2.72 g, 18.11 mmol) in acetone (10 mL) was heated under reflux conditions for 3 hours. The reaction was cooled to room temperature. The mixture was filtered through celite and the solid washed with acetone. The solvent was removed under reduced pressure and the residue was dissolved in ethyl acetate (30 mL) and washed with water (30 mL) and brine (2×30 mL). The organic extract was dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a using a gradient elution from 0% to 50% methyl tert-butyl ether in cyclohexane to afford the title compound (3.1 g, 8.2 mmol, 90% yield). LCMS RT=1.25 min, ES+ve m/z 379.2 [M+H]+.
    • (7S,8R,9S,13S,14S,17S)-7-(4-(2-(2-(Benzyloxy)ethoxy)ethoxy)butyl)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one
  • Figure US20190127359A1-20190502-C00857
  • A solution of KOtBu, in THF (1M, 3.2 mL, 3.2 mmol) was added to a cooled solution (0° C.) of (8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one (600 mg, 1.6 mmol) in anhydrous THF (6 mL). The reaction mixture was stirred at 0° C. for 45 minutes and then cooled to −78° C. A solution of ((2-(2-(4-Iodobutoxy)ethoxy)ethoxy)methyl)benzene (910 mg, 2.4 mmol) in THF (3 mL) was added dropwise. The solution was stirred at −78° C. for 2 minutes then allowed to warm to 0° C. and stirred for 1.5 hours at that temperature. The reaction was partitioned between water (30 mL) and ethyl acetate (30 mL). The organic extract was separated, dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 50% ethyl acetate in cyclohexane to afford the title compound (450 mg, 0.72 mmol, 45% yield). LCMS RT=1.49 min, ES+ve m/z 625.5 [M+H]+.
    • (7S,8R,9S,13S,14S,17S)-7-(4-(2-(2-(Benzyloxy)ethoxy)ethoxy)butyl)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one
  • Figure US20190127359A1-20190502-C00858
  • A solution of aqueous HCl (6M, 4.6 mL, 27.6 mmol) was added to a solution of (7S,8R,9S,13S,14S,17S)-7-(4-(2-(2-(benzyloxy)ethoxy)ethoxy)butyl)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one (470 mg, 0.752 mmol) in THF (4.6 mL). The reaction mixture was stirred at room temperature for 18 hours. Water (30 mL) was added and the product was extracted with ethyl acetate (50 mL). The organic extract was washed with brine (2×30 mL), dried using a hydrophobic frit and concentrated under reduced pressure to afford the title compound (390 mg, 0.727 mmol, 97% yield). LCMS RT=1.08 min, ES+ve m/z 537.2 [M+H]+, 554.2 [M+NH4]+.
    • (7R,8R,9S,13S,14S,17S)-7-(4-(2-(2-(Benzyloxy)ethoxy)ethoxy)butyl)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
  • Figure US20190127359A1-20190502-C00859
  • Triethylsilane (commercially available from for example Aldrich) 1.161 mL, 7.27 mmol) was added to a solution of (7S,8R,9S,13S,14S,17S)-7-(4-(2-(2-(benzyloxy)ethoxy)ethoxy)butyl)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one (390 mg, 0.727 mmol) in TFA (4.2 mL, 54.5 mmol). The reaction was stirred at room temperature under an atmosphere of nitrogen for 18 hours. The mixture was partitioned between ethyl acetate (50 mL) and brine (50 mL). The organic extract was washed with brine (2×30 mL), saturated sodium bicarbonate (30 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The residue was dissolved in MeOH (10 mL) and treated with aqueous NaOH (2M, 5 mL, 10.0 mmol). The reaction mixture was stirred at room temperature for 1 hour. The solvent was removed under reduced pressure. The residue was partitioned between ethyl acetate (30 mL) and aqueous HCl solution (1M, 20 mL). The organic extract was washed with brine (20 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by reverse phase chromatography using a gradient elution from 5% to 95% acetonitrile (+0.1% formic acid) in water (+0.1% formic acid) to afford the title compound (270 mg, 0.517 mmol, 71% yield). LCMS RT=1.18 min, ES+ve m/z 523.5 [M+H]+, 540.5 [M+NH4]+.
    • (7R,8R,9S,13S,14S,17S)-7-(4-(2-(2-(Benzyloxy)ethoxy)ethoxy)butyl)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene
  • Figure US20190127359A1-20190502-C00860
  • Chloro(methoxy)methane (commercially available from for example Aldrich) (0.390 mL, 5.14 mmol) was added to a cooled (0° C.) solution of (7R,8R,9S,13S,14S,17S)-7-(4-(2-(2-(benzyloxy)ethoxy)ethoxy)butyl)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol (270 mg, 0.517 mmol) and DIPEA (1.083 mL, 6.20 mmol) in THF (16 mL). The reaction mixture was warmed to room temperature, stirred for 1 hour and then heated at 70° C. for 40 hours. The reaction mixture was cooled to 0° C., additional DIPEA (0.271 mL, 1.550 mmol) and chloro(methoxy)methane (0.098 mL, 1.291 mmol) was added. The reaction was heated to 70° C. and stirred for a further 24 hours. The reaction was cooled to room temperature, and was partitioned between ethyl acetate (100 mL) and water (100 mL). The organic extract was washed with brine (2×50 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% methyl tert-butyl ether in cyclohexane to afford the title compound (220 mg, 0.36 mmol, 70% yield). LCMS RT=1.62 min, ES+ve m/z 628.6 [M+NH4]+.
    • 2-(2-(4-((7R,8R,9S,13S,14S,17S)-3,17-Bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)butoxy)ethoxy)ethanol
  • Figure US20190127359A1-20190502-C00861
  • A mixture of (7R,8R,9S,13S,14S,17S)-7-(4-(2-(2-(benzyloxy)ethoxy)ethoxy)butyl)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene (220 mg, 0.36 mmol) and 10% w/w palladium on carbon (100 mg, 0.094 mmol) in ethanol (4 mL) was stirred at room temperature under an atmosphere of hydrogen for 1 hour. The palladium on carbon was filtered through celite, washed with ethanol (50 ml) and the filtrate was evaporated under reduced pressure to afford the title compound (186 mg, 0.357 mmol, 99% yield) LCMS RT=1.36 min, ES+ve m/z 521.5 [M+H]+, 538.5 [M+NH4]+.
    • Tert-butyl 2-(2-(2-(4-((7R,8R,9S,13S,14S,17S)-3,17-iso(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta [a]phenanthren-7-yl)butoxy)ethoxy)ethoxy)acetate
  • Figure US20190127359A1-20190502-C00862
  • Sodium hydride, 60% w/w mineral oil (25.0 mg, 0.625 mmol) was added to a cooled solution (0° C.) of 2-(2-(4-((7R,8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)butoxy)ethoxy)ethanol (186 mg, 0.357 mmol) in DMF (4.5 mL). The reaction was stirred at 0° C. for 10 minutes and tert-butyl 2-bromoacetate (commercially available from for example Aldrich) (79 μL, 0.536 mmol) was added. The reaction was stirred at 0° C. for 1 hour and at room temperature for a further 6 hours. The reaction was cooled to 0° C. and additional sodium hydride, 60% w/w in mineral oil (15.72 mg, 0.393 mmol), followed by tert-butyl 2-bromoacetate (0.053 mL, 0.357 mmol) was added. The reaction was stirred at room temperature for a further 18 hours. The reaction mixture was partitioned between ethyl acetate (30 mL) and water (30 mL). The organic layer separated, washed with brine (30 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% methyl tert-butyl ether in cyclohexane to afford the title compound (90 mg, 0.142 mmol, 40% yield). LCMS RT=1.56 min, ES+ve m/z 652.6 [M+NH4]+, 657.5 [M+Na]+.
    • 2-(2-(2-(4-((7R,8R,9S,13S,14S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)butoxy)ethoxy)ethoxy)acetic acid
  • Figure US20190127359A1-20190502-C00863
  • Tert-butyl 2-(2-(2-(4-((7R,8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)butoxy)ethoxy)ethoxy)acetate (80 mg, 0.126 mmol) was dissolved in THF (1 mL) and treated with aqueous HCl (6M, 1 mL, 6.0 mmol). The reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was subjected directly to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (23 mg, 0.047 mmol, 37% yield). LCMS RT=0.89 min, ES+ve m/z 491.4 [M+H]+.
    • (2S,4R)-1-((S)-16-((7R,8R,9S,13S,14S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-2-isopropyl-4-oxo-6,9,12-trioxa-3-azahexadecan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00864
  • HATU (12 mg, 0.03 mmol) was added to a mixture of (2S,4R)-1-((S)-2-amino-3-methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (23 mg, 0.05 mmol), 2-(2-(2-(4-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)butoxy)ethoxy)ethoxy)acetic acid (10 mg, 0.02 mmol) and DIPEA (0.04 mL, 0.20 mmol) in DMF (0.8 mL). The reaction was stirred at room temperature for 30 min. The reaction mixture was subjected directly to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (15 mg, 0.017 mmol, 84% yield). LCMS RT=0.98 min, ES+ve m/z 889.7 [M+H]+.
    • 18-Bromo-1-phenyl-2,5,8,11,14-pentaoxaoctadecane
  • Figure US20190127359A1-20190502-C00865
  • To a suspension of sodium hydride, 60% w/w in mineral oil (0.85 g, 21.3 mmol) in DMF (8 mL) was added a solution of 1-phenyl-2,5,8,11-tetraoxatridecan-13-ol (commercially available from for example TCI Europe Fine Chemicals) (4.0 g, 14.2 mmol) in DMF (8 mL) at 0° C. After stirring for 25 minutes, 1,4-dibromobutane (commercially available from for example Aldrich) (7.62 mL, 63.8 mmol) dissolved in DMF (8 mL) was added dropwise to the mixture. The reaction was warmed to room temperature and stirred under an atmosphere of nitrogen for 30 minutes. A further aliquot of sodium hydride, 60% w/w in mineral oil (0.85 g, 21.3 mmol) was added and the reaction was stirred at room temperature overnight. Another aliquot of sodium hydride, 60% w/w in mineral oil (0.85 g, 21.3 mmol) was added and the reaction stirred at room temperature for 2 hours. A final aliquot of sodium hydride, 60% w/w in mineral oil (0.43 g, 10.6 mmol) was added and the reaction stirred at room temperature for 1 hour. The reaction mixture was filtered through celite and the solid washed with DCM. The filtrate was partitioned between DCM (50 mL) and water (50 mL). The organic extract was washed with brine (2×50 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 85% methyl tert-butyl ether in cyclohexane to afford the title compound (3.93 g, 9.37 mmol, 63% yield). LCMS RT=1.16 min, ES+ve m/z 419.3/421.2 [M+H]+.
    • 18-Iodo-1-phenyl-2,5,8,11,14-pentaoxaoctadecane
  • Figure US20190127359A1-20190502-C00866
  • A mixture of 18-bromo-1-phenyl-2,5,8,11,14-pentaoxaoctadecane (2.08 g, 4.91 mmol) and sodium iodide (1.47 g, 9.82 mmol) in acetone (10 mL) was heated under reflux conditions for 3 hours. The reaction was cooled to room temperature, filtered through celite and the solid was washed with acetone. The solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate (30 mL), and washed with water (30 mL) and brine (2×30 mL). The organic extract was dried using a hydrophobic frit and concentrated under reduced pressure to afford the title compound (759 mg, 1.80 mmol, 95% yield). LCMS RT=1.21 min, ES+ve m/z 467.0 [M+H]+, 484.0 [M+NH4]+.
    • (7S,8R,9S,13S,14S,17S)-3,17-Bis(methoxymethoxy)-13-methyl-7-(1-phenyl-2,5,8,11,14-pentaoxaoctadecan-18-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one
  • Figure US20190127359A1-20190502-C00867
  • A solution of KOtBu in THF (1M, 5.34 mL, 5.34 mmol) was added to a cooled solution (0° C.) of (8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one (1 g, 2.67 mmol) in anhydrous THF (10 mL). The reaction mixture was stirred at 0° C. for 45 minutes and then cooled to −78° C. 18-Iodo-1-phenyl-2,5,8,11,14-pentaoxaoctadecane (1.87 g, 4.01 mmol) in THF (5 mL) was added dropwise. The solution was stirred at −78° C. for 2 minutes, allowed to warm to 0° C. and stirred for 1.5 hours at that temperature. The reaction was partitioned between water (50 mL) and ethyl acetate (2×50 mL). The organic extracts were dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% ethyl acetate in cyclohexane to afford the title compound (883 mg, 1.24 mmol, 46% yield). LCMS RT=1.47 min, ES+ve m/z 713.5 [M+H]+.
    • (7S,8R,9S,13S,14S,17S)-3,17-Dihydroxy-13-methyl-7-(1-phenyl-2,5,8,11,14-pentaoxaoctadecan-18-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one
  • Figure US20190127359A1-20190502-C00868
  • A solution of aqueous HCl (6M, 9.2 mL, 55.2 mmol) was added to a solution of (7S,8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7-(1-phenyl-2,5,8,11,14-pentaoxaoctadecan-18-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one (883 mg, 1.24 mmol) in THF (9.2 mL). The reaction mixture was stirred at room temperature for 18 hours. Water (30 mL) was added and the product was extracted with ethyl acetate (50 mL). The organic extract was washed with brine (2×30 mL), dried using a hydrophobic frit and concentrated under reduced pressure to afford the title compound (772 mg, 1.23 mmol, 99% yield). LCMS RT=1.06 min, ES+ve m/z 625.3 [M+H]+, 642.3 [M+NH4]+.
    • (7R,8R,9S,13S,4S,17S)-3-Methyl-7-(1-phenyl-2,5,8,11,14-pentaoxaoctadecan-18-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
  • Figure US20190127359A1-20190502-C00869
  • Triethylsilane (commercially available from for example Aldrich) (2.0 mL, 12.9 mmol) was added to a solution of (7S,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7-(1-phenyl-2,5,8,11,14-pentaoxaoctadecan-18-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one (830 mg, 1.29 mmol) in TFA (8.5 mL, 110 mmol). The reaction was stirred at room temperature under an atmosphere of nitrogen for 16 hours. The mixture was partitioned between ethyl acetate (50 mL) and brine (50 mL). The organic extract was washed with brine (2×50 mL), saturated sodium bicarbonate (50 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The residue was dissolved in MeOH (10 mL) and treated with aqueous NaOH (2M, 10 mL, 20.0 mmol). The reaction mixture was stirred at room temperature for 1 hour. The solvent was removed under reduced pressure. The residue was partitioned between ethyl acetate (40 mL) and 1M HCl solution (20 mL). The organic extract was washed with brine (20 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by reverse phase chromatography using a gradient elution from 5% to 90% acetonitrile (+0.1% formic acid) in water (+0.1% formic acid) to afford the title compound (375 mg, 0.614 mmol, 47% yield). LCMS RT=1.17 min, ES+ve m/z 611.5 [M+H]+, 628.6 [M+NH4]+.
    • 18-((7R,8R,9S,13S,14S,17S)-3,17-Bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-1-phenyl-2,5,8,11,14-pentaoxaoctadecane
  • Figure US20190127359A1-20190502-C00870
  • Chloro(methoxy)methane (commercially available from for example Aldrich) (0.5 mL, 6.58 mmol) was added to a cooled (0° C.) solution of (7R,8R,9S,13S,14S,17S)-13-methyl-7-(1-phenyl-2,5,8,11,14-pentaoxaoctadecan-18-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol (375 mg, 0.614 mmol) and DIPEA (1.5 mL, 8.59 mmol) in THF (20 mL). The reaction mixture was warmed to room temperature, stirred for 1 hour and heated at 70° C. for 72 hours. The reaction was cooled to room temperature. The reaction was partitioned between ethyl acetate (100 mL) and water (100 mL). The organic extract was washed with brine (2×50 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% methyl tert-butyl ether in cyclohexane to afford the title compound (357 mg, 0.51 mmol, 72% yield). LCMS RT=1.60 min, ES+ve m/z 716.7 [M+NH4]+, 721.7 [M+Na]+.
    • 16-((7R,8R,9S,13S,14S,17S)-3,17-Bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3,6,9,12-tetraoxahexadecan-1-ol
  • Figure US20190127359A1-20190502-C00871
  • A mixture of 18-((7R,8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-1-phenyl-2,5,8,11,14-pentaoxaoctadecane (357 mg, 0.444 mmol) and 10% w/w palladium on carbon (157 mg, 0.148 mmol) in ethanol (5 mL) was stirred at room temperature under an atmosphere of hydrogen for 1.5 hours. The palladium on carbon was filtered through celite and the filtrate evaporated under reduced pressure to afford the title compound (300 mg, 0.41 mmol, 93% yield) LCMS RT=1.37 min, ES+ve m/z 609.6 [M+H]+, 631.6 [M+Na]+.
    • Tert-butyl 19-((7R,8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3,6,9,12,15-pentaoxanonadecan-1-oate
  • Figure US20190127359A1-20190502-C00872
  • Sodium hydride, 60% w/w in mineral oil (30 mg, 0.75 mmol) was added to a cooled solution (0° C.) of 16-((7R,8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3,6,9,12-tetraoxahexadecan-1-ol (300 mg, 0.43 mmol) in DMF (5 mL). The reaction was stirred at that temperature for 10 minutes and tert-butyl 2-bromoacetate (0.095 mL, 0.643 mmol) was added. The reaction was stirred at 0° C. for 1 hour and then at room temperature for a further 18 hours. The reaction mixture was partitioned between ethyl acetate (30 mL) and water (30 mL). The water layer was extracted with additional ethyl acetate (2×30 mL), and the combined organic layers were washed with brine (2×30 mL), dried (hydrophobic frit) and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% methyl tert-butyl ether in cyclohexane to afford the title compound (177 mg, 0.245 mmol, 57% yield). LCMS RT=1.58 min, ES+ve m/z 740.6 [M+NH4]+, 745.6 [M+Na]+.
    • 19-((7R,8R,9S,13S,14S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3,6,9,12,15-pentaoxanonadecan-1-oic acid
  • Figure US20190127359A1-20190502-C00873
  • Tert-butyl 19-((7R,8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3,6,9,12,15-pentaoxanonadecan-1-oate (177 mg, 0.189 mmol) was dissolved in THF (2 mL) and treated with aqueous HCl (6M, 2 mL, 12.0 mmol). The reaction mixture was stirred at room temperature for 7 hours. The reaction mixture was subjected directly to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (64 mg, 0.111 mmol, 59% yield). LCMS RT=0.92 min, ES+ve m/z 579.4 [M+H]+, 596.5 [M+NH4]+.
    • (2S,4R)-1-((S)-22-((7R,8R,9S,13S,14S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-2-isopropyl-4-oxo-6,9,12,15,18-pentaoxa-3-azadocosan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00874
  • HATU (16 mg, 0.04 mmol) was added to a mixture of (2S,4R)-1-((S)-2-amino-3-methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (25 mg, 0.06 mmol), 19-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3,6,9,12,15-pentaoxanonadecan-1-oic acid (16 mg, 0.03 mmol) and DIPEA (0.048 mL, 0.28 mmol) in DMF (0.8 mL). The reaction was stirred at room temperature for 30 minutes. The reaction mixture was subjected directly to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (17.7 mg, 0.018 mmol, 65% yield). LCMS RT=0.99 min, ES+ve m/z 977.4 [M+H]+.
    • (2S,4R)-1-((S)-2-(Tert-butyl)-22-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-4-oxo-6,9,12,15,18-pentaoxa-3-azadocosan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00875
  • HATU (16 mg, 0.04 mmol) was added to a mixture of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (25 mg, 0.05 mmol), 19-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3,6,9,12,15-pentaoxanonadecan-1-oic acid (16 mg, 0.03 mmol) and DIPEA (0.048 mL, 0.28 mmol) in DMF (0.8 mL). The reaction was stirred at room temperature for 30 minutes. The reaction mixture was subjected directly to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (17.5 mg, 0.017 mmol, 63% yield). LCMS RT=1.03 min, ES+ve m/z 991.4 [M+H]+.
    • (7S,8R,9S,13S,14S,17S)-7-(5-(Benzyloxy)pentyl)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one
  • Figure US20190127359A1-20190502-C00876
  • A solution of KOtBu in THF (1M, 4.81 mL, 4.81 mmol) was added to a cooled solution (0° C.) of (8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one (900 mg, 2.403 mmol) in anhydrous THF (10 mL). The reaction mixture was stirred at 0° C. for 45 minutes and then cooled to −78° C. (((5-Iodopentyl)oxy)methyl)benzene (can be prepared following the procedure described in J. Chem. Soc., Perkin Trans. 1 1990, 129-132) (2.193 g, 7.21 mmol) in THF (0.5 mL) was added dropwise. The solution was stirred at −78° C. for 2 minutes and allowed to warm to room temperature and stirred for 1 hour at that temperature. The reaction was partitioned between water (70 mL) and ethyl acetate (70 mL). The organic extract was dried using a hydrophobic frit and concentrated under reduced pressure. The intermediate was purified by chromatography on silica using a gradient elution from 0% to 50% ethyl acetate in cyclohexane. The residue was dissolved in THF (16 mL) and aqueous HCl (6M, 16 mL, 96 mmol) was added. The reaction was stirred at room temperature for 16 hours. The reaction mixture was partitioned between ethyl acetate (20 mL) and water (20 mL). The organic extract was dried (hydrophobic frit) and concentrated under reduced pressure. The product was purified by reverse phase chromatography using a gradient elution from 5% to 85% acetonitrile (+0.1% formic acid) in water (+0.1% formic acid) to afford the title compound (487 mg, 1.053 mmol, 44% yield). LCMS RT=1.16 min, ES+ve m/z 463.4 [M+H]+.
    • (7R,8R,9S,13S,14S,17S)-7-(5-(Benzyloxy)pentyl)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
  • Figure US20190127359A1-20190502-C00877
  • Triethylsilane (1.681 mL, 10.53 mmol) was added to a solution of (7S,8R,9S,13S,14S,17S)-7-(5-(benzyloxy)pentyl)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one (487 mg, 1.053 mmol) in TFA (6 mL, 78 mmol). The reaction was stirred at room temperature under an atmosphere of nitrogen for 16 hours. The mixture was partitioned between ethyl acetate (30 mL) and brine (30 mL). The organic extract was washed with brine (2×30 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The residue was dissolved in MeOH (4 mL) and treated with aqueous NaOH (2M, 4 mL, 8.00 mmol). The reaction mixture was stirred at room temperature for 3 hours. The solvent was removed under reduced pressure. The residue was partitioned between ethyl acetate (30 mL) and water (30 mL). The organic extract was washed with brine (30 mL), dried (hydrophobic frit) and concentrated under reduced pressure. The product was purified by reverse phase chromatography using a gradient elution from 10% to 95% acetonitrile (+0.1% formic acid) in water (+0.1% formic acid) to afford the title compound (410 mg, 0.914 mmol, 87% yield). LCMS RT=1.30 min, ES+ve m/z 449.1 [M+H]+.
    • (7R,8R,9S,13S,14S,17S)-7-(5-(Benzyloxy)pentyl)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene
  • Figure US20190127359A1-20190502-C00878
  • Chloro(methoxy)methane (0.7 mL, 9.22 mmol) was added to solution of (7R,8R,9S,13S,14S,17S)-7-(5-(benzyloxy)pentyl)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol (410 mg, 0.914 mmol) and DIPEA (2 mL, 11.45 mmol) in THF (8 mL). The reaction vessel was sealed, placed under an atmosphere of nitrogen and heated at 70° C. for 2 days. The reaction was cooled to room temperature. The reaction was partitioned between ethyl acetate (50 mL) and brine (50 mL). The organic extract was washed with brine (2×50 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% methyl tert-butyl ether in cyclohexane to afford the title compound (474 mg, 0.883 mmol, 97% yield). LCMS RT=1.72 min, ES+ve m/z 554.5 [M+NH4]+.
    • 5-((7R,8R,9S,13S,14S,17S)-3,17-Bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)pentan-1-ol
  • Figure US20190127359A1-20190502-C00879
  • A mixture of (7R,8R,9S,13S,14S,17S)-7-(5-(benzyloxy)pentyl)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene (474 mg, 0.883 mmol) and 10% w/w palladium on carbon (100 mg, 0.094 mmol) in ethanol (5 mL) and methyl tert-butyl ether (2 mL) was stirred at room temperature under an atmosphere of hydrogen for 1.5 hours. The palladium was filtered through celite and the filtrate concentrated under reduced pressure to afford the title compound (371 mg, 0.831 mmol, 94% yield). LCMS RT=1.39 min, ES+ve m/z 447.5 [M+H]+ (weak ionisation).
    • 5-((7R,8R,9S,13S,14S,17S)-3,17-Bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)pentyl 4-methylbenzenesulfonate
  • Figure US20190127359A1-20190502-C00880
  • 4-Methylbenzene-1-sulfonyl chloride (400 mg, 2.098 mmol) was added to 5-((7R,8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)pentan-1-ol (371 mg, 0.831 mmol) in pyridine (5 mL). The reaction mixture was stirred at room temperature for 20 hours. The reaction mixture was partitioned between ethyl acetate (30 mL) and aqueous HCl (2M, 30 mL). The organic extract was washed with sat Na2CO3 (30 mL), brine (30 mL), dried (hydrophobic frit) and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% methyl tert-butyl ether in cyclohexane to afford the title compound (401 mg, 0.667 mmol, 80% yield). LCMS RT=1.60 min, ES+ve m/z 623.4 [M+Na]+.
    • Tert-butyl 18-((7R,8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-13-methyl-4,7,10-trioxa-13-azaoctadecan-1-oate, formic acid salt
  • Figure US20190127359A1-20190502-C00881
  • A microwave vial was charged with 5-((7R,8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)pentyl 4-methylbenzenesulfonate (100 mg, 0.166 mmol), tert- butyl 5,8,11-trioxa-2-azatetradecan-14-oate (can be prepared following the procedure described in WO2012054110A2) (145 mg, 0.499 mmol) and DIPEA (0.291 mL, 1.664 mmol) in THF (2 mL). The vial was sealed and placed under an atmosphere of nitrogen using a vacuum purge. The reaction was heated at 75° C. for 48 hours. The reaction was cooled to room temperature. The reaction mixture was subjected directly to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (102 mg, 0.133 mmol, 80% yield). LCMS RT=1.22 min, ES+ve m/z 720.6 [M+H]+.
    • 18-((7R,8R,9S,13S,14S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-13-methyl-4,7,10-trioxa-13-azaoctadecan-1-oic acid, formic acid salt
  • Figure US20190127359A1-20190502-C00882
  • Tert-butyl 18-((7R,8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-13-methyl-4,7,10-trioxa-13-azaoctadecan-1-oate, formic acid salt (100 mg, 0.131 mmol) was dissolved in THF (1 mL) and treated with aqueous HCl (6M, 1 mL, 6.00 mmol). The reaction was stirred at room temperature for 6 hours. The reaction mixture was subjected directly to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (24 mg, 0.039 mmol, 30% yield). LCMS RT=0.74 min, ES+ve m/z 576.5 [M+H]+.
    • (2S,4R)-1-((S)-2-(Tert-butyl)-21-((7R,8RS,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-16-methyl-4-oxo-7,10,13-trioxa-3,16-diazahenicosan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
  • Figure US20190127359A1-20190502-C00883
  • HATU (13 mg, 0.034 mmol) was added to a mixture of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (13 mg, 0.028 mmol), 18-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-13-methyl-4,7,10-trioxa-13-azaoctadecan-1-oic acid, formic acid salt (12 mg, 0.019 mmol) and DIPEA (0.03 mL, 0.172 mmol) in DMF (0.8 mL). The reaction was stirred at room temperature for 10 minutes. The reaction mixture was subjected directly to two purifications by mass-directed automated preparative HPLC (formic acid modifier followed by ammonium carbonate modifier) to afford the title compound (13 mg, 0.013 mmol, 68% yield). LCMS RT=0.84 min, ES+ve m/z 988.8 [M+H]+.

Claims (30)

What is claimed is:
1. A compound of chemical structure:

ULM-L-PTM,
wherein:
L is a bond or a chemical linker coupling the ULM to the PTM;
PTM is a moiety that binds to a target protein or polypeptide which is to be ubiquiniated by VHL; and
ULM is a small molecule Von Hippel Lindau E3 ubiquitin ligase (VHL) binding moiety of formula:
Figure US20190127359A1-20190502-C00884
wherein
R1′ is —OH or a group which can be metabolized to —OH;
R2′ is selected from the group consisting of optionally substituted —NR1—XR2′-alkyl group, optionally substituted —NR1—XR2′-Aryl group; optionally substituted —NR1—XR2′-HET group, optionally substituted —NR1—XR2′-Aryl-HET group, and optionally substituted —NR1—XR2′-HET-Aryl group;
R1 is H or C1-C3 alkyl;
XR2′ is optionally substituted —(CH2)n—, —(CH2)n—C(Xv)═C(Xv)— (cis or trans), —(CH2)n—C≡C—, —(CH2CH2O)n— or C3-C6 cycloalkyl;
R3′ is optionally substituted C1-C6 alkyl, optionally substituted —(CH2)n—(V)n′—(CH2)n—(V)n′—RS3′ group, optionally substituted —(CH2)n—N(R1′)(C═O)m′—(V)n′—RS3′ group, optionally substituted —XR3′-alkyl group, optionally substituted —XR3′-Aryl group, optionally substituted —XR3′-HET group, optionally substituted —XR3′-Aryl-HET group, or optionally substituted —XR3′-HET-Aryl group;
RS3′ is optionally substituted C1-C6 alkyl, optionally substituted Aryl group, or a HET group;
R1′ is H or C1-C3 alkyl;
V is O, S, or NR1′;
XR3′ is optionally substituted —(CH2)n—, —(CH2)n—CH(Xv)═CH(Xv)— (cis or trans), —(CH2)n—CH≡CH—, —(CH2CH2O)n— or C3-C6 cycloalkyl;
Xv is H, halo or C1-C3 alkyl which is optionally substituted with one or two hydroxyl groups or up to three halogen groups;
Alkyl is optionally substituted C1-C6 alkyl;
Aryl is optionally substituted phenyl or naphthyl;
HET is optionally substituted oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, benzofuran, indole, indolizine, azaindolizine, quinoline or a group of chemical structure:
Figure US20190127359A1-20190502-C00885
wherein
Sc is CHRSS, NRURE, or O;
RHET is H, CN, NO2, halo, optionally substituted C1-C6 alkyl, optionally substituted O(C1-C6 alkyl) or optionally substituted acetylenic group —C≡C—Ra, where Ra is H or C1-C6 alkyl;
RSS is H, CN, NO2, halo, optionally substituted C1-C6 alkyl, optionally substituted O—(C1-C6 alkyl) or optionally substituted —C(O)(C1-C6 alkyl);
RURE is H, C1-C6 alkyl, or a —C(O)(C1-C6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogens, or optionally substituted heterocycle; and
YC is N or C—RYC, where RYC is H, OH, CN, NO2, halo, optionally substituted C1-C6 alkyl, optionally substituted O(C1-C6 alkyl) or optionally substituted —C≡C≡C—Ra group, where Ra is defined as above;
RPRO is H, optionally substituted C1-C6 alkyl, optionally substituted aryl, optionally substituted heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, benzofuran, indole, indolizine, azaindolizine;
RPRO1 and RPRO2 are each independently H, optionally substituted C1-C3 alkyl, or together form a keto group;
m′ is 0 or 1;
each n is independently 0, 1, 2, 3, 4, 5, or 6;
each n′ is independently 0 or 1;
or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, or polymorph thereof.
2. The compound of claim 1, wherein ULM is a group of chemical structure:
Figure US20190127359A1-20190502-C00886
wherein
R1′ is —OH or a group which can be metabolized in a patient or subject to —OH;
R2′ is a —NR1—XR2′-Aryl or —NR1—XR2′-Aryl-HET, wherein Aryl and HET are independently optionally substituted with at least one selected from the group consisting of alkyl, alkoxy, halogen, acid, ester, cycloalkyl and heterocycloalkyl;
XR2′ is optionally substituted —(CH2)n;
R3′ is optionally substituted alkyl, —(CH)RCR3′—NH—C(O)—R3P1 or —(CH)RCR3′—R3P2group;
RCR3′ is optionally substituted C1-C4 alkyl;
R3P1 is optionally substituted C1-C6 alkyl, optionally substituted oxetane group, —(CH2)nOCH3 wherein n is 1 or 2, or optionally substituted phenyl group, or a morpholino group linked to the carbonyl at the 2- or 3-position;
R3P2 is
Figure US20190127359A1-20190502-C00887
or optionally substituted aryl;
HET is optionally substituted thiazole, oxazole, isoxazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrrolidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, benzofuran, indole, indolizine, azaindolizine, and quinolone, wherein the substitution is independently a C1-C3 alkyl group, or a halo group;
RHET is H, halo, CN, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, or optionally substituted aryl; and
the ULM group is covalently bonded to a linker group to which is attached a PTM group,
or a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
3. The compound of claim 2, wherein the ULM is selected from the group consisting of:
Figure US20190127359A1-20190502-C00888
Figure US20190127359A1-20190502-C00889
wherein the ULM group is covalently bonded to a linker group to which is attached a PTM group,
or a pharmaceutically acceptable salt, stereoisomer, solvate, or polymorph thereof.
4. The compound of claim 1, wherein the ULM is
Figure US20190127359A1-20190502-C00890
wherein
X is Cl, F, C1-C3 alkyl, or an optionally substituted heterocycle;
R1 and R2 are each independently H, C1-C3 alkyl, or phenyl; and
the ULM group is substituted with a linker group or a linker group to which is optionally attached a PTM group, or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate, or polymorph thereof.
5. The compound of claim 1, wherein the ULM group is:
Figure US20190127359A1-20190502-C00891
wherein
n is 0 or 1;
R is a linker or a linker attached to a PTM group linked to the ULM group through an amide, ester, ether, carbamate or heterocyclic group; and
X is independently is H, F, Cl, C1-C3 alkyl optionally substituted with one or two hydroxyl groups, heterocyle, —O—C(O)NR3R4 or —C(O)NR3R4, wherein each of R3 and R4 is independently H, C1-C3 alkyl, or phenyl, or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof.
6. The compound of claim 1, wherein L is at least one member selected from the group consisting of a bond, —(CH2)i—O—, —(CH2—CH2—O)i—, —(CH2)i—S—, —(CH2)i—NR—, —(CH2)i—X1Y1—,
Figure US20190127359A1-20190502-C00892
and any combinations thereof, wherein
each i is independently 0 to 100;
R is H, C1-C3 alkyl, an alkanol group, or a heterocyclic group;
Y is independently a bond, O, S or N—R;
X1Y1 forms an amide group, a urethane group, ester or thioester group;
D is independently a bond (absent),
Figure US20190127359A1-20190502-C00893
j is an integer ranging from 1 to 100;
k is an integer ranging from 1 to 100;
m′ is an integer ranging from 1 to 100;
n is an integer ranging from 1 to 100; and
X1 is O, S or N—R; and
CON is a bond (absent), a piperazinyl group, optionally substituted alkylene, heterocycle,
Figure US20190127359A1-20190502-C00894
X2 is O, S, NR4, S(O), S(O)2, —S(O)2O, —OS(O)2, or OS(O)2O;
X3 is O, S, CHR4 or NR4; and
R4 is H or a C1-C3 alkyl group, which is optionally substituted with one or two hydroxyl groups.
7. The compound of claim 6, wherein i is 1 to 10.
8. The compound of claim 6, wherein L is a (poly)ethyleneglycol having from 1 to 100 ethylene glycol units.
9. The compound of claim 6, wherein R is morpholino, piperidinyl, or piperazinyl.
10. The compound of claim 6, wherein CON is a
Figure US20190127359A1-20190502-C00895
group, an amide group, or a piperazinyl group.
11. The compound of claim 1, wherein the ULM is selected from the group consisting of:
Figure US20190127359A1-20190502-C00896
Figure US20190127359A1-20190502-C00897
Figure US20190127359A1-20190502-C00898
Figure US20190127359A1-20190502-C00899
Figure US20190127359A1-20190502-C00900
Figure US20190127359A1-20190502-C00901
Figure US20190127359A1-20190502-C00902
Figure US20190127359A1-20190502-C00903
Figure US20190127359A1-20190502-C00904
Figure US20190127359A1-20190502-C00905
Figure US20190127359A1-20190502-C00906
Figure US20190127359A1-20190502-C00907
Figure US20190127359A1-20190502-C00908
Figure US20190127359A1-20190502-C00909
Figure US20190127359A1-20190502-C00910
Figure US20190127359A1-20190502-C00911
Figure US20190127359A1-20190502-C00912
Figure US20190127359A1-20190502-C00913
Figure US20190127359A1-20190502-C00914
Figure US20190127359A1-20190502-C00915
Figure US20190127359A1-20190502-C00916
Figure US20190127359A1-20190502-C00917
Figure US20190127359A1-20190502-C00918
wherein the ULM is modified to be covalently bonded to the PTM group through a linker group, or a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate, or polymorph thereof.
12. The compound of claim 1, wherein the ULM is a member selected from the group consisting of:
Figure US20190127359A1-20190502-C00919
Figure US20190127359A1-20190502-C00920
Figure US20190127359A1-20190502-C00921
Figure US20190127359A1-20190502-C00922
Figure US20190127359A1-20190502-C00923
Figure US20190127359A1-20190502-C00924
Figure US20190127359A1-20190502-C00925
Figure US20190127359A1-20190502-C00926
Figure US20190127359A1-20190502-C00927
Figure US20190127359A1-20190502-C00928
Figure US20190127359A1-20190502-C00929
wherein the ULM is modified to be covalently bonded to the PTM group through a linker group, or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate, polymorph or prodrug thereof.
13. A compound selected from the group consisting of
Figure US20190127359A1-20190502-C00930
wherein each of R1PC, R2PC, R3PC, R4PC, R5PC, R6PC, R7PC, R8PC, R9PC, R10PC, R11PC, R12PC, R13PC and R14PC is are each independently H or a
Figure US20190127359A1-20190502-C00931
group; and
wherein L is a linker group and PTM is a protein targeting moiety, or a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate, or polymorph thereof.
14. The compound of claim 13, which is:
Figure US20190127359A1-20190502-C00932
wherein R7PC and R10PC are each independently a
Figure US20190127359A1-20190502-C00933
group or H, or a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate, or polymorph thereof.
15. The compound of claim 13, which is:
Figure US20190127359A1-20190502-C00934
wherein R7PC, R11PC R12PC, R13PC and R14PC are each independently a
Figure US20190127359A1-20190502-C00935
group or H, or a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate, or polymorph thereof.
16. The compound of claim 13, which is:
Figure US20190127359A1-20190502-C00936
wherein R7PC, R8PC, R9PC, R10PC are R each independently a
Figure US20190127359A1-20190502-C00937
group or H, or a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate, or polymorph thereof.
17. The compound of claim 1, wherein the linker group is a polyethylene group comprising from 1 to 10 ethylene glycol units.
18. The compound of claim 1, wherein the PTM group is a moiety which binds to a target protein selected from the group consisting of B7.1 and B7, TINFRlm, TNFR2, NADPH oxidase, Bcl, Bax, C5a receptor, HMG-CoA reductase, PDE V phosphodiesterase, PDE IV phosphodiesterase, PDE I, PDEII, PDEIII, squalene cyclase inhibitor, CXCR1, CXCR2, nitric oxide (NO) synthase, cyclo-oxygenase 1, cyclo-oxygenase 2, 5HT receptor, dopamine receptor, G Protein, Gq, histamine receptor, 5-lipoxygenase, tryptase serine protease, thymidylate synthase, purine nucleoside phosphorylase, GAPDH trypanosomal, glycogen phosphorylase, Carbonic anhydrase, chemokine receptor, JAK, STAT, RXR, H1V 1 protease, HIV 1 integrase, influenza, neuramimidase, hepatitis B reverse transcriptase, sodium channel, multi drug resistance (MDR), protein P-glycoprotein (and MRP), tyrosine kinase, CD23, CD124, tyrosine kinase p56 Ick, CD4, CD5, IL-2 receptor, IL-1 receptor, TNF-alphaR, ICAM1, Cat+ channel, VCAM, VLA-4 integrin, selectin, CD40/CD40L, newokinin receptor, inosine monophosphate dehydrogenase, p38 MAP Kinase, Ras, Raf, MEK, ERK, interleukin-1 converting enzyme, caspase, HCV, NS3 protease, HCV NS3 RNA helicase, glycinamide ribonucleotide formyl transferase, rhinovirus 3C protease, herpes simplex virus-1 (HSV-I), protease, cytomegalovirus (CMV) protease, poly (ADP-ribose) polymerase, cyclin dependent kinase, PI3-kinase, focal adhesion kinase, vascular endothelial growth factor, oxytocin receptor, microsomal transfer protein 5 alpha reductase, angiotensin 11, glycine receptor, noradrenaline reuptake receptor, endothelin receptor, neuropeptide Y receptor, adenosine receptor, adenosine kinase, AMP deaminase, purinergic receptor (P2Y1, P2Y2, P2Y4, P2Y6, P2X1-7), farnesyltransferase, geranylgeranyl transferase, TrkA a receptor beta-amyloid, tyrosine kinase Flk-IIKDR, vitronectin receptor, integrin receptor, Her-21 neu, telomerase inhibition, cytosolic phospholipaseA2, EGF receptor tyrosine kinase, IGFR, FKBP ecdysone 20-monooxygenase, GABA gated chloride channel, acetylcholinesterase, voltage-sensitive sodium channel protein, calcium release channel, chloride channel, Acetyl-CoA carboxylase, adenylosuccinate synthetase, protoporphyrinogen oxidase, enolpyruvylshikimate-phosphate synthase.
19. The compound of claim 1, wherein the PTM group is an Hsp90 inhibitor, a kinase inhibitor, a phosphatase inhibitor, a humanMDM2 inhibitor, a compound which targets human BET Bromodomain-containing proteins, an HDAC inhibitor, a human lysine methyltransferase inhibitor, a compound targeting RAF receptor, a compound targeting FKBP, an angiogenesis inhibitor, an immunosuppressive compound, a compound targeting an aryl hydrocarbon receptor, a compound targeting an androgen receptor, a compound targeting an estrogen receptor, a compound targeting a thyroid hormone receptor, a compound targeting a growth factor receptor, a focal adhesion kinase inhibitor, a compound targeting HIV protease, a compound targeting HIV integrase, a compound targeting HCV protease or a compound targeting acyl protein thioesterase 1 or 2.
20. The compound of claim 18, wherein the PTM group is selected from the group consisting of:
derivatized YKB:
Figure US20190127359A1-20190502-C00938
wherein a linker moiety L or a
Figure US20190127359A1-20190502-C00939
group is attached via the terminal amide group;
derivatized p54:
Figure US20190127359A1-20190502-C00940
wherein a linker moiety or a
Figure US20190127359A1-20190502-C00941
group is attached via the terminal acetylene group;
derivatized (5-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-n-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide) having the structure:
Figure US20190127359A1-20190502-C00942
wherein a linker moiety L or a
Figure US20190127359A1-20190502-C00943
group is attached via the amide group or a hydroxyl group; derivatized PU3:
Figure US20190127359A1-20190502-C00944
wherein a linker moiety L or a
Figure US20190127359A1-20190502-C00945
group is attached via the butyl group;
derivatized Geldanamycin ((4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] wherein a linker or a
Figure US20190127359A1-20190502-C00946
group is attached via the amide group;
derivatized tanespimycin(17-alkylamino-17-desmethoxygeldanamycin (17-AAG)) wherein a linker or a
Figure US20190127359A1-20190502-C00947
group is attached via the amide group;
derivatized 17-(2-dimethyl aminoethyl)amino-17-desmethoxygeldanamycin (17-DMAG),
wherein a linker or a
Figure US20190127359A1-20190502-C00948
group is attached via the amide group;
derivatized erlotinib:
Figure US20190127359A1-20190502-C00949
wherein R is a linker moiety L or a
Figure US20190127359A1-20190502-C00950
group attached via the ether group;
derivatized sunitinib:
Figure US20190127359A1-20190502-C00951
wherein R is a linker moiety L or a
Figure US20190127359A1-20190502-C00952
group which is attached to the pyrrole moiety;
derivatized sorafenib:
Figure US20190127359A1-20190502-C00953
wherein R is a linker moiety L or a
Figure US20190127359A1-20190502-C00954
group attached to the phenyl moiety;
derivatized dasatinib:
Figure US20190127359A1-20190502-C00955
wherein R is a linker moiety L or a
Figure US20190127359A1-20190502-C00956
group attached to the pyrimidine;
derivatized lapatinib:
Figure US20190127359A1-20190502-C00957
wherein a linker moiety L or a
Figure US20190127359A1-20190502-C00958
group is attached via the terminal methyl of the sulfonyl methyl group;
derivatized U09-CX-5279:
Figure US20190127359A1-20190502-C00959
wherein a linker moiety L or a
Figure US20190127359A1-20190502-C00960
group is attached via the amine (aniline), carboxylic acid or cyclopropyl group;
derivatized Y1X:
Figure US20190127359A1-20190502-C00961
wherein a linker moiety L or a
Figure US20190127359A1-20190502-C00962
group is attached via the propyl group;
derivatized Y1W:
Figure US20190127359A1-20190502-C00963
wherein a linker moiety L or a
Figure US20190127359A1-20190502-C00964
group is attached via the propyl group or the tert-butyl group;
derivatized 6TP:
Figure US20190127359A1-20190502-C00965
wherein a linker moiety L or a
Figure US20190127359A1-20190502-C00966
group is attached via the terminal methyl group bound to amide moiety;
derivatized OTP:
Figure US20190127359A1-20190502-C00967
wherein a linker moiety L or a
Figure US20190127359A1-20190502-C00968
group is attached via the terminal methyl group bound to the amide moiety;
derivatized 07U:
Figure US20190127359A1-20190502-C00969
wherein a linker moiety L or a
Figure US20190127359A1-20190502-C00970
group is attached via the secondary amine or terminal/primary amino group;
derivatized YCF:
Figure US20190127359A1-20190502-C00971
wherein a linker moiety L or a
Figure US20190127359A1-20190502-C00972
group is attached via either of the terminal hydroxyl groups;
derivatized XK9:
Figure US20190127359A1-20190502-C00973
wherein a linker moiety L or a
Figure US20190127359A1-20190502-C00974
group is attached via the terminal hydroxyl group;
derivatized NXP:
Figure US20190127359A1-20190502-C00975
wherein a linker moiety L or a
Figure US20190127359A1-20190502-C00976
group is attached via an amine group;
derivatized afatinib, wherein a linker moiety L or a
Figure US20190127359A1-20190502-C00977
group is attached via the aliphatic amine group;
derivatized fostamatinib, wherein a linker moiety L or a
Figure US20190127359A1-20190502-C00978
group is attached via a methoxy group;
derivatized gefitinib:
Figure US20190127359A1-20190502-C00979
wherein a linker moiety L or a
Figure US20190127359A1-20190502-C00980
group is attached via a methoxy or ether group;
derivatized lenvatinib, wherein a linker moiety L or a
Figure US20190127359A1-20190502-C00981
group is attached via the cyclopropyl group;
derivatized vandetanib, wherein a linker moiety L or a
Figure US20190127359A1-20190502-C00982
group is attached via the methoxy or hydroxyl group;
derivatized vemurafenib, wherein a linker moiety L or a
Figure US20190127359A1-20190502-C00983
group is attached via the sulfonyl propyl group;
derivatized imatinib:
Figure US20190127359A1-20190502-C00984
wherein R is a linker moiety L or a
Figure US20190127359A1-20190502-C00985
group attached via the amide group or optionally the L or
Figure US20190127359A1-20190502-C00986
group is attached via the aniline amine group;
derivatized pazopanib:
Figure US20190127359A1-20190502-C00987
wherein R is a linker moiety L or a
Figure US20190127359A1-20190502-C00988
group attached to the phenyl moiety or optionally the L or a
Figure US20190127359A1-20190502-C00989
group is attached via the aniline amine group;
derivatized AT-9283:
Figure US20190127359A1-20190502-C00990
wherein R is a linker moiety L or a
Figure US20190127359A1-20190502-C00991
group attached to the phenyl moiety;
derivatized TAE684:
Figure US20190127359A1-20190502-C00992
wherein R is a linker moiety L or a
Figure US20190127359A1-20190502-C00993
group which is attached to the phenyl moiety;
derivatized nilotinib:
Figure US20190127359A1-20190502-C00994
wherein R is a linker moiety L or a
Figure US20190127359A1-20190502-C00995
group attached to the phenyl moiety or optionally L or a
Figure US20190127359A1-20190502-C00996
group is attached via an aniline amine group;
derivatized NVP-BSK805:
Figure US20190127359A1-20190502-C00997
wherein R is a linker moiety L or a
Figure US20190127359A1-20190502-C00998
group attached to a phenyl moiety or optionally L or a
Figure US20190127359A1-20190502-C00999
group is attached via the diazole group;
derivatized crizotinib:
Figure US20190127359A1-20190502-C01000
wherein R is a linker moiety L or a
Figure US20190127359A1-20190502-C01001
group which is attached to the diazole group or optionally L or a
Figure US20190127359A1-20190502-C01002
group is attached via a phenyl moiety;
derivatized:
Figure US20190127359A1-20190502-C01003
wherein R is a linker moiety L or a
Figure US20190127359A1-20190502-C01004
group attached to the phenyl moiety;
derivatized foretinib:
Figure US20190127359A1-20190502-C01005
wherein R is a linker moiety L or a
Figure US20190127359A1-20190502-C01006
group which is attached to the phenyl moiety or a hydroxyl or ether group on the quinoline moiety;
derivatized PTP1B:
Figure US20190127359A1-20190502-C01007
wherein a linker group L or a
Figure US20190127359A1-20190502-C01008
group is attached at R;
derivatized inhibitor of SHP-2 domain of tyrosine phosphatase:
Figure US20190127359A1-20190502-C01009
wherein a linker group L or a
Figure US20190127359A1-20190502-C01010
group is attached at R;
derivatized inhibitor of BRAF (BRAFV600E)/MEK:
Figure US20190127359A1-20190502-C01011
wherein a linker L or a
Figure US20190127359A1-20190502-C01012
group is attached at R;
derivatized inhibitor of tyrosine kinase ABL:
Figure US20190127359A1-20190502-C01013
wherein R is a linker group L or a
Figure US20190127359A1-20190502-C01014
group;
derivatized nutlin-3:
Figure US20190127359A1-20190502-C01015
wherein a linker moiety L or a
Figure US20190127359A1-20190502-C01016
group is attached at the methoxy group or via a hydroxyl linkage;
derivatized nutlin-2:
Figure US20190127359A1-20190502-C01017
wherein a linker moiety L or a
Figure US20190127359A1-20190502-C01018
group is attached at the methoxy group or via a hydroxyl group;
Figure US20190127359A1-20190502-C01019
derivatized nutlin-1:
wherein a linker moiety or a
Figure US20190127359A1-20190502-C01020
group is attached via the methoxy group or via a hydroxyl group;
derivatized trans-4-Iodo-4′-Boranyl-Chalcone, wherein a linker moiety L or a
Figure US20190127359A1-20190502-C01021
group is attached via a hydroxy group;
a derivatized compound targeting human BET Bromodomain-containing protein Brd2, Brd3, Brd4 selected from the group consisting of:
Figure US20190127359A1-20190502-C01022
wherein R is a linker L group or a
Figure US20190127359A1-20190502-C01023
group;
derivatized SAHA:
Figure US20190127359A1-20190502-C01024
wherein R is a linker group L or a
Figure US20190127359A1-20190502-C01025
group;
derivatized BIX-01294:
Figure US20190127359A1-20190502-C01026
wherein each R is independently a linker group L or a
Figure US20190127359A1-20190502-C01027
group;
derivatized UNC0244:
Figure US20190127359A1-20190502-C01028
wherein each R is independently a linker group L or a
Figure US20190127359A1-20190502-C01029
group;
derivatized azacitidine, wherein a linker group L or a
Figure US20190127359A1-20190502-C01030
group is attached via the hydroxy or amino groups;
derivatized decitabine, wherein a linker group L or a
Figure US20190127359A1-20190502-C01031
group is attached via either of the hydroxy groups or at the amino group;
derivatized GA-1;
derivatized estradiol;
derivatized dihydroxytestosterone;
derivatized ovalicin;
derivatized fumagillin;
derivatized AP21998;
a derivatized glucocorticoid selected from the group consisting of hydrocortisone, prednisone, prednisolone, methylprednisoloneand beclometasone dipropionate, wherein a linker group L or a
Figure US20190127359A1-20190502-C01032
group is attached;
derivatized methotrexate, wherein a linker group L or a
Figure US20190127359A1-20190502-C01033
group is attached to either of the terminal hydroxyls;
derivatized ciclosporin, wherein a linker group L or a
Figure US20190127359A1-20190502-C01034
group is attached at any of the butyl groups;
derivatized tacrolimus (FK-506) or rapamycin, wherein a linker group L or a
Figure US20190127359A1-20190502-C01035
group is attached at one of the methoxy groups;
derivatized actinomycin, wherein a linker group L or a
Figure US20190127359A1-20190502-C01036
group is attached at one of the isopropyl groups;
a derivatized compound targeting the aryl hydrocarbon receptor (AHR) selected from the group consisting of Apigenin, SR1 and LGC006, wherein a linker group L or a
Figure US20190127359A1-20190502-C01037
group is attached;
derivatized PLX4032:
Figure US20190127359A1-20190502-C01038
wherein R designates a linker group L or a
Figure US20190127359A1-20190502-C01039
group;
a derivatized compound targeting FKBP according to the chemical structure:
Figure US20190127359A1-20190502-C01040
wherein R designates a linker group L or a
Figure US20190127359A1-20190502-C01041
group;
a derivatized compound targeting androgen receptor (AR) according to the chemical structure:
Figure US20190127359A1-20190502-C01042
wherein R designates a linker group L or a
Figure US20190127359A1-20190502-C01043
group;
a derivatized SARM ligand of Androgen Receptor according to the chemical structure:
Figure US20190127359A1-20190502-C01044
wherein R designates a linker group L or a
Figure US20190127359A1-20190502-C01045
group;
a derivatized Androgen Receptor Ligand DHT according to the chemical structure:
Figure US20190127359A1-20190502-C01046
wherein R designates a linker group L or a
Figure US20190127359A1-20190502-C01047
group;
a derivatized compound targeting Estrogen Receptor (ER) according to the chemical structure:
Figure US20190127359A1-20190502-C01048
wherein R designates a linker group L or a
Figure US20190127359A1-20190502-C01049
group;
a derivatized compound targeting Thyroid Hormone Receptor (TR) according to the chemical structure:
Figure US20190127359A1-20190502-C01050
wherein R designates a linker group L or a
Figure US20190127359A1-20190502-C01051
group and MOMO indicates a methoxymethoxy group;
a derivatized compound targeting HIV Protease according to the chemical structure:
Figure US20190127359A1-20190502-C01052
wherein R designates a linker group L or a
Figure US20190127359A1-20190502-C01053
group;
a derivatized Inhibitor of HIV Integrase according to the chemical structure:
Figure US20190127359A1-20190502-C01054
wherein R designates a linker group L or a
Figure US20190127359A1-20190502-C01055
group;
a derivatized compound targeting HCV Protease according to the chemical structure:
Figure US20190127359A1-20190502-C01056
wherein R designates a linker group L or a
Figure US20190127359A1-20190502-C01057
group; and
a derivatized compound targeting Acyl-protein Thioesterase-1 and -2 (APT1 and APT2) according to the chemical structure:
Figure US20190127359A1-20190502-C01058
wherein R designates a linker group L or a
Figure US20190127359A1-20190502-C01059
group.
21. A pharmaceutical composition comprising the compound of claim 1 and at least one pharmaceutically suitable carrier.
22. A method of regulating the amount or activity of a target protein in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of claim 2.
23. The method of claim 22, wherein the target protein is selected from the group consisting of structural proteins, receptors, enzymes, cell surface proteins, aromatases, motor activity proteins, helicases, proteolytic proteins, kinases, oxidoreductases, transferases, hydrolases, lyases, isomerases, ligases, enzyme regulators, signal transduction proteins, lipid binding proteins, carbohydrate binding proteins, receptors, cell motility proteins, membrane fusion proteins, cell communication proteins, developmental proteins, cell differentiation proteins, cell adhesion proteins, pro- and anti-apoptotic proteins, transport proteins, nuclear transport proteins, hormone receptors, ion transporter proteins, carrier proteins, permeases, secretory proteins, electron transport tproteins, chaperone regulator proteins, nucleic acid binding proteins, transcription regulatory proteins, and translation regulator proteins.
24. The method of claim 22, wherein the target protein is selected from the group consisting of B7.1 and B7, TINFRlm, TNFR2, NADPH oxidase, BclIBax and other partners in the apotosis pathway, C5a receptor, HMG-CoA reductase, PDE V phosphodiesterase type, PDE IV phosphodiesterase type 4, PDE I, PDEII, PDEIII, squalene cyclase inhibitor, CXCR1, CXCR2, nitric oxide (NO) synthase, cyclo-oxygenase 1, cyclo-oxygenase 2, 5HT receptors, dopamine receptors, G Proteins, i.e., Gq, histamine receptors, 5-lipoxygenase, tryptase serine protease, thymidylate synthase, purine nucleoside phosphorylase, GAPDH trypanosomal, glycogen phosphorylase, Carbonic anhydrase, chemokine receptors, JAW STAT, RXR and similar, HIV 1 protease, HIV 1 integrase, influenza, neuramimidase, hepatitis B reverse transcriptase, sodium channel, multi drug resistance (MDR), protein P-glycoprotein (and MRP), tyrosine kinases, CD23, CD124, tyrosine kinase p56 lck, CD4, CD5, IL-2 receptor, IL-1 receptor, TNF-alphaR, ICAM1, Cat+ channels, VCAM, VLA-4 integrin, selectins, CD40/CD40L, newokinins and receptors, inosine monophosphate dehydrogenase, p38 MAP Kinase, RaslRaflMEWERK pathway, interleukin-1 converting enzyme, caspase, HCV, NS3 protease, HCV NS3 RNA helicase, glycinamide ribonucleotide formyl transferase, rhinovirus 3C protease, herpes simplex virus-1 (HSV-I), protease, cytomegalovirus (CMV) protease, poly (ADP-ribose) polymerase, cyclin dependent kinases, vascular endothelial growth factor, oxytocin receptor, microsomal transfer protein inhibitor, bile acid transport inhibitor, 5 alpha reductase inhibitors, angiotensin 11, glycine receptor, noradrenaline reuptake receptor, endothelin receptors, neuropeptide Y and receptor, estrogen receptors, androgen receptors, adenosine receptors, adenosine kinase and AMP deaminase, purinergic receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2X1-7), farnesyltransferases, geranylgeranyl transferase, TrkA a receptor for NGF, beta-amyloid, tyrosine kinase Flk-IIKDR, vitronectin receptor, integrin receptor, Her-21 neu, telomerase inhibition, cytosolic phospholipaseA2 and EGF receptor tyrosine kinase. Additional protein targets include, for example, ecdysone 20-monooxygenase, ion channel of the GABA gated chloride channel, acetylcholinesterase, voltage-sensitive sodium channel protein, calcium release channel, chloride channels, acetyl-CoA carboxylase, adenylosuccinate synthetase, protoporphyrinogen oxidase, and enolpyruvylshikimate-phosphate synthase.
25. A method of treating a disease state or condition in a patient, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of claim 2, wherein the compound regulates the amount or activity of a target protein in the subject, wherein the target protein's dysregulated amount or activity is responsible for the disease state or condition in the subject.
26. The method of claim 25, wherein the disease state is cancer.
27. The method of claim 26, wherein the cancer is squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the bladder, bowel, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias; benign and malignant lymphomas, particularly Burkitt's lymphoma and Non-Hodgkin's lymphoma; benign and malignant melanomas; myeloproliferative diseases; sarcomas, including Ewing's sarcoma, hemangiosarcoma, Kaposi's sarcoma, liposarcoma, myosarcomas, peripheral neuroepithelioma, synovial sarcoma, gliomas, astrocytomas, oligodendrogliomas, ependymomas, gliobastomas, neuroblastomas, ganglioneuromas, gangliogliomas, medulloblastomas, pineal cell tumors, meningiomas, meningeal sarcomas, neurofibromas, and Schwannomas; bowel cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, esophageal cancer, pancreatic cancer, stomach cancer, liver cancer, colon cancer, melanoma; carcinosarcoma, Hodgkin's disease, Wilms' tumor or teratocarcinomas.
28. The method of claim 26, wherein the cancer is T-lineage Acute lymphoblastic Leukemia (T-ALL), T-lineage lymphoblastic Lymphoma (T-LL), Peripheral T-cell lymphoma, Adult T-cell Leukemia, Pre-B ALL, Pre-B Lymphomas, Large B-cell Lymphoma, Burkitts Lymphoma, B-cell ALL, Philadelphia chromosome positive ALL, and Philadelphia chromosome positive CML
29. The method of claim 25, wherein the disease state is prostate cancer, Kennedy's Disease, breast cancer, Lymphoma, diabetes, diabetes melittus type I, diabetes melittus type II, obesity, colorectal cancer, head & neck cancer, immune system disorders, leukemia, stem cell growth, wound healing, atherosclerosis, hepatocellular carcinoma, endometrial cancer, McCune-Albright Syndrome, adenocarcinoma, acute lymphoblastic leukemia (ALL), myeloproliferative diseases, and large B-cell lymphoma.
30. A method of degrading a target protein in a cell, wherein the method comprises contacting the cell with an effective amount of the compound of claim 1, wherein the compound promotes degradation of the target protein in the cell.
US16/224,088 2012-01-12 2018-12-18 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase Pending US20190127359A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/224,088 US20190127359A1 (en) 2012-01-12 2018-12-18 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261585769P 2012-01-12 2012-01-12
PCT/US2013/021136 WO2013106643A2 (en) 2012-01-12 2013-01-11 Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
US201414371956A 2014-07-11 2014-07-11
US16/224,088 US20190127359A1 (en) 2012-01-12 2018-12-18 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2013/021136 Continuation WO2013106643A2 (en) 2012-01-12 2013-01-11 Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
US14/371,956 Continuation US10730862B2 (en) 2012-01-12 2013-01-11 Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase

Publications (1)

Publication Number Publication Date
US20190127359A1 true US20190127359A1 (en) 2019-05-02

Family

ID=48782088

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/371,956 Active US10730862B2 (en) 2012-01-12 2013-01-11 Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase
US16/224,088 Pending US20190127359A1 (en) 2012-01-12 2018-12-18 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/371,956 Active US10730862B2 (en) 2012-01-12 2013-01-11 Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase

Country Status (12)

Country Link
US (2) US10730862B2 (en)
EP (2) EP2802608A4 (en)
JP (5) JP2015508414A (en)
KR (2) KR102204989B1 (en)
CN (2) CN117736134A (en)
AU (5) AU2013207900B2 (en)
BR (1) BR112014017095A2 (en)
CA (1) CA2861066C (en)
HK (1) HK1208875A1 (en)
MX (2) MX358660B (en)
RU (1) RU2666530C2 (en)
WO (1) WO2013106643A2 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020027225A1 (en) 2018-07-31 2020-02-06 ファイメクス株式会社 Heterocyclic compound
WO2021092174A1 (en) * 2019-11-06 2021-05-14 Dana-Farber Cancer Institute, Inc. Selective histone deacetylase (hdac) degraders and methods of use thereof
WO2021207172A1 (en) 2020-04-06 2021-10-14 Arvinas Operations, Inc. Compounds and methods for targeted degradation of kras
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
WO2022169780A1 (en) 2021-02-02 2022-08-11 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
WO2022187650A1 (en) * 2021-03-04 2022-09-09 The Scripps Research Institute Heterobifunctional compositions for targeted protein degradation and methods for their use
US11597768B2 (en) 2017-06-26 2023-03-07 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
WO2023034411A1 (en) 2021-09-01 2023-03-09 Oerth Bio Llc Compositions and methods for targeted degradation of proteins in a plant cell
US11701357B2 (en) 2016-08-19 2023-07-18 Beigene Switzerland Gmbh Treatment of B cell cancers using a combination comprising Btk inhibitors
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
WO2023220425A1 (en) * 2022-05-12 2023-11-16 Kymera Therapeutics, Inc. Bcl-xl/bcl-2 degraders and uses thereof
WO2024050016A1 (en) 2022-08-31 2024-03-07 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
WO2024081913A1 (en) * 2022-10-14 2024-04-18 76Bio, Inc. Dual-specific bifunctional fusion proteins for ubiquitin-mediated degradation
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use

Families Citing this family (252)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
MA34397B1 (en) 2010-07-02 2013-07-03 Gilead Sciences Inc NAPHTH-2-YLACETIC ACID DERIVATIVES IN AIDS TREATMENT
US9266860B2 (en) 2010-09-30 2016-02-23 St. Jude Children's Research Hospital Aryl-substituted imidazoles
UA111841C2 (en) 2011-04-21 2016-06-24 Гіліад Сайєнсіз, Інк. BENZOTHIAZOL COMPOUNDS AND THEIR PHARMACEUTICAL APPLICATION
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
WO2013102242A1 (en) * 2012-01-06 2013-07-11 Spinifex Pharmaceuticals Pty Ltd Heterocyclic compounds and methods for their use
RU2666530C2 (en) 2012-01-12 2018-09-11 Йейл Юниверсити Compounds and methods for enhanced degradation of target proteins and other polypeptides by an e3 ubiquitin ligase
PE20141558A1 (en) 2012-04-20 2014-11-06 Gilead Sciences Inc DERIVATIVES OF BENZOTHIAZOLE-6-IL ACETIC ACID AND THEIR USE TO TREAT HIV INFECTION
GB201311910D0 (en) * 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel Compounds
WO2014187777A1 (en) * 2013-05-21 2014-11-27 Mediapharma S.R.L. Novel inhibitors of pvhl-elongin c binding
GB201311891D0 (en) * 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2015160845A2 (en) * 2014-04-14 2015-10-22 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US20180228907A1 (en) * 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
EP3139942B1 (en) 2014-05-05 2019-12-18 Bioventures, Llc COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
WO2015184383A1 (en) * 2014-05-29 2015-12-03 St. Jude Children's Research Hospital Aryl-substituted imidazoles and methods of making and using same
US10071087B2 (en) 2014-07-22 2018-09-11 Bioventures, Llc Compositions and methods for selectively depleting senescent cells
US10071164B2 (en) * 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
WO2016045115A1 (en) * 2014-09-28 2016-03-31 姜凡 Hiv-1 integrase inhibitor
JP6815318B2 (en) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド How to Induce Targeted Proteolysis by Bifunctional Molecules
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
AU2016209349B2 (en) * 2015-01-20 2020-05-07 Arvinas, Inc. Compounds and methods for the targeted degradation of the Androgen Receptor
GB201504314D0 (en) * 2015-03-13 2015-04-29 Univ Dundee Small molecules
WO2016149668A1 (en) * 2015-03-18 2016-09-22 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
HUE054474T2 (en) * 2015-03-30 2021-09-28 Mission Therapeutics Ltd 1-cyano-pyrrolidine compounds as usp30 inhibitors
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201506872D0 (en) * 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
CN108136044B (en) * 2015-06-04 2021-08-10 阿尔维纳斯运营股份有限公司 Imide-based proteolytic modulators and related methods of use
US20180147202A1 (en) 2015-06-05 2018-05-31 Arvinas, Inc. TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
SG11201710272VA (en) * 2015-06-19 2018-01-30 Etsuko Miyamoto Protein degradation inducing tag and usage thereof
CN105085620B (en) * 2015-06-25 2018-05-08 中山大学附属第一医院 A kind of compound for targeting ubiquitination degraded Smad3
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
AU2016291578C1 (en) * 2015-07-10 2021-07-15 Arvinas Operations, Inc. MDM2-based modulators of proteolysis and associated methods of use
US20170037004A1 (en) * 2015-07-13 2017-02-09 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
ES2773046T3 (en) * 2015-07-14 2020-07-09 Mission Therapeutics Ltd Cyanopyrrolidines as DUB inhibitors for cancer treatment
AU2016301196B2 (en) 2015-08-06 2022-09-08 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
GB201516243D0 (en) 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
RU2018119510A (en) 2015-10-30 2019-12-05 Тимбер Фармасьютикалз ЭлЭлСи COMPOSITIONS OF ISOTRETINOIN AND THEIR APPLICATION AND METHODS
EP3370715A4 (en) 2015-11-02 2019-05-15 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
GB201522768D0 (en) * 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
RU2752677C2 (en) * 2016-04-12 2021-07-29 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Vet protein decomposers
US10781205B2 (en) 2016-04-20 2020-09-22 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
KR102447884B1 (en) * 2016-04-21 2022-09-27 바이오벤처스, 엘엘씨 Compounds inducing degradation of anti-apoptotic BCL-2 family proteins and uses thereof
WO2017185023A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 9 (cdk9) by conjugation of cdk9 inhibitors with e3 ligase ligand and methods of use
CN107305202B (en) * 2016-04-22 2020-04-17 北京睿创康泰医药研究院有限公司 HPLC method for analyzing impurities of levovatinib mesylate and preparation thereof and application of impurities as reference standard
CN109475528B (en) * 2016-04-22 2022-01-11 达纳-法伯癌症研究所股份有限公司 Bifunctional molecules for EGFR degradation and methods of use
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109562113A (en) 2016-05-10 2019-04-02 C4医药公司 Loop coil degron body for target protein degradation
CN109562107A (en) * 2016-05-10 2019-04-02 C4医药公司 Heterocycle degron body for target protein degradation
CN105943526B (en) * 2016-05-18 2018-08-14 上海交通大学医学院附属上海儿童医学中心 Applications of the PD0325901 in maintaining arterial duct to open
ES2858151T3 (en) 2016-05-20 2021-09-29 Hoffmann La Roche PROTAC-Antibody Conjugates and Procedures for Use
KR101825065B1 (en) * 2016-05-24 2018-02-05 한국화학연구원 Pharmaceutical composition for inducing the degradation of ALK protein and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient
GB201610147D0 (en) * 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201610156D0 (en) * 2016-06-10 2016-07-27 Otsuka Pharma Co Ltd Cliptac compositions
WO2017223415A1 (en) * 2016-06-23 2017-12-28 Dana-Farber Cancer Institute, Inc. Degradation of tripartite motif-containing protein 24 (trim24) by conjugation of trim24 inhibitors with e3 ligase ligand and methods of use
US11285218B2 (en) 2016-06-23 2022-03-29 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
CN110294788A (en) 2016-07-12 2019-10-01 冰洲石生物科技公司 New compound and application thereof
CN106279120A (en) * 2016-07-15 2017-01-04 谢阳 A kind of N aryl-amino-carbonyl proline compounds and pharmaceutical composition thereof and application
CN106318920B (en) * 2016-09-14 2019-10-11 中国科学院天津工业生物技术研究所 Flavones -6- hydroxylase and its application in scutellarin synthesis
GB2554071A (en) 2016-09-14 2018-03-28 Univ Dundee Small molecules
WO2018053354A1 (en) 2016-09-15 2018-03-22 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
AU2017330443B2 (en) 2016-09-26 2023-08-24 Dana-Farber Cancer Institute, Inc. Chromobox protein inhibitors and uses thereof
WO2018064589A1 (en) 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
JP6899993B2 (en) * 2016-10-04 2021-07-07 国立医薬品食品衛生研究所長 Heterocyclic compound
PL3660004T3 (en) * 2016-10-11 2023-10-02 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
JP2019537585A (en) 2016-10-28 2019-12-26 アイカーン スクール オブ メディスン アット マウント シナイ Compositions and methods for treating EZH2-mediated cancer
KR20230127371A (en) 2016-11-01 2023-08-31 아비나스 오퍼레이션스, 인코포레이티드 Tau-protein targeting protacs and associated methods of use
CN106749060B (en) * 2016-11-11 2019-07-23 湖北龙翔药业科技股份有限公司 A kind of refining methd of ponazuril
BR112019009565A2 (en) * 2016-11-15 2019-10-08 Univ Tokyo Science Found molecular kinetics evaluation method and tracking method
KR20190087460A (en) 2016-11-15 2019-07-24 갓코호우징 도쿄리카다이가쿠 Ras proteolysis-inducing molecule and pharmaceutical composition
EP3542821A4 (en) 2016-11-15 2020-05-27 Tokyo University of Science Foundation p53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION
AU2017363252B2 (en) * 2016-11-22 2021-08-19 Dana-Farber Cancer Institute, Inc. Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
IL266842B (en) * 2016-12-01 2022-09-01 Arvinas Operations Inc Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
WO2018103027A1 (en) 2016-12-08 2018-06-14 杭州领业医药科技有限公司 Crystal form of tipifarnib and preparation method and pharmaceutical composition thereof
WO2018106870A1 (en) 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
JP2020505327A (en) 2016-12-23 2020-02-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． EGFR proteolytic targeting chimeric molecules and related methods of use
IL294423B2 (en) 2016-12-23 2024-01-01 Univ Yale Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
WO2018118598A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US11191741B2 (en) * 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
CN106749513A (en) * 2017-01-23 2017-05-31 中国药科大学 Bifunctional molecule and its preparation and application based on the induction BET degradeds of VHL parts
BR112019015312A2 (en) * 2017-01-26 2020-03-10 Arvinas Operations, Inc. MODULATORS OF PROTEOLYSIS BY THE ESTROGEN RECEPTOR AND ASSOCIATED METHODS OF USE
CN110612294B (en) * 2017-01-31 2024-01-16 阿尔维纳斯运营股份有限公司 Human cerebulin ligands and bifunctional compounds comprising same
US20190374657A1 (en) * 2017-02-08 2019-12-12 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation with heterobifunctional compounds
JP7227912B2 (en) 2017-02-08 2023-02-24 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド Regulation of chimeric antigen receptors
JP7134183B2 (en) * 2017-04-14 2022-09-09 ユニバーシティ・オブ・ダンディー small molecule
US10787443B2 (en) 2017-04-28 2020-09-29 Zamboni Chem Solutions Inc. RAF-degrading conjugate compounds
CN108976278B (en) * 2017-06-05 2021-04-06 海创药业股份有限公司 Chimeric molecule and preparation and application thereof
CN110891605A (en) * 2017-06-07 2020-03-17 希沃尔拜克治疗公司 Antibody conjugates of immunomodulatory compounds and uses thereof
US20200190136A1 (en) * 2017-06-09 2020-06-18 Dana-Farber Cancer Institute, Inc. Methods for generating small molecule degraders and dimerizers
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
SG11201912071QA (en) 2017-06-22 2020-01-30 Catalyst Biosciences Inc Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
BR112020001825A2 (en) 2017-07-28 2020-07-21 Arvinas Operations, Inc. compounds and methods for targeted androgen receptor degradation
CA3073125A1 (en) * 2017-08-18 2019-02-21 Cambridge Enterprise Limited Modular binding proteins
CN109422751B (en) * 2017-09-03 2022-04-22 上海美志医药科技有限公司 Compound with activity of degrading tyrosine protein kinase JAK3
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag Dihydrobenzimidazolones
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
CN111278816B (en) 2017-09-04 2024-03-15 C4医药公司 Dihydro quinolinones
AU2018332887B2 (en) * 2017-09-13 2022-12-08 Amgen Inc. Bisamide sarcomere activating compounds and uses thereof
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
IL273432B (en) 2017-09-22 2022-09-01 Kymera Therapeutics Inc Protein degraders and uses thereof
HRP20221196T1 (en) 2017-10-05 2022-12-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
KR102129367B1 (en) 2017-10-20 2020-07-03 한국화학연구원 Compound for inducing the degradation of cereblon protein, preparation method thereof and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient
WO2019084026A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-hydroxamate compounds and methods of use thereof
EP3706736A4 (en) 2017-11-10 2021-08-11 The Regents of the University of Michigan Ash1l degraders and methods of treatment therewith
EP3710002A4 (en) * 2017-11-16 2021-07-07 C4 Therapeutics, Inc. Degraders and degrons for targeted protein degradation
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
JP2021014409A (en) * 2017-11-21 2021-02-12 京都薬品工業株式会社 Protein-binding drug
JP2021506820A (en) * 2017-12-13 2021-02-22 上海科技大学Ｓｈａｎｇｈａｉ Ｔｅｃｈ Ｕｎｉｖｅｒｓｉｔｙ ALK proteolytic agents and their use in cancer therapy
EP3728251A1 (en) 2017-12-18 2020-10-28 F. Hoffmann-La Roche AG Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moiety
SG11202005912PA (en) 2017-12-26 2020-07-29 Kymera Therapeutics Inc Irak degraders and uses thereof
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
JP2021512153A (en) 2018-01-26 2021-05-13 イエール ユニバーシティ Imide-based modulators of proteolysis and how to use
TW201945357A (en) 2018-02-05 2019-12-01 瑞士商赫孚孟拉羅股份公司 Compounds
CA3091041A1 (en) * 2018-02-22 2019-08-29 Ichan School Of Medicine At Mount Sinai Protein arginine methyltransferase 5 (prmt5) degradation / disruption compounds and methods of use
CA3092677A1 (en) 2018-03-06 2019-09-12 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (akt) degradation / disruption compounds and methods of use
WO2019170150A1 (en) 2018-03-09 2019-09-12 上海科技大学 Protein degradation targeting bcr-abl compound and antitumor application thereof
EP3765026A4 (en) 2018-03-10 2021-12-22 Yale University Modulators of btk proteolysis and methods of use
WO2019183523A1 (en) 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
US11666661B2 (en) 2018-03-23 2023-06-06 The Regents Of The University Of California Methods and compounds for targeted autophagy
CN111902141A (en) 2018-03-26 2020-11-06 C4医药公司 Glucocerebroside binders for IKAROS degradation
EP3774789A1 (en) * 2018-04-01 2021-02-17 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
CA3095494C (en) * 2018-04-04 2023-11-07 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
AU2019251223A1 (en) 2018-04-13 2020-11-26 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
EP3774802A4 (en) 2018-04-13 2021-12-29 Board of Regents, The University of Texas System Compounds and methods for selective proteolysis of glucocorticoid receptors
CN112312904A (en) 2018-04-16 2021-02-02 C4医药公司 Spiro compounds
EP3556760A1 (en) 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiro compounds
CN111741769B (en) * 2018-04-20 2022-09-16 四川科伦博泰生物医药股份有限公司 Multifunctional compound, preparation method and medical application thereof
WO2019218904A1 (en) * 2018-05-18 2019-11-21 四川科伦博泰生物医药股份有限公司 Unnatural amino acid derivative, preparation method therefor and use thereof
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
KR20210020107A (en) 2018-06-13 2021-02-23 암피스타 테라퓨틱스 엘티디 Bifunctional molecules for targeting UchL5
US11925690B2 (en) 2018-06-13 2024-03-12 Amphista Therapeutics Limited Bifunctional molecules for targeting Rpn11
WO2019238886A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting usp14
WO2019246570A1 (en) * 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
US20230070613A1 (en) * 2018-07-05 2023-03-09 Icahn School Of Medicine At Mount Sinai Protein tyrosine kinase 6 (ptk6) degradation / disruption compounds and methods of use
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
WO2020023851A1 (en) * 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
CN112912376A (en) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 Proteolytic targeted chimeric (PROTAC) compounds with E3 ubiquitin ligase binding activity and targeting alpha-synuclein for the treatment of neurodegenerative diseases
CA3109981A1 (en) 2018-09-07 2020-03-12 Arvinas Operations, Inc. Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US20220047596A1 (en) * 2018-09-12 2022-02-17 Board Of Regents, The University Of Texas System Combination of parp inhibitor and brd4 inhibitor for the treatment of cancer
CN113015746A (en) * 2018-09-19 2021-06-22 拉荷亚免疫研究所 PTPRS and proteoglycans in rheumatoid arthritis
WO2020081450A1 (en) 2018-10-15 2020-04-23 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
TW202037381A (en) * 2018-10-24 2020-10-16 瑞士商赫孚孟拉羅股份公司 Conjugated chemical inducers of degradation and methods of use
US20220001017A1 (en) * 2018-11-09 2022-01-06 Shanghai Qiangrui Biotech Co., Ltd. Micromolecular compound specificallydegrading tau protein, and application thereof
CN111171113B (en) * 2018-11-09 2023-05-16 汪义朋 Small molecular compound for specifically degrading tau protein and application thereof
CN111233661B (en) * 2018-11-29 2023-03-31 暨南大学 Compound for targeted ubiquitination degradation of ERR alpha protein and medicinal composition and application thereof
US11352350B2 (en) 2018-11-30 2022-06-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
CN113473987A (en) 2018-12-19 2021-10-01 细胞基因公司 Substituted 3- ((3-aminophenyl) amino) piperidine-2, 6-dione compounds, compositions thereof, and methods of treatment using the same
CA3124130A1 (en) 2018-12-19 2020-06-25 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
US11547759B2 (en) 2019-01-30 2023-01-10 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
WO2020160295A1 (en) 2019-01-30 2020-08-06 Montelino Therapeutics, Llc Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
EP3922632A4 (en) * 2019-02-07 2023-02-15 Korea Research Institute of Chemical Technology Target protein eed degradation-inducing degraducer, preparation method thereof, and pharmaceutical composition for preventing or treating diseases related to eed, ezh2, or prc2, comprising same as active ingredient
WO2020168172A1 (en) * 2019-02-15 2020-08-20 Zamboni Chem Solutions Inc. Conjugate compounds for the degradation of raf
CN113557235A (en) 2019-03-06 2021-10-26 C4医药公司 Heterocyclic compounds for use in medical therapy
WO2020191369A1 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
CA3133314A1 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicle conjugates and uses thereof
MA55565A (en) 2019-04-05 2022-02-09 Kymera Therapeutics Inc STAT DEGRADING AGENTS AND THEIR USES
WO2020210508A1 (en) 2019-04-09 2020-10-15 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
WO2020206608A1 (en) * 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
WO2020210630A1 (en) 2019-04-12 2020-10-15 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
CN110151767B (en) * 2019-05-08 2022-10-18 武汉威立得生物医药有限公司 Application of GNF-7 in preparation of medicine for treating influenza virus infection
AU2020274113A1 (en) 2019-05-14 2021-11-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US20220257774A1 (en) * 2019-05-17 2022-08-18 Hinova Pharmaceuticals Inc. Aromatic amine ar ahd bet targeting protein degradation chimera compound and use
MX2021013751A (en) 2019-05-17 2022-01-26 Nurix Therapeutics Inc Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof.
EP3976621A4 (en) * 2019-06-03 2023-11-15 Regents of the University of Minnesota Compounds that degrade kinases and uses thereof
US11890346B2 (en) 2019-06-12 2024-02-06 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of c-MYC protein
MX2021015995A (en) 2019-06-28 2022-03-11 Kymera Therapeutics Inc Irak degraders and uses thereof.
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
CN114174299A (en) * 2019-07-26 2022-03-11 百济神州有限公司 Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligands and methods of use
EP4010336A4 (en) * 2019-08-05 2023-08-23 Dana-Farber Cancer Institute, Inc. Degraders of cyclin-dependent kinase 7 (cdk7) and uses thereof
CN114787159A (en) * 2019-10-01 2022-07-22 阿尔维纳斯运营股份有限公司 BRM targeting compounds and related methods of use
CA3154386A1 (en) * 2019-10-17 2021-04-22 Michael Berlin Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety
JP2022553409A (en) 2019-10-23 2022-12-22 スティヒティング ヘット ネーデルランズ カンケル インスティテュート－アントニ ファン レーウェンフーク ジーケンハウス Chimeric polypeptides for immune cell regulation
CN112707900B (en) * 2019-10-24 2022-06-10 上海科技大学 Protein degrading agents and their use in the treatment of disease
CN110713480B (en) * 2019-10-28 2021-02-26 浙江省医学科学院 AChE protein degradation product and preparation method and application thereof
CN110759902B (en) * 2019-11-01 2022-04-22 海南一龄医疗产业发展有限公司 SET8 lysine methyltransferase inhibitor and preparation method and application thereof
CN110684022B (en) * 2019-11-01 2022-07-08 海南一龄医疗产业发展有限公司 SET8 lysine methyltransferase inhibitor and intermediate, preparation method and application thereof
WO2021097046A1 (en) 2019-11-13 2021-05-20 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4069237A1 (en) 2019-12-04 2022-10-12 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
AU2020398241A1 (en) 2019-12-04 2022-06-30 Omeros Corporation MASP-2 inhibitors and methods of use
US11904006B2 (en) 2019-12-11 2024-02-20 University Of Iowa Research Foundation Poly(diaminosulfide) particle-based vaccine
CN112979747A (en) * 2019-12-16 2021-06-18 江苏恒瑞医药股份有限公司 Hydroxyproline derivative for preparing protein degradation targeting chimera
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. Irak degraders and uses thereof
BR112022011651A2 (en) 2019-12-17 2022-08-23 Kymera Therapeutics Inc IRAK DEGRADATORS AND USES THEREOF
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2021127561A1 (en) 2019-12-20 2021-06-24 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of egfr
TW202136242A (en) 2019-12-23 2021-10-01 美商凱麥拉醫療公司 Smarca degraders and uses thereof
EP4114830A1 (en) * 2020-03-04 2023-01-11 Genentech, Inc. Heterobifunctional molecules as tead inhibitors
JP2023516073A (en) 2020-03-05 2023-04-17 シーフォー セラピューティクス， インコーポレイテッド Compounds for targeted degradation of BRD9
JP2023518423A (en) 2020-03-19 2023-05-01 カイメラ セラピューティクス， インコーポレイテッド MDM2 degrading agents and their uses
IL296648A (en) 2020-03-21 2022-11-01 Arvinas Operations Inc Indazole based compounds and associated methods of use
US11858940B2 (en) 2020-03-21 2024-01-02 Arvinas Operations, Inc. Selective modulators of mutant LRRK2 proteolysis and associated methods of use
KR102337029B1 (en) 2020-03-27 2021-12-09 (주) 업테라 PLK1 Selective Degradation Inducing Compound
EP4129402A1 (en) * 2020-03-31 2023-02-08 Mitsubishi Tanabe Pharma Corporation Hydroxypyrrolidine derivative and medicinal application thereof
EP4138921A1 (en) * 2020-04-23 2023-03-01 University Of Iowa Research Foundation Gper proteolytic targeting chimeras
CN113563414B (en) * 2020-04-29 2022-08-12 泰比棣医药科技(石家庄)有限公司 Tissue-targeted protein targeted degradation compound and application thereof
CN111606969B (en) * 2020-05-13 2023-02-03 四川大学 PARP1 protein degradation agent and application thereof in tumor resistance
GB202007106D0 (en) 2020-05-14 2020-07-01 Ucl Business Plc Cyclosporine analogues
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
GB202008201D0 (en) * 2020-06-01 2020-07-15 Neophore Ltd Inhibitor compounds
CN113321700B (en) * 2020-06-02 2022-07-01 泰比瑞医药科技(石家庄)有限公司 Bifunctional compound for degrading target protein and application thereof
TW202210483A (en) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Crystalline forms of irak degraders
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
KR20230111615A (en) 2020-10-21 2023-07-25 아비나스 오퍼레이션스, 인코포레이티드 Compounds and methods for targeted degradation of androgen receptor proteins
CN112174999A (en) * 2020-11-02 2021-01-05 兰州理工大学 Titanium metal complex post-modification product with anticancer activity and preparation method and application thereof
EP4240733A1 (en) 2020-11-06 2023-09-13 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor and associated methods of use
KR20230106637A (en) * 2020-11-11 2023-07-13 제넨테크, 인크. 1-(2-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)acetyl)-4-hydroxy-N-(benzyl)pyrrolidine as a VHL inhibitor for the treatment of anemia and cancer E-2-carboxamide derivatives
AR124189A1 (en) * 2020-11-30 2023-02-22 Genentech Inc COMPOUNDS AND PROCEDURES FOR USE THEREOF
WO2022120355A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
WO2022173032A1 (en) * 2021-02-15 2022-08-18 アステラス製薬株式会社 Quinazoline compound for inducing degradation of g12d-mutation kras protein
WO2022192878A1 (en) * 2021-03-09 2022-09-15 Baylor College Of Medicine Cellular selectivity profiling against rna helicases and splicing regulators
CN115043817A (en) * 2021-03-09 2022-09-13 苏州泽璟生物制药股份有限公司 SOS1 proteolysis regulator and preparation method and application thereof
CR20230449A (en) 2021-03-19 2023-11-23 Arvinas Operations Inc Indazole based compounds and associated methods of use
CA3214408A1 (en) 2021-03-23 2022-09-29 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
IL305860A (en) 2021-04-16 2023-11-01 Arvinas Operations Inc Modulators of bcl6 proteolysis and associated methods of use
CN115232114B (en) * 2021-04-23 2023-12-19 上海领泰生物医药科技有限公司 SOS1 degradation agent and preparation method and application thereof
CN113603676B (en) * 2021-04-28 2022-05-24 浙江工业大学 Erlotinib-based EGFR protein targeted degradation small molecule compound and preparation method and application thereof
EP4089103A1 (en) 2021-05-12 2022-11-16 Universität Duisburg-Essen Clpcp protease-binding cyclic heptapeptides
WO2022266258A1 (en) 2021-06-15 2022-12-22 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of irak-4
WO2023283130A1 (en) 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof
US11981672B2 (en) 2021-09-13 2024-05-14 Montelino Therapeutics Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
WO2023096987A1 (en) 2021-11-24 2023-06-01 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
WO2023097031A1 (en) 2021-11-24 2023-06-01 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
GB202117225D0 (en) * 2021-11-29 2022-01-12 Neophore Ltd Protac compounds
CN113979999B (en) * 2021-12-23 2022-05-20 北京鑫开元医药科技有限公司 Compound for targeted ubiquitination degradation of BCR-ABL kinase and preparation method, composition and application thereof
WO2023141570A2 (en) * 2022-01-21 2023-07-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of kras
AR128330A1 (en) 2022-01-26 2024-04-17 Genentech Inc CHEMICAL DEGRADATION INDUCERS CONJUGATED WITH ANTIBODY AND METHODS OF THESE
CN116676273A (en) * 2022-02-22 2023-09-01 中国科学院深圳先进技术研究院 Proteolysis targeting influenza virus and preparation method and application thereof
CN114560908A (en) * 2022-03-11 2022-05-31 国家纳米科学中心 Polypeptide PROTAC molecule, and preparation method and application thereof
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
WO2024006781A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and use thereof
WO2024006776A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and medical use thereof
WO2024020221A1 (en) 2022-07-21 2024-01-25 Arvinas Operations, Inc. Modulators of tyk2 proteolysis and associated methods of use
WO2024035780A1 (en) * 2022-08-09 2024-02-15 Board Of Regents Of The University Of Nebraska Akr1c3 targeted heterobifunctional small molecule proteolysis targeting chimeras
CN115028679B (en) * 2022-08-11 2022-11-15 深圳湾实验室 PROTAC compound with Cyclophilin A degradation activity and preparation method and application thereof
WO2024033538A1 (en) 2022-08-12 2024-02-15 Astellas Pharma Inc. Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity
WO2024033537A1 (en) 2022-08-12 2024-02-15 Astellas Pharma Inc. Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity
KR20240025485A (en) * 2022-08-17 2024-02-27 한국화학연구원 Compounds for inhibiting or degrading CDK2 and/or CDK9 and medical uses thereof
WO2024040080A1 (en) * 2022-08-19 2024-02-22 Erasca, Inc. Kras inhibitor conjugates
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2024075051A1 (en) 2022-10-07 2024-04-11 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
CN117024413B (en) * 2023-10-07 2024-01-09 天津匠新致成科技有限公司 3-aminopyrazine-2-formamide targeted proteolytic chimera, and preparation method, pharmaceutical composition and application thereof
CN117402178B (en) * 2023-12-15 2024-03-08 英矽智能科技(上海)有限公司 Pyrimidine compounds as JAK inhibitors and PHD inhibitors

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962475A (en) * 1996-10-25 1999-10-05 Eli Lilly And Company Substituted benzo(B)thiophene compounds having activity as selective estrogen receptor modulators
US6218425B1 (en) * 1996-08-06 2001-04-17 Eli Lilly And Company 8-substituted B-nor-6-Thiaequilenin compounds having activity as selective estrogen receptor modulators
US6262098B1 (en) * 1998-08-07 2001-07-17 Chiron Corporation Estrogen receptor modulators
US6417394B2 (en) * 2000-04-05 2002-07-09 Bristol Myers Squibb Pharma Company Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
US20020099096A1 (en) * 2000-08-24 2002-07-25 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US20020173445A1 (en) * 2000-06-28 2002-11-21 Salvati Mark E. Selective androgen receptor modulators and methods for their identification, design and use
US20050014952A1 (en) * 2003-06-13 2005-01-20 Ng Raymond A. Novel thiazoline derivatives as selective androgen receptor modulators (SARMS)
US20050245485A1 (en) * 2004-05-03 2005-11-03 Lanter James C Novel indole derivatives as selective androgen receptor modulators (SARMS)
US20070208014A1 (en) * 2006-01-24 2007-09-06 Alford Vernon C Jr Novel 2-substituted benzimidazoles as selective androgen receptor modulators (sarms)
US20100256129A1 (en) * 2007-12-21 2010-10-07 Lin Zhi Selective androgen receptor modulators (sarms) and uses thereof
US7989487B2 (en) * 2006-07-06 2011-08-02 University Of Medicine And Dentistry Of New Jersey Estrogen receptor modulators and uses thereof

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE69411003T2 (en) 1993-04-07 1998-10-08 Pfizer CYCLOALKYLHYDROXY UREAS AND THEIR USE AS LIPOXY GENASE INHIBITORS
JP2000512979A (en) * 1996-04-24 2000-10-03 ペプチド セラピュティックス リミテッド Combinatorial library by self-deconvolution method
CA2204082A1 (en) 1996-05-03 1997-11-03 Michael William John Urquhart Pharmaceutical compounds
HRP970566A2 (en) 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser
ATE460423T1 (en) 1997-05-14 2010-03-15 Sloan Kettering Inst Cancer METHOD AND PREPARATIONS FOR DESTROYING CERTAIN PROTEINS
AU740597B2 (en) 1997-07-10 2001-11-08 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
AU1203000A (en) 1998-10-09 2000-05-01 President And Fellows Of Harvard College Targeted proteolysis by recruitment to ubiquitin protein ligases
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
AU769012B2 (en) 1999-02-26 2004-01-15 Oklahoma Medical Research Foundation Novel component of von Hippel-Lindau tumor suppressor complex and SCF ubiquitin ligase
JP2002543129A (en) * 1999-05-05 2002-12-17 メルク エンド カムパニー インコーポレーテッド New prolines as antimicrobial agents
EP1225918A2 (en) 1999-10-19 2002-07-31 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6740495B1 (en) 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US7041298B2 (en) 2000-09-08 2006-05-09 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
JP2005507363A (en) * 2001-02-16 2005-03-17 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Angiogenesis-inhibiting tripeptides, compositions and methods of their use
HN2002000136A (en) * 2001-06-11 2003-07-31 Basf Ag INHIBITORS OF THE PROTEASE OF HIV VIRUS, COMPOUNDS CONTAINING THEMSELVES, THEIR PHARMACEUTICAL USES AND THE MATERIALS FOR SYNTHESIS
DE60238620D1 (en) * 2001-08-03 2011-01-27 Vertex Pharma KINASEIN HIBITORS DERIVED FROM PYRAZOL AND THEIR USE
US20030133927A1 (en) 2001-10-10 2003-07-17 Defeo-Jones Deborah Conjugates useful in the treatment of prostate cancer
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
US7053046B2 (en) * 2001-12-21 2006-05-30 Mcgrath Kevin Peptide activators of VEGF
CA2491041A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
US20030143590A1 (en) 2002-11-18 2003-07-31 Shyam Ramakrishnan Regulation of human dopamine-like g protein- coupled receptor
EP1651595A2 (en) * 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
JP4874965B2 (en) 2004-07-08 2012-02-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Androgen regulator
DE102008020113A1 (en) 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituted dihydropyrazolones and their use
NZ589670A (en) 2004-12-20 2013-01-25 Genentech Inc Pyrrolidine inhibitors of iap
WO2006113942A2 (en) * 2005-04-20 2006-10-26 Schering Corporation Method of inhibiting cathepsin activity
US7718846B2 (en) 2005-05-16 2010-05-18 Gideon Koren Animal models of long QT syndrome and uses thereof
JP2009509923A (en) * 2005-08-26 2009-03-12 メシルジーン、インコーポレイテッド Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase
ATE484499T1 (en) 2005-08-30 2010-10-15 Boehringer Ingelheim Int GLUCOPYRANOSYL-SUBSTITUTED BENZYL DERIVATIVES, MEDICATIONS CONTAINING SUCH COMPOUNDS, THEIR USE AND PRODUCTION METHOD THEREOF
CA2643267A1 (en) 2006-03-03 2007-09-20 Novartis Ag N-formyl hydroxylamine compounds
WO2008011392A2 (en) 2006-07-20 2008-01-24 Ligand Pharmacueticals Incorporated Proline urea ccr1 antagonists for the treatment of autoimmune diseases or inflammation
CA2668286C (en) 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
WO2008067495A2 (en) 2006-11-29 2008-06-05 Rutgers, The State University Of New Jersey Chemotherapeutic conjugates and methods of use
US20080233850A1 (en) * 2007-03-20 2008-09-25 3M Innovative Properties Company Abrasive article and method of making and using the same
WO2008134679A1 (en) 2007-04-30 2008-11-06 Genentech, Inc. Inhibitors of iap
KR20100038108A (en) 2007-07-25 2010-04-12 브리스톨-마이어스 스큅 컴퍼니 Triazine kinase inhibitors
KR101600634B1 (en) 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 Antitumor agent
WO2010027564A2 (en) 2008-07-18 2010-03-11 Glaxosmithkline Llc Amido anti-viral compounds, compositions, and methods of use
CN101768155B (en) 2008-12-30 2012-09-05 天津药物研究院 Derivatives containing (aminomethyl-five-membered heterocyclo-4-carbonyl)-pyrrolidine-2-carboxylic acid, preparation method thereof and use thereof
US20120135089A1 (en) * 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
WO2010141805A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of trpa1
WO2011005510A2 (en) 2009-06-22 2011-01-13 Cerapedics, Inc. Peptide conjugates and uses thereof
AU2010273220B2 (en) * 2009-07-13 2015-10-15 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110164191A1 (en) 2010-01-04 2011-07-07 Microvision, Inc. Interactive Projection Method, Apparatus and System
BR112012029057A2 (en) 2010-05-14 2020-10-13 Dana-Farber Cancer Institute, Inc. leukemia compositions and treatment methods
SI2902030T1 (en) 2010-05-14 2017-01-31 Dana-Farber Cancer Institute, Inc. Thienotriazolodiazepine compounds for treating neoplasia
WO2011160016A2 (en) 2010-06-17 2011-12-22 The Trustees Of Columbia University In The City Of New York E3 binding pockets and identification and use of e3 ligase inhibitors
EP2588129A4 (en) 2010-06-30 2014-07-09 Univ Brandeis Small-molecule-targeted protein degradation
EP2590656B1 (en) 2010-07-07 2017-11-15 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
PT2592933T (en) 2010-07-16 2017-05-23 Gaweco Anderson Mif inhibitors and their uses
US8809377B2 (en) 2010-09-24 2014-08-19 The Regents Of The University Of Michigan Deubiquitinase inhibitors and methods for use of the same
AR084070A1 (en) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc BROMODOMINIUM INHIBITORS AND USES OF THE SAME
WO2012078559A2 (en) 2010-12-07 2012-06-14 Yale University Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
US20140243282A1 (en) 2010-12-31 2014-08-28 Satish Reddy Kallam Methods and compositions for designing novel conjugate therapeutics
WO2012142498A2 (en) 2011-04-13 2012-10-18 Innovimmune Biotherapeutics, Inc. Mif inhibitors and their uses
WO2013106646A2 (en) 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
RU2666530C2 (en) 2012-01-12 2018-09-11 Йейл Юниверсити Compounds and methods for enhanced degradation of target proteins and other polypeptides by an e3 ubiquitin ligase
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
EP2846784A4 (en) 2012-05-11 2016-03-09 Univ Yale Compounds useful for promoting protein degradation and methods using same
IN2014DN11269A (en) 2012-06-25 2015-10-09 Oncoethix Sa
JP6407504B2 (en) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Method for inhibiting constitutively active phosphorylated FLT3 kinase
GB201311910D0 (en) * 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel Compounds
NL2011274C2 (en) 2013-08-06 2015-02-09 Illumicare Ip B V 51 Groundbreaking platform technology for specific binding to necrotic cells.
EP2958923A1 (en) 2013-02-22 2015-12-30 Bayer Pharma Aktiengesellschaft 4-substituted pyrrolo- and pyrazolo-diazepines
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) * 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3071203B1 (en) 2013-11-18 2020-12-23 Forma Therapeutics, Inc. Tetrahydroquinoline compositions as bet bromodomain inhibitors
WO2015160845A2 (en) 2014-04-14 2015-10-22 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
US20160022642A1 (en) 2014-07-25 2016-01-28 Yale University Compounds Useful for Promoting Protein Degradation and Methods Using Same
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
RU2697393C2 (en) 2014-10-02 2019-08-14 ГлаксоСмитКлайн Интеллекчуал Проперти (N 2) Лимитед Crystalline solid form of a benzene sulphonic acid salt and 2-[(4s)-6-(4-chlorophenyl)-1-methyl-8-(methyloxy)-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide, method for production thereof and pharmaceutical composition containing thereof
CR20170219A (en) 2014-10-27 2017-08-14 Tensha Therapeutics Inc BROMODOMINUM INHIBITORS
AU2016209349B2 (en) 2015-01-20 2020-05-07 Arvinas, Inc. Compounds and methods for the targeted degradation of the Androgen Receptor
GB201504314D0 (en) 2015-03-13 2015-04-29 Univ Dundee Small molecules
WO2016149668A1 (en) 2015-03-18 2016-09-22 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
US20180147202A1 (en) 2015-06-05 2018-05-31 Arvinas, Inc. TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
EP3370715A4 (en) * 2015-11-02 2019-05-15 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218425B1 (en) * 1996-08-06 2001-04-17 Eli Lilly And Company 8-substituted B-nor-6-Thiaequilenin compounds having activity as selective estrogen receptor modulators
US5962475A (en) * 1996-10-25 1999-10-05 Eli Lilly And Company Substituted benzo(B)thiophene compounds having activity as selective estrogen receptor modulators
US6262098B1 (en) * 1998-08-07 2001-07-17 Chiron Corporation Estrogen receptor modulators
US6417394B2 (en) * 2000-04-05 2002-07-09 Bristol Myers Squibb Pharma Company Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
US20020173445A1 (en) * 2000-06-28 2002-11-21 Salvati Mark E. Selective androgen receptor modulators and methods for their identification, design and use
US20020099096A1 (en) * 2000-08-24 2002-07-25 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US20050014952A1 (en) * 2003-06-13 2005-01-20 Ng Raymond A. Novel thiazoline derivatives as selective androgen receptor modulators (SARMS)
US20050245485A1 (en) * 2004-05-03 2005-11-03 Lanter James C Novel indole derivatives as selective androgen receptor modulators (SARMS)
US20070208014A1 (en) * 2006-01-24 2007-09-06 Alford Vernon C Jr Novel 2-substituted benzimidazoles as selective androgen receptor modulators (sarms)
US7989487B2 (en) * 2006-07-06 2011-08-02 University Of Medicine And Dentistry Of New Jersey Estrogen receptor modulators and uses thereof
US20100256129A1 (en) * 2007-12-21 2010-10-07 Lin Zhi Selective androgen receptor modulators (sarms) and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Oxford (Dictionary of Biochemistry and Molecular Biology, Revised Edition, Oxford University Press, 2006, pages 373-398 (Year: 2006) *
Wikipedia entry for ligand, obtained from https://en.wikipedia.org/w/index.php?title=Ligand_(biochemistry)&oldid=470945797, version dated January 12th, 2012 (Year: 2012) *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11701357B2 (en) 2016-08-19 2023-07-18 Beigene Switzerland Gmbh Treatment of B cell cancers using a combination comprising Btk inhibitors
US11597768B2 (en) 2017-06-26 2023-03-07 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
WO2020027225A1 (en) 2018-07-31 2020-02-06 ファイメクス株式会社 Heterocyclic compound
US11639354B2 (en) 2018-07-31 2023-05-02 Fimecs, Inc. Heterocyclic compound
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
WO2021092174A1 (en) * 2019-11-06 2021-05-14 Dana-Farber Cancer Institute, Inc. Selective histone deacetylase (hdac) degraders and methods of use thereof
WO2021207172A1 (en) 2020-04-06 2021-10-14 Arvinas Operations, Inc. Compounds and methods for targeted degradation of kras
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
WO2022169780A1 (en) 2021-02-02 2022-08-11 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
WO2022187650A1 (en) * 2021-03-04 2022-09-09 The Scripps Research Institute Heterobifunctional compositions for targeted protein degradation and methods for their use
WO2023034411A1 (en) 2021-09-01 2023-03-09 Oerth Bio Llc Compositions and methods for targeted degradation of proteins in a plant cell
WO2023220425A1 (en) * 2022-05-12 2023-11-16 Kymera Therapeutics, Inc. Bcl-xl/bcl-2 degraders and uses thereof
WO2024050016A1 (en) 2022-08-31 2024-03-07 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
WO2024081913A1 (en) * 2022-10-14 2024-04-18 76Bio, Inc. Dual-specific bifunctional fusion proteins for ubiquitin-mediated degradation

Also Published As

Publication number Publication date
AU2013207900B2 (en) 2017-12-07
AU2020239664B2 (en) 2022-04-21
RU2018126714A3 (en) 2021-10-14
EP2802608A4 (en) 2015-08-05
KR20200063135A (en) 2020-06-04
AU2022205187B2 (en) 2024-04-04
JP2021185202A (en) 2021-12-09
AU2018201554B2 (en) 2020-06-25
EP2802608A2 (en) 2014-11-19
MX2014008520A (en) 2015-08-14
AU2024201732A1 (en) 2024-04-11
WO2013106643A2 (en) 2013-07-18
EP3608317A1 (en) 2020-02-12
CA2861066A1 (en) 2013-07-18
JP2015508414A (en) 2015-03-19
KR102204989B1 (en) 2021-01-20
AU2018201554A1 (en) 2018-03-29
RU2014133019A (en) 2016-02-27
AU2013207900A8 (en) 2014-07-31
US10730862B2 (en) 2020-08-04
RU2018126714A (en) 2019-03-12
RU2666530C2 (en) 2018-09-11
AU2013207900A1 (en) 2014-07-24
JP2020063314A (en) 2020-04-23
KR20220124816A (en) 2022-09-14
CN117736134A (en) 2024-03-22
KR20150010935A (en) 2015-01-29
US20140356322A1 (en) 2014-12-04
AU2020239664A1 (en) 2020-10-15
HK1208875A1 (en) 2016-03-18
KR102438072B1 (en) 2022-08-31
AU2022205187A1 (en) 2022-07-28
JP2019023206A (en) 2019-02-14
WO2013106643A3 (en) 2013-09-06
CN104736569A (en) 2015-06-24
JP2023171589A (en) 2023-12-01
CA2861066C (en) 2024-01-02
MX2022009478A (en) 2022-10-10
BR112014017095A2 (en) 2017-06-13
MX358660B (en) 2018-08-30

Similar Documents

Publication Publication Date Title
US20190127359A1 (en) Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase
US11512083B2 (en) Compounds and methods for the enhanced degradation of targeted proteins
US20220162163A1 (en) Alanine-based modulators of proteolysis and associated methods of use
RU2781452C2 (en) Compounds and methods for enhancing degradation of target proteins and other polypeptides, using e3 ubiquitin ligase
RU2782063C2 (en) Compounds and methods for improved cleavage of target proteins
KR102668696B1 (en) Compounds and Methods for the Enhanced Degradation of Targeted Proteins and Other Polypeptides by an E3 Ubiquitin Ligase

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED